<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec3190d9-654f-47a8-8254-cb7fc4b75c73">
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34ca1d12-904f-49ad-a6df-b14090a36a40">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3519ee6c-eef1-4d30-b112-996fa0591c7b">
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>Prosaposin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0ec76f4-c11d-4d88-80c6-0d107537d8b4">
        <rdfs:label>PSAP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b084f1d-27f3-4857-9b9f-f8e484ac6111">
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22d8068a-e6c3-4243-8c75-86d3ef5e8d0c">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b4dbe9f-7ba2-495f-9626-7449671f35b7">
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51090685-60dd-4a34-8fd6-265fbcff9a5f">
        <rdfs:label>and</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06de2649-1b40-4271-8909-ff848832d04a">
        <rdfs:label>RPS26</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75e76540-05bf-45a2-bf94-fad22c1765e4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
        <rdfs:label>RPL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83e87bc4-3121-465f-8b90-617f2cc7b8df">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
        <rdfs:label>RPS17</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4dcaadb-4819-415f-b838-763568704b8b">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a275930f-cdc7-44ca-9df2-56081ca20308">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/665abd1a-b931-4072-8089-991940e5e6cd">
        <rdfs:label>RPS7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8443e887-de6b-4c60-9d89-24608f1cb8c2">
        <rdfs:label>RPS19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e832947-a242-4d41-a766-02e70a8f758e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
        <rdfs:label>RPL35A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e3fc55d6-ccfc-4c6c-af8e-50dc4ed02d2e">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b9176d23-5aa8-4395-8d09-7d11be06e623">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/796bf10c-3ba4-42dc-89af-21d0962ac5ac">
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e3a43399-c48d-4eb3-a3c4-47348ab73b9c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
        <rdfs:label>PYGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/597c81ab-7ab9-4c2f-a4d7-1f53921bc025">
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/035c7cfa-c220-49ee-827a-2d326ce02e3c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
        <rdfs:label>ECM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9ee9bb27-5aaf-42a6-b816-75fd55eca849">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b28b63ca-a0aa-4b21-9db8-2088f66a5043">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d582162-9aa6-4369-a68c-7171e0a8f4ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a103108-b461-40e5-8bc9-cc64cd9e0104"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/685cbc8e-1cfb-4bd7-996b-2a355de5e5c0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42253eeb-87a4-44c1-8b59-7a65e7da59bc">
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:DDIEM_0000011>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/21e987e6-4803-41b4-af53-d11411680954">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/627b4ecf-13bb-4a5e-bd92-559faad1e5c4">
        <rdfs:label>PTPS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a2d20920-c1fe-460e-a638-dc4014b01dca">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3209b8ab-6a60-41e6-a574-33213ac622b8"/>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9388934-80ad-4fd4-8987-ff8614b65c06"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c86c32d5-43f3-4d74-bc0a-5bff3ba809df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa047d84-db64-4130-ae59-889231f1e8f8">
        <rdfs:label>Lactic acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9">
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f59442-252d-43e0-ba14-2f6a00d3c444">
        <dc:identifier>HP:0002572</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:label>Repeated vomiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3641236c-17a8-4cdf-90ef-fec3a0485cd9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Encephalopathy</rdfs:label>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f70b0c26-0ef1-4588-8079-5c16f539542c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f12ff25-2fbb-4d16-bada-f60906e58149"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcca9e97-c774-4189-ae45-c18cac755aeb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/97181c48-dd1b-4941-b770-da716b62ecae">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4441d141-8e00-4fe4-b748-55165efc2063"/>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91e6ff59-2ea3-4194-b1af-c6989f5888b6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e46bf337-dd46-4796-8328-529581cd5598">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ae2a504-e448-42e7-bd5f-c363c5e2b793"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4b02a13d-5645-4478-bb59-d4c5ee0ca6de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/633f4fa6-5845-4cd5-9f18-7d215e71c2b4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f3507a1-3c81-4321-a7ea-efd3e0ff5951"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9e98f39-8898-436b-a22a-5b38a6ed6dea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25350eed-6a36-4ce1-9517-5b1ebdb89287"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72717f6e-657c-472a-a722-1940378f49e0">
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39890d66-6dbf-4fa7-af24-845b9a74e4db">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
        <rdfs:label>SLC12A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3c906d20-b247-4ae2-a7e9-f923b69f9d9b">
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a23c4ae-ed40-4885-a437-c385928e33ed">
        <rdfs:label>AKR1D1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/adb576b3-e3ef-415a-8514-a95055e555e8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b823323-4bc6-4d82-b972-cca4133c356c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d720cccb-6245-4d18-9257-1bc9b670dd55"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81962e55-ae79-4df5-b02d-53b56626795c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b43df554-0024-45cf-91a6-dc6762b4e5cd"/>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8b981ad6-9710-4115-b0d7-027194adc9cc">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05491772-2264-4244-b4b9-07a5f035803f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28c852f5-040c-4627-af46-ee2ed0fd02a7">
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:label>Haemolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf7cc404-6b04-4d1c-87c4-c8f6c001e57f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Fatigue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d16b62c-83ba-47a4-b81f-ad092585f861">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fd59463-de14-4906-8573-89a09c19f134"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77988ccf-3679-4dc7-8767-39d5416fdd41">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:label>Anorexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05cc4c32-378d-461d-98bd-5562a95c81fd"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/854a308a-a3f3-4cbf-ba36-7799e6a91fd8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:label>Spasticity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edae5663-b3dc-4bd5-bad8-b4749a6000ee">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002395</dc:identifier>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d327e52-da4a-4fae-97de-1d30ce90f684">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7a90f9e-e3e8-488c-a632-3615f6739e32">
        <rdfs:label>Impaired renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/205878fc-da0a-4c1f-991a-30a40098ebfd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <rdfs:label>Delirium</rdfs:label>
        <dc:identifier>HP:0031258</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a9e092c-d14a-48cd-b754-8e34d3b806a7"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7ca179ae-9c8c-41cd-8576-e6f94589eb7b">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b8fbc13a-bd7c-4a86-8446-9af0e70625d6"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/622eb153-9b63-44f3-a847-49100a687aa1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/642f7f69-4eac-4cc2-8c10-cc537adde5cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66a0f59e-2b9b-4e73-81ab-c2b31afcbc7c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/101c6f48-5952-4f3c-81c0-46bd1c918538">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/350accf1-9b58-484b-8e4d-5e597adea30d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/0a39c08a-d002-423e-8722-f0a85b5badce">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b78044f4-811f-41d3-a33c-d04dae27e687">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:label>Scaling Skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/434eba34-70d3-411b-b9ab-e03e9b16defb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce1cde33-8e27-4304-9307-5bb9e9a689ef">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Itchy skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b28b63ca-a0aa-4b21-9db8-2088f66a5043"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/069fd4e7-cff1-4b20-a0ee-8175ac4b7b52">
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5151a35a-e14d-4b6d-a4f1-60b3a5e6aff3"/>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d459df12-c49e-4490-bfed-cc3d38a96b9e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb6f5bf2-8c19-45e4-b376-d5af6a678796">
        <dc:identifier>HP:0031517*</dc:identifier>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06b84268-e684-4188-ba54-131724c72f97">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2126b5ec-e457-4bdb-a501-969bbd312ef4">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/329dfe13-7081-47cd-b605-a52f86b6c320">
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6798a40c-154e-4aff-bae5-b4e7f5c79fb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e64c6c97-d59a-42f9-9b2f-aa727d46824f">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26edb501-50db-4aa4-abc2-11378f779ee3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus</rdfs:label>
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cdbcad1-c48d-4a2b-923d-1f23a0b7a3ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/be1fed4c-cc07-4b0d-b564-27502f88392c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89572c12-c297-49bb-9117-ae0823d3fb34">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78c5c9da-764b-45ee-aa72-d64f587010cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee69027e-706b-45b9-8cdf-556244b3a5ac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55da3f2c-01f7-4c17-850f-55277649fcf8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39952800-730e-45f2-b8ba-d33e123e84fd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d42bef3b-65d3-4f2e-9af6-eb5b9a4dbebd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f66c286-412a-40f2-86ef-72d2352b0b64">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f9c5501-0400-4232-ad31-02778acb954e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
        <rdfs:label>PHKA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1de5c4a6-1c20-4458-b04c-d80b4129b78b">
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11c2383b-8c1a-4a10-8e74-5dcff2c57127">
        <rdfs:label>SGCA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26a52f9b-1f0e-4824-bd6a-0f6e805cd088">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ea61f6d-7ec5-4338-a0ae-6465e8946076">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GALT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a33e734c-e014-4e47-b299-1a9fd092231f">
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b61e17f-406b-44eb-a79c-8100161ceb87">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8e687144-aa42-4fd8-8817-5ca21f7e8048">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/90144aff-adbc-426f-ae09-cfe8543cd0cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8395ed38-e7c2-4831-ac87-b27e33884663">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05482037-dfac-44a3-a678-a39ebb6cb94f">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e32410e4-dbcb-4da9-866b-c59b7cfce6b7">
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a619967d-78df-4f1b-9146-acaa33b1a826">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
        <rdfs:label>FBP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eadce3f4-8102-477d-a108-0d6f6fd7c81c">
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a971e804-5c62-41b1-9aee-e09d0feb2b05">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/609cea45-479c-4219-8b3a-56f9b3a54f88">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41acc4aa-392c-4a5f-96e3-1a16966f89bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3de240ca-6588-4088-8bfe-0576458d71ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a2d0d39-666e-4efb-8a76-3791b65fe7ec">
        <dc:identifier>HP:0003162</dc:identifier>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <dc:identifier>ECO:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b6cc3ad3-b419-46f6-bbf5-aa14239d524c"/>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07d89790-5215-4bc4-bc30-811a96e91232">
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e4297cd-ec69-422e-89f1-ea0013e042e0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b41ca36-98f6-449e-9bc7-0d1689d10bb1">
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6cc3ad3-b419-46f6-bbf5-aa14239d524c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec2a1e63-81a6-447e-90ca-fad77024dee0">
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/057a2de2-797e-4965-bf54-2a79a2777841">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
        <rdfs:label>AGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7fcc8584-f945-4bf8-8e36-fc7a0eedc363">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1abcb9a5-dd51-4e87-b821-b29e6aa971da">
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91301828-e4a3-46d3-af7c-4906caf8e53a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7041ce95-7ac2-4be1-a49e-94b8cd5250eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05482037-dfac-44a3-a678-a39ebb6cb94f"/>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17e869f4-636a-4d91-a248-ab2941f4661c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5690691-3b20-45d6-8a10-079b50f2bd95"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9caa6fc-d2d5-4525-88fa-3743e2026e0a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9efbe5dd-9efb-450d-946b-16c28d2c658b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b69b660f-8e34-4777-8424-35b349e937c4"/>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5f340be-27d8-4ca7-86c2-cf23363cd30a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c50a0256-1ee7-481f-8661-fcd639e2802a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33f4f030-0b07-4855-8ade-888211832c32">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d1fdd82-7c7c-4050-94af-f956d707f872">
        <dc:identifier>HP:0008315</dc:identifier>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1c58008c-5387-4eec-815f-cb6f5c7fa73b">
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec7ac8d7-6a05-44be-bc1d-c1fe7f1d7c43">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
        <rdfs:label>ETFA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a863028-bee3-48d7-9a9e-4cedb09a187b">
        <rdfs:label>ETFB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79bbe318-a9bb-4e16-a77a-90995e63a470">
        <rdfs:label>ETFDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/76abbf33-6d0d-40d9-bd72-e3c38b6bad93">
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9bb2cf74-7236-42d2-8e06-80c40a832f22">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
        <rdfs:label>TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85f5e716-2d33-451d-936f-a599a1ff73e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
        <rdfs:label>GCH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd99f9d1-9507-414c-88b6-f0719ecb69f0">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e50aa61-1831-4aaa-9d79-6a4521f02807">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd7313f1-36f7-4df7-abe7-c536b3e47a6d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/420bbd61-254f-44f9-9523-865941399b92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/581e121e-b9e9-427c-b162-a667058dbca1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48071bd5-9834-44d7-b094-2ac462068116"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/976dee0e-eb00-4a55-a054-49d3d5fdb9d2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>Nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fe3d1327-82e2-467a-b621-32ec93d8c141">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55907745-315e-4223-926c-06b3d34910d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dc58794-8b68-4744-9e9c-987f5fdea33d">
        <rdfs:label>Hyperurecemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>done</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7518c543-0474-43ad-ae33-d5c4d7025401">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a394a3e5-51f5-46c1-8f15-2b72b5600dcf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc38de89-4e4b-487e-8e18-32cad06a2a94"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4bdb7d95-40ec-40f1-bed7-674c559bd12c">
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/18f0e624-4a52-4523-a16a-f278ba9f2dbd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
        <rdfs:label>APRT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/106fda10-a405-4266-83e2-68c614d2cf49">
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33965aae-aaf6-45eb-9e63-54aee58aec53">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4c0e452-bcc9-4246-904c-86a76b9297de">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ff1a090-e44a-437b-b15c-cc86346fd683"/>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7436bef-bd44-46cf-bef4-d160720362c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3fb65b7b-12e7-4bcb-a041-bd29bc062394"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a67215e2-01d3-4e39-b2bb-2c1c78ef4490">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <dc:identifier>HP:0010818</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82b51ada-93d4-4170-b565-eed5774bcaae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/41584cc8-2421-4f9a-9507-7b1a0443bc7d">
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9dd0e2e5-e16e-4d60-b556-5765061bca1c">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4d597d2a-95a2-4d2c-806c-01e7c23d459f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da23be51-3a9d-4f34-bae6-89cc4e7ef859">
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28127ec4-9cf9-4e9a-8625-e665c2e2fc60">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e5ab73e-7c5b-4347-86b9-27ca418dce27"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94755115-98f6-4dba-8180-6ea57caa4107">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/601ea546-63e7-4104-baf3-3cb2c2be36b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ff17079-185b-409c-9d48-d501ccfaaf53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c52d81c4-79df-4479-8bc0-a1cda7ab2e23"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2654ac1-0833-4ebd-af86-c8fcbd1e646f"/>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5140a666-6bfc-4968-a450-957ae3cee99a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/88f15feb-a3e7-4bc9-a259-6cedfabf89fb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/934c04f9-cbb1-4d9d-bf6a-a2db753348a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21db5658-30e9-4d1c-b502-2a96094db68d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e3d1ae2-fa07-4f84-a586-ad833a941778">
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af2d8e33-d81b-4730-acbd-f9c71c800488"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42bb02f1-8ea1-4030-947f-194e881e12ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d466f579-5df8-4858-8b49-7da29bf430d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb19894c-da52-488c-b501-2d71c6d8ab4c">
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/476f85db-957e-4103-9454-1f88b07d2d14">
        <rdfs:label>low muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d60850a-a3ab-45ed-bb56-38147ab9f41b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f20ba0b-ace6-478e-9223-9c52389a074a">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Epilepsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99ad1a32-a7e4-44fd-b3b0-9474ea405aae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a2c8b17-74f4-4b14-8152-c56f0e3e12aa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <dc:identifier>HP:0001285</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f37d0f1d-cb2f-412b-9d71-6edb474a6dba">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f359abb7-b26b-4cbf-89f9-e8b2c1b9577c">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/da5620d7-b485-458e-a038-a294d75edc3b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle weakness</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a863028-bee3-48d7-9a9e-4cedb09a187b"/>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79bbe318-a9bb-4e16-a77a-90995e63a470"/>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec7ac8d7-6a05-44be-bc1d-c1fe7f1d7c43"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77ee0e92-a910-434c-918f-c07afca5e32f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e3cc7c9-ccfd-4677-8598-d41631ec23cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a536af69-0491-4ef2-b99c-4901f215abb8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05759883-3817-4cec-ad45-935ea5a99bcc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40023f35-84f6-431a-a1df-f29a9c2bb87d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8eacd105-142d-44ff-ac64-9d8d42390754">
        <dc:identifier>HP:0001250*</dc:identifier>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46f52d32-e657-4c80-8f0c-8f48cea728c0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/475ae2d1-b763-4900-9537-460216badcf6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c64d1835-849f-42c7-86c1-c53323f54942"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/218e593e-6d45-4d4e-ad11-49e5bed38b5b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/078b9576-42ed-41b3-a71b-f5d14494ff1a">
        <rdfs:label>ABCD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/32a6281d-e988-4ed3-b029-ecb0ce705432">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91301828-e4a3-46d3-af7c-4906caf8e53a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a156be5-8e6f-45be-b531-6f1a1a3689a3"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca9ca021-feda-4deb-94c3-31593954f0ba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/494b5d87-a26b-41c6-a735-0011d7c73d6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eca4eac4-8810-4fd1-bf48-f421ac273d69">
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>Metabolic stress</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Developmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea1fc93-221a-412a-828e-b32aa32a8667">
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77ee0e92-a910-434c-918f-c07afca5e32f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64615a2c-02ef-45d1-828e-e359ac8dd32c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9f56d90-5a83-4df6-b5ba-7dcff8ee43a8">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28340e8f-0171-47e1-8e23-0845729a1341">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/807cb628-7632-4fd0-b858-599dbbfd44d2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e314f4f-ce8e-4739-882a-465b1e55f36b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11dc018f-0fc0-4b0e-ae79-f406c3ffe26a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa8f1ec2-5fc2-4337-8a8d-049a08c3a056">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e19aebbf-1afb-45e4-8187-fc64c7e99a36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f633c381-660e-4a29-a855-28bbb03ea047"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19cff33e-70e2-4d0c-bca3-b75f9d16d36e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0015748d-6038-43a5-9558-4fbedf78160f"/>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/5e3750c5-8616-46b8-a62a-a84b2e07fbba">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e19aebbf-1afb-45e4-8187-fc64c7e99a36"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36f736fc-9ac9-4944-9fc1-b34f4880bbc2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cff33e-70e2-4d0c-bca3-b75f9d16d36e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000009>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/dc371dcd-1dc5-466e-b913-9f3931824430">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69853395-b75c-4590-9d2e-34b38fc4ff3f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d47a1281-1412-46eb-abe3-47e0e7fa29ba"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/63e46bb5-197b-44d9-9262-1b4e3c4e4bf4"/>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77ee0e92-a910-434c-918f-c07afca5e32f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/351b4a8c-3c21-405c-9c54-a975c27dbbc1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/71e2db0f-c127-40f1-9788-ec18d2dddd44">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33f4f030-0b07-4855-8ade-888211832c32"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d1fdd82-7c7c-4050-94af-f956d707f872"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83d06fd9-71ea-4ff3-9bf9-7f3eae3bb9d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b8b3270-1f4c-40ad-83e4-d522a8bc1806">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2972dfec-5bc2-4bcd-b657-f5bf16c9bc61">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a6e0c4c-1c3e-4ac1-94a0-9e6e9589a64f">
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/85f5e716-2d33-451d-936f-a599a1ff73e5"/>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/17fe2643-f65f-442a-85eb-7499913fa4c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67f5d367-40fa-4384-ad7c-17cf7d033e9c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/210b0655-bdde-4652-b7b1-7d05a3a3eb06">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>High serum creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:DDIEM_0000012>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a074eff-ca97-44b4-bbc7-be457cf74a84">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4394775c-3105-4bdd-90a6-67c09b2fee35">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12649390-d7e8-405b-9e32-cf284fa6561d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
        <rdfs:label>PLA2G6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b53afa5e-e8e9-4d75-baf1-1d5960a945e1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82d049f9-31a1-4e9d-a054-41a71b85ebb3"/>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bafc20a9-9c5c-4b6a-9418-7f08a09ad41f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fb5bc71-32e8-4063-970f-316d9706a377"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8f3d98c-c10f-476a-acdd-0286f3042cf1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <rdfs:label>Dehydration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001944</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05b5008e-88dc-4d3c-b9de-ae2dcd9c7f9c">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94db4179-fa44-4350-98d4-b94c0bb9e847"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39a74059-4daf-473c-9ab2-f5eb444a133e">
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/63e46bb5-197b-44d9-9262-1b4e3c4e4bf4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
        <rdfs:label>MCCC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d47a1281-1412-46eb-abe3-47e0e7fa29ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bde3de91-d8a4-42c3-baae-a015d6554736">
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e356bb6d-7dce-411f-b3ff-2abb42f891c9">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/18e7c723-ed3a-4b64-b47c-ea19528d4161">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/750f1bee-ced8-4a05-b6b0-2f24d8fa6feb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d95bf5e0-a5c8-4106-8ddc-0bdd79946ba2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d54bc25-c6ab-4fdd-90e8-c24495615a0d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a440b48a-bddd-4b14-a2a4-c2716d03e093"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da311163-3ebb-4273-93af-1bf3ea365b77">
        <rdfs:label>Splenomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/108d0d01-c9ef-48fe-a176-cab9dc2c81ca">
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3ed4198-8f61-474c-bb8c-3b39866106df">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81bc2561-37cf-4547-b28c-dc5061458af8">
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66f7361e-41a6-4567-b7e8-a70024631b95">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96daf737-2b00-4ddf-8472-77f0b2ecb8bf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58b7bc57-dd4d-46c0-b4cf-c317441ff326">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0094ecfb-374c-43ac-a68e-8cf3612424d6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0dbb192e-67cb-4e0b-9c40-5758dee217df">
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8ecf17b-2c2c-4df6-8044-19bdb28c0a37">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f5cdab1-d325-4a1c-ad4a-bddcbb36ad45">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f014341a-77cc-411f-8538-3372cfe69923">
        <rdfs:label>GNA11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/05e5322f-8d2b-442e-84a5-7c091540fcc1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d389d5b5-4406-4b39-9ba1-f2cbfd5adf6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cdd5f256-4720-4d1d-ad6f-cedc6f6225b5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7f1caaf2-d2fa-4097-beda-93d894e10f34"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40f0ab57-82a2-42e1-b1d9-6a3149beee10"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41b0238a-8674-4b4a-b196-397c3362baeb"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab55a841-f54b-4561-9110-3303820022fb"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1de05da-b334-4a5f-ac4a-d80331636aee"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41caa02c-6715-42d1-9056-374460af9e79"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9779c90-26af-442a-9ead-e13453c05af8"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8bb0db0c-53fa-4f6f-959a-990089903d60"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4f7a35a-6acb-476f-9d01-2b94c7a2d6c1">
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db6dd881-c389-427b-9d97-073c689019ef">
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <dc:identifier>HP:0030890</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57f6b646-eb54-4300-906c-030d3a2c4360">
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/45a51d2b-aa80-4e90-80a0-e4745c02068d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7067f900-77f3-48a9-afba-bc2aacdb5ffa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44e51447-c581-4d65-a77c-693906396d30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89d57a52-a507-45f5-960b-51340b878bae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/17eff3f7-baf5-4394-bdcd-20a4bb1b9632">
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5624289f-324c-4818-9d6a-6b0d91132a8d">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b640314d-8703-4cd5-9401-090a39522ada">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3215ee73-23ea-4262-bcf1-dd389ad914ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c450a7ff-5a58-4ba2-a015-c343267071a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1257d94f-7671-43b4-914e-760a2e766f06"/>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/adf0850e-be51-41f5-a1ed-21d63aee936f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e22d8a3f-6098-4371-b83d-0edb8ff018db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4355403d-3ea8-403b-8cb0-dff8340cbb25">
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91c6c5ed-98cc-41dc-aacf-ef7c04dd68da">
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/372b491a-b469-4b58-b180-d16731971bf9">
        <rdfs:label>APOA5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad12df28-03f0-4746-b493-25cb4cad632a">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8d4524a-a5d9-499a-8208-7d0d06b1c785">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
        <rdfs:label>BCKDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9b83228-371e-4909-8640-d4bf5e72a0f6">
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/633f4fa6-5845-4cd5-9f18-7d215e71c2b4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ca07def4-87ed-4294-af2e-d4701341a398">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5736315-1d0e-407d-a8ef-344e5986d46f">
        <rdfs:label>Slow recovery</rdfs:label>
        <dc:identifier>HP:0012823*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/35e2d531-9108-4365-a5ad-4db602dfb567"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/74f39258-717c-4f0f-b777-6f7902cdf729">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/80d9f508-25c5-4f0d-bde0-03fcd901e345"/>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9712171-61f6-41ef-8f7f-8656e88b375b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a5ea39d-3d95-4fa0-a7b7-5b16b0cbae77"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b822f59f-4862-47e8-9ae7-1ad46c9df129">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47a2255e-04eb-40df-ab8a-eabef017c588"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7f11a7d-7e53-4da9-b912-fea1f52882a6">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b0d4652-3731-4acd-88b6-6d7bc8fa3fd3">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0f0ff96-ae66-46bf-b6ec-7759226f9957">
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cef3eb58-147d-409e-a1f6-69140914469a">
        <rdfs:label>ATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a7c7b7ac-aadf-4067-a9dc-966f0707938d">
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab61a3b3-9085-44de-9721-596390b08d80"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00d14dfd-2bea-424b-b9be-abd46359d5ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebf62dd6-233d-4cae-be30-ca154170abc7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/011da28d-ba83-4bc6-a5dc-4b71a91de658">
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/34ca1d12-904f-49ad-a6df-b14090a36a40"/>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/571bc535-0a73-42f8-8521-05989e5f07c9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/425d9905-5e3f-4b71-b2fb-b038d7086d6b">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Fukutin</rdfs:label>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/609c9d02-9f5f-438e-9dae-96d6b944a207">
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d59347a0-3266-4288-a17a-488fc7779577">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/401e17a1-af54-41f1-9bd8-cbcb5fdd6482">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04aedfd3-d90b-494c-b3f3-763f5d6e2e1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e27261f9-b746-4e0f-9d10-8e82fd59f654">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth abnormality</rdfs:label>
        <dc:identifier>HP:0001507</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb4c22b1-ea97-4c8a-b437-eb1041c515d6"/>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/895f0cdb-9a8b-4f4e-9d4a-dc53a34ad92e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56b82fb5-f3ce-4ad5-9543-7058c93162f0">
        <rdfs:label>ALPL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7500db7-c392-40c5-8630-361bb9d0325f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/208f6527-dfe7-43ee-8b3e-8250a100107c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e64ec0d9-c167-4a48-b125-b12385cc20e1">
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7436bef-bd44-46cf-bef4-d160720362c3"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85743731-1c3d-462f-a79b-5ab1e8b3c479"/>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/99da6d71-0e9f-4f2c-afb6-0b5e4d6469a0">
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac0592a9-e0a5-49b6-947c-3d1e4ea2e73e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b50bf73-7aaf-42f7-bf98-5d024363d157">
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <rdfs:label>battenin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab54e3f9-5e93-4b24-8743-f30ed7b8ff7a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b613074-899d-4adf-8ed3-b92370cd8787">
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8478918-0d5c-45b7-a5f3-aa8edf176ce4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8fb1b4c5-b836-4b02-af2c-46f496df0114">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3d8fb89a-5c20-4353-b202-be313f8d3260">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87397094-de71-4794-be2d-59c21496a7fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fb3199e-8163-4c03-8de7-352fce5967ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc7e3859-563e-4765-92c2-dfdd23bd8f1c">
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>social interaction defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e314f4f-ce8e-4739-882a-465b1e55f36b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5835b6fb-2ecf-4354-8fbb-9128c553020c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29824d69-0fd7-4398-9495-efd8b8255fd3">
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56fbd55d-01b9-4040-83f2-0e26c71488e3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec586026-bad2-455f-843c-91260c7f0e88">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65a59384-8030-443a-a1d2-d6d7d07ea39b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae06f21b-80f4-494f-8ad9-f0466e9f6b0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fad259bd-062c-4d3f-be23-0da0aaf5efb5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aba779cb-dc26-4753-a207-8b34504ed1fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bcd7f2db-bfcb-458d-87a6-d7a592c90d0c"/>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4b55c69-ce75-4afa-9246-e1701b163d04">
        <rdfs:label>MAN1B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/985be5cb-eee1-4179-8e27-e2334a0eaa10">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa81bdb6-53ab-46af-a657-81a9f67d4dda">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fa147134-6af9-4bff-896a-29f62b5f34de">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af19e374-dc22-412c-b157-d14170041e95">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low brain creatine phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bda1621f-70f2-4af9-a72c-e19f3ad519e5">
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cff33e-70e2-4d0c-bca3-b75f9d16d36e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19d96701-127f-4244-b6cd-1fcdc938e941">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e19aebbf-1afb-45e4-8187-fc64c7e99a36"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/284a58b1-3d32-4ad6-b3f3-7dcebb1df31a">
        <rdfs:label>low cerebral creatine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <dc:identifier>HP:0025051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f20ba0b-ace6-478e-9223-9c52389a074a"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e61f7c5-4a46-48ec-9b5e-a499d83a199e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <dc:identifier>HP:0011443</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/10246b75-97d2-4a0d-a4d2-99a23dab29fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d09d94b8-e4b7-48d5-9641-97d3f60fe433">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a8a099e-a045-4a86-b122-d231e7487c5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0538346-a3fa-4a70-9e6e-126d0d7399c9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0ddb4cc4-7e28-40d5-beb5-fe4b54928f40">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
        <rdfs:label>SLC37A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a50200c-3906-4aba-9e97-1013feec1c5e">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ebb29c1-61fe-456b-9284-1dd1668f33af">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc38de89-4e4b-487e-8e18-32cad06a2a94">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
        <rdfs:label>UMOD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <rdfs:label>uromodulin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/15f5c04d-a5cc-45d8-94bb-c3f7a196c5a3">
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d0ec76f4-c11d-4d88-80c6-0d107537d8b4"/>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9035cf54-06bd-447a-921f-58b77e04f0d7">
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/041d9a0a-60ae-4789-b33a-21e525049c2f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
        <rdfs:label>LRPPRC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1725adbe-e9c6-4d23-8cc7-5dc2dd91e6da">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62519325-810f-43ca-9f46-4bc065402c18">
        <rdfs:label>SLC6A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31a94039-9085-4702-9d0e-e53047af9293">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9e6c341-aac7-483a-971d-ddb4638ce57b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/32774f71-6917-4b09-86f6-06ef2a0041ab">
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b43df554-0024-45cf-91a6-dc6762b4e5cd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
        <rdfs:label>TFR2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin receptor 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2af1513a-8af3-4923-a770-699f5ce1ef9a">
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/372b491a-b469-4b58-b180-d16731971bf9"/>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0df1bdb7-1e02-4792-b2ba-45358aa66d56">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c322587b-744d-4826-95ac-b3c4ac083df9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05bfc3a9-6fda-4f43-9b29-3ee3a839d7ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/acaa7b2f-50c6-44f3-a080-c50fe9e8cffd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/505623f0-f63c-46c3-b9f2-ae58b0235be9"/>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bf768c5-77f6-4533-837b-795491d0fa44">
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0003530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f3af5795-e26a-4c12-87a7-441a92688ca7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9712171-61f6-41ef-8f7f-8656e88b375b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baa1564d-a05b-4606-9fde-0fd6f0fafb77">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7b1024e-67bf-4140-af38-f37b0ef5044d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5a23c4ae-ed40-4885-a437-c385928e33ed"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57ce22c4-f91f-4871-a545-028ab90d56d3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a36e8fb3-10f8-4f42-b2a3-e1bff2bf9243">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b72ae1b9-a10d-444d-9ea7-b3c8ce2a2bc2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71e2f2bf-01e5-4c05-9f4e-7e3fa73aa4d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f522e3f-b378-4de3-b14e-6aad20933e1b"/>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c9d3ee1-8c56-4ba7-95e1-1307ecd76b3a">
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f85bc2a-98d5-43c4-9838-fe38aff9b35e">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3077fabf-167b-46ff-abb7-1cf4f15b7788">
        <rdfs:label>OPA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6567375a-9192-4fcc-8def-e857f57115dc">
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a38d2776-cb09-43cb-8a21-334883c594dc">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e38fda0-ad9e-4fab-b066-3f19c790a2ed">
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5151a35a-e14d-4b6d-a4f1-60b3a5e6aff3">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/70a8bdf0-9c47-4f9e-a1a4-f5fd0eff336a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64d9e5b8-60d2-47ea-8c04-6033350e1897">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7460bcf-92d9-4f07-ba74-717101cd812b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60585f8e-fa82-4b0b-ba3f-ee3f914d3ca1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:label>Petechiae</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000967</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0023195-b2e1-4372-b5f6-bab886d68eb9">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc4ca39e-58e9-4799-8c21-8fbe08f44f09">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bafc5ca-d1a6-47e3-8859-423f6af3ec79">
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/792ceb15-ce9e-4e27-9332-50300a7d62ba">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85fc3fef-fada-4210-b684-be4d92801b2d">
        <rdfs:label>Chorea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1bf5404-5095-4301-80c8-123ea580e46b"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a94fecb-7933-42d6-b9fe-43f4094f9e04"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0bd0ad0a-7ef3-4445-9104-65098ca4cc46">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebf80f3c-d300-440c-ac81-79d789ba4d2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67b5c1b7-6666-4093-b60c-a2d2a114336c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0718ede9-ab2f-4fca-8249-c3eb88c4931e">
        <rdfs:label>Bradykinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <dc:identifier>HP:0002067</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce2a9144-6e72-4dd3-a7c6-d026ab504bda">
        <rdfs:label>Kinetic tremor</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030186</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85600bcd-0d73-40c9-86ef-553b5789350e">
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90a4f58e-8c3b-4843-b050-e4b9752bbce3">
        <rdfs:label>Postural tremor</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <dc:identifier>HP:0002174</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d9239df8-0172-4593-b631-80e71faf9a6c">
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/675104df-2a6c-4712-b2c0-edc933f9ef51">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7a3e8bc-99ac-447c-8efa-0a8ed41c70d2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e704855-951f-41cc-a509-58a386e6700d">
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c5c9da-764b-45ee-aa72-d64f587010cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cef3eb58-147d-409e-a1f6-69140914469a"/>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d348d8c0-6423-43d2-b058-35c18aee16a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81bc34db-dacf-4553-a21d-ab23570d80a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63e6a39f-9d8d-45cd-be6b-9c5d4c54b42c">
        <dc:identifier>HP:0040088</dc:identifier>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed698945-aa24-4cc3-91c0-253151fe56a8">
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/87f994f5-d9ab-48e0-a3b4-d78c33761645">
        <rdfs:label>CTNS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fad9618a-b813-40e3-add6-0bfacfe34bd8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
        <rdfs:label>PIGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/50b39d26-8f52-4b9a-93bb-6916c9aa79fb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6453a82-864a-4768-9356-ed44e11cc3d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f4aae54-6169-4817-8675-55710bdaa7e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/90144aff-adbc-426f-ae09-cfe8543cd0cf"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aa7c4f1-a891-48d7-8aa7-bbc11a9b8768">
        <rdfs:label>Muscle dystrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <dc:identifier>HP:0006785</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0d847f14-8392-4b3d-8cb3-1ee962367699">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c1ca0b2-9f9f-4344-b316-f910d6e25ada">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9cccb17-7431-428c-833f-e9405e4426a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40f8ffbe-3663-451a-85ba-35d34337a52e"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b35933d-a4ab-462b-8dae-38d493f6446c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/217521a2-f9ba-4be0-b1af-6c6de4323349"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9945337-6304-4fe1-bff5-148658c8248b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7bfe255b-9b12-4d19-aef1-21c244e7c3a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1b256e0b-f014-4d27-adb8-9814c3c8ff1a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664">
        <rdfs:label>Disease progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75cfa682-06a5-45b4-83b7-5ddb4178c95a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aff149d3-95eb-4229-b94b-6b22208c2bc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67f5d367-40fa-4384-ad7c-17cf7d033e9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05bfc3a9-6fda-4f43-9b29-3ee3a839d7ed"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff9368fd-555a-401e-8621-a0f2c33b1277">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eff97e68-8c24-4649-af1b-4d51fcef4cc9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <dc:identifier>HP:0000505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28127ec4-9cf9-4e9a-8625-e665c2e2fc60"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/879d60bb-29ec-4429-9868-9ecb2f3cb9e9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <dc:identifier>HP:0012638</dc:identifier>
        <rdfs:label>Muscular abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8fb1b4c5-b836-4b02-af2c-46f496df0114"/>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77c2112c-58e3-444f-baac-910b1d1d2975">
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f522e3f-b378-4de3-b14e-6aad20933e1b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
        <rdfs:label>TWNK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/590e26ed-4065-4afa-b75e-4c9be8ac9377">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
        <rdfs:label>POGLUT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19ca1b75-e866-4bff-8817-6f06b68643fb">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05491772-2264-4244-b4b9-07a5f035803f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d16b62c-83ba-47a4-b81f-ad092585f861"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa8bd664-09da-442b-87b5-77961423d049">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06b85780-34aa-4171-ba1c-5d54355a5834">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/922773c3-01eb-4f5a-ad36-561704af45c7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a2d0d39-666e-4efb-8a76-3791b65fe7ec"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e56531c9-de22-49e5-8eaa-0d4c6ff571a1">
        <rdfs:label>Sleep disturbance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41acc4aa-392c-4a5f-96e3-1a16966f89bf"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/057a2de2-797e-4965-bf54-2a79a2777841"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/df6587be-794f-477a-bf56-70965e0dcd56">
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05cc4c32-378d-461d-98bd-5562a95c81fd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3733df29-86c2-4739-8792-c6c5f64c9de2">
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3077fabf-167b-46ff-abb7-1cf4f15b7788"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73190c4b-315e-41e2-99b0-d000033842ca">
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14dec6cf-1fd3-47ce-9783-fb55553a2963">
        <rdfs:label>GNPTAB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9e80d286-2d3b-4f10-99f0-8b7c677f3d27">
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <dc:identifier>ECO:0001565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/74feb7ce-5f1b-4f5d-970d-8e43252c5d23"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50852027-a562-4b34-a769-b1e4c4e1d67e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <rdfs:label>brain atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012444</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f559847-6d10-4ed3-b770-e5ff6804c8db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4de899b3-a519-41f4-9e5e-5712320a0ad1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/293311d9-4214-4a51-bf0f-b1459c9017b8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/76841825-4ebd-4e53-9dd1-c4f156809a4f">
        <rdfs:label>ABCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/38fab753-8058-4fec-a855-e2b0486b2d6c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df268575-c308-4706-8307-a691fcfa4259">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/721c860c-937e-4c1e-8c60-181363664632">
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0a44c056-4386-497f-85f9-fb620b3ba110">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e08de331-891d-40ec-a8d3-9bb6c801652a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52368c01-9604-4cb2-a499-593ceacea017">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10c50e20-09bc-4aca-979d-a8c585fd9134"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd4f0b65-14fc-48b0-a366-b64495f12ee7"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1728b57-6a81-413c-9fa0-2a61ce65a553">
        <rdfs:label>LBR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7c2ed0ed-f036-461a-acba-dd2452739545">
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6693fe50-3be7-4609-83c9-4f604e6427dc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
        <rdfs:label>B3GALNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cfd3347-d6f0-4185-a916-7356b0d30da9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0ceba95b-2e28-4b8c-8561-c4a9283a3225">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
        <rdfs:label>LMNA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/831655ff-8e4d-48aa-b20a-91ef8fdd2e29">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da36c816-78c4-492c-ba78-4314a27e3f5e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <dc:identifier>HP:0025546</dc:identifier>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/209220af-4dba-459a-a264-e3f84508ef0d"/>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e581433-089a-4426-b08d-d0feee43f8d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025065</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91301828-e4a3-46d3-af7c-4906caf8e53a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/98f1c409-65d0-420e-b4b1-7b92a8dbca93">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b1ef0e-b558-43b5-8553-d6353b181487">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>low visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67dcd18b-17db-4da9-b63b-c36618a2342a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/551ac471-bcdc-42f6-a423-7968d4b78554">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <dc:identifier>HP:0011505</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cystoid macular edema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/40d0c528-a9e4-4c0f-a6ba-9ed0ab91ca73">
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5dd5adaa-9085-42ef-8571-c1effbb35ee7">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d2db1e89-b23d-4b82-b7a1-86f4ca7df22e">
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55467eb6-ee00-442f-afdf-97bf5272119a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/417c5202-26f8-450e-802e-8968cf9e5a4f">
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b031b7dd-635e-4e04-88c4-10cdd7052e16">
        <rdfs:label>HGD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9304a5dc-b64c-457e-b6e7-f21550c0dc43">
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98969b66-8edb-4659-a927-ed38fc1b890b">
        <rdfs:label>KCNJ1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6b0dc248-d91e-4281-82db-d641bd5bef3c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bce1ca25-8e30-45d3-baff-f18728868b34"/>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a5f3215-9a26-4142-82cb-5ed7f378e71c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b153f7e-e8f6-48fb-9cf3-03389dda1d22">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fd982d6-99a8-472a-97bb-cc08550c238c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>developmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13b67926-184b-402f-985a-804b8ae22608">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/110969e9-a150-4dcf-b2cf-60d671ed3085">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9db50618-e8a8-4d99-a9f0-f4b9865db0b0">
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a6725ce-6827-4994-beff-cfe2a580ff8b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
        <rdfs:label>POMT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5cc275f3-c1a1-4514-9baf-7ca139ca74a5">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3c02844-bc44-4f19-9c95-ccb9d37f74e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c5faff7-416c-4949-acd4-7b0134c2c660"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8430c159-9fd7-4997-832d-de69d823e879"/>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c01590e5-a1a6-4756-b71d-9402fd2af2d2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <rdfs:label>Difficulty walking</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2972dfec-5bc2-4bcd-b657-f5bf16c9bc61"/>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c786376b-3a43-4769-9009-59964a30e5f5">
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <rdfs:label>enolase 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1bf10f0e-ea20-4f6b-bf1a-69b7f9211ec4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
        <rdfs:label>ENO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01527b64-868b-4e22-8f1f-e9b5c3241e83">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d42bef3b-65d3-4f2e-9af6-eb5b9a4dbebd"/>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd1ca763-caf9-4502-bbbd-fcc06b16f61b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88487ef9-4cbd-42a0-87eb-4c1aff453894"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/193b9a91-b6e3-42c9-aaaa-74655df814b4">
        <dc:identifier>HP:0003657</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0fd045c-73bc-4966-963d-632e7f3b6d81">
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9e04255-da0a-4ad4-b77b-36ecd70a0844">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <dc:identifier>HP:0004372</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected alertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f003f20-4bff-4888-8ddf-4187569520bc">
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:label>irritability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86cff7d7-267f-45de-a852-7774f2d2d44f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1257d94f-7671-43b4-914e-760a2e766f06">
        <rdfs:label>SLC7A7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d88201a2-35bc-4498-a6b9-5268ece0acce">
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62c49c82-25b1-4ac3-a642-0599be86aba9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c6b295f-22d6-4018-99ad-f3b157b59628"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90d9574a-f00c-4f21-9c46-7b7cef3e8ab8">
        <dc:identifier>HP:0000939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <rdfs:label>Osteoporosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/984ac810-06e0-4d78-a5fd-182ea9e56db7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa8772c6-6261-4e3f-a2a7-7c269dfda600"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a29bd0ba-0784-468b-b78f-5728c5bf2109">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
        <rdfs:label>POMT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d73ec512-c552-4944-a1ca-c011f0ef54f7">
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71e1a425-302e-48c9-9c48-4cdd30e03ea9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24ddc6fa-4493-46ba-8f28-9ca5e02f561c">
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/590e26ed-4065-4afa-b75e-4c9be8ac9377"/>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98fc00ca-240a-4895-9436-93e13386d719">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
        <rdfs:label>KRT5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/94b46031-ddae-4faf-b1a0-be4d5cdc21cf">
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e7d5196f-d6ad-41fb-b90c-177f617b7af5">
        <rdfs:label>MANBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/528ac0fd-5c68-46bd-9f87-9d064f475589">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d98fce3-6b5c-4149-9567-670f140942cc">
        <rdfs:label>Dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05491772-2264-4244-b4b9-07a5f035803f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74ce1f98-dfb3-4a5e-b951-96ee1c4ecd57">
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <dc:identifier>HP:0000649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c16a2f9-a52d-41d0-81ae-236692c18fd3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <dc:identifier>HP:0006958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d8c41f-6a6b-46a1-850b-1b62abeaf083">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>Mental impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc414128-fac5-4243-a311-84a6af7228cc">
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c01590e5-a1a6-4756-b71d-9402fd2af2d2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d16b62c-83ba-47a4-b81f-ad092585f861"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/874b32e1-1cba-4560-b2a9-3293d1eda701">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Emotional lability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f6b8ced-3f74-46bb-9b45-8e2476d64b55">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f4b5691-bb06-402d-b9ea-cfcdc8ee3749">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16bf1c28-9ed2-45c1-93c7-fe147be27876">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1d92d93-00d1-4ff1-853d-5ded33cc6b7a">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a3bb4c7e-448e-4f60-91e3-cc66d1ff252e">
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73c56702-c133-411a-9d91-510e02b1fa9f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1fa161b1-5057-49c1-9361-bec9e2ce86d7">
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e4321e7-a14d-4ab0-a03d-5a5a6afa3713">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82655f20-bec0-47ac-ad14-b3cee6799db7">
        <rdfs:label>RXYLT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fbf61c1e-f2cc-490d-b48b-6e505d4bd5cc">
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a8e94db-2c6c-4664-8d2a-97c76ffc78f5">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a2b546a-149b-4bbf-8bb8-804c805f1d34">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e60d113-a60f-4253-9884-2aaeb033594d">
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/866b50e3-dfc7-4896-8d95-f27710221237">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d811bbb0-f38b-46eb-af5c-c00197fd0299">
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Dysphagia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c01590e5-a1a6-4756-b71d-9402fd2af2d2"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67f5d367-40fa-4384-ad7c-17cf7d033e9c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/379ba428-3c42-4579-bbf3-febcd983d319">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/223a17e6-55d8-4178-8b7e-548c5476cfe0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/261310f0-a5ac-4be3-b49c-1c6c0c735b1f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1eaaeba5-071e-44df-979d-6efcc49e69e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73c56702-c133-411a-9d91-510e02b1fa9f"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/258ed3aa-fe9b-4ca3-97df-b60b5b3869c4">
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8fbc13a-bd7c-4a86-8446-9af0e70625d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
        <rdfs:label>QDPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3941bc3f-6fc8-464a-a120-b86e57827d69">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dec06607-3029-4c93-b644-1a64fdc53fb0">
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <dc:identifier>HP:0001896</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aff88abf-9922-40e7-8947-1b462015c715"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d1c6eab-c016-4dfd-bab0-05e24a4bc0e9">
        <rdfs:label>low Hb level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/383c92c8-2d49-48c4-b1ff-a33459c8a25d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c36a3dd-3424-45d9-98c1-665a7ca4fb0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06de2649-1b40-4271-8909-ff848832d04a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51090685-60dd-4a34-8fd6-265fbcff9a5f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b9176d23-5aa8-4395-8d09-7d11be06e623"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75e76540-05bf-45a2-bf94-fad22c1765e4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/665abd1a-b931-4072-8089-991940e5e6cd"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8443e887-de6b-4c60-9d89-24608f1cb8c2"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e832947-a242-4d41-a766-02e70a8f758e"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e3fc55d6-ccfc-4c6c-af8e-50dc4ed02d2e"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a275930f-cdc7-44ca-9df2-56081ca20308"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83e87bc4-3121-465f-8b90-617f2cc7b8df"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4dcaadb-4819-415f-b838-763568704b8b"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc89cfb6-76d3-4b0b-bf87-bcf42a3666e5">
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85f9abf8-141f-42d8-ba7d-13dc0e9c67b1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
        <rdfs:label>PGM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c6089da6-c96a-4b34-8c2d-39b2c7f54566">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85743731-1c3d-462f-a79b-5ab1e8b3c479">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
        <rdfs:label>DPYD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/379b63b7-49ff-4c31-8f00-a2bc34eab994">
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6bd1115f-080d-4fa0-a813-d59e76104262">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
        <rdfs:label>TF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <rdfs:label>transferrin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf46c6cf-754a-42c8-8016-c5ab79d5e3a4">
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a96034e9-91ba-474e-a8ab-c50b5c92844d">
        <rdfs:label>SLC2A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30705b63-56db-416a-8603-c23296280250">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd8d2db8-fec6-405c-8071-5614f945cb92">
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d57c20c-0126-4afe-840f-66c3cb9bfc4a">
        <rdfs:label>ACAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fffe5669-6287-4510-bc51-38b9998d0fe1">
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4441d141-8e00-4fe4-b748-55165efc2063">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7d0f968-41a6-4d2e-b694-e2b9d8bb6f36">
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0015748d-6038-43a5-9558-4fbedf78160f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8711d261-61bc-4cc8-9e90-3b1da9c14b64">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1aae0655-746e-4cfd-a2ee-6be462884e0f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dcfce55-1979-4389-894e-9fa699597a6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7670644a-8874-4f23-bf91-e300afdff16b"/>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67e4beb6-650b-4a20-8897-1d58b0901d98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33ca4878-81f2-4004-b022-a4c3057c3d1c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9187f28-6372-476e-bd79-e34a01450759">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:label>Learning impairment</rdfs:label>
        <dc:identifier>HP:0001328</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73ac3987-6e63-4bba-bbeb-1f117dc544a8">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive imapirment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d742a0-980b-4522-a056-6c4b370d1361">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c48bfacb-a852-4d3f-9b2a-254c2ce42b37">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:label>Memory impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0d6c727-89d8-4eae-84b0-fd45f89af12b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/442e8174-8a4e-495d-871d-44e87fbe2b8c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e280503a-1777-4069-9dcd-050f5f6fbf28">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/251a55cc-7d9f-42e2-aabb-0cf33f1b8144">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c568bc44-4fd8-4f0a-b9ba-ed941781d0e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6d911d5-25c3-48e1-bfef-5f495b20651d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>xanthomas</rdfs:label>
        <dc:identifier>HP:0000991</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09a581e6-3993-45f3-b555-06414a6329a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <rdfs:label>angina pectoris</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001681</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f9620d4-3fdd-45b0-a2f7-95ba6f874385">
        <dc:identifier>HP:0001677</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a49d913-b628-4648-98f7-9f984c492ccf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8bdaf66-0c67-4eb4-850a-45f4e626f324"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86894eab-e52a-4135-a918-b95b59b6d012">
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89616262-d6c0-429b-9c28-8b2ab0f54ab5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
        <rdfs:label>ANKH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77099bdc-d811-402d-800e-e8c8ee6f5e29">
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82d049f9-31a1-4e9d-a054-41a71b85ebb3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
        <rdfs:label>SLC5A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9f35fcc-3fdf-4a27-a61f-5f873ba46b5d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/625da948-4836-4256-a281-719173f71856">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9de0575d-4613-4b7f-92c6-5d36b5cd7572">
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5a8ba973-c399-421a-8a4c-f928beafd335">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa808552-e9da-49f0-9d1c-f3f69490bd7d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa36b9b2-7600-4b5a-946f-4c531e8460a3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2654ac1-0833-4ebd-af86-c8fcbd1e646f">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79871f1a-8d82-4768-9c2d-33be8542409d">
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0200ee3e-551d-480c-ab0c-389eb840bb9b">
        <rdfs:label>SUGCT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bdfdb569-a184-47b8-827a-733fb74d2d10">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6453a82-864a-4768-9356-ed44e11cc3d7"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a29bd0ba-0784-468b-b78f-5728c5bf2109"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aa7c4f1-a891-48d7-8aa7-bbc11a9b8768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88de7bf2-72af-4f0d-91a5-557cdb589d97">
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/486d1a9a-0c13-4a28-9edc-9ae31cb1eb1c">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae893e76-1a8c-4a7b-988d-5c09f6f98713">
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/351cf9d7-ea4a-49de-8cd2-8a061b985469">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
        <rdfs:label>MVK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/88d55b61-0fb1-4634-85f4-f2074de843ac">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91e6ff59-2ea3-4194-b1af-c6989f5888b6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86ef87af-042b-4b9c-8811-74fa513b7b81">
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19c346b5-84de-4e37-92e6-a7751d8b1b78">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29b6cc8b-d439-4f81-b3e9-64c3d8fa7cea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2833bcfc-e935-461b-bbfd-dddfb5a43d43"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/997cc391-9b40-4cb0-8a1a-4c7438a1116d">
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5a074eff-ca97-44b4-bbc7-be457cf74a84"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8da888f-129d-411c-9f84-9606179f9032">
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8877aae-e2c3-4014-8aee-b66656e00232">
        <rdfs:label>ATP7A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/987ada16-8fb7-494d-9f2e-fb715d4f81a7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05b1a277-ddd4-4712-b914-5577d12b7bd3">
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <rdfs:label>lethargy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5903d6b4-3361-4078-a25d-f0287d08ad82">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <dc:identifier>HP:0004337*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb32fdd6-07a9-4f50-bf50-e3236e166327">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5003094c-da39-492d-99a3-7ae98da9e14e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Poor growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7413c858-a08b-4497-a7f7-8517b788f7e4"/>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de1db207-a2cf-4c44-9c54-003048f60fab">
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27fccc54-79bf-4d06-85f6-62de15a43a7c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d66451e-b7ce-47b8-944b-d87246376f9d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f284280-126d-40dc-bc92-4ea3408352ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e81aa05d-86b4-4836-ade8-a59cc79bd571">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e633a977-2ec9-4984-a5d9-cbd9fead5029">
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/da321f11-f29e-439b-9e0c-0a294b480ea0">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2540f97b-ff6e-46d4-b64d-8d015031376a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0870e9a6-3fee-472e-9ed4-38f4cdd896a5">
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e7f009c-f0c1-41a1-b4b3-cba0c488138e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24dfb7b7-915a-432a-8915-616a7ad133ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88b701fe-bf30-4aa0-9694-4bef8acdcb8e">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8fb1b4c5-b836-4b02-af2c-46f496df0114"/>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <rdfs:label>Sar1b protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b75bbbca-f58f-4f9a-baec-bd8ab53d9998">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5624289f-324c-4818-9d6a-6b0d91132a8d"/>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7dd2f562-77b3-4a5d-bfa0-7a377916f4f0">
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb5e5a6a-808f-404a-b442-021ae939330d">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a67afbda-7117-41f8-a97f-1ba1a926a2c1">
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c2931cf2-483b-4cf3-b293-18e2649bddb8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28f9e5ec-0d7c-48e5-a503-3ef6f5c0be92">
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9bb2cf74-7236-42d2-8e06-80c40a832f22"/>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a38d2776-cb09-43cb-8a21-334883c594dc"/>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0f705f8-f209-49ee-a6c9-6548d345849a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/65962b9f-c70c-4b0d-9fa8-d7c9cea6853a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
        <rdfs:label>PRPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <dc:date>4.10.19</dc:date>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3795d7cf-45e5-4a15-8042-05dadc0f7ea7">
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8430c159-9fd7-4997-832d-de69d823e879">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
        <rdfs:label>DNA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/44bd082d-ad3a-42c3-b541-a761ddd77b35">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0edfe420-fdab-40fb-adfc-7257ceca0a63">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8cd9089-63a3-45ca-89a5-0731ab1eb7ec"/>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7436bef-bd44-46cf-bef4-d160720362c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/476b928a-f91c-4d5f-9f86-35f467933f51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa6267d6-44ba-4b24-952b-12dc4bba598f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aacf4d21-bcb2-4116-a4a6-b4e1cbdc02e3">
        <dc:identifier>HP:0001943*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2f7afca9-3ccc-45d1-a8ec-549641dbf526">
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72c4ab67-0b6f-4efa-b276-11eca0ad40dc">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51a94444-5242-48f2-8bb4-087bb5436c37">
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b8fbc13a-bd7c-4a86-8446-9af0e70625d6"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de6084c6-bd47-4215-ba6e-82a7cab675fb">
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/685aea18-5f42-466e-9bdf-6e7c66679579">
        <rdfs:label>OCRL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/963dcaec-fe2a-4af4-bc28-1fc0e9ecfaa5">
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/026c8ec5-211e-43ff-8dd2-7bbc62220c8e">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:date>3.10.19</dc:date>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/11d5ab15-3050-4320-b512-4304da846e86">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6ee4370-522a-4448-85c7-8aa883f81961">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/abca3fb1-76ba-4c69-8ab1-80c7fadb334c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9e98f39-8898-436b-a22a-5b38a6ed6dea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb6129ec-c7f3-4e84-adad-a41cec16ebce">
        <rdfs:label>Hyperglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe9cb648-b62b-4cd0-b974-43a847ead557">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad621d03-be60-49fb-98f5-67c98919a3f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f28a726-c0a2-475e-bd5b-ee661fb20955">
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fbb6a0e-774b-44fe-99a8-b944fb71ea69">
        <rdfs:label>FXN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c2391455-6fee-4a05-a05e-f1042b535b35">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e1085a4-b99b-4dc0-86e2-f0e6c9078635">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67a61688-547d-4b4e-bdce-de1851bd85ea">
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b95c234-c7a3-4e97-906f-9d776c8792f9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b2fdbab-e7da-470c-9beb-fd6f1296b2db">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1326ae86-74fa-431c-b1fb-233ca3a3e1e0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <rdfs:label>codanin 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2e45305-270f-46f0-8313-12dc15838e94">
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/30705b63-56db-416a-8603-c23296280250"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/be0822f4-e887-4774-92cb-1e5c54a7fef5">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd0f4c2f-81c7-4f0e-baaf-df93441f5ac4"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b29e75cd-25f0-480e-9474-552d0fcaa4ac">
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a059549c-d1a3-496a-b2b7-1437276dc5b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a076f20c-3f73-43da-9fcf-2f80b4d84d49">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3d2871c3-8895-4f07-9402-d51fb3f5e35f">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c509aa1-583d-4f87-be3e-880b19a4771a">
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/700c28e1-af03-416c-b573-eaef22903269">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
        <rdfs:label>POMGNT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9763717c-af06-40bd-a897-fe659347eb3f">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/940a2203-f6a3-41fe-ac20-c4756d0890d9"/>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d348d8c0-6423-43d2-b058-35c18aee16a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f41aff2f-01aa-4458-8392-3bee70d5fee2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/832cb235-9e48-4e8c-a989-4233a41560d8">
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b31da116-39c7-4788-93cc-f262bab197ac">
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <rdfs:label>anoctamin 5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c38ad995-398d-43e9-a108-2d7cba2f8293">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
        <rdfs:label>ANO5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ee5d996-924f-4d1e-99c9-68bc32c6ca64">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64615a2c-02ef-45d1-828e-e359ac8dd32c">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/06a83ea1-5d4d-4ab3-bce9-6f77f80fe94d">
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64636607-3c32-4404-9325-8b4ab6d75965">
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54d00604-c14d-4325-8c53-fd9336a02312">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64f4f5dc-8357-4eda-a185-60bf00adea89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f52279b6-a407-40fe-a452-c04972c9261c">
        <rdfs:label>DNAJC5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3c36744-16f0-4d3b-b97f-8866fa780042">
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <rdfs:label>acid ceramidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d65a25f-c841-4672-93eb-1fdb15c6aa16">
        <rdfs:label>ASAH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/159c1d05-d207-4914-8fcd-0ab0b878d4b7">
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7691bcf1-f0fd-47b8-82ab-f9af08e7dd6b">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03bbb8c9-99cf-42ec-9817-1ee26ed18824">
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8a50200c-3906-4aba-9e97-1013feec1c5e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a011d56b-ae49-4057-836a-8a0fcb96b864">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af749e94-69bb-400d-8a56-2242baf6cc96">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <rdfs:label>calpain 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b258521c-7e17-496d-8a89-6f14a8f40052">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0487e46e-832a-4030-97ac-abcd7ba83dc9">
        <rdfs:label>ACADSB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/980c3ca9-c535-4fd9-92d6-d88b86540b03">
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ce05822-467c-4c28-9ecd-602120f04f49">
        <rdfs:label>FKRP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c5c6b74-bc82-4dc6-b145-e6235714dc88">
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9bd6263b-73da-4827-94c3-fe5f7b0879d1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
        <rdfs:label>CUBN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/99e7cf1b-9818-4c7c-bf40-8df7c84cafb1">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/59a73bbe-16d8-4b31-90b0-ecbae0dfbbb8">
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71da8695-8ab3-4fda-aa45-9b6ef9a9948f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
        <rdfs:label>SLC39A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8404c4f-c96a-4d98-9a18-9fb568fec402">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43ff2654-6269-4249-b177-ccf2e43c6b99">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
        <rdfs:label>MAT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4104585f-bb9c-47ab-ac6b-a53d2a67e86a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11b464b9-04f4-402f-8b3d-ec96fa669e5a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/40f8ffbe-3663-451a-85ba-35d34337a52e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c58379cb-ce58-4bc3-a63d-122164b40ab8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3209b8ab-6a60-41e6-a574-33213ac622b8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61080a7d-132e-4292-b228-164981e769c8">
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d4b55c69-ce75-4afa-9246-e1701b163d04"/>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be2a42a8-4d8f-49dd-9c96-87f49d200e24">
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45320a68-487e-4b9a-be75-cc3d530513a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <dc:identifier>HP:0002664</dc:identifier>
        <rdfs:label>neoplastic growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b0596f6-ad4e-4d72-93a6-8fe9a0401afc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a21ef6a-f7c5-45bb-970a-c042ce9d332e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee9107a4-b5a4-42f5-b094-4cb0f173c6e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f4ae5db-3de3-456f-9c22-4722f0f7e985"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2fae89b9-c13f-43c8-a10e-2d04d3d2c052"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89b8a5c1-f42b-4381-aa76-51bc9bfc23d2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8d7821d9-aca9-4a8e-80fe-4c42b875409b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1de556a-fc98-4e1e-aaf1-58b97b4fc5cd">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fad9618a-b813-40e3-add6-0bfacfe34bd8"/>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec4c7afc-4a52-42ad-a7db-958133f84cc4">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1eb68d4c-7b36-47d3-bfce-afd609881f83">
        <rdfs:label>GIF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/909a7823-5396-4181-923b-92fd67763145">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/275c144e-c261-4559-a3c9-6786c8170354">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ADCK3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/34d8d6f0-b075-4cc9-9fb5-3b2b537aad85">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d1c6eab-c016-4dfd-bab0-05e24a4bc0e9"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c78b0678-b2af-436c-aff4-e906b4f9e28e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9579314d-5c80-434c-9dbe-29c31a171bb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/63ab764e-be72-4408-bd4b-a14d291b2e73">
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb4c22b1-ea97-4c8a-b437-eb1041c515d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
        <rdfs:label>ACAD8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a6c95fd0-fa61-4c1b-9793-c1866ae8244a">
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bce0e1a6-b973-4b00-a302-231eb31d6cd6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/848a311c-5df0-4720-83ed-35e181411567">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/05482037-dfac-44a3-a678-a39ebb6cb94f"/>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2ecdebc8-6981-4095-acf7-feb2f1e08bd7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5409780f-035c-457d-abf9-95260a592c4a">
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/84bede05-2189-485b-bf73-0441204e7652">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea42855c-582b-4687-bff7-aca2f6e83c34">
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1913c309-412a-4c84-a31c-4289d2395860">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4492024-84ae-4f89-8e8d-8291d958da55">
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f52279b6-a407-40fe-a452-c04972c9261c"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1475712a-ef8e-46c5-9456-a4a24ca1dd86">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/abb728e5-3bc4-4a97-9d2e-570d5bafb48c">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed2df585-c5ab-4548-a389-71d066893d0b">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ff1a090-e44a-437b-b15c-cc86346fd683">
        <rdfs:label>AASS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe049d85-1368-490b-9a2e-654e860d8b74">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a29bd0ba-0784-468b-b78f-5728c5bf2109"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14dec6cf-1fd3-47ce-9783-fb55553a2963"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6dbd43c9-b8e0-498d-be61-41c21ea1e8e9">
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ada9f282-7979-4faa-bbc8-2834b3cf2062">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
        <rdfs:label>GLA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad621d03-be60-49fb-98f5-67c98919a3f7"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d173dea9-39d9-422f-b5d7-8ec41fec30d1">
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <rdfs:label>dolichol kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4bb81a2-5472-4235-abe0-be565e627f86">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc3a3c71-ecb5-400e-8292-d25302caefe3">
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/223a17e6-55d8-4178-8b7e-548c5476cfe0">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a745557a-9ec9-48f0-9a5e-63abeeb0f690">
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/401e17a1-af54-41f1-9bd8-cbcb5fdd6482"/>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
    <rdfs:label>Ribonuclease H1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1000d3d8-a2bf-4468-805d-82c479ff3d0a">
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a99e91a9-b4d2-492f-b11a-1145c526e644">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a25174f3-e632-4cfa-b526-07cd1ba5adbe">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6b0d4652-3731-4acd-88b6-6d7bc8fa3fd3"/>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47636af0-cfc3-4f8b-87d9-7b6bbb543177">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/505623f0-f63c-46c3-b9f2-ae58b0235be9">
        <rdfs:label>GCDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/be58f20f-18ec-44da-b648-07650f8fedd7">
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4a78621-4c63-4ea0-84bb-5c54124df374">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
        <rdfs:label>DPM3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b013a546-5954-49a4-9d6d-008f5c4cdb11">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91684b4b-dcef-4331-aac4-af091082e2cc">
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9f522e3f-b378-4de3-b14e-6aad20933e1b"/>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d9c26f37-dd00-46ae-9c21-95c7c28129c4">
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/947f9074-b02f-4ee9-8406-f79435787dca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
        <rdfs:label>BCS1L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a932f802-bca5-4cb0-a080-33215898f346">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64551097-69b9-47a8-9854-e602e18c34f7">
        <rdfs:label>Study is still recruiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/062e0c5b-9296-4b4d-b7b2-1192a07b0bf0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62bc0fe3-d088-43c1-8e90-2b5f71f73da0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b452f14d-bb25-4dba-94cf-69305f4c844d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b942473-0658-4ee7-8af3-435d9b8a8979">
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc022c13-dcc5-4bbc-8c64-63386b86c26c">
        <rdfs:label>AGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cda74fcd-56f8-4d95-92b2-028dad898a0e">
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67d7efec-fee3-48f4-b15b-cf9d1c00f186">
        <rdfs:label>CBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a803133-40c9-4077-8d8e-4845bf5e4695">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a8cb0000-f3f7-4e12-bafe-6b49df4265d1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
        <rdfs:label>DBT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6d700f38-0bfc-49df-aef8-6f75d77e780c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6956be7-d355-4211-9c02-20b0e3246b01">
        <rdfs:label>AP2S1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12fd63ed-63fd-45b4-8088-7bc1f6ef344b">
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6f134e3-ae3a-4eea-8cf2-8828c0237875">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0ec76f4-c11d-4d88-80c6-0d107537d8b4"/>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7098bcac-06e6-41b6-b966-378859661872">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/40f0ab57-82a2-42e1-b1d9-6a3149beee10">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b67d725a-3e3b-4c5b-a6c1-d0ed43b95bb1">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41caa02c-6715-42d1-9056-374460af9e79">
        <rdfs:label>MT-ND6</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9779c90-26af-442a-9ead-e13453c05af8">
        <rdfs:label>MTTC</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8bb0db0c-53fa-4f6f-959a-990089903d60">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab55a841-f54b-4561-9110-3303820022fb">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1de05da-b334-4a5f-ac4a-d80331636aee">
        <rdfs:label>MT-TL1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cdd5f256-4720-4d1d-ad6f-cedc6f6225b5">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
        <rdfs:label>MT-ND5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7f1caaf2-d2fa-4097-beda-93d894e10f34">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
        <rdfs:label>MT-TS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41b0238a-8674-4b4a-b196-397c3362baeb">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
        <rdfs:label>MT-TQ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/56301ae7-caca-4ad0-baaa-16ebe863cecc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0870e9a6-3fee-472e-9ed4-38f4cdd896a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/929444d9-d785-43e4-9bd2-41d1fd165d17">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:label>High serum  prolactin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56433e61-b0ee-4576-9538-0566d67dbc35">
        <dc:identifier>HP:0010893</dc:identifier>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94755115-98f6-4dba-8180-6ea57caa4107"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
  </obo:DDIEM_0000009>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0925c1e4-bfe5-4434-8030-93ee51349e9a">
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/74feb7ce-5f1b-4f5d-970d-8e43252c5d23">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1df6bd19-a7df-41bc-8e31-4cc0d73fb18d">
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46f52d32-e657-4c80-8f0c-8f48cea728c0">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7e3e7ae-b4da-46d9-b968-e31459e7ccfb">
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/269f0de0-7a9e-42fe-a141-b042b8bfba62">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/810b3e6d-2dc6-4d24-afb2-221987a3612c">
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/db307552-71aa-4d32-96c1-b96abe034901">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
        <rdfs:label>GATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c39e7c84-2e69-4d69-ac85-4f50cb3752a4">
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2fae89b9-c13f-43c8-a10e-2d04d3d2c052">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8a2c6a0-b310-47ef-974a-3fdf0ba56965">
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/07084c47-6ab1-4e9c-ab0f-b3277b31adae">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/262066ae-2997-4b1f-a970-1e8d4239dd1a">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c8f5c02-eda3-43ed-ae02-ee2003b342a4">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62519325-810f-43ca-9f46-4bc065402c18"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9e6c341-aac7-483a-971d-ddb4638ce57b"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/16ad306c-fea1-42f6-bee4-b68a17c05bbc">
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30e58355-aef7-447b-af75-c2b02a918171">
        <rdfs:label>DARS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc28058a-cacf-4722-aad7-b6a49210d2cc">
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bcd7f2db-bfcb-458d-87a6-d7a592c90d0c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3eee3133-1456-409c-8ee4-f7a8fd200f49">
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb"/>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/93116a26-c803-4976-9ca2-cf9b26e7bd3b">
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe10d771-2894-45e2-9228-5112102db4b6">
        <rdfs:label>PAH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/acb380c0-c959-4beb-989a-f5ed029c15a9">
    <rdfs:label>glutathione synthetase</rdfs:label>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/594918e0-0ab7-4523-a7d9-3db4e71e0fa5">
        <rdfs:label>GSS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd63441a-855a-485b-bb1c-fb6929a1954c">
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1bb2259e-8325-4346-9604-f068d958a735">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
        <rdfs:label>PNPO</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79b5442e-fe59-4bea-b9a3-e3422fa01ffe">
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b452f14d-bb25-4dba-94cf-69305f4c844d"/>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b033ec78-eecd-4539-8ae2-1ab001a5e4ac">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aa7c4f1-a891-48d7-8aa7-bbc11a9b8768"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ce05822-467c-4c28-9ecd-602120f04f49"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6453a82-864a-4768-9356-ed44e11cc3d7"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb773654-4f38-4884-86c0-5269414ee25f">
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af2d8e33-d81b-4730-acbd-f9c71c800488">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
        <rdfs:label>APOE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <rdfs:label>apolipoprotein E</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1851ac9-ac03-4dbd-a65c-a08544fd2d27">
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c803b9a-7385-4ca5-a40a-9dc527c07034">
        <rdfs:label>APOB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/145586b8-30fd-4b80-a425-7c301173b01e">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f4fad9f-bcec-4d22-823e-3ee0e7cba736">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
        <rdfs:label>BCKDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52a5be39-2d03-42e5-a1b6-92ee0542d73a">
        <rdfs:label>DAG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8a9754a7-8a43-4742-9411-4ef0c8ecf105">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e4297cd-ec69-422e-89f1-ea0013e042e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac668e77-caa5-494a-9131-3bd26810620f">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41acc4aa-392c-4a5f-96e3-1a16966f89bf"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0ddb4cc4-7e28-40d5-beb5-fe4b54928f40"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a2d0d39-666e-4efb-8a76-3791b65fe7ec"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8147c21-553a-48ff-96a0-7ba9344735c5">
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/020f294b-e824-4cb4-9bc5-c0321b0f7610">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2126b5ec-e457-4bdb-a501-969bbd312ef4"/>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7fe4d343-79a5-4c21-af89-ef2f9a3c2a92">
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82bb6101-f1cf-45af-80b6-741359c77b5b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
        <rdfs:label>DNAJC19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b21f31a4-dc3d-4211-b320-8d2140c768e1">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7ce05822-467c-4c28-9ecd-602120f04f49"/>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb5be74b-788f-4963-8904-3688fe11e7f7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ff590d8-9e39-4f31-a699-2fe888ae2971">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
        <rdfs:label>GLUD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79cd9d5e-6e40-4ded-a1fe-57cc6dcbdf3c">
        <rdfs:label>LDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf396141-abf5-4fb0-966f-a3ebe607950b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ac0592a9-e0a5-49b6-947c-3d1e4ea2e73e"/>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e52c0f6f-bce1-4a2c-84b7-fee823556ba9">
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64d0ebf7-1eae-41c9-9224-ca52ad96896a">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7890fdb-88ee-4e91-985d-7beb2cea8e0a">
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/89b8a5c1-f42b-4381-aa76-51bc9bfc23d2"/>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb556bd7-9280-40e0-bdea-225e74036fe6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8068180-8b11-4c7f-81e0-bfde78b56d71">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a392feff-82d8-4f68-8d4b-e64400259b32">
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5a23c4ae-ed40-4885-a437-c385928e33ed"/>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f359abb7-b26b-4cbf-89f9-e8b2c1b9577c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e4321e7-a14d-4ab0-a03d-5a5a6afa3713"/>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/519dd0d8-834c-414b-a48c-c8146ce8e59e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a156be5-8e6f-45be-b531-6f1a1a3689a3">
        <rdfs:label>FTCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c8478918-0d5c-45b7-a5f3-aa8edf176ce4"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/305aa151-257d-4a13-ad37-4ffad1a6f960">
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3209b8ab-6a60-41e6-a574-33213ac622b8"/>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a40428a8-57e5-491c-8135-2a0cae4ebcac">
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ed7e87d0-6861-4a79-a57c-b7e70ce79d0f">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/69151f7b-390d-4809-9995-430b39342f99">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd4f0b65-14fc-48b0-a366-b64495f12ee7">
        <rdfs:label>SGCG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/90b34c65-0bff-4569-81d0-547c954e3d18">
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6b587e3-1990-480e-af2c-63fd8c3992f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
        <rdfs:label>FUCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a28f50d1-677f-4da8-90f0-d6083a331b4f">
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/93dd36f6-8750-4a0a-af27-0de57644658e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
        <rdfs:label>HMBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75d92bf2-4fe8-4dc6-854d-75129b36e111">
        <rdfs:label>LDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dba4ba66-1d6c-4d7e-bdd8-4e8c83c08517">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a9e9e6a-3843-4119-a027-7e54720bb9d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c29c9433-6e99-4e48-8be5-a1e561d4b05e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/652ca187-552c-4218-9aab-8042aea84e0c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08a1ffc4-5544-4360-bacd-8a331933b3c6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4bb81a2-5472-4235-abe0-be565e627f86"/>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a1a5fcc3-6419-45fd-96a8-0b652612a1f0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bce1ca25-8e30-45d3-baff-f18728868b34">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
        <rdfs:label>SLC25A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bde2058d-1367-445e-9575-c86b19ffbaec">
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05072add-8c87-48c3-bd65-5fdf632b1906">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
        <rdfs:label>FA2H</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/17d73130-baa0-4449-b2b5-bd8e28c30428">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7dae6ee-444b-4f12-b7ff-0b5ce8a12e83">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b427f099-62ee-4861-8adc-417f2bf462ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad259bd-062c-4d3f-be23-0da0aaf5efb5"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ff590d8-9e39-4f31-a699-2fe888ae2971"/>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0987d636-ff1b-4049-b778-75ff0f37030d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e392336-7f53-4dbd-973f-b297fd293d6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b903fdf4-9aa3-43b5-9eb7-59ec7e719e7d">
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab61a3b3-9085-44de-9721-596390b08d80">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e7d5196f-d6ad-41fb-b90c-177f617b7af5"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56a678da-73af-4fcc-8dd0-a57c6fdec79d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e8068180-8b11-4c7f-81e0-bfde78b56d71"/>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c29e194-5449-45fe-abb1-3332132b9b04">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/40f8ffbe-3663-451a-85ba-35d34337a52e"/>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d9f0f72e-88ff-49fa-9d41-7599897dc108">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad87683a-a7df-48bf-88b9-b0f900f84168">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/655572b0-505e-4843-b8bd-4f0cc82c656c">
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5869566-d522-4be0-b305-1b424cf58ead">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
        <rdfs:label>LIAS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1d35f15-804a-4a0f-a881-75cb704cdb06">
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3fdff1c6-bc90-4f91-bfc9-d489b451e8ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16bf1c28-9ed2-45c1-93c7-fe147be27876"/>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/276b986f-a2e7-43f8-b9e1-6aac8f2cb4dd">
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b013a546-5954-49a4-9d6d-008f5c4cdb11"/>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e837350-cb3c-4f04-9741-5b76951d3f3e">
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/80d9f508-25c5-4f0d-bde0-03fcd901e345">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6999fd19-f7dd-4b99-a4a4-3f0754dbc3b8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45ca4080-3bf0-4530-935f-7ba92e549d7c">
        <rdfs:label>CLN6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c023f107-5311-479a-814c-e2f6c4237d15">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac05b6fa-9d44-4697-a3e4-d97b43cb16d5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
        <rdfs:label>ADA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/30f20c01-c932-449f-b733-c2aecc3cf6e6">
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1520381-e35f-4e14-b6e1-d245b62f1c57">
        <rdfs:label>ARG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88312c3f-a26f-462e-9d45-879d720dae8a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd0f4c2f-81c7-4f0e-baaf-df93441f5ac4">
        <rdfs:label>PYGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c54b29e-abf3-43cf-871e-fa25956b893b">
        <rdfs:label>GALK1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4452b00a-7cd0-4ff0-b5ac-15dc4fd62f54">
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/75754550-f825-48a6-8d60-6d698eb8063f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/52ad4fb3-8bb4-4d60-9a74-3dc421657781">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa808552-e9da-49f0-9d1c-f3f69490bd7d"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91ea84f2-b286-4f79-a53c-79cfc85f562d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/313bdd86-cac2-4154-bc41-1751f191e11a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c83d85c2-26e2-47ba-bd43-bda040d59f31">
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/940a2203-f6a3-41fe-ac20-c4756d0890d9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
        <rdfs:label>DHCR24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55f1d0cb-3287-4c0f-a940-af2c844136a9">
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/75d92bf2-4fe8-4dc6-854d-75129b36e111"/>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/79cd9d5e-6e40-4ded-a1fe-57cc6dcbdf3c"/>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8018beb-2c1d-4e4e-8df0-e33353fcc994">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e860abc4-3533-4591-8257-46ce4a7281bb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f70a0d96-7d9f-4e0e-bf28-7c43e028bbd8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/186083a1-45ab-44fd-ba06-c4bc7f006573">
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e1728b57-6a81-413c-9fa0-2a61ce65a553"/>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c38ad995-398d-43e9-a108-2d7cba2f8293"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf591971-1369-4294-bfbf-3c96bfd357ca">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4d3de198-7b8a-426b-8948-adeec4e7d4c6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
    <rdfs:label>dysferlin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbdb3d24-728b-4d29-91e0-4d7cf4eeda5e">
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8cd9089-63a3-45ca-89a5-0731ab1eb7ec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5a8311c-caec-4e79-8275-394d9bb36eb7">
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/210ec608-b211-49bd-9df7-07456f327e93">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e81ed4f5-f487-4539-aa4c-11b6b83429ca">
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12f5ccc4-60c2-416c-8e52-81b9d35e5187">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b4a78621-4c63-4ea0-84bb-5c54124df374"/>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb6070e8-b7e6-4a8a-ac80-a0a7980b67df">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7413c858-a08b-4497-a7f7-8517b788f7e4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
        <rdfs:label>SLC25A13</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70ca34ba-609d-4339-b5ea-1a43e9351fbf">
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/209220af-4dba-459a-a264-e3f84508ef0d">
        <rdfs:label>DHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a3913bc9-6697-4cc3-a324-2bc621c706f4">
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/12649390-d7e8-405b-9e32-cf284fa6561d"/>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b662ebc5-de9b-46b4-baff-388bb08517bf">
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d642d8a2-8902-4cda-8bb5-4969316b422e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e74e3a45-fe91-455f-ad5e-68b6260ae1c6">
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa8772c6-6261-4e3f-a2a7-7c269dfda600">
        <rdfs:label>ASL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/149d0698-819a-49ad-9adb-549b534c5dda">
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81589553-3b00-4235-a51b-f2f40dbee352">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
        <rdfs:label>MLYCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1771c22-5627-4340-b8ee-13ef958899a4">
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45befccd-4adc-426e-9a1e-3d3af41c2030">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e2797b1-faec-4f44-8d78-4f3971cdd9a4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81d79ae2-7b76-4407-a4e5-bcf6b64dc8e6">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5ac122f7-0752-4866-8cfd-9b716c9c0e05">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
        <rdfs:label>UROD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9667be3e-b49b-4aea-9f24-76228a9fa0bf">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2ecdebc8-6981-4095-acf7-feb2f1e08bd7"/>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/847d8cc9-4e0d-4090-a77b-d714c8b68de8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b73ff3f5-e45d-44d9-b5da-9f6bfe4247e9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>kynureninase</rdfs:label>
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1c016e57-ee97-4ce3-aac8-3c9f6ae6cfab">
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b102860-feeb-4e2f-a323-b860627ae27f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
        <rdfs:label>CP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <rdfs:label>Ferroxidase</rdfs:label>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/163a4528-3c02-44fd-b6b0-d8d9ff72b8c6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dceea310-1792-468c-8ca9-2b267b85642d">
        <rdfs:label>CPT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/81167976-c26a-4c31-a59a-8d5bf072f1c4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/685cbc8e-1cfb-4bd7-996b-2a355de5e5c0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ec66eca-0c13-4614-81de-a91502364a04">
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e8f934e-ed08-4205-98e4-82c14445ddf4">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9dd7e08-8392-4f56-bdc6-307fd29dd45d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1bf5404-5095-4301-80c8-123ea580e46b">
        <rdfs:label>HPRT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/643faaf4-775d-41b0-80c8-93baa47dbc25">
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7670644a-8874-4f23-bf91-e300afdff16b">
        <rdfs:label>IGF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9312153b-02cb-446e-898a-16242744127a">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/56b82fb5-f3ce-4ad5-9543-7058c93162f0"/>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/040d6684-fe4d-482e-bbb7-7366a64a033b">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16f4ba39-9580-4645-884a-f5421835ac80">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d65b5453-c37b-488f-b634-782ee79c7f21">
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3341a12d-a879-4ade-acff-64f4748ae2a2">
        <rdfs:label>LCAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2127141f-4fdb-45be-9a61-461a173a4512">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fdc6821-f5de-4013-8db6-a4e01e7a2f94">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ferrochelatase</rdfs:label>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/09738276-5a23-4c6e-bd5a-6d0d19dbdfef">
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/625da948-4836-4256-a281-719173f71856"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d70f2ad9-6861-4b52-8075-11ad5b3e4a2a">
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/71e1a425-302e-48c9-9c48-4cdd30e03ea9"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88b1ee73-5159-4d24-81a2-3f7f99b0e6a7">
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14ebbebf-74ee-4b76-ac8b-74b0d29b9cb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75e6eb93-910c-4f85-a969-6280465f8b80">
    <rdfs:label>thiamine transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f29db70-580d-45c7-967e-8b4732860d81">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef28212a-31c4-4b4f-8704-d8a1d1152a04">
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea97423a-9b42-4417-b542-2b7688f7dad9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
        <rdfs:label>NPC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3d50448a-df4f-4e2a-97e2-c2b39b82ec04">
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c4e6e68-2b5f-482b-a654-4e8ec599e708">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b14abf04-42d4-49a8-9fbb-a34d268f8394">
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <rdfs:label>GABA-transaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a100b19-2af1-4851-b545-7e2e255ca142">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/b807135a-f8aa-4e0a-8e77-d33b6176b41d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f9c5501-0400-4232-ad31-02778acb954e"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e8e8ac2-d3d3-456f-a4ef-d860b63f4049">
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c9c7c12-a890-4dcf-8f11-1d9d71acac33">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62eaecbb-0254-46df-bb64-b27182dd8af5">
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89ad98fc-3882-4d4d-87d3-e11d3ceaedbd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
        <rdfs:label>LIPC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61086471-d7ed-47b2-be5f-fe6e34988bd8">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84b13729-0b85-4a7a-8382-562a2c8d73ca">
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/82655f20-bec0-47ac-ad14-b3cee6799db7"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e6b7a9a9-7791-4e47-8ed0-65b04f4e42f8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53d3e90f-794f-4a53-a693-4fee65009da2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
        <rdfs:label>PHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47e7cbda-ee58-45b3-bda3-3a47eeb250ee">
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e9d2356-0227-4546-aad5-2a69591fc59e">
        <rdfs:label>MTRR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/abc9394f-b3e7-4e4e-88af-4ebba0cc5f0d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/425d9905-5e3f-4b71-b2fb-b038d7086d6b"/>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/507bdc40-14db-4b15-aab9-5488b6f2d139">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/35e2d531-9108-4365-a5ad-4db602dfb567">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f26fdf4e-cca6-4776-9e08-a471502db6c4">
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b457ecc9-3efa-47c3-bae3-82cf6790cfb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
        <rdfs:label>GLYCTK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5de2a4e8-8c0f-4a4c-af44-3a01ab4238ca">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/067237fe-57fa-40d4-86b4-e6bcb51bb3e7">
        <rdfs:label>PIGN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7c2ccd96-8ce6-4102-a96e-90562ba3a80e">
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/52a5be39-2d03-42e5-a1b6-92ee0542d73a"/>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <rdfs:label>Dystroglycan</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ddbc4784-bf35-477c-9ad7-c30bc6536415">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/814d42fa-edc6-442f-888a-2d93cbd19ae8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
        <rdfs:label>GK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <rdfs:label>Glycerol kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48c8a3bf-9c0f-4858-a3b2-982549a958ca">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/41caa02c-6715-42d1-9056-374460af9e79"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ab55a841-f54b-4561-9110-3303820022fb"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ee003f7-7887-4a49-af8e-b0071697cb8f">
        <rdfs:label>MT-ND4L</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/deddf4e7-ef3a-489b-8187-55267f827df2">
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33ab5b92-8f84-42db-b476-9f4d85668466">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
        <rdfs:label>SLC25A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b46ed99c-f57b-4f5b-93f6-b4e01af459fc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f014e44-944f-4e8c-8145-7264a4a3a7ea">
        <rdfs:label>GNE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7b60e391-3da1-4b46-a7c6-d968abde8cd6">
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/50d02435-1b9d-4473-a774-a9de9ad0e16a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
        <rdfs:label>GLB1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/106c79c8-6da8-41cd-b037-4088cb209c34">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6c54b29e-abf3-43cf-871e-fa25956b893b"/>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d5a12f89-d918-41bb-a168-a5c0688c1753">
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/254ed982-597c-491d-8f21-ecd4be585b8d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
        <rdfs:label>LPIN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e997e87e-7222-48c7-9c92-7cd0b31ee48b">
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1629d304-1b56-45b5-be15-4cc824510a55">
        <rdfs:label>ABCC8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6854e01-4a66-460c-a484-82ab3ee1c84c">
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eb05e3eb-e84d-48e6-8f14-ce2b336c6b24">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a0d48ba-3469-40c4-ac7c-6706cb9c7a26">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/105145e6-9fef-4105-81e7-140375a5391d">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7b02094-e7bf-4454-a018-2e92bca86fbe">
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b69b660f-8e34-4777-8424-35b349e937c4">
        <rdfs:label>GLUL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1564490-f49c-4e04-8697-4cdce432203d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a9e6c341-aac7-483a-971d-ddb4638ce57b"/>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe084208-905e-41cd-a8d6-75668dca8978">
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d062be0b-a577-4569-a921-b8483425297b">
        <rdfs:label>HPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/df791ee9-9fb6-4bec-9293-a52421ac22ad">
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/efd0ad9d-4a27-45b6-9d6f-832d30010d47">
        <rdfs:label>SLC25A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb5d8dd8-d720-44fd-b16c-2ebe79edb371">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0094ecfb-374c-43ac-a68e-8cf3612424d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5f4ad0a5-c1e2-46b5-9694-58a5095d467b">
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bfa59c02-6f8c-49a6-86d4-edda9ddcd86f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
        <rdfs:label>BSND</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>barttin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1bf10f0e-ea20-4f6b-bf1a-69b7f9211ec4"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f9e5faf-891e-4afe-884d-7dd89db3200d">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4144fe69-e214-4bf3-944a-78dd5db5d6b0">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/78c3e4f7-a447-48bf-affa-c04115c0ea01">
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67dcd18b-17db-4da9-b63b-c36618a2342a">
        <rdfs:label>OAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce948b2c-086d-450e-ad47-69ad9d10ebd2">
    <dc:identifier>HP:0007359</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Focal seizures</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9cb91f48-6422-40aa-a95c-7a752f2f8226">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e314f4f-ce8e-4739-882a-465b1e55f36b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb"/>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c6855ec1-31c6-446c-b3a2-0c1ee5480df0">
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05072add-8c87-48c3-bd65-5fdf632b1906"/>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55d4c68e-25ee-4c52-be18-a9ced8ad4a00">
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d499e90-28ed-4e7e-95a6-bc01b6ecf646">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/640222d3-e661-45ee-b6cc-95742b4cd17f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/3c565c51-27e8-45d4-b6f6-06b6c4f37d1e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67f5d367-40fa-4384-ad7c-17cf7d033e9c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4c05f95-70b5-43fa-9be6-3ae67368d9a2">
        <rdfs:label>Brain damage</rdfs:label>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05bfc3a9-6fda-4f43-9b29-3ee3a839d7ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5fafd94-8701-4881-b3e0-a75e845b8835">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5a2dd1d-f852-431c-b20a-ec730255cc7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4d5c4be-e220-4a97-9f41-b7c7e93da58f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:identifier>HP:0100021</dc:identifier>
        <rdfs:label>Cerebral palsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c912b98-9610-4f9d-a4d9-ade710154f5a">
    <dc:identifier>DB00458</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <rdfs:label>Imipramine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/596f0d03-9bcc-4e46-89fe-c0f2d5ac9959">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/753156bb-0b5b-44d8-b707-648f4ba2deb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e72e22fa-1a83-43a5-9529-110ee88288c1"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b00facf8-3a7e-42ca-9267-a79efcde8335">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f7e553dd-e18a-4b93-bb3f-9917acc1f582">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9362855b-178f-4a5a-972e-e1482eb79255">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:label>Arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89616262-d6c0-429b-9c28-8b2ab0f54ab5"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34ca1d12-904f-49ad-a6df-b14090a36a40"/>
    <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
    <rdfs:label>HURLER SYNDROME</rdfs:label>
    <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/413308fd-e296-4469-8e52-3c03e8256255">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23f12e7d-1e5d-4797-81c8-bf418d392322">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypsarrhythmia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
        <dc:identifier>HP:0002521</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f70b0c26-0ef1-4588-8079-5c16f539542c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6b5d035-184c-491b-9ee1-d6d259bbefda">
        <dc:identifier>HP:0001992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:label>Organic aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44852d88-281e-42f3-8c9b-b7163122dddc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c7880850-8769-4a26-86d2-0fbfe33c593e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/067237fe-57fa-40d4-86b4-e6bcb51bb3e7"/>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72ae1b9-a10d-444d-9ea7-b3c8ce2a2bc2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e52c29f-192c-4bd2-8306-576805350301">
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003158</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a9b8ae4-c302-42df-9e8f-c17de2760c2b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2971ba05-71da-48c3-9f42-91c67bb5fb38">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030390*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
        <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97a79961-d203-4811-be3e-54ada3d1483e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa81bdb6-53ab-46af-a657-81a9f67d4dda"/>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/278a4b33-a42d-4481-a230-c92881268189">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a06db302-bcd4-412a-a68b-2cd78947ce42"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d389d5b5-4406-4b39-9ba1-f2cbfd5adf6b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/206be8bc-b268-4f42-910f-1bd1c577b935">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b92d3993-4837-4f8f-a368-28a95798ca3b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee861003-be2c-456e-85e7-5f497cbb5263"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37d99a31-0c68-4e7d-840e-f821589cdcce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c747c24c-f737-410e-b80d-0aaecfb1b873"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5172ec6d-d94d-4050-8622-5d94936d490b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78fd34be-11a0-4f90-8c50-7acebbb409bd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e39d78e-1e1d-4de0-8ced-eb222e25d15e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ef313cc-8953-46a9-add9-e056c1483580">
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09081</dc:identifier>
    <rdfs:label>Idebenone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3501d68b-6200-4f48-bb09-80a31ea52313">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99db20f3-f5bb-4e40-9f3f-6ca5a0cfe8b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
        <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6b2fe1e-3ab3-48af-9098-d3583b847925"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4ae7269-a70b-4cfa-bc13-eb0d94d5dbd2"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd655256-8824-4be8-a1fe-1193c9fe2974"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7c83123-68aa-4e9d-b9b7-69ff8231cefb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e656016f-e3b2-4ab9-8f05-9fbee6a5d2ad"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7cccf0e-8443-43eb-a8c5-66858298fc1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/baa53c16-5187-4413-8de4-2990d833d5e4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29b6cc8b-d439-4f81-b3e9-64c3d8fa7cea"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f58807c0-cd9d-4d0d-bfd4-d0ccbafe8868">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <dc:identifier>HP:0007346</dc:identifier>
        <rdfs:label>Subcortical calcification</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/331effe9-0ab8-4493-ae78-a6c3ef33d25d">
        <rdfs:label>Seizure</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ae2f58c-9acd-4789-b99b-c783645e7d5d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
        <dc:identifier>HP:0002135</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000006>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/708f5fe7-a7c6-491e-bfca-18d17a88707c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95d045a3-8936-4ab0-a308-fab67c5e0c0e">
        <dc:identifier>HP:0006462</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12970e08-d782-405a-8455-82dfd5593399">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003239</dc:identifier>
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10d59a2f-2eb0-4981-ae4d-12a100e3984b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <dc:identifier>HP:0100036</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55bb5843-d72f-4d80-bdbe-498152f3a351">
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <dc:identifier>HP:0002756*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be278389-48a4-477b-b9f5-a5ec297bd6f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e52fce3d-9cba-40ef-986f-0ddc2bf6c30f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/827b871c-4f7f-498e-816f-b9357eda7025">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003260*</dc:identifier>
        <rdfs:label>High bone turnover markers</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eca81d0b-6ffe-4e91-9800-db2f046b7a83">
        <rdfs:label>metatarsal stress fractures</rdfs:label>
        <dc:identifier>HP:0001832</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02e72cee-6549-4770-8c1a-75f69222fc8f">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4482c21-f60c-478b-8ca7-943404743e04">
        <rdfs:label>mobility problems</rdfs:label>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8ae9718-b3bf-4449-80a2-6d6c1d3ac3e9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>Pain</rdfs:label>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56b82fb5-f3ce-4ad5-9543-7058c93162f0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cb29a242-25de-4da4-a603-799e65c27669">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4154e542-87a1-47de-bf70-917094b8a1e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e503e930-21cd-4d71-89be-bb55194d5966"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/35a5329f-cf2f-4cdd-9916-027fcaac23c2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12a35f8e-ad3e-45b9-8df4-179c24de47cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>Low quality of life</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/020f294b-e824-4cb4-9bc5-c0321b0f7610"/>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44852d88-281e-42f3-8c9b-b7163122dddc"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c32a31e-6d6a-4aa5-88c8-3087083347a8">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tonic-clonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26edb501-50db-4aa4-abc2-11378f779ee3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b7bd32-f19a-4657-bba7-5ddeb6dbb61f">
        <rdfs:label>Poor appetite</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b0a13a3-84c5-4dc5-a069-b5a13efa3e49">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
    <rdfs:label>thrombocytopenia</rdfs:label>
    <dc:identifier>HP:0001873</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bdad02e3-1614-4311-9260-26f11ae7f684">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71e1a425-302e-48c9-9c48-4cdd30e03ea9"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72ae1b9-a10d-444d-9ea7-b3c8ce2a2bc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e956f426-2b44-4171-9eab-f5e945378460">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c422e84e-6b35-42cc-8084-cabb1dc75094">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f1865b6-ce09-46ef-ad65-5c85e9770bc9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55266525-bd33-4637-820f-2437f9712689">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c87f9f82-3c26-4a80-a641-09d5c8d1b269">
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <dc:identifier>HP:0003165</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daf563bf-d3b1-4e4b-9cea-706b963d3c97">
        <dc:identifier>HP:0003127</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
        <rdfs:label>low calcium urine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b6956be7-d355-4211-9c02-20b0e3246b01"/>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea4629c7-e693-443c-bfb0-ca7fd4999364">
    <rdfs:label>Abnormal enzyme activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/75f0c261-739d-4962-953a-d6dde2f2fa0e">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/350accf1-9b58-484b-8e4d-5e597adea30d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/627b4ecf-13bb-4a5e-bd92-559faad1e5c4"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d52d7e4-e004-4822-988b-46ec659896c8">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f118846c-5167-4881-9d02-fbbe2e4f183a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8b28d4b-5d81-4c12-8639-d2b2fe3b849d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a55326aa-f7df-4017-b431-641638fd0fed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29b126f4-0faf-4696-be11-89add3af5973"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/625be5d6-9ebc-4ae7-a322-4b348a71c737"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ede4c1fc-0476-4a90-b33a-4ee7ac9b757c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <rdfs:label>Hydrocortisone</rdfs:label>
    <dc:identifier>DB00741</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99d7c691-ec13-404f-a39f-d152e63de824">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fa87fdb-a1f8-468b-8d43-ac62714993ba">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Neurodegeneration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb31ec24-6df4-4b42-beb2-b4b141aaf029">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rapid progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e94eec25-8f06-4d1b-8cbe-cea2a7818148">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/19f66f39-da5a-446a-8968-0add0cceeb31"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e3d9cb5-2695-4f11-b7f3-a11e82ab5c54">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b34a942-57d5-44b3-ad07-cde2cbf60dbc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0023195-b2e1-4372-b5f6-bab886d68eb9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e36509f9-dccd-4952-869f-5d1e1be3d4d1">
        <rdfs:label>Fine motor impairment</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/441ac53d-4856-4cfe-ba79-717f7b68bb9e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <dc:identifier>HP:0040006*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f20bb845-d71f-49d9-8c02-ddbf8dad6b15">
        <dc:identifier>HP:0001392</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
        <rdfs:label>Liver injury</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c3387c9-0367-411d-9a5e-360d14b78170">
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Poor swallowing</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75285b6a-4aa3-4dd3-8fd4-f0c4f51d9f39">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9f79523f-5ce9-46e6-8ec0-d283cd295199">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/088fcdeb-1433-4ab1-998a-fb8b9834cab0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4947beb-2136-4e56-86b9-204e1ffa9d05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc414128-fac5-4243-a311-84a6af7228cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ab9c9ed-e567-4de9-8d88-aca334880127">
        <rdfs:label>Lower extremity weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007340</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/148d950e-d748-424e-a249-0cd4c60936bd">
        <dc:identifier>HP:0002317</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <rdfs:label>Gait instability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0ef1295d-e519-46ab-8dcc-6bc176d3f93e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b35933d-a4ab-462b-8dae-38d493f6446c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fb37f56-4206-47f0-b172-f55fca23c364">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c2d92ff-0a5f-4391-a365-81f454389a7b">
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <dc:identifier>HP:0004319</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd982d6-99a8-472a-97bb-cc08550c238c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef0d8ef1-771f-47a1-8dc9-9eb445de8d50">
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000847*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40f8ffbe-3663-451a-85ba-35d34337a52e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11b464b9-04f4-402f-8b3d-ec96fa669e5a"/>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c00c6d1-aca2-46c3-9755-61508adfb1e9">
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9dd0e2e5-e16e-4d60-b556-5765061bca1c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67a753d2-3cb2-4f9a-84af-00864353083e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/31246c32-9d42-437a-8062-f22311fd579c">
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39cc4249-1396-42f0-b6dc-428a9fc0b436">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/053086d0-6677-4f83-9250-bec02771af20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ff3fbcc-e9c2-42e3-b396-3db03a594c6d">
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3aff46e2-f2db-4d20-a3b4-9a149b003af5">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dfe94d89-498c-44ee-aa33-67d6ca8d5a75">
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0668b96-6ba3-49cf-acc2-01ec87b04022"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e05c0326-080a-438c-a89d-6eea326b54e8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
        <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9be668a1-a526-461e-97d2-6fae0fd7fbbe">
    <dc:identifier>DB09210</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/17a209b5-7ccb-4650-b901-045fe0ee6720">
        <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c5c2557-c878-4175-bbbf-7bdd4a5ff458"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/941c7a26-5a82-44df-b1fb-2635ed50001b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Piracetam</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/98923d44-c770-404e-b3be-8da2e6d4bcce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a1ea8ab-7a31-4216-98bd-3dc27f27419c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90785db8-f6b2-4614-9890-61ffbeb5b5d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78cc2e12-34ac-4a0d-833d-398c06a3d0e6">
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <dc:identifier>HP:0001283</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90f03ee9-fa7c-4d6e-9a96-e03bfd1e0e52">
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:label>Defective eye motor function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938">
        <rdfs:label>Poor head control</rdfs:label>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12649390-d7e8-405b-9e32-cf284fa6561d"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf38466e-9987-4b61-896a-d61a70274f8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2a29d1a-6113-487f-a341-1e709669febe">
        <dc:identifier>HP:0012450</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic constipation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f57ab270-2576-4c30-b294-429158c3ed2d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12a35f8e-ad3e-45b9-8df4-179c24de47cd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd2b03d8-3318-49eb-bbb6-4a2fa4743a41">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiomyopathy</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b330e67-adae-4979-b0ca-dbbbb06b4528">
        <rdfs:label>Rhabdomyolysis</rdfs:label>
        <dc:identifier>HP:0003201</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7691bcf1-f0fd-47b8-82ab-f9af08e7dd6b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3437c9ed-14fe-4aaa-893a-4016f351f91c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e90b86f-b5cf-4d3c-bf7e-89bc1ae584f4">
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/55c1f9b1-76d5-4e39-b18d-9dddfa0b0dff">
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e651931-0a41-440b-8d2c-3cce17d2d499"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/794598fb-6750-4de7-899f-a72ef1d85397">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e651931-0a41-440b-8d2c-3cce17d2d499"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00028</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/36dc8477-0ebb-44cd-8d28-de808e74d884">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/597672c7-ac67-4bea-a821-9f5d51de34a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
        <dc:identifier>HP:0001874</dc:identifier>
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9982c21-f899-4a33-96dd-d5b47bcda3e9">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c045aaa9-e215-47b3-8972-94047b2d17f2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>Neutropenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abb17fd2-c6d1-4c73-8657-c79ddbf04e86">
        <rdfs:label>CNS damage progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007367</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59ec2e21-f469-48a7-8a61-65c349a57422">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>retinal dystrophy</rdfs:label>
        <dc:identifier>HP:0000556</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22d16a17-9760-40b3-8722-c75e297c83c1">
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/493389ff-7fa0-4d43-a249-0be11141e907">
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c78f586a-e34e-4c7d-8e7e-3e52b63b613b">
    <rdfs:label>electrolytes</rdfs:label>
    <dc:identifier>B05BB01</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/58a552fc-6fa2-4665-857f-dd620b885b88">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f8211aa-c390-4843-a406-41679e83cb17"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3626044-e627-46dd-af4b-f2267db2ba0f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/251d818c-d073-4a8e-bd77-c577d3f0b336">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef624fb3-f2cd-4565-ae78-e13a16d757b7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low serum ICFBP level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a20226db-0eb3-4e81-9ff3-f3b3b19bf541">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b8fa08b-ef6a-47b1-99a7-be295f0b9cdf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/583a1133-05a2-421f-bced-2e839d4786ea">
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Growth retardation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/313bdd86-cac2-4154-bc41-1751f191e11a"/>
    <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/f17b072f-5405-444b-a980-69412f5a5ff2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab9705d8-832f-4204-a9ba-8113e8046e89">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b54470a8-26d0-49d6-bd2b-0b2cf1ec4b1d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Bile flow defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94a67fcb-b789-47a4-a180-f2779ce88a8e">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/784419b3-d37d-41e4-9ef3-7e8c49418143">
        <rdfs:label>Atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9712171-61f6-41ef-8f7f-8656e88b375b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/deb29519-6858-4847-8f99-743a82d14058">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de1558ca-d27c-4ace-85ae-44a2d567e09a">
        <rdfs:label>Cirrhosis</rdfs:label>
        <dc:identifier>HP:0001394</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8068180-8b11-4c7f-81e0-bfde78b56d71"/>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddfaa587-3d80-4895-a9ef-8d93675ff6ce">
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2703065c-1219-41f8-a4f3-56f6510cdd9d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5a5cff4-ec4c-4747-b6cf-7ddd2972de14">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected bile flow</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09084357-cd1d-40c9-8931-638424328f15">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05975cc3-80b3-4505-8a0e-387c3892a3ba">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
    <rdfs:label>Self-mutilation</rdfs:label>
    <dc:identifier>HP:0000742</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c50bbfb-477f-4cc2-b75e-119489f84d23">
    <rdfs:label>Liver fibrosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001395</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3341a12d-a879-4ade-acff-64f4748ae2a2"/>
    <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
    <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
    <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23966648-9453-4e67-8edd-7d554ee831df">
    <rdfs:label>Low endurance</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c6a6dc40-3462-4b8a-bf66-47a34d24226c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2a47878-5657-412d-b4cd-5e97c6890432">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d94a4b6b-986a-4359-b893-45a18ee3ff62">
        <rdfs:label>Behavioural Disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/154f5e9a-4a87-4317-8364-0004e7ac3424">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000870</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:label>High prolactin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b7d7a54-a646-468b-b17f-436de4f32388">
        <rdfs:label>Movement Disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5c2b686-a2d9-407e-b110-d72704e03cfb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f48203fd-1984-4a6d-b5ec-50879a91b333"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8cee700-93b6-4264-af69-afd6455efda8">
    <rdfs:label>Malnutrition</rdfs:label>
    <dc:identifier>HP:0004395</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/34309472-ff3f-40dc-bdaf-61897d402e7b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9fe6db6-6825-41c1-a201-77cb93661c3c">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60c37644-e24a-4d97-b85a-fe7efad1c939">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High VLDL triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14ebbebf-74ee-4b76-ac8b-74b0d29b9cb7"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
    <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8443881-05a5-468c-ab3a-8a31898558e3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4144fe69-e214-4bf3-944a-78dd5db5d6b0"/>
        <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e7694e9-d80e-463c-82e5-f36681db4632">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000982</dc:identifier>
        <rdfs:label>Keratoderma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aa1b8d8-cdd7-4929-9487-6072ab2d39a4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
        <dc:identifier>HP:0000166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef4ab317-adbc-4fd3-a768-81aff8353381">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b781930-1b09-433f-83cf-87fbda0fe769"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7c2ed7c6-91ff-4dc0-a36b-69386122ca38">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05bfc3a9-6fda-4f43-9b29-3ee3a839d7ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/638473b0-c70b-437c-99ee-19be7fa742cf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8398c3d-7e19-4bf8-8f2c-6e884a6d8122">
        <dc:identifier>HP:0030980</dc:identifier>
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6605d59-1f7b-4e3e-ba74-752761295720">
        <dc:identifier>HP:0002329</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>unalertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e08923a8-b1f6-446f-9e35-6d69c3653b0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG results</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe22923d-7b62-4237-88e1-e7c3db07a933">
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
        <dc:identifier>HP:0030213</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ffed74d-1ce2-4563-8260-38e181c65d95">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d942faf2-74f0-4e54-b44d-49724f1b0d5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <dc:identifier>HP:0030980*</dc:identifier>
        <rdfs:label>Low CSF glutamine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
    <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07084c47-6ab1-4e9c-ab0f-b3277b31adae"/>
    <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/910591da-57c3-4ae5-b007-ea3fff61c3a2">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1326ae86-74fa-431c-b1fb-233ca3a3e1e0"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b52d362d-fcdd-4ef1-bb0f-4f336fb9a082">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14a5db13-c287-460c-941d-5d4b92d6243f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a344a1f-d9db-468d-a558-1beb677655a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdeb2c47-8f6b-4426-970b-0b06830c826c">
    <rdfs:label>Hyperpigmentation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
    <dc:identifier>HP:0000953</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3aaaeef3-259f-4b88-bc75-e378c7608fff">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f40183a6-bcde-46c0-8962-ea50705d4d4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2a326148-10e5-4d8f-b1f4-429a28fbc3a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ed7e87d0-6861-4a79-a57c-b7e70ce79d0f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5bed1300-e534-4556-9435-72e861082a36">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ab88bda-f135-4be7-a6c8-c392d3bc4f4a">
        <rdfs:label>movement disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80ce5afb-9e31-4e9d-bb55-c00312f45181">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:label>hyperprolactinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000870</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5c2b686-a2d9-407e-b110-d72704e03cfb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f095a25-ef10-4065-a2af-95aa0487e9d7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>behavioral disability</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ec3dd4-f548-4d94-8725-800343e5b6ac">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dopamine deficiency</rdfs:label>
        <dc:identifier>HP:0012656</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad33cee8-53cd-4f2d-a0c8-ddcf0d88eac9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c05b5710-2790-423d-87da-369649a0954e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <dc:identifier>HP:0006530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a1547d5-a4b0-43b1-a1d5-1d30c2edafcf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0603950a-fcfe-41d3-974f-7ec14aae9ebc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e8f934e-ed08-4205-98e4-82c14445ddf4"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db858b32-212b-44f8-b88c-d904c233acef">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:label>Difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2afb7bb5-9f51-4013-b634-2249222bd0a6">
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002086</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/22b5e90d-70bd-42da-95b8-eca8b67478c6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31a52851-e3be-48fb-a265-64e9ea7f6dcd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97617ecb-6c03-4caf-9454-dedb0abff201">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>blood coagulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
        <dc:identifier>HP:0001928</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5978eeab-82b0-48f0-bc0f-c5949649ea5e">
        <rdfs:label>urinary tract infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <dc:identifier>HP:0000010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b936a90-f14b-4e6e-8500-33525aae30bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5e6913c-8541-4bf2-a413-5c5a6bb948e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc42d2b6-2f7b-4720-8476-1b995096af36">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0005567</dc:identifier>
        <rdfs:label>hypoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9206d2a-a82d-46b1-80e4-010d6a4bc74f">
        <rdfs:label>protein-losing enteropathy</rdfs:label>
        <dc:identifier>HP:0002243</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06b85780-34aa-4171-ba1c-5d54355a5834"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e3a9d22-372c-436c-b8bb-8862e372fe17">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>hypoglycaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b5bcfda-0395-4d22-86bf-65c2fbb9810e">
        <rdfs:label>Metabolism abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0668b96-6ba3-49cf-acc2-01ec87b04022">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a33a58ab-ea44-49f5-bbff-c3dc4651e0d9">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56b82fb5-f3ce-4ad5-9543-7058c93162f0"/>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9c3735e-d730-4b5a-88c9-b7efeffd49af">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/487cf2b4-5555-4632-a684-6ff2ebcf9f3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/457696fc-76b0-487d-97a5-cffa70409b1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fd09d12f-0d66-405c-8d48-dfa8af7d5806">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c045aaa9-e215-47b3-8972-94047b2d17f2"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72c4ab67-0b6f-4efa-b276-11eca0ad40dc"/>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6496e5c8-f771-4b91-b3e5-57c185914194">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a83414e-d9ec-44f8-9d93-d7e3b3e927cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c3cbbc9-c0a6-4bad-9ef4-ea47940b2403">
    <rdfs:label>Impaired social interaction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
    <dc:identifier>HP:0000735</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
    <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/351cf9d7-ea4a-49de-8cd2-8a061b985469"/>
    <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
    <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0a44c056-4386-497f-85f9-fb620b3ba110"/>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdde00ad-edc8-43e4-bdcc-bf660295f732">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000002</dc:identifier>
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec6ed6d0-c876-4b71-9db8-17e256b3f216">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f47c4938-09f0-4dc9-8142-1702f421e329">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82162deb-484a-40d0-a8c9-df9c095052f8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15ad15bc-0311-41b6-b619-f21a0d38572e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a8e94db-2c6c-4664-8d2a-97c76ffc78f5"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1f2cb63-b447-4e6e-9cb6-f0417fcba51c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a6df4f35-2b8c-471f-89e5-ab909835b8b6">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/09b90bb8-6188-42c8-95ab-de5c0ebcdc02"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab45aa14-ac03-471a-94db-fee5b0e7680c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/476b928a-f91c-4d5f-9f86-35f467933f51"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <dc:identifier>DB00999</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a79e3c4e-625a-4e32-bbda-ae10fd25264f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <dc:identifier>DB09144</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6fa3677a-7e15-4940-bd6d-ee100e94d346">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a380bf19-3828-4400-aa9f-834ee2262c74"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c46855a8-2a23-4d1a-96ef-62a5b267ced3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0d663fd-7964-44e7-ba5c-d3efe3cb8452"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
        <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/13b9f5f4-1fef-434f-abf1-f3e869124705">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf530dcb-7645-41bf-808a-4efadc25cf4c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3f9740a-de40-4d49-ad3e-5b3c994c2e31">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac4681b4-3938-423e-9062-bea9046e056f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low plasma arginine levels</rdfs:label>
        <dc:identifier>HP:0005961</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/985365f6-506d-4152-b24b-1d7714905e72">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
    <dc:identifier>HP:0012410</dc:identifier>
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52c537a9-1f3e-4641-bff8-3f9ba71b9943">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6338e241-d9b5-4ee6-babf-cae28188abdc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc08fa40-ce4f-45db-ac89-e1673eddde83"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbf48d89-1e0b-4162-b938-69483669f040"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
    <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a96034e9-91ba-474e-a8ab-c50b5c92844d"/>
    <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
    <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5581bf90-9f85-448c-93d1-c8dbb2952066">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1675440-6ebc-4c0c-b491-f49e2cd065af">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a69630e-47c3-4ce7-b53d-77f97ffd3c2d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6475b583-bd2b-4bfd-b616-06ca365b3388"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a343c8e-96e0-480d-bc5c-739ca819931f">
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ada9f282-7979-4faa-bbc8-2834b3cf2062"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94118289-80f7-4b54-978e-311956c062ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
        <dc:identifier>HP:0001712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3848d87e-240b-40ce-85df-2e6534dd47ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20226f3b-9c61-4d03-9cdf-1bd14818e1d9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result was added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6dd49b2a-0118-48f8-9d63-cb9bb76a3dd3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49800004-5112-4637-b4b4-962bcddd096c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/442e8174-8a4e-495d-871d-44e87fbe2b8c">
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b71b441f-7d0a-4ae2-ab8a-a92f057dcb89">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0d6c727-89d8-4eae-84b0-fd45f89af12b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9c4c41-84af-4e99-858e-673ed0d5367d"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/88fd9ff4-bd99-4be4-9690-1670727eb93b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b84a409-ecc5-442f-a38a-3e958aef2218"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0d6c727-89d8-4eae-84b0-fd45f89af12b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e742eb03-ad4f-46df-8644-9915fb30bba4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9c4c41-84af-4e99-858e-673ed0d5367d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0d6c727-89d8-4eae-84b0-fd45f89af12b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/71df11b4-694e-4cbe-96e4-5837e8299572">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea178112-64a7-40de-be4f-63e722c03e52"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0d6c727-89d8-4eae-84b0-fd45f89af12b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45d57aa4-3449-4f87-91b0-84d4c10dea23">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/840936f7-b876-4c7f-bab3-725f6102bf7e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f010f97-56e0-498b-8807-4cd2f36e321b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/876aa880-f04c-4586-ad07-78a6b3b5bdb4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d78e242-014a-428d-8733-2592bded9c3d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66c016b3-c624-4c63-ae1e-42c5ba69aa52"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/54eb5eb8-940a-46fd-828e-72dc18b2eb8b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1baedf16-cc72-49d0-a9ff-cb283b110e8d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed30845b-4c2f-4c66-a4c7-8173616ae0e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71101da0-6826-44bc-b283-8833b308f849">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>cardiomyopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/563e5968-240d-4be1-9cd3-67a2c79de611">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <dc:identifier>HP:0011025*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88b242a4-0653-4467-8377-ce2b9712e8a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35be2f8f-4b4d-4d73-aecd-ced69cb372ca">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a42e87e8-cc51-4504-a13d-3e1357fa5c71">
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d20894a0-0c51-4645-8490-e302f1b968d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>high creatine kinase</rdfs:label>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4178ae2b-95c9-4567-9b8c-d7a1836dcfe9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1016df30-95a6-40b7-b452-eaa42d740622">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c3c1c48-e77d-4287-8540-395df2e25b32">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>Oedema</rdfs:label>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
        <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3341a12d-a879-4ade-acff-64f4748ae2a2"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
        <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae745b09-3508-4293-8547-97c8dfa5d143">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8b2608b-e3a9-44e5-ad6e-46ad24788c9d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ece07602-78ef-403b-b959-0a8d0732657e">
    <dc:identifier>DB00030</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a845cc8-061c-4984-bd6d-b39275861fce">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa3ed17d-8f7f-4fe2-9d5f-7ae2bd8e948d"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ee47ed7-23ee-4439-b286-315bb4f31730"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Insulin Human</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/58281d92-f32c-4b8b-8455-9f688c2663c8">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa3ed17d-8f7f-4fe2-9d5f-7ae2bd8e948d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ee47ed7-23ee-4439-b286-315bb4f31730"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b733ada3-e965-4d04-ad6c-701f7e452655">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa3ed17d-8f7f-4fe2-9d5f-7ae2bd8e948d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b07b2f97-55af-42da-91e4-01e64e3de0d6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b4f0f6f9-29af-48cc-81b9-2eb684baa5fd">
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b64ad351-1642-486e-96bd-07e2139f8706">
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:label>thirst</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09173022-229b-4f97-8aa8-1d5d34625936">
        <rdfs:label>polydipsia</rdfs:label>
        <dc:identifier>MP:0001426</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5df024e8-7202-4396-8e1b-a86b4d7c3a35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01a0e726-e70a-4dd7-b986-07de6d229d3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01d4a2c7-a5e1-4c02-bece-2f38e5e399d2">
    <rdfs:label>neurological damage</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9af71b72-a2ee-4238-bb6d-ea1819150335">
    <rdfs:label>hypolysinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/41d7615b-0681-4dc1-b996-7d9f12a2f916">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/91301828-e4a3-46d3-af7c-4906caf8e53a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/583b20ee-280f-42d3-9bc6-ad1d1923271a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9009fb1-b7ce-42fe-9e7a-b327a1e1bebd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6fbdedc-18d3-484a-9bd7-e21d1d9f436c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anaemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1df1921f-d74f-46bd-8f92-b92dc03e57a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bae2e13b-d0bb-4fc2-bebd-cabe44306418"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/bd269e6d-5e4a-4adf-aba2-86ac36d0a558">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/896de6bc-cd71-4afc-96ef-4277019efaae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f566e6b-969c-455a-b727-e57c00ddb601"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f0973a0-c2b7-4578-92e6-f8b954a9a2c4">
        <rdfs:label>Acidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0ec35733-0e50-410f-bd3e-a38fb1b5d77c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34d92945-a530-4930-98b2-0cceabd34e69">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e1d1aaf-729e-4faa-8ba1-fd3e6fb19e9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b31299b5-d049-4ac5-8fe3-4967e7949e60">
        <dc:identifier>HP:0001300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12649390-d7e8-405b-9e32-cf284fa6561d"/>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06015a70-7b59-4aba-bf29-733e86e64c3a">
    <dc:identifier>MP:0004144</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
    <rdfs:label>Drawing inabiliity</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/492cc352-49fb-475a-9b4b-ec526b99d5f6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a19d22ec-18b9-44e0-96c6-4457737994c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97fdcab7-65bb-41a4-907d-d75695c1e2dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4574a72d-558e-4e84-a0df-baa296024a4d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004387</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/bf56ea21-852d-423c-aff8-479dd2ba73ce">
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67d7efec-fee3-48f4-b15b-cf9d1c00f186"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbac2c61-a0c1-4105-8bad-483d2842243f">
        <dc:identifier>HP:0012379*</dc:identifier>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55305ab7-5d4c-49be-b935-fefd2c045213">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23966648-9453-4e67-8edd-7d554ee831df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a338e045-8982-4df9-b596-1cce7da829d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Failurre to thrive</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81589553-3b00-4235-a51b-f2f40dbee352"/>
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79149d83-e0ed-4a81-998e-a9704f334a87">
        <rdfs:label>High blood malonylcarnitine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
        <dc:identifier>HP:0031544</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c08749ea-843c-445f-9d3c-40513754c670">
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
        <dc:identifier>HP:0003679</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b217ad6-d7db-4524-9596-4c034c69f3e2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
    <dc:identifier>HP:0012029</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a94db8c8-156c-42f4-a4c9-2cee01456386">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <dc:identifier>HP:0001738</dc:identifier>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/22715c38-26a2-41a4-80f8-b674db7dd60c">
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2398aaa-ad56-422d-9b47-581d89ae7843">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64e5d7e8-2ad7-44bd-817d-dfb2c7bd2f95">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/243e811e-b84f-4f6b-958d-4c1fa1868418">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fecd4d0-367e-46bf-a122-220e5170b4b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca8ad04f-73fe-4ebb-a588-151ce30fe7c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/172df0ba-bb6b-49ee-add4-635a7b1c9aec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8877aae-e2c3-4014-8aee-b66656e00232"/>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2096a6a0-463c-42ca-bfd7-e574503a508b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b95b9cc-a8c0-4ca8-9ba6-236fa5f8d33e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7cc6767-5d13-4907-99c3-a5570e18dd3f">
    <rdfs:label>pathology in many somatic tissues</rdfs:label>
    <dc:identifier>HP:0000924*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/ebbf60f1-ce99-47e7-8e69-cad415f5181c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ac541b1-ca96-4617-a5c8-356aa6b2f893">
        <rdfs:label>Disease progresssion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35b1ef0e-b558-43b5-8553-d6353b181487"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c58a0d1d-d466-4851-aa7e-7e7fb2d53cb1">
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:label>High ornithine plasma level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f033fda-6577-4c47-8692-5ce23af4cf1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46b10ad3-ac0f-4958-ada5-38d27179351f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5172ec6d-d94d-4050-8622-5d94936d490b">
    <dc:identifier>HP:0010438*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/05dbf711-3dd5-4734-8b82-387e48c32d47">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87c7e68b-1d2c-4a7c-9307-e6507494a40e">
        <rdfs:label>Abnormal reflexes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001347</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0200ec43-32dd-414a-a6c0-c9db7f5835df">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:label>encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f70b0c26-0ef1-4588-8079-5c16f539542c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/000865e4-4aa4-46f6-b7e1-6aef36a764a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
        <dc:identifier>HP:0030178</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f29db70-580d-45c7-967e-8b4732860d81"/>
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f43a2d34-9e0b-4556-92ed-63678dd117be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal movement</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc06348e-1378-4136-b731-d98810fb7040">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3c4b4c1-e555-48f9-912d-883c336c7d13">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91473db4-b36b-45eb-b622-547e25e4dd09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e1f68866-15dc-44cf-af28-43e62d0eff3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fe61f5c-e7a0-4bbc-a496-817e2f7a7c07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/268c15cd-f04d-4865-93aa-d358d9fad074">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Large central visual field defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
        <dc:identifier>HP:0001129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/12696d71-aaf6-4db5-a6bd-f713c1c6ae61">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/112932c1-407e-4139-8a27-280c3e247dde">
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac9fe024-19c7-4670-aa7e-43bd267920ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/988a38b8-0894-4ce5-9d22-2b15126f1f49"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/715fefe6-7c43-4d22-b6c8-3b7866af3f4e">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/d545f1a3-8bab-4113-a73d-56c8d6d6423a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80871588-ee7d-4b70-965e-bbce985a6e14"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63173562-25ef-4de4-9ed8-4a7170c79ed3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4033c14d-6985-477a-a0ef-370c8753cf97"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d18c66ce-d6f0-4945-9076-2f540d9dc2e1">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/449625b3-edfd-4073-bf7a-f0066fd08813">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f659889a-e1ef-4477-977f-02c787a8da38"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5953d9bd-9fdc-4b72-8b87-083145d3920a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a72af486-eee4-461a-9ff2-177fb65f9867"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c79f6e22-1d9b-4f35-b3bf-1c73b0b48fc9"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/237a07d8-a573-42e5-97c7-b96f8469a4fb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04062a2b-836e-4709-ba9d-dcb79ef26c51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73bed9a0-9a3d-44f2-a874-5296a3903eef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85fdeb75-c230-4bc5-a21d-81a12163c617">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypomagnesemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <dc:identifier>HP:0002917</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b81a3ad6-de7d-405d-bc80-dff850683511">
        <dc:identifier>HP:0000934</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>chondrocalcinosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/825a2979-6fb4-4953-b9e8-a39f61942927">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/350accf1-9b58-484b-8e4d-5e597adea30d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fde57bc2-5356-40a0-90d2-e838216a6502">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007166</dc:identifier>
        <rdfs:label>Paroxysmal movements</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bf20dce-0827-43b4-acbd-8d91cd8c20e2">
        <rdfs:label>Movement disorder</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04d3a528-b7ff-4330-82f2-3de3ad29b3f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b031b7dd-635e-4e04-88c4-10cdd7052e16"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/952dba46-7a3d-42b6-88d9-f1012bde1cd4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44eb3ab3-50e9-4bac-9460-78c238a2a3f1">
        <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
        <dc:identifier>HP:0004355</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8fede44c-b2d9-4ac4-a87a-036ecd00dea9">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc7cec43-1a08-44e7-ab35-97e70d9cca27">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ed00c12-9193-48ba-9b6f-f100fc916fc3">
        <rdfs:label>gouty arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <dc:identifier>HP:0001997</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/69a33d72-4c0d-461a-8f5b-30dcdb4d0d73">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ef87af-042b-4b9c-8811-74fa513b7b81"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
        <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
        <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
        <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe10d771-2894-45e2-9228-5112102db4b6"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
    <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f4ae5db-3de3-456f-9c22-4722f0f7e985">
    <dc:identifier>DB00188</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/54567d49-d725-44d3-b02f-e597e50efd95">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
        <obo:RO_0003304>I278T</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbac2c61-a0c1-4105-8bad-483d2842243f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee9107a4-b5a4-42f5-b094-4cb0f173c6e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/eb34fb9d-7c57-4b95-8f7e-b47245d57e20">
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd68f6c-7a97-42c5-a318-60f79699bd42"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee9107a4-b5a4-42f5-b094-4cb0f173c6e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa9b8dac-4c83-43bb-9a03-d92bb08c2dfb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/843c41c5-fad0-4afc-9578-476bab34ed06"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7f88cbf-a6f3-42c0-934c-e19e2235d7c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Bortezomib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0769c0aa-ae26-4fd5-a8a5-08bb2147c3d9">
    <dc:identifier>DB00936</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e1a216a2-3a97-4fa1-b0ef-e21557cf3ad5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28df7831-08d7-4a46-aa43-92afa7c854be"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/861407f3-8bf0-410d-b3d9-cc9b0a320561"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a744236-cac1-48bf-a210-1d4166d48438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <rdfs:label>Salicylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15c5a987-9615-4635-a938-651014d51108">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>shorter life expectancy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da2f813e-4a1c-4d76-89d0-9dbd559cdb5f">
    <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
    <dc:identifier>HP:0040081</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a6350f68-ae44-499d-867b-a7ec2e9f8df9">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c762ed44-8b19-4f55-9247-24ec9dcee637">
        <rdfs:label>depletion of cerebral folate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85f5e716-2d33-451d-936f-a599a1ff73e5"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42beb2f3-22ec-4909-b50c-4cd8c3f5f1ac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012335</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ac2f51b0-5791-4d90-9561-18b02c973de5">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46f6a162-9b11-427f-8ee8-415c8dab1a66">
        <rdfs:label>Woolly hair</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <dc:identifier>HP:0002224</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8968652d-94c6-41e3-9e8f-a2dc6ef7630d">
        <rdfs:label>Neurologic burden</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db981695-d34f-4592-afb6-c22c248e5358">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012389</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/162d6001-5d3c-47be-a99a-60f223c867f7">
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>Poor weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2b2976c-48c3-437a-90dd-1807f0fac040">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <dc:identifier>HP:0001010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ba0d4d4-ac8f-4be3-8f55-c372e7688b22">
        <rdfs:label>Rapid disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1bf921e6-f5ad-4b3e-871a-29daa6b6b75f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f302911-c676-4af4-8938-71a760fe3155"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/911e9465-ac47-4837-a846-9bb17d629d86">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low muscular tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0dd9adb-7f5c-4310-9869-7c38a62443d6">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f1dd765-9376-4c1d-b41a-74ad6e2cd7df">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025373</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11f88b90-9d42-43df-9826-ee74c156b0d0">
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2e79751-3587-4831-93ae-b7dba4ca24e4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/88624e7a-3655-49f3-bb5e-3fc537705ca0">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b67d725a-3e3b-4c5b-a6c1-d0ed43b95bb1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1de05da-b334-4a5f-ac4a-d80331636aee"/>
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/652ca187-552c-4218-9aab-8042aea84e0c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d928d32-81ea-4168-a620-6b85235767e7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>Involuntary movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/145abfd1-1f3c-4f04-bc35-9ce1e70cdd09">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal neuromotor function</rdfs:label>
    <dc:identifier>HP:0002333</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d381bd98-396b-4c01-839f-b915e34089cb">
    <dc:identifier>HP:0200125</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
    <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dceea310-1792-468c-8ca9-2b267b85642d"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6b2fe1e-3ab3-48af-9098-d3583b847925">
    <dc:identifier>HP:0000630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Retinal thickness</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/940e0cc7-efa9-4a6b-85ee-55f9e8ec58a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53d3e90f-794f-4a53-a693-4fee65009da2"/>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f3403f4-a8b3-4b24-88c3-ff4057e836c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>Short Stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d974f183-adcb-4073-822e-e93cd703e730">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/54f8ffe0-ca8c-4733-9b5a-e75c9cb10ae1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/81a1a65b-b1de-402a-a59e-0bcc7c7fcdec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/625da948-4836-4256-a281-719173f71856"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57e93c7e-5b12-4a2f-88af-7f1d4a4efbac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:label>Fatty liver</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8d7368a-1db9-4f96-bd56-465c252cc94f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002181</dc:identifier>
    <rdfs:label>Brain oedema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e902456-025d-4650-99b9-69331a198d0b">
    <rdfs:label>Congestive heart failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001635</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ea591d4-308a-4639-9c59-ce4cd8a6f06f">
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c5302907-4f78-4cae-870b-301c54d986c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dcf394a-ece0-4c4e-aab0-7d0e4f1369f9">
        <rdfs:label>Fat malabsorption</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e161222a-b192-4466-8a68-d1b58c0daefa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b72e30cb-c6e2-4a98-a220-dc8c10a877e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b8fa08b-ef6a-47b1-99a7-be295f0b9cdf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/251d818c-d073-4a8e-bd77-c577d3f0b336"/>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <dc:identifier>DB14751</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/127feb38-3620-4475-bd38-cf3dff2fbe54">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/148d950e-d748-424e-a249-0cd4c60936bd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/314f2462-f381-4381-8756-6ac333dc645a">
        <rdfs:label>Myelopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002196</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d885a10-bbee-4a9e-abe9-501f1b2fc447">
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d98fce3-6b5c-4149-9567-670f140942cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45b8ef9d-80ad-4de1-a230-e604eaa869cc">
        <rdfs:label>Methylmalonic aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca9ca021-feda-4deb-94c3-31593954f0ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/de812c3b-a9f7-4ad7-9e93-0eca1f01a831">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc022c13-dcc5-4bbc-8c64-63386b86c26c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3111fe4-c37e-4a6d-9627-3b9c06fbef97">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8fcc73e0-da32-459b-9ec4-a86918467ce1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0fd0a78-57eb-4e62-9140-81e71fe040af"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38e1ab36-dd18-4663-84d0-101e64240609">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased body mass index</rdfs:label>
    <dc:identifier>HP:0045082</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea178112-64a7-40de-be4f-63e722c03e52">
    <rdfs:label>high plasma ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/024612c3-5ce4-4701-8565-5f494f0c82cc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cc3f7ea-7c68-44c3-b9ee-c2d45da184a1">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/145abfd1-1f3c-4f04-bc35-9ce1e70cdd09"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/93dd36f6-8750-4a0a-af27-0de57644658e"/>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8dcf28a-4a6c-42f8-994d-ea6f99bbedfa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec94bc57-8e62-402e-9b43-a0fdf580bf67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a21ef6a-f7c5-45bb-970a-c042ce9d332e">
    <rdfs:label>Vandetanib</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0f86edb-eacd-4e93-9065-515bc1735b5d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a66d31f-8aab-48d3-beb4-70f09e8c6390"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffd3b8ae-b8f7-4d4f-899c-55335670b01a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/634c748b-c7f1-44f8-a5e0-cdc0de7b1433"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/beabe563-a6b5-4b11-824e-a3ff8e85d4bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f797b47-dbde-4309-a77b-7ba381df75f5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bac894e3-e86f-48c0-a29c-3b657833b5e3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ae9718-b3bf-4449-80a2-6d6c1d3ac3e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a234b73a-30b8-4bc1-bcff-9c5b75aa9078"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
        <obo:RO_0003304>M918T</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99641708-f8ad-4ff5-ac2f-8382299c8cb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
        <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fac3629e-6b95-4cb2-a07c-a04c0266d231"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b0596f6-ad4e-4d72-93a6-8fe9a0401afc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a380bf19-3828-4400-aa9f-834ee2262c74"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB05294</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a9e092c-d14a-48cd-b754-8e34d3b806a7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/27b7d8f0-ec0b-4afb-ab37-f4055f0d5408">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a4d99284-d937-4e08-8bbb-6b5fbc9d5b93">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/239c7bae-ad4a-442f-aecd-25fc765d0404"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f5d4291-82ed-483b-9a97-ce2bd78660b3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0e69cfe-286e-4259-84f9-fd99d0f515fd"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca9ca021-feda-4deb-94c3-31593954f0ba"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d75a15e-098c-402e-bdf3-661f7f643c16"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d84f2a91-33b6-4c56-aa1c-a40eab618c3d">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4c403e10-83e9-412c-8c12-bb08823020db"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121dc8ef-ca19-4356-a438-3c35fd5d52a5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab2ec0a3-36d8-42f1-bd25-f303b732f1ec"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be264992-32a0-4067-b1e6-2a10bb3e4c68"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/127feb38-3620-4475-bd38-cf3dff2fbe54"/>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/914b4236-56fd-4c36-8a54-ef43a5837ce7">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d062be0b-a577-4569-a921-b8483425297b"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af66a460-14f8-4d9a-a814-b2445b8a8e2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10b76844-b370-42c4-b5fd-28954870b102"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ee8b469-c56d-4825-9504-a3fd8a140a77">
        <dc:identifier>HP:0002148</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:label>Hypophosphatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c472182e-228f-4fc1-ad4a-ccf8d73f819f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030532</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
    <rdfs:label>Abnormal visual acuity</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb4b5e9c-f173-4723-be17-6e71d2fbe141">
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb"/>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62c49c82-25b1-4ac3-a642-0599be86aba9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c26039a0-66d7-462c-b3e9-955229a1b6e7">
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/999041aa-3977-4b25-99d2-380b14362fc6">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/140e54c3-d3dc-4042-8925-9a6b477cd5e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d501342b-0d23-4e68-a4d4-32b295881839"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/87f994f5-d9ab-48e0-a3b4-d78c33761645"/>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d8e7b1a-4934-4d34-8e05-d03e4aae1dd8">
        <rdfs:label>Low serum testosterone levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:004017</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/009b2035-37d4-4cf6-93ef-e12a84a8e824">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
        <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
        <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
        <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a619967d-78df-4f1b-9146-acaa33b1a826"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0987d636-ff1b-4049-b778-75ff0f37030d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75193a2e-0d51-4fae-96e3-2b009db28227">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70dd0d16-d164-4ce1-a9da-2e2d2214efa5">
        <rdfs:label>Low FVC%</rdfs:label>
        <dc:identifier>HP:0030878*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1eaaeba5-071e-44df-979d-6efcc49e69e5"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc1d3c55-805f-4434-8f2f-8d38c082b465">
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19d92124-3591-46af-8171-3898ae0b611a">
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6e2cb5b-2a49-4653-9580-0c169d1552f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7f6ee6a-0378-44e9-9347-1e481e94b8a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8865010c-53e1-45e5-a6c8-8198e23a58a1">
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52708d26-9e55-4983-b8dc-36726366800a">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab1cdddf-e84d-4e95-a996-e8b5209c66c9">
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b64f5619-da8d-42e7-934e-9629123a33ac">
        <rdfs:label>cognitive deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/803f73b6-73ab-4e4a-b4de-6b4972361154">
    <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/54814fbd-5960-4506-b4bf-feb104674424">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <rdfs:label>Tocofersolan</rdfs:label>
    <dc:identifier>DB11635</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/86b54591-44d2-44d6-8761-340e666de8d3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ef10091-f2b2-4ece-905d-6f566e1e05fd"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26588078-c20a-4c15-90d7-9cbd1ef59746"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4a3b2670-8741-4113-8bc7-1abe76396553">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b00cdcb-a67d-4088-97a8-62a2789c27ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b85fe616-2ea4-4730-8b71-3aff168f5261"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8cf4502-9556-4b51-a8ec-33d0cfa9c4d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e5c6bdd-e70a-4466-bb1f-154707628115">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:label>Exercise intolerance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d2354db-ce54-4198-a7f9-4e3c5c7dccd1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
    <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d8c63ad-f4ca-490c-83b5-8709f8d77970">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/078b9576-42ed-41b3-a71b-f5d14494ff1a"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47a603c8-6e04-4c2f-a8a8-ed42f095f56b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/286f8a1b-fde4-4fc7-940c-522037ee995c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/207d5e2c-827b-409f-bce6-7f5f8e55d294"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fad14cd7-acaf-4043-b104-42a35c2f535d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80722cd5-68ee-4f94-b530-95bbf4239480">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
    <dc:identifier>HP:0001250</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a83414e-d9ec-44f8-9d93-d7e3b3e927cc">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3961b565-cd49-4898-9b72-104e57966b08">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6496e5c8-f771-4b91-b3e5-57c185914194"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24dd241f-77c8-4c0a-888c-23dc554e19fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f03403a-80e4-4acc-99ee-3d3f5fe6b168"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd09d12f-0d66-405c-8d48-dfa8af7d5806"/>
    <dc:identifier>DB00020</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <rdfs:label>Sargramostim</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3fabe2f2-506c-4ed3-8088-7c39d25a487b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e78dc90-2430-4458-a697-ec50e76833f0">
        <rdfs:label>Increased ROS formation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41518c2e-a45b-43f3-b5b9-35e9eda86e86">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2251382d-1c02-42f5-9246-d4ed40aa4bf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fdc6821-f5de-4013-8db6-a4e01e7a2f94"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fac5859-06d9-4ffa-88b2-47ed385abdb3">
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <rdfs:label>Increased urine output</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/97aaafa0-bfa1-40b0-b15f-3b4e19c21f9a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/475df5d4-ba51-4dea-ba06-b1bd9692d6b3">
        <dc:identifier>HP:0012279</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
        <rdfs:label>Low plasma serine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd80a14f-24e0-447e-9a5b-48891c9155a1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:label>High total homocysteine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a12181-45f1-4fde-8d8b-43aaae6cd005">
        <rdfs:label>High total cysteine levels</rdfs:label>
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5211bc38-34e4-467a-aa40-283e11d7a62b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf7cc404-6b04-4d1c-87c4-c8f6c001e57f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17e869f4-636a-4d91-a248-ab2941f4661c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bce9435-2180-4285-aab2-78895bf9066c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9e5a6b6-f562-4d6d-83de-a9d8da84a740">
    <dc:identifier>HP:0002156</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Homocystinuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f00d25c-c194-48a6-b268-a366eb5960ff">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd14692f-7a8c-4f13-a600-3a4e257d7a41">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
        <dc:identifier>HP:0025548</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb814a09-0b50-450a-909b-23e936196c58">
        <rdfs:label>Low Hemoglobin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0020062</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02f3f738-1b6c-41ed-af33-21e3fed4838f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100502</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/148dd5a4-b405-4d9d-a00f-2562301a3960">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
        <dc:identifier>HP:0004312</dc:identifier>
        <rdfs:label>Abnormal reticulocyte count</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1eb68d4c-7b36-47d3-bfce-afd609881f83"/>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28893bf5-4447-48c4-9585-6de90aa97768">
    <rdfs:label>Filgrastim</rdfs:label>
    <dc:identifier>DB00099</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8a4acbb8-4a6e-48e4-b2d5-d50dbba13f9e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55a97889-0993-4b18-827c-d0287653d0bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c045aaa9-e215-47b3-8972-94047b2d17f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4713e53-fe5e-4f99-9f06-c0b643e7baf4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3af231e5-7d1e-4367-aa97-64eeadb423b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
        <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6f9b036-eba2-4dee-bb0a-f83e7d038b13">
    <dc:identifier>HP:0040144</dc:identifier>
    <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbb81349-0657-4eca-8654-9d0a69af483f">
    <dc:identifier>HP:0000992</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cutaneous photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/90cb0f7b-1219-45e7-b6d7-51e803840784">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/408ec176-faa4-4da0-b7a7-7fa486114e5d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ad0b1d2-8e42-4271-bf8f-1baba8ba742f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:label>Impaired nerve conduction</rdfs:label>
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac95aad1-7757-4cdc-9114-a49de9f0effd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55467eb6-ee00-442f-afdf-97bf5272119a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e6dc6b0e-c76e-43ca-b5bc-4aa9bb87eb6d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17c93b88-9ba0-4dc9-90fd-2043e2f91399">
        <dc:identifier>HP:0001019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Exfoliative erythema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5adf6c1-b57f-4804-a334-15cc16072a75">
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003073</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4154e542-87a1-47de-bf70-917094b8a1e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9e6c341-aac7-483a-971d-ddb4638ce57b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4be203b7-b246-44ba-ae6f-3ca46ba8721d">
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:label>Chronic diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/52ad4fb3-8bb4-4d60-9a74-3dc421657781"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/75754550-f825-48a6-8d60-6d698eb8063f"/>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e1f68866-15dc-44cf-af28-43e62d0eff3a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/818080fe-9860-419a-9859-d2d1b0899d50">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9dcd1b3-084f-45c9-82d3-2651caae882a"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a24f5b99-b4af-4f31-8635-82e1ba0dcc22"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe227ee2-8a9c-41cb-b58f-7043820bc71e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80c6d16a-7489-40b1-b5ae-db19218f350a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4566926-eb46-4ec0-9753-075224c7bf0f">
        <rdfs:label>Atrial fibrillation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005110</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/f58b4748-0a21-4b19-a2e3-f6ccda8f4b1b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/727a96ed-6ca5-435c-ab43-74a0af73dd0e">
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <dc:identifier>HP:0012535*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c30e9f3-660c-4e51-89db-e18e225c80e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58d679c3-7a44-4ded-b7b2-10f138c20711"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/879f892a-f7a1-48da-9167-477bb40984f2">
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e883eca-1634-4c04-8b8e-a93a819a1b5d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalties</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67d54d30-238b-4738-886d-8df98d6ed82f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc264361-c630-4baa-a62b-a53ca1dd9a99">
        <rdfs:label>Abnormal growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001507</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faf83ed2-84a4-4195-8359-b41e772fe9c2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e7edc730-e126-49a8-a6f6-1fd577916ea3">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/195291ad-13d3-446e-9fd8-1d8fd2389e02">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf7af3b5-5fda-46d8-957a-a0511c870656"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05975cc3-80b3-4505-8a0e-387c3892a3ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b19d04e9-3b03-4e3a-8a9b-14e3a2e24320">
    <rdfs:label>Pain in the skin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
    <dc:identifier>HP:0025280*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0dff735c-51d0-48a0-afc9-2caeb241c7bc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Delayed motor milestone</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b0bc5397-9f77-4e98-9be4-b73d009012c0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3843cb8-fffb-44e2-8e8e-13d4c85b9669">
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>photosensitivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/716a2ef4-c9bc-42fd-a9f8-2619b72caa9c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/857e9942-3fc2-4150-bb69-a1cc126c37e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ac29dd7-5e06-4764-8f7a-30f9f15eee17">
    <rdfs:label>chronic diarrhoea</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
    <dc:identifier>MP:0001665</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/16164bd2-9eea-48bf-9a06-06b0d1753da5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6b5d035-184c-491b-9ee1-d6d259bbefda"/>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4d57c20c-0126-4afe-840f-66c3cb9bfc4a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10b76844-b370-42c4-b5fd-28954870b102">
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/914b4236-56fd-4c36-8a54-ef43a5837ce7"/>
    <dc:identifier>DB14573</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2f5341a-31ad-4f29-857c-248b3336ea57">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a7e025b-28bc-49ba-bc4f-9fd6ee9a9ae3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <dc:identifier>HP:0003040</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54ef6c74-b260-4640-8a62-0ba0196ba883">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>swollen joint</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53b37733-1d18-45af-b190-5ca9c7bda55a">
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c670e3e6-a636-4cdb-969f-ab05901442d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/697ea308-2fd9-4c12-97e4-aa098cee0156"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98e43462-8803-46a7-a881-463048171eee">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:label>Developmental abnormality</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/6914ebe5-e979-4daf-a5b9-ee19d5150103">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afc6fee2-bbd3-4d39-bbb0-9902b54e677e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57110376-8214-436d-aab9-1b3f320cdea7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b102860-feeb-4e2f-a323-b860627ae27f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c472182e-228f-4fc1-ad4a-ccf8d73f819f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d83aa50-81d5-4497-b8b1-40d2b5c53b8e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
    <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/db307552-71aa-4d32-96c1-b96abe034901"/>
    <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4cd9ccb-a5d5-4f4d-a248-c7b0deb03fc9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/044d8f22-902b-4bb6-a016-90c31ce88e13">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df37e5f8-8d41-419d-9571-fc72a4b76a67"/>
        <dc:identifier>DB00509</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef53cab3-a100-49ce-92d4-e9c1390cfea5"/>
        <rdfs:label>Dextrothyroxine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5db1e47d-5c7a-4801-be12-95704f42f93f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8defca1-97b3-40f6-91b6-30334ad0fc2b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025303</dc:identifier>
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b5045c3-53ae-4fd7-b8a6-9792a7f9515e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3c466da-9eac-439a-9d18-5e3403e9fd44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aff73725-54de-4ee1-92e2-5d1fe6dd8d19">
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b1a6fee-b053-4f7e-8dcd-66f09b571f60">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd760c1d-383b-4aac-9649-a75775e386c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/242b0a0a-71e5-49d3-8d6b-9f2f5d95aeb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/99e7cf1b-9818-4c7c-bf40-8df7c84cafb1"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bd6263b-73da-4827-94c3-fe5f7b0879d1"/>
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/55fe6dcb-c15b-4317-b249-1a5b00bd6a4d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36c5f4d9-e40d-4816-9fa7-00947ceee22a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af9b1ef9-5ded-4f83-9acc-f53b3699938c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fc3f217-e76e-4b12-a0c0-36c7974f6f4f">
        <rdfs:label>hypersomnolence</rdfs:label>
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea7223d6-84d9-47d0-a61f-88b68172c627">
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>excessive adventitious movements</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44852d88-281e-42f3-8c9b-b7163122dddc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feaea220-2e46-4420-ab35-3b2fb96ba463">
        <dc:identifier>HP:0000657</dc:identifier>
        <rdfs:label>Oculomotor apraxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc4ca39e-58e9-4799-8c21-8fbe08f44f09"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a100b19-2af1-4851-b545-7e2e255ca142"/>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6605d59-1f7b-4e3e-ba74-752761295720"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df37e5f8-8d41-419d-9571-fc72a4b76a67">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41117a53-a5bd-4ade-a79a-d7b704a35224">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b4cd9ccb-a5d5-4f4d-a248-c7b0deb03fc9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba370630-42e7-472e-baeb-69c920565b9f">
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dc58794-8b68-4744-9e9c-987f5fdea33d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0fcb44bc-64bf-4c08-893c-c88ed6864465">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c6ea638-1eff-47bc-9b5e-d14137c3eaf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/87c727bf-031b-4e14-b6ca-f7f8995bedc7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ee34cc9-5602-46f9-867b-6a4465207765">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf79f82d-7a9f-4e26-a16f-d58ede2aab74">
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c284925-8ca1-4695-83a0-7ed4a554965a">
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hemolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e01dd8ff-6edb-4fc3-9898-cf24ae445c5f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal immune function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1660a1a3-e992-4f8b-90ef-8949b0682f07">
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cfd8fe0-935b-4ec7-91b5-02052acef502">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69c2529a-521b-4ab8-a52b-64c8d44070e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low weight</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/515c802d-87c3-478e-a60c-fdd5b0f513f8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0ac2ff0-a821-4e67-9cd7-3bb322fa5913"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ac05b6fa-9d44-4697-a3e4-d97b43cb16d5"/>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14b9ac8d-6b97-46d8-b4c9-87dcd3c991ce">
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001879</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/073b1e95-efe1-47cc-afd4-4a9f279a4a22">
        <rdfs:label>lymphopenia</rdfs:label>
        <dc:identifier>HP:0001888</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb6653f6-3d97-4518-98fb-c171a2f2d57c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:label>Poor motor coordination</rdfs:label>
    <dc:identifier>HP:0002275</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40decc3e-df7c-4149-8d26-c41bc7f406e1">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>High serum triglyceride</rdfs:label>
    <dc:identifier>HP:0002155</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c5f600a-35b4-4fb4-b48c-8bd284cfb455">
    <dc:identifier>HP:0000969</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>pitting edema</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6f93c49-9649-43d1-bfdc-c733588b0b9b">
    <dc:identifier>DB00951</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/4d8c45fa-a51e-4f24-b32f-6c6fbd9950f7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/291db2ae-89b1-4606-b9a7-abb208896f2c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef32a5f0-4489-44a8-b984-5ee4025569f0"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <rdfs:label>Isoniazid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0d855926-3682-42b1-9e40-4484e71014ff">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c8a311b-7b42-471e-894a-0c7ed234c05d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>crystalline nephropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdb230bf-3c83-4da9-9ae9-4292049ad296">
        <rdfs:label>urolithiasis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
        <dc:identifier>HP:0000787</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71253433-3c1a-4472-a284-b4f59407bf4d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0dd243dc-e954-4e72-ad44-619b39d6578c">
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>Chronic kidney disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaeb6362-5a19-4b8f-a259-f3f2f87e0f96">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100518</dc:identifier>
        <rdfs:label>Dysuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/18f0e624-4a52-4523-a16a-f278ba9f2dbd"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a24ab314-3ca4-4425-a3ff-893e933a3ff2">
        <rdfs:label>Kidney stones</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/703106c6-6ff3-479e-846d-788fb4ce8732">
        <rdfs:label>Hematuria</rdfs:label>
        <dc:identifier>HP:0000790</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dd2c009-9dbf-4404-8bc1-851f8ada660a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <dc:identifier>HP:0000010</dc:identifier>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/bf611714-48f8-44b7-9a10-fafcc51cbb5a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e55f40e-c638-479d-b78a-05676aba4261">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11587bfc-a247-4e76-8e8f-162b77828e02">
        <rdfs:label>unalertencess</rdfs:label>
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76440696-53f0-45fb-b2ab-f1340c403788">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Receptive language delay</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd982d6-99a8-472a-97bb-cc08550c238c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a0b435d9-9441-4c58-875e-7f282f6fc2f0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24dd241f-77c8-4c0a-888c-23dc554e19fb">
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
        <dc:identifier>HP:0006517</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f03403a-80e4-4acc-99ee-3d3f5fe6b168">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79f58799-1ce2-4c82-ace9-e114c98e548c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b5b9e90e-d5b7-4c86-acfc-686cee566bdb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a86344fb-552d-4d0c-960d-c67c335cc453">
    <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fed558ff-986d-4282-9f35-4455904c55f3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/307264cb-41b6-4a70-a4ef-ee98e9e85fdc"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6df09c2-c881-4ae9-8d3b-0c0bc22db771"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/23f304ea-57d5-4edb-b2bc-8b655723e4a1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d385322-ef7c-4045-b261-20b987687f7c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a928d4a-0ba8-4bc0-bc9f-8415558b9903">
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a8cb0000-f3f7-4e12-bafe-6b49df4265d1"/>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/006bf1eb-42ad-4200-b8c1-be84a6253158">
    <dc:identifier>HP:0006670</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8237787b-6bdf-4a1b-9f10-617a8c1a5cd2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e23fb56e-f98a-4b9e-9818-2cdef3d9a656">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94a67fcb-b789-47a4-a180-f2779ce88a8e"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56f37687-a36c-4a6c-8bdb-b2106e8e3ce4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>biochemical abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6049834a-9171-4744-a2c4-1f495a06f8fa">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9712171-61f6-41ef-8f7f-8656e88b375b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4777143d-c9f1-4eb2-8fff-94f831e21ed8">
        <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e4f1cc5-045f-41d3-a86d-2460b935ee0c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b54470a8-26d0-49d6-bd2b-0b2cf1ec4b1d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2199a2dd-773d-4781-8d8a-4febe56ac471">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18126e48-fd20-4894-9aa0-04e4e1c221ab">
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5723d01-c818-4c72-9771-4885458683e6">
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0500014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c286857-6671-436c-bf5c-cd318229f077">
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/037fc5d2-e0f8-4aa5-9a87-6eaf6a3c4a99">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
        <dc:identifier>HP:0500014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2d97e4d-396a-459c-954f-fb1b30aa0892">
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003434</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6cabb0db-56bc-4b0a-aeed-97265304f7a1">
    <rdfs:label>Thioridazine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6bdf7b7c-4cd8-42bd-8c9a-90915c1d7b4f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75cfa682-06a5-45b4-83b7-5ddb4178c95a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0412d721-f32f-41ff-811c-8013924d72fb"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05001839-b91a-44e7-a421-0545da65b8de"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <dc:identifier>DB00679</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/977fc78d-07c0-46e6-bbce-49c02a282984">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28127ec4-9cf9-4e9a-8625-e665c2e2fc60"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6a25c54-a137-405b-9213-042cd4f16435">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b09694dc-d8e8-4d0a-a18f-aa884d437815"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab0ce5ce-9d1a-4bc7-a771-be6fee0d8c46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/804d6434-0216-45e2-81d1-bae38d2b9965"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cbff235-14e2-4693-b0a3-37d7427b7cfe">
        <rdfs:label>Abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2703065c-1219-41f8-a4f3-56f6510cdd9d"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3449ca3e-778e-4700-93b9-77ad033d3eb6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Failure to thrive</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f1ce509-6da6-4d82-9845-7fe4568181f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a101e038-9af8-4302-9f3d-b4f5c5a0e73c">
    <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002069</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/918edba5-66fa-4a39-8eeb-8510ddd27454">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07084c47-6ab1-4e9c-ab0f-b3277b31adae"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf7d2cbd-c6b6-41ad-b389-6afb298fa4f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
        <dc:identifier>HP:0003656</dc:identifier>
        <rdfs:label>abnormal glucocerebroside level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29824d69-0fd7-4398-9495-efd8b8255fd3"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ad7bb64-c16a-47fd-aa31-ab5b44b3c4e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4491ff9-2861-433a-9ad8-f13b0f3cca40"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0cd8df3-c21f-4bb9-96f1-08827df89001">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc1fa6a5-b2c0-4305-bcd7-00e167f039cf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0b1abc2-2f3a-44c2-8fcf-9101bd25b43d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5da8ede-79fe-47ec-822e-f8974e5ac131"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/685aea18-5f42-466e-9bdf-6e7c66679579"/>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c34ef994-538b-4de2-9bb1-9b27b27fc9a2">
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ee8b469-c56d-4825-9504-a3fd8a140a77"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/607c8c98-8bea-45e4-bbb8-9137902faf5f">
        <dc:identifier>HP:0002748</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:label>Renal rickets</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af66a460-14f8-4d9a-a814-b2445b8a8e2c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/bd4c3b99-389c-4158-9230-75d8157d9bdd">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39d6452e-8393-44ab-bbef-54cb9dbdcad4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b893c863-26c0-4a40-987a-be38284827d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e0c8fcf-cabd-4c05-b528-89e20883dc28">
        <dc:identifier>HP:0030872</dc:identifier>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb6d0c8-c4dc-45d7-aa6d-c579141a6ed3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05b6b149-5e27-484b-a526-e1d9bd3e9f56">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8f6007c-f44e-4485-a94b-61ec900b2fe1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <dc:identifier>HP:0006670*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/039d3be5-19a7-4356-9f54-4ca6bb04b794">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001714</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/09c4d20f-9c3c-4a74-bcda-841fed5235da">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6453a82-864a-4768-9356-ed44e11cc3d7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aa7c4f1-a891-48d7-8aa7-bbc11a9b8768"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/700c28e1-af03-416c-b573-eaef22903269"/>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cebb3e29-69b0-4870-a271-7a1ec86cb415">
    <dc:identifier>HP:0012350</dc:identifier>
    <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b9ed7db8-93d6-4545-8b4a-3de25d4a68e4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7027b79-d5c2-4c90-b09e-fae1b74a5a1b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High ferritin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85f591bf-ded7-4fd5-b60e-c19c932ee117">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52e231e1-b574-4b0e-8aca-448974d6ff9a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdd9fd00-16cc-47f8-bbd7-1bb20b1064fa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6bd1115f-080d-4fa0-a813-d59e76104262"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be579552-3fd3-4caa-a92e-be83f684b612">
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <dc:identifier>HP:0025521</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb513799-44a1-434a-9b9e-aa90fec7e33a">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33ee5666-37fc-4bc9-82a5-544771a3a6e1">
        <rdfs:label>Pruritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5540e9d-fe60-479c-a980-9b054f2b675e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9e04d21-40d2-4ed1-9918-f51640410924"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff1b0975-30c2-4504-b76b-4187e8f309a0">
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>scaling</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/210ec608-b211-49bd-9df7-07456f327e93"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/685f0728-fd80-470c-aaae-f5f8f865f81d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:label>erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bba55650-7890-401a-9aa7-2985dfd38e3a">
        <rdfs:label>Ichthyosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5116760b-a3db-4631-843d-4a8cd3ab0f82">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c8c2ab0-29b4-4908-bd30-1c7f2a5cc651">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
        <rdfs:label>oxidative injury*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025463</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8240dd50-e8fd-4473-a201-ac6710ed36ec">
        <rdfs:label>lipid peroxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f8177c6-d553-4239-a1f5-cf71251fb498">
        <rdfs:label>Protein oxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee81f54-a74d-4170-a8e0-f3e62a110fb9">
        <dc:identifier>HP:0003254*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
        <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
        <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71e1a425-302e-48c9-9c48-4cdd30e03ea9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/00243f40-69be-4a46-8b72-3d63e080ba75">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71101da0-6826-44bc-b283-8833b308f849"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f9e46a0-e26f-4241-95bb-b5d653d7b93b">
        <dc:identifier>HP:0002415</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>progressive leukodystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6362ade-448d-4f8f-acb9-c227926cf29a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003470</dc:identifier>
        <rdfs:label>paralysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/006bf1eb-42ad-4200-b8c1-be84a6253158"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92e63bde-e967-4c6b-99c7-d79600a6ee2f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47c70c13-8064-475d-a61d-a92a8eb5e5d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9bcca5c-a893-4aa0-94ec-4c8b6b8d7831">
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal spleen size</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89c8c6d0-4e3a-4ca4-966c-a1b45f595d9c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e4f5f07b-3604-4fd6-a3e8-34a0a3d9fb7b">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/696b9cee-3a7e-4060-9a44-dca48856ed49"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/642f7f69-4eac-4cc2-8c10-cc537adde5cb">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b397460-05ee-4d42-be72-94b6e3e57329">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01111570-441b-4d08-8a8a-94c7f0ec3509">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2bb68ca-0239-418c-a288-d70de0af85e3"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc4ca39e-58e9-4799-8c21-8fbe08f44f09"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ccb5b112-02d0-47a1-a9c5-2875d3905b67">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/106b02dd-0879-412e-910d-8df183975b9b">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2e9c3b5e-5715-497d-8212-e3bf64cde510">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3973188-ab6d-4b26-b790-3f21ae14739a"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/75115609-35ee-4918-96aa-55d5c95f0c84">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3973188-ab6d-4b26-b790-3f21ae14739a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ba290e9-3ffb-40e9-a1ca-d2a4cf9fe24d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0718ede9-ab2f-4fca-8249-c3eb88c4931e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187a3a1a-dac9-464a-ae40-44d42ed0e87a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/646ccbb2-3c31-40b9-80b3-020942a07146"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee86276a-6069-4cdb-b90f-d2d4b20e3913"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc62b5d4-9118-480a-9696-9e01a12a88e4"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8f9000cb-b7d7-41b8-a957-1c2219a5bf52">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e18bfd7d-7ba0-45f1-9407-e84b3d478164">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b31299b5-d049-4ac5-8fe3-4967e7949e60"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4b2906e8-4167-49e6-909f-d4895e758f09">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/825a2979-6fb4-4953-b9e8-a39f61942927"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/438783a1-09d3-43ad-b0cd-54ba538a52e9">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3973188-ab6d-4b26-b790-3f21ae14739a"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dc2d19e8-cb83-4440-b38d-4cebdcb3a2d2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/002ab948-5ba4-474a-b5e9-aaf0d83b493d">
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c747c24c-f737-410e-b80d-0aaecfb1b873"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3973188-ab6d-4b26-b790-3f21ae14739a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22cf5f1d-f0f0-4484-8ae1-6a27710a004d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1f74994f-9145-4213-aa45-a389c5b9946f">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/33b25b60-2558-4e7a-8458-2289f995a958">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f6155ef-084c-48c0-ba93-7102ee3936e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/041d9a0a-60ae-4789-b33a-21e525049c2f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d05c0e03-b7a6-4272-9d3b-0d3fb9251603">
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf72a545-950d-4b11-99d0-73e9ffcfd2ae">
    <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
    <dc:identifier>HP:0003676</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8e09587-2462-4129-ad1a-3db601656201">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36a18548-8e6f-4c90-8fcb-c29f35799470">
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
        <rdfs:label>Reduced hematocrit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c78b0678-b2af-436c-aff4-e906b4f9e28e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d1c6eab-c016-4dfd-bab0-05e24a4bc0e9"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b84a409-ecc5-442f-a38a-3e958aef2218">
    <rdfs:label>hypochromic anemia</rdfs:label>
    <dc:identifier>HP:0001931</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fbf3224c-7482-4838-9c33-27701afaaa97">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/619d5c67-2e18-4bf3-aa5a-e5cec5d9542d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581e121e-b9e9-427c-b162-a667058dbca1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f84b3368-2a48-497e-b174-4a9cb88cde85">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
        <dc:identifier>HP:0012212</dc:identifier>
        <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/552ec24e-910f-4641-b33e-0c6cce8cb2b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68720a0f-6541-4ee7-a9ae-00eef220ab0d">
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42253eeb-87a4-44c1-8b59-7a65e7da59bc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/161ed7f1-083a-4069-bee0-e9aa8c458d2c">
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3be32f59-010c-4e46-90ed-2ccc64890b13">
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aca18ad9-85ce-46b8-b7e4-c225af694a94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac864456-7e1c-4e52-8253-37701deb2cdd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eabb7b91-f8e6-43b6-b12c-5a0e774b5afd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23eabb7a-e872-4867-ac34-4adc1f7e85ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a687f674-5d5a-4f22-b4b5-da4062bbb760"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/429fe02b-52ef-4af6-ab2b-36327577d209">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39cc4249-1396-42f0-b6dc-428a9fc0b436"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0475ca0-4140-40ce-9975-95aba0060e0f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:label>mitochondrial toxicity*</rdfs:label>
        <dc:identifier>HP:0012103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/625da948-4836-4256-a281-719173f71856"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2fbb4e84-c137-4fd7-a070-898dd1ddc7ee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e7b0341-2904-4f54-a438-402394b74fc9">
        <rdfs:label>Photosenstivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fe2ea1a-425c-4e0d-8333-74b08202408b">
        <dc:identifier>HP:0000969</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fluid retention</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09d6f67d-a9ed-4417-bd84-e50b828a29e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8d07656-108c-40c3-976b-c1ad30faac8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33ee5666-37fc-4bc9-82a5-544771a3a6e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6182d6e-ae34-487f-adcb-eb0161324c1b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function test</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a195edad-7c37-4cb6-b526-31a83b79b263">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d84560db-e691-4553-a52b-28da3f306b7b">
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:label>Abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/badd9626-39c1-4540-97e5-02a1a28d244a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
    <dc:identifier>HP:0002013</dc:identifier>
    <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/217be06e-68c0-4838-a051-bcfdd0b7762f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b28b63ca-a0aa-4b21-9db8-2088f66a5043"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe3a63d8-a9f3-48d7-85bd-7355351b7e89">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce59c889-ca3a-4b2f-8618-64eca684a1ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c90d2bc4-e781-43f5-bb83-e18ff2b5a356">
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <dc:identifier>HP:0031517</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bf88f5f-aa3a-48c6-821a-47e928d02f11">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
    <dc:identifier>HP:0008972*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8e0dc87-268f-46e3-a6fc-195bb3df9113">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a84aaef-69b3-4bfe-b5c6-65bd109a5655">
        <rdfs:label>epileptic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b813d42-2487-4f2e-832c-39cfe5684d55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:label>Hyperinsulinism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000842</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad259bd-062c-4d3f-be23-0da0aaf5efb5"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a6b2710-d7d8-44de-b497-0e818ef536e5">
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa6267d6-44ba-4b24-952b-12dc4bba598f">
    <rdfs:label>Chlorpropamide</rdfs:label>
    <dc:identifier>DB00672</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c35c3ac-501f-4a21-8472-c50a2a02f0c6">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/476b928a-f91c-4d5f-9f86-35f467933f51"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fab9721-b6f0-4c0e-ab7e-302703e0ed7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6eb9660-152c-47dc-b580-236f2797f92e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
    <dc:identifier>HP:0000989</dc:identifier>
    <rdfs:label>Pruritus</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1141efd7-2950-43cb-8aea-cc60031379af">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated long chain fatty acids</rdfs:label>
    <dc:identifier>HP:0003455</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e20cfd4e-df62-49ff-8f54-c3599be999ba">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/525b61d4-e4d3-4c20-9134-0aee637c779d">
        <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/243799ea-6d4d-47e9-ba2a-5b25f48ec5f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ca2d08f-4496-4429-8477-afd8ce39a51b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f7f1bd6e-ee10-4bb5-afc3-174e6f49a4ef">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d97b0f6-1ae2-4dfc-9331-7d93f4f2c076">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36838b75-0843-4f08-9553-9b8c30fdc7cc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/269f0de0-7a9e-42fe-a141-b042b8bfba62"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c4034eb-ba1f-4f59-b517-be56026683e2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
    <dc:identifier>HP:0003676*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/486306e7-ae7d-4515-bc33-e3f4c98f0aef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8863788-a816-41d4-9529-5c539d3d0424">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72268952-7838-44e7-9188-18096dbab6b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f6008c-1467-4e1d-83eb-41d99defe2e3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased niacinamide level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5d1c76c4-89d5-4415-8591-0dd3b1b393bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64d0ebf7-1eae-41c9-9224-ca52ad96896a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0fd0a78-57eb-4e62-9140-81e71fe040af">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de812c3b-a9f7-4ad7-9e93-0eca1f01a831"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <rdfs:label>Amlexanox</rdfs:label>
    <dc:identifier>DB01025</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5885dd0-ffce-4474-b82a-09a48795b38d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f026c81-03a6-4f3a-afcb-9f4722bbea60">
        <rdfs:label>Captopril</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d0b01b7-8f9b-41d2-b5c6-4699b2bc5478"/>
        <dc:identifier>DB01197</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb018ced-49c8-4d1f-b61b-dad1cff0588d"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f637994c-b9c5-4104-b8bd-3c409de6c1c6">
    <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <dc:identifier>HP:0011123</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/14a07da8-e409-47fe-bd3b-3c207a725abd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2096d725-cfcd-4a72-8af6-457d6369d737">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc964cc3-2ee6-4e40-be4a-a0ad5a3980e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd7beeab-f95a-453d-a33d-ea2db3250414"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93f36d71-77f1-417c-8031-53590ac52fe0">
    <rdfs:label>Low dopamine level</rdfs:label>
    <dc:identifier>HP:0012656</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a46cf0b2-1e68-4201-aaa9-172d71f30ed7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72874cd6-ff88-4839-86ae-9e603709ef5c">
        <rdfs:label>tricuspid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4095c320-042d-45c0-ac3a-f9412a537fb3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:label>pulmonary regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5e00e08-c1bf-4dbf-9f8c-33aa5a56544c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc37896-f741-4854-8b71-bc18e4d67b28">
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
        <dc:identifier>HP:0011729</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c73a97d4-8356-4ba5-8177-3d87885bc9d5">
        <rdfs:label>dyspnea at rest</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <dc:identifier>HP:0012763</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f699d21f-6dc1-46f7-8de2-3b07f31e6ef4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5795f9e4-6a34-4ecc-b36a-8a9cb1f0e696">
        <dc:identifier>HP:0030953</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
        <rdfs:label>conjunctival irritation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcf5c62a-5537-45dd-9257-e71f35f5487b">
        <dc:identifier>HP:0002877</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ab88502-1fe3-4720-9234-9c4e7ea1b9ca">
        <rdfs:label>photophobia</rdfs:label>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b2bb535-19b0-4184-9641-2b62d21b7d9c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e822c069-ff10-4744-bba2-644a0ff59359">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22c46b47-09fa-4dc4-9853-7f317f487094"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d126bdd-d273-47f2-aba6-86239facc10c">
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:label>Sleep apnea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1494a08-9b6c-456f-99db-1a338398892e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low exercise endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22aee595-5122-489d-b095-4278349362f6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <dc:identifier>HP:0002189</dc:identifier>
        <rdfs:label>Daytime somnolence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db27d8c8-9eed-4a7b-acc9-6c10645d0b5c">
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4fdbb00-a69d-44e2-98f4-333e18d85554">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
        <rdfs:label>brain ventricular dilatation</rdfs:label>
        <dc:identifier>HP:0002119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c5f600a-35b4-4fb4-b48c-8bd284cfb455"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe2f0a11-ed24-48a4-b1f5-6d1fad2a4ea2">
        <dc:identifier>HP:0003541</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29824d69-0fd7-4398-9495-efd8b8255fd3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58c8d806-0f20-4909-8005-c657b36973b0">
        <rdfs:label>low quality of sleep</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff5020d4-a449-41a6-980f-0ceaa424fb30">
    <rdfs:label>Metabolic alkalosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0200114</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/923a8d29-271f-413f-9c21-ec49505f8b0a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3202570a-5fb4-4c79-9d5a-e595ed2ab52d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a6d9abf-a625-4c11-9dd0-3d6d06add5c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/915980e9-ada5-44f4-9d86-8a7220c7a80b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <dc:identifier>HP:0002020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c97d9c79-dea0-4536-bae9-631178967c4f">
        <dc:identifier>HP:0410019</dc:identifier>
        <rdfs:label>Epigastric pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f881fd4-9cbe-4fce-a6a9-79a1a02bad98">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor development</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/17810f92-e463-4cf8-8087-38f00e0db66e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e640a45-2522-4152-90fe-0a53e5b86129">
        <rdfs:label>oxidative stress</rdfs:label>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f41f7cc-7f86-4907-8cc3-e3ad3fc92706">
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ffc71ee-7830-4d8f-bbcd-2a519dcb8c8b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b36ea9a-8557-46f7-a5ba-db763cac70f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7e038171-594c-4f19-b805-24abebea4df1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/056195a0-5e42-4c16-8a46-433e91e0ab4d">
        <rdfs:label>Renal tubular acidosis</rdfs:label>
        <dc:identifier>HP:0001947</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95a13eb5-f6b7-4314-b28e-d9f1578679d9">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f6f134e3-ae3a-4eea-8cf2-8828c0237875"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/934c04f9-cbb1-4d9d-bf6a-a2db753348a5"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/045722df-9cb5-4dfa-bcef-6cc79b9e0134">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8a1a090-c686-4452-bc10-94d32d3bf46e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <rdfs:label>Xanthoma</rdfs:label>
        <dc:identifier>HP:0001114</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/abb728e5-3bc4-4a97-9d2e-570d5bafb48c"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9efbe5dd-9efb-450d-946b-16c28d2c658b">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6811c1df-5744-489a-9956-2ddefd397000">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a928d4a-0ba8-4bc0-bc9f-8415558b9903"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ba850e77-5885-4123-8375-1e1ac366010d">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f13e7e1-3e94-4474-92a2-3ffaa68a359e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ab8ce253-81b6-4452-a788-3b8342a6ec15">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c6b7447-927e-477a-b4d7-bc390983c2fb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5e65a18-f51e-4f93-9663-b00fc22f26aa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>p.I480M</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be976290-903c-42cb-881b-cdf274981ba2"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <rdfs:label>Thiamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05dbf711-3dd5-4734-8b82-387e48c32d47"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
    <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
    <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
    <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f014e44-944f-4e8c-8145-7264a4a3a7ea"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/adf41a86-b87a-4bc7-8ef5-af4ef6f4634a">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c66bac3-2a6f-449d-a485-84483843ac0d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythroderma</rdfs:label>
        <dc:identifier>HP:0001019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bba55650-7890-401a-9aa7-2985dfd38e3a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfa6e3dc-c83a-470d-bc9e-8d1a78a73c8d">
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df271d5c-5c38-4c25-b5b4-8f2024d98b51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb642674-ddb2-4d76-9983-f7f061002cdf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d5540e9d-fe60-479c-a980-9b054f2b675e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/069fd4e7-cff1-4b20-a0ee-8175ac4b7b52"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e283e4e3-825a-42f8-98d9-e7348dee4081">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189*</dc:identifier>
        <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c986c5e9-21bf-40ae-a34f-0a6656b17a08">
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
        <dc:identifier>HP:0007479*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c6d063b-eec8-4241-881c-998b7e96c3dd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e314f4f-ce8e-4739-882a-465b1e55f36b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <rdfs:label>ARGININEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1520381-e35f-4e14-b6e1-d245b62f1c57"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/465415c8-257d-4202-aac4-f538c25f7673">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8aa6dd30-3e11-42ea-9cce-8bd0c1406bf0">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09d17419-367e-4116-aaf8-3ef664a896ac"/>
        <rdfs:label>Ezetimibe</rdfs:label>
        <dc:identifier>DB00973</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/382b7801-833d-4a77-9a54-7312be0f67c5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0051438c-98ac-412a-b1f4-b9bd5e6a69d9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
        <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
        <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
        <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d59347a0-3266-4288-a17a-488fc7779577"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce3343ac-2b69-4d04-898e-790c6a846443">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003362</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a32ccd7b-3f03-417a-8409-80d9b903ce7c">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/208f6527-dfe7-43ee-8b3e-8250a100107c"/>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4b27663-3aad-4a35-9388-2b6fa6ac9c77">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4a3a9cc-5449-46ce-b960-91fa8c1ad812">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e99c2a85-5e76-4732-99af-f65f60165167"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7241ece-d476-4814-aedd-841b3de5d2e9">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2962b8ec-b3a9-4cb3-bc01-30bd1af612eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e852b1b8-e728-4954-9e3d-94e5309093b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaaf83f0-f364-431a-beba-fd54e0287336">
        <rdfs:label>low physical capacity</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ac0592a9-e0a5-49b6-947c-3d1e4ea2e73e"/>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/93d7453b-03f9-4210-b403-51532a4818f7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffbecc95-ba28-49f1-bdfa-a1ca726f6824">
        <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ef87af-042b-4b9c-8811-74fa513b7b81"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e54dd8cb-381c-4ede-969c-8998237f7e7b">
        <rdfs:label>Muscular hypotonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <dc:identifier>HP:0001252</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/800ad657-c0ee-4619-9515-aa6821a0e75a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Growth failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d642d8a2-8902-4cda-8bb5-4969316b422e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5af5b64a-e820-4c58-b41b-57ca85cbcbca">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4eaa9e4-fafc-4e55-9229-6db886774b16">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100660</dc:identifier>
        <rdfs:label>Dyskinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ead28abc-7f5d-41bc-bb61-b43f3f49e536">
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>movement disorders</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ff3c548-4e5a-4089-a41f-4666a29d3eb6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ed71768-ede3-4abf-ac38-79e0bebf0b52">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
        <dc:identifier>HP:0011197</dc:identifier>
        <rdfs:label>EEG with focal spike waves</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d6bc8b5-406d-4467-b5f1-3015d6ed30e1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42f35284-eb91-45b5-9bc2-9e74f9d8c643">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a91dcbd8-ab21-4bf4-ba18-c154f88b6235"/>
        <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/78c7b2ac-3360-4f3d-b84f-ca8a6fbbb697">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73b606c1-790d-4376-97a1-bfa3dbd017e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbfbf2d0-ec23-46aa-9360-8103cac9e06a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35abedc0-2c9d-45a9-a8c0-cb9f4231b6ad">
        <dc:identifier>HP:0002715</dc:identifier>
        <rdfs:label>immune dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07dc99bd-5d3d-446b-810c-0d09223b43b4">
        <rdfs:label>neurological malfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76163d50-2f4b-4384-a9bb-7243ab2772a5">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82e138c9-9e4f-4dc8-bcb2-1c5160cf267c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be0e7fcd-2266-4ed4-b228-4b220f8f2630"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae4531e7-eba4-480b-b680-9918a3ce4fbe">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab0ce5ce-9d1a-4bc7-a771-be6fee0d8c46"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94a64f98-a6bd-4e09-a540-a28ad3acbab2">
        <dc:identifier>HP:0001892</dc:identifier>
        <rdfs:label>Bleeding tendency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21c9c95a-83c3-4d8b-9807-6e72fec37765">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vitamin K insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a96f3cf-fc3c-4e82-8828-4f81558d8a9c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hepatomegly</rdfs:label>
    <dc:identifier>HP:0002240</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8301e174-ddbc-453e-bcd6-53ca88ef9b00">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6533950-d7ad-47fd-9136-4864fb732f90">
        <dc:identifier>HP:0000546</dc:identifier>
        <rdfs:label>Retinal degeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28127ec4-9cf9-4e9a-8625-e665c2e2fc60"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9dcd1b3-084f-45c9-82d3-2651caae882a">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9b370ce2-eff9-492a-a852-8e8293e352f8">
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e472f70-33a4-4d41-987d-05e5255f8ce5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0465afad-16a4-4070-b36e-4d714dd69822"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338"/>
    <dc:identifier>C09CA</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/50448211-bed2-43fa-808b-b56d6b78b049">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff4fcca9-362f-4a9c-a208-81837708930d">
        <rdfs:label>polyuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b35933d-a4ab-462b-8dae-38d493f6446c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72e767a6-ef88-4608-bf65-441cfa1d84e2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>renal salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11c9fba8-feed-4a61-9015-de22ea998075">
        <dc:identifier>HP:0004324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
        <rdfs:label>weight gain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7403953-56db-41bf-b71b-d7e373117457">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
        <dc:identifier>HP:0000114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/31b01c26-cd5a-4a05-bcad-18d22997d648">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86fd24c5-aa11-4b1e-839b-744a938aa4ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91ecc086-af2f-4998-acf4-cc8ca6e6c9b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2a23588-f3de-4d21-899e-5d7ec81cffd3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bbfe43e-6941-40c8-8dd0-3ba4635be466">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>intolerance to sunlight</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f1865b6-ce09-46ef-ad65-5c85e9770bc9">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30617d3d-d085-4713-84cd-655f853c0c0b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79542252-67e2-45fc-b309-3f68ad8eee97"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145980"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c422e84e-6b35-42cc-8084-cabb1dc75094"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/741a046f-7d7c-4adb-baac-57c7c9f4669d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e0ed8fe-055c-4e7d-999c-bde0a1fe1df9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c226ce17-b71c-4bca-81c7-4bc4a344aec3"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e956f426-2b44-4171-9eab-f5e945378460"/>
    <rdfs:label>Cinacalcet</rdfs:label>
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/43b3fb8d-d793-4ec4-a062-6944442b639f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c422e84e-6b35-42cc-8084-cabb1dc75094"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c87f9f82-3c26-4a80-a641-09d5c8d1b269"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55266525-bd33-4637-820f-2437f9712689"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ebb5358d-d733-434c-8a06-d449ebc6860d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc964cc3-2ee6-4e40-be4a-a0ad5a3980e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2292700-d462-46b5-b4b0-3f0a34a15bd8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e1085a4-b99b-4dc0-86e2-f0e6c9078635"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1d4cc7f-4c0d-4e64-acf9-03f8a6c0394a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e640a45-2522-4152-90fe-0a53e5b86129"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c69f025-7896-47be-8860-10452ceebc1b">
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2aa59c6-0b48-4b93-a12a-7fa2110a360c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ab47009-1bb7-4277-92db-2c7bae0d9cd3"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b95b9535-97b8-473e-8b5b-ba8b9f859454"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9275e36-8047-49d5-ac25-996df37d2ddb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bc507ec-102b-447b-bc39-c379ea132105">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d348d8c0-6423-43d2-b058-35c18aee16a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c50bbfb-477f-4cc2-b75e-119489f84d23"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57e93c7e-5b12-4a2f-88af-7f1d4a4efbac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec87ddca-fa98-45e6-b53e-0d175d14eff8">
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver steatosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1913c309-412a-4c84-a31c-4289d2395860"/>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2f887dd-1648-49db-a9b5-4ad3849266df">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
    <dc:identifier>HP:0000713</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Agitation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/104892d4-c057-4256-b4df-df54d8c75e59">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f71e73d1-bbfb-4885-8397-28f8510883dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbff36b6-c38c-495a-a17c-a9a879e97ab2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a39637c7-a1e2-4a65-9f4b-2c7487ce38f0">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3a2d63ed-571c-4a5c-954b-02f899471e90">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9aed8fe-73c4-464c-b9f2-4f0534c5f59e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>Splenomegly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb08a6ce-736c-43bf-b122-7b743a74e90e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High chitotriosidase level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da311163-3ebb-4273-93af-1bf3ea365b77"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07084c47-6ab1-4e9c-ab0f-b3277b31adae"/>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74eefe72-6a94-433b-b126-b0ee77d8ef5e">
        <rdfs:label>Anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f273287-a7aa-47de-a1d3-de46ba55aa87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f85228b-698a-4109-8737-b8ca96a2b2bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cf095d4-0e0d-4fde-bb62-ed1c4f6d2203">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>Thrombocytpenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a96f3cf-fc3c-4e82-8828-4f81558d8a9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000012>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ef10091-f2b2-4ece-905d-6f566e1e05fd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/54814fbd-5960-4506-b4bf-feb104674424"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1315bd09-7451-4793-ad7b-7f1b4899b1e8">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48e4eaa7-624e-4a43-8deb-526cd6dded62">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec73915e-8a89-4eb7-a63d-59c4367b4da6">
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c568bc44-4fd8-4f0a-b9ba-ed941781d0e6">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/37d72170-3c5a-42aa-94f3-f0b510bd98bb">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88dfccc6-5d14-4681-9bc3-0757bee83be0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bde885f-13b1-463e-b6ee-bd12196253c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>TT-1131</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/49db992b-77ea-48e1-af1b-c8ba8da83eaa">
        <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/251a55cc-7d9f-42e2-aabb-0cf33f1b8144"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6149371-46eb-41be-94da-bb49ecbebff9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a47cc31-dc30-439b-b02c-4a1b82c37b69"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/447ee8cf-65ee-43b1-9f77-b4e4fdfc6c99">
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6298fd6-853f-47ee-a9df-c64a4dff5dc0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d7fcbe9-74e4-42a4-9436-7be860d978fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/251a55cc-7d9f-42e2-aabb-0cf33f1b8144"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fabd464d-8c5c-4349-b2d9-3b2f37358e67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1744b140-c3ab-4510-981e-b13350efccc2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce3343ac-2b69-4d04-898e-790c6a846443"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40decc3e-df7c-4149-8d26-c41bc7f406e1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1d326afe-d1af-474c-a2e7-75f13689023f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9e932f3-ab2e-42e3-8f42-de4f22cc1787"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46d3dbad-6608-4546-80a4-b66964df830a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Atorvastatin</rdfs:label>
    <dc:identifier>DB01076</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/378e0bfa-ed1f-4a65-a037-66ae1e71a073">
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3c02844-bc44-4f19-9c95-ccb9d37f74e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ed2da1-e4ce-4fd4-bb48-65330690807b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lactic acidemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b4f5d3-24f7-4b95-9515-4b4d81bbc6ad">
    <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040210</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9549949f-5336-4b26-9b4f-d28b26c536ac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a67b003-4f0d-46cd-9a1b-b582fb51d3bd">
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1df1921f-d74f-46bd-8f92-b92dc03e57a1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2499ae24-adbe-4efa-a69f-c047fbe59491">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <dc:identifier>HP:0001992*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/103fabb5-791c-407e-99af-b39cfcfb4f0a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0ec76f4-c11d-4d88-80c6-0d107537d8b4"/>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1ca763-caf9-4502-bbbd-fcc06b16f61b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8766821a-7c3f-4fee-b63b-fdfd5af3557f">
        <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e9ab5411-9cba-4421-b36a-cee2e5657b55">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9aa15b5-7d69-4715-ab4d-7b0af2ed7aab">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>High triglyceride levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/254ed982-597c-491d-8f21-ecd4be585b8d"/>
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2af5357-c881-481e-91a8-e2a1d55742e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d15310f-ddbb-4e88-b324-f5c72ccb0a9f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76034d3a-a394-48d4-8a00-566822ccaf45">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/01c8d7fc-2b4e-4079-95f3-18a922e5b1ca">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c34f9260-08e1-42db-90a0-0847dc990e78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a88e009-517e-4b0a-b385-c7973a722461"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fab9721-b6f0-4c0e-ab7e-302703e0ed7b">
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <rdfs:label>Polyurea</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
    <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df268575-c308-4706-8307-a691fcfa4259"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80dd499e-cce1-4088-936f-8e2e290376fd">
    <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
    <dc:identifier>HP:0001507*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/abe55b60-c4c4-4b95-8734-3b72aa36fe3d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4664a1e4-02cd-402b-be18-b6c8c759662c">
        <rdfs:label>Central nervous degeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
        <dc:identifier>HP:0007009</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6533950-d7ad-47fd-9136-4864fb732f90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c803b9a-7385-4ca5-a40a-9dc527c07034"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46162d91-21e8-4bb3-b7ab-2bd52e7d51ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Neuromuscular degeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2d97e4d-396a-459c-954f-fb1b30aa0892"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7698a3c1-6fc6-4795-9148-39cd8d0dc7fd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
    <rdfs:label>tachycardia</rdfs:label>
    <dc:identifier>HP:0001649</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7753a4f7-5909-407a-9ea4-d76e931d0b69">
    <rdfs:label>Decreased cellular ATP level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <dc:identifier>HP:0011925*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ced34975-7664-481a-b94d-ac67366b853c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2bdfc0a0-0c1d-43e8-a5e2-56a4ae5e5b2f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72db09cd-6793-4500-b59b-81d604dab0a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b26cfdb-6053-47ec-8610-3c48acb01523">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum amyloid A protein</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62cfd707-19d2-4eb3-b55c-56ce393d6e6f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <dc:identifier>HP:0011227</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f8c6cc3-7ab0-4717-9bd2-64eb2ebbeb7f">
        <dc:identifier>HP:0001945</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>Fever</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae06f21b-80f4-494f-8ad9-f0466e9f6b0d">
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/27f5dad0-a232-4941-af12-56327afffaaa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6da24abb-eda8-4a2b-93e5-262074dc231a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a59384-8030-443a-a1d2-d6d7d07ea39b"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/257c0b6c-04c8-4bfc-9625-7f041a86898b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65a59384-8030-443a-a1d2-d6d7d07ea39b"/>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac2dde9d-1706-4ce0-838c-b13dfcdb9f81"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c12e044-a2ea-45bd-8a11-14ae7432ea64"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0720afbe-8474-403c-b981-8cb64d70fed4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB09341</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b781930-1b09-433f-83cf-87fbda0fe769">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8443881-05a5-468c-ab3a-8a31898558e3"/>
    <dc:identifier>DB00926</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <rdfs:label>Etretinate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/70547826-21f2-40f6-8f22-c6a27b20a62c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e314f4f-ce8e-4739-882a-465b1e55f36b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/105cef1a-daa6-4acc-ae13-c1e3f682d35f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/538c4105-3ffe-4605-bec0-d9bca04c49c7">
        <rdfs:label>Macular cystoid changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
        <dc:identifier>HP:0008028</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7228803-879f-4b77-9e2a-2f61c0af48ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/726aaccd-5a57-4f57-a9af-a410de20a3f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/acadea54-2814-4ca9-b9cd-88cc6b715d78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7cba3624-a5b4-4cf2-b794-2f53ff619fd6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6e860fa8-02bd-4c64-980a-0e4a4e2b22b4">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0ec76f4-c11d-4d88-80c6-0d107537d8b4"/>
        <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
        <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a56684e-4229-4066-92f8-2092cdaf4951">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29385abd-a782-4813-b45e-6b66ad637645"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aff88abf-9922-40e7-8947-1b462015c715">
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/44325a09-e0ea-4e88-bb11-628db5171763">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c10b310-2e55-49a8-9c58-07ab6f9106da"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f0ae8fd-155f-4605-8f5c-20a19d042fa4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f883700-8c3f-4dfa-bb17-7cbd73a89fbc"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26d20f15-e68b-480f-ab9c-76942762ea6f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f00d9c19-334e-432f-985a-005ca2911f86"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7e553dd-e18a-4b93-bb3f-9917acc1f582"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d103882b-20ee-4521-8ce2-cb0f533fa850">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a5ec850-f1ea-450f-a78d-15de4d569c3d"/>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aad6b2-4e4f-4e05-946e-01d6a7b9da68"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87475880-5599-4592-a0b2-8fcd73bc0e30"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d156625-019d-435f-b5b5-16a3be6dbfd2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03f9cfb1-6416-4ece-b3cf-7840c6750092"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90cb0f7b-1219-45e7-b6d7-51e803840784"/>
    <dc:identifier>DB00635</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a440b48a-bddd-4b14-a2a4-c2716d03e093">
    <dc:identifier>CHEBI_23456</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ef8519d-ee06-4881-9c38-87a0be3cb7b3">
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f28a4bb-f387-48df-8f55-63b6285f62d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d54bc25-c6ab-4fdd-90e8-c24495615a0d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78ce9a21-9ba4-4e8c-abfd-200a8f3fe2b3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>cyclodextrins</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b6faf3e6-e956-4c45-9105-48ec35554609">
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fbb6a0e-774b-44fe-99a8-b944fb71ea69"/>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48071bd5-9834-44d7-b094-2ac462068116">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/619d5c67-2e18-4bf3-aa5a-e5cec5d9542d"/>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fdc1b5e7-8d19-412b-800d-b44c7608e6ef">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e97a1548-8d6f-410b-b746-304e1979f7cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
        <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f7a4790-9398-43a7-ba48-76874d8acc4f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d89eb76-34cb-4a0c-b0d4-99ab2d35ef4e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581e121e-b9e9-427c-b162-a667058dbca1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0337cce-5de5-4ab1-9d56-821d99f6bd13"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>C09C</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ecc444ff-17dd-4dc7-a7d3-6e2d7b6df9a1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610198"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0687244e-284e-46d0-be3f-23737b2f7ef5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/275cc2e8-8777-4488-9374-d27e83c8d25e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581e121e-b9e9-427c-b162-a667058dbca1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/384101a0-cef5-45fa-9be8-6f51a68338f6"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/036fa013-9ce6-4ce5-87b9-5f071e5762db">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/551ac471-bcdc-42f6-a423-7968d4b78554"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d51ffa61-4048-4334-b23e-53988ded13b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f04a79bf-89e6-4662-be95-f3bd941cbb29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/020337bb-f421-4987-a331-b4c654c03fd8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba0ebfa6-bc71-4e5f-bf7e-616ba342124b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3986ae93-48d5-4641-bd42-84336a1e4f6a">
    <rdfs:label>Cystathioninuria</rdfs:label>
    <dc:identifier>HP:0003153</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/becc3a59-a7fc-4a91-985d-cb20245fde7b">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f85bc2a-98d5-43c4-9838-fe38aff9b35e"/>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7cc6eb3d-dba0-42db-bfe8-fb0af2170a2f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/758f9e95-676a-4d21-aaf5-5c08761b6f1c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66dd0931-b1ec-44be-a6a7-379c508337fb">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/275c144e-c261-4559-a3c9-6786c8170354"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
    <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/457696fc-76b0-487d-97a5-cffa70409b1e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a33a58ab-ea44-49f5-bbff-c3dc4651e0d9"/>
    <dc:identifier>DB00147</dc:identifier>
    <rdfs:label>Pyridoxal</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c6a45ac-2d10-4b49-87e2-714a242cf48f">
    <rdfs:label>Limb muscle weakness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
    <dc:identifier>HP:0003690</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e7abcdc8-0822-476c-90ee-fef57f3dacee">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/697acb87-e4de-4634-b079-0b0e54ffb9f1">
        <rdfs:label>T wave abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
        <dc:identifier>HP:0005135</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13f0c187-ddb4-43e2-8de0-b4696c39e035">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low myocardial function</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a51670ee-f252-4a32-85ae-126b1b7eef6f">
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed Growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd27c653-8201-4519-9713-80acefcded57">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <dc:identifier>HP:0003146</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ff811e8-f9a6-40c3-9185-df3ea82e4111">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8527ff9e-e713-4a9f-a135-331620c2955e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6552b1df-619b-4c12-bd1a-7b162bb2d80e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c045aaa9-e215-47b3-8972-94047b2d17f2"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30142f63-f142-42d3-b7f4-b66002d848b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e9f1751-0652-4765-a74a-3bc5ec9167cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ff48149f-6c6b-4473-af68-daf813d3313f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d4c398-f509-49dc-a324-a7e6f6e5b1a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9386382c-7603-4c02-8fcc-664ade7ba1c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b153f7e-e8f6-48fb-9cf3-03389dda1d22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b02ed988-0f55-4658-82d6-ef5daf13ef7c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/026753e1-7e7b-464b-ac6f-f21a4578ab9c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c5c9da-764b-45ee-aa72-d64f587010cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa623e52-2977-4c5b-aba4-4a96f9299562">
    <rdfs:label>Orlistat</rdfs:label>
    <dc:identifier>DB01083</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6c552212-3095-404e-a0b1-55a4a38c5f81">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
        <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b69d1170-d24b-4dae-9323-fd2f8ac75e34"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5abf853-297d-4a61-94fc-d31b65d37161"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/06676b35-be4f-4ff9-8ef8-d71b58fd423c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5abf853-297d-4a61-94fc-d31b65d37161"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b69d1170-d24b-4dae-9323-fd2f8ac75e34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38f708bc-b753-4b72-bc82-28a4ae3eaf47"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7df02af3-c5c3-4c09-bea3-4fe5d585a50a"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f5f918b0-26ef-4b97-8a20-6360a83a5ff5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cd2c702-b6e5-4221-b4bd-b70ee0d222fa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cerebral folate depletion</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5e6913c-8541-4bf2-a413-5c5a6bb948e3">
    <dc:identifier>DB12907</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22b5e90d-70bd-42da-95b8-eca8b67478c6"/>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e816d93f-1673-42aa-bd7f-6e8bd22bc91a">
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4d65a25f-c841-4672-93eb-1fdb15c6aa16"/>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <dc:identifier>ECO:0000305</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ee4b439-76bf-4c86-ba34-e2012a301c00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d91970a-176a-4ab4-a7f6-c5cc506a8658"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef7ea760-6ecf-4e27-93d1-58af680eeecf">
        <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef53cab3-a100-49ce-92d4-e9c1390cfea5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/898c8348-a49c-4cb5-9357-b7cfbc368b74">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>Hepatomeglay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b4cd9ccb-a5d5-4f4d-a248-c7b0deb03fc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b29e75cd-25f0-480e-9474-552d0fcaa4ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf4076c6-9efa-4f5a-89fa-841242f89e57">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50aa7186-d10f-4e7a-86a6-033bbd133d74">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ca7f057-322c-4214-a218-9483177ad777">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7f5816f-8762-47c6-a4d7-8edc5a612d3f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da07bfcb-58b3-4692-af9b-9533da3ea352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba0c2670-2a1d-4378-9c3a-e46ac18abc35"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e69c273-3962-4153-b049-31e00fbfe5ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee546695-d047-4353-b78e-34ebe83ac83a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0e34bd9-4770-4c53-a6d4-2f45c1202537"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/508b4f5f-b99c-4780-8049-9c4ac5be928f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba09584a-ec41-4797-9794-dafaa1ff5fb8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fbd2f09-a8b6-42eb-92df-2e0804449689"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dab92b0d-58f2-42b9-bdc0-d47a8d1abf41"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e979489-9066-471f-8aa4-222bad677a9b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fccc54-79bf-4d06-85f6-62de15a43a7c"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09105</dc:identifier>
    <rdfs:label>Asfotase alfa</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b46117eb-2296-41ba-8224-4828d9cd472f">
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9305bea5-faf3-41a7-9d46-456eeb5c64f2"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31c08c9c-95ec-4666-bbb8-a85e581fba0a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fe08c5-87af-40f8-9138-f810ff24b081"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/988bacd3-74b5-4999-9d5d-897b81b5197e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba0c2670-2a1d-4378-9c3a-e46ac18abc35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00c94a5e-ea80-4759-81e9-a1a78da8977c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03366bec-be0a-4609-98a1-1638b6b2cfd5">
    <rdfs:label>Deep venous thrombosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002625</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c234eea0-def0-4f12-a8fd-4d4b339ce3fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cedf995-4c95-436f-9cc7-187c8bb1d676">
        <rdfs:label>High LDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/372b491a-b469-4b58-b180-d16731971bf9"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4c75885-94d3-47c5-b8cd-dbfa078c025a">
    <rdfs:label>failure to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76f85a00-9cb1-4310-b29e-79e168c45f0c">
    <dc:identifier>DB01329</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/70ed1eb7-77e7-48be-a5ad-afe4818a5de1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adcc782f-84af-492e-b408-6280a0a66241"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/218dce71-277a-49a7-9d2b-893bafdb19a0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Cefoperazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8da3c6f3-7238-4191-8ab6-19c9231f716b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53290e83-2678-48bc-93b3-0687b1988e77">
        <rdfs:label>growth impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be"/>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb18ad3e-a436-4760-a1f9-5ff8b16a85d3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
    <dc:identifier>HP:0009020</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a213d5-2880-4504-8ae9-02af529cfa5e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain lysosomal storage disease</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4365f6c2-3666-4ecd-a3e8-1c50ec8999e7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da2f813e-4a1c-4d76-89d0-9dbd559cdb5f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb31ec24-6df4-4b42-beb2-b4b141aaf029"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dddcad6d-8bfd-4ccc-a4fb-99dbb3acdffa">
        <dc:identifier>HP:0100614</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:label>Myositis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ce05822-467c-4c28-9ecd-602120f04f49"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3215ee73-23ea-4262-bcf1-dd389ad914ec"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c01590e5-a1a6-4756-b71d-9402fd2af2d2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34802085-d5ba-404c-9565-abbc42601092">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8aa7c4f1-a891-48d7-8aa7-bbc11a9b8768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41dfdbc2-39e0-4d3e-9b61-02020a3c34a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e56531c9-de22-49e5-8eaa-0d4c6ff571a1"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72dd0d26-69eb-4103-9a72-97f466b8dbb9">
        <rdfs:label>spasticity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/817676b7-3b4b-460b-a467-c1e9f01e53a0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e10f52c6-d536-40e3-be30-796efb8013ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c26293a7-46ba-47ac-b329-3ca0370e34b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6449c173-e3da-469d-b191-39c5092f4d34">
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>abnormal motor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/9c3e69dc-3c31-41e9-be54-d7c021dad2e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8769c690-4550-42e3-b758-dd535f2417eb">
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2cc43ade-8234-4d21-a9cf-857b69e0ae57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62cefd31-2040-4f0d-847a-56f1e545f786"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4d0b01b7-8f9b-41d2-b5c6-4699b2bc5478">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5885dd0-ffce-4474-b82a-09a48795b38d"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29b126f4-0faf-4696-be11-89add3af5973">
        <rdfs:label>Hypertension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c322587b-744d-4826-95ac-b3c4ac083df9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13b9f5f4-1fef-434f-abf1-f3e869124705"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/977e049b-fe90-4b1e-abcc-e8123f1935b5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f33e2bb9-a610-4d4f-b479-6cbf9a231a6d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02d4166b-871d-4c76-b930-b2a34b159ddc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e952b9c-4a94-41a1-bb5b-821fc837a3c7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c621b14b-23b8-47ce-9607-194d39e637f7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9af71b72-a2ee-4238-bb6d-ea1819150335"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d9040c2c-6de7-4213-8195-76a2701ab5d7">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3641236c-17a8-4cdf-90ef-fec3a0485cd9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>L-Arginine</rdfs:label>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2bdca0f-0b17-45d9-bf77-f03565ee36eb">
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f0e9d-edae-4aac-a6d5-c915e24a68b4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e902456-025d-4650-99b9-69331a198d0b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8225000a-9ec2-49e9-8b37-6836b6cd2157"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/039ebbd4-12de-46df-83b5-64ef874057b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28ad646f-ef12-40e9-b42c-55b623efafac"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1698c7c8-430b-45b8-9f0e-6b387c8f3580">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b6cbc68d-c0dd-4526-b8b0-7b386bd8881d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd74485e-2f62-45fd-914f-fb0870cbe285"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cebb3e29-69b0-4870-a271-7a1ec86cb415"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d78cc4da-10f3-4131-a82a-ab1c3798ee9d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012363</dc:identifier>
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cc234a8-0db8-4c18-8b1d-0fea49df9f9c">
        <dc:identifier>HP:0003805</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
        <rdfs:label>Rimmed vacuoles</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fca47af-2c43-46f7-9f85-404c90bc25d1">
        <rdfs:label>Amyloid deposition</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
        <dc:identifier>HP:0003216*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db8b223c-3e5d-4b55-8b27-457598bdcf35">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3bed68f3-dc5a-4ae9-b4b3-3c28e3b5c471">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc1697c-7ba1-42cb-937c-729ef06d8a0a"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94755115-98f6-4dba-8180-6ea57caa4107"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57a9ae98-3f11-4efb-a36c-151e84abb66a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9da3b06b-6776-4902-9ad8-f920e17b40cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/004dbdfd-54af-41cf-8242-b6f0539e12c3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdeb2c47-8f6b-4426-970b-0b06830c826c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7882a5a-7689-428b-931b-ef427bb33b8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4a545c4-f324-4e20-b16b-253b719b9bb9"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <dc:identifier>DB03614</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8a15b9ad-a33b-4c73-80d3-58f43b855af7">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bdddf59e-e222-453a-a4cd-06e75ab0d1e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58087c53-b643-4846-b063-28f0f0db0de9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/470392f8-e525-45da-b329-0a5cf52fd87d">
        <dc:identifier>HP:0000479*</dc:identifier>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d75a15e-098c-402e-bdf3-661f7f643c16">
    <dc:identifier>HP:0001873</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
    <rdfs:label>Thrombocytopenia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c7aa0c2-2913-444b-8986-52298b9630ba">
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f29bdea-cc7b-4043-8a3f-f22cc5eb2157">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60f7ec0a-5506-422f-bb41-c074334ba029"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e1fb8a9-1311-4b8c-8e89-6fdf5edceb47">
    <rdfs:label>Acute decompensation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c2652921-f588-4cf6-8a51-66728d37fea5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ae9718-b3bf-4449-80a2-6d6c1d3ac3e9"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6eb9660-152c-47dc-b580-236f2797f92e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/581dbd2c-9f6b-4c49-a097-2c6829f37994">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f60a0fdd-6675-43ab-8a5b-4b0e9d153d01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69a4740b-0e43-4c30-a239-ece783bd2e16">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14cc0f9b-9125-492f-8ffb-a8d44cb262f9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002173</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
    <rdfs:label>hypoglycemic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a103108-b461-40e5-8bc9-cc64cd9e0104">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34309472-ff3f-40dc-bdaf-61897d402e7b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/13348966-c4e5-481a-939b-de327afac6b7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2af6372b-e9a1-48c1-a775-83bfb6f2ed57"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1189619e-38ac-4639-84b4-563352a2bb0f">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80871588-ee7d-4b70-965e-bbce985a6e14"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/552ec24e-910f-4641-b33e-0c6cce8cb2b1"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/650a5013-0ede-47df-bed6-5c0c297a17dd">
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3fc14c7-7bdf-4832-82d1-b07469250722"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73f1607a-3f76-4728-895e-37f592dc2c9a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbb1cfb4-db89-4e2d-b7d2-1a7c3f936ce0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26f63f72-d27a-46be-be23-6fd8b70e0f2d"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a38ffc-d954-4ef7-8b0e-21d3d4c4739a"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <rdfs:label>Simvastatin</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d801b913-700a-4b9e-b8c1-37f5ca3b1d6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7b04f34-53f0-47d0-bd00-302c4ce40b60">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003566</dc:identifier>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/757dadfa-0f23-43f7-9721-0186ae586a4b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <dc:identifier>HP:0002150</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba9f3e2e-9a9b-4261-ba42-7d121114db06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52f6dc7c-2f84-4f6f-b20d-1e5db3338c81"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e0ed8fe-055c-4e7d-999c-bde0a1fe1df9">
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4d0de93-b60e-4d09-9b77-3021f6520cfb">
    <dc:identifier>DB00855</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8cbea48e-be5e-473b-b623-0b5e60e0ec5b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbac2c61-a0c1-4105-8bad-483d2842243f"/>
        <obo:RO_0003304>R266K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85ea3d9f-7dd5-470a-9859-25eb12b5d371"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9e5a6b6-f562-4d6d-83de-a9d8da84a740"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0003304>R125Q</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6475b583-bd2b-4bfd-b616-06ca365b3388">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/2eb82bd2-4d71-48fb-b234-98000e9779ec">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a69630e-47c3-4ce7-b53d-77f97ffd3c2d"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Migalastat</rdfs:label>
    <dc:identifier>DB05018</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5581bf90-9f85-448c-93d1-c8dbb2952066"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1500a1d9-13bf-4117-be28-93475917c493">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003808</dc:identifier>
    <rdfs:label>Abnormal muscle tone</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8cb3931-b36e-4397-88ad-a96948dd03de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d215fddc-a331-4d08-a77c-170b37e3ddbe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a64d9970-6975-4e28-b2f1-4f75216d0e47"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1df281f7-777f-428c-9fc4-fd97ff45c1ba">
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71a5cd68-cde8-4fe1-9562-8d8b349013f0">
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>motor malperformance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1f1bcc-fa40-4bed-8ded-abacfcb7bb35">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
    <rdfs:label>metabolic acidosis</rdfs:label>
    <dc:identifier>HP:0001942</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19a7db8f-3108-4051-9d5f-66377be0a822">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b">
        <rdfs:label>Abnormal liver function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87ab5568-a609-47cc-9ae6-68fa312a110e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
    <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
    <dc:identifier>HP:0012011</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e1be79bc-4ff8-40db-9e01-90708e730f38">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89ad98fc-3882-4d4d-87d3-e11d3ceaedbd"/>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/646bc4d3-64d8-416d-9cf8-51e0079a13ec">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9146efb-2073-43b6-bbb3-e1c70aa31e43">
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fea7714-c039-42d0-b9fc-2b4eadf8dea5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b44925b4-3171-4340-b8cd-5c03de26f4e7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e60d113-a60f-4253-9884-2aaeb033594d"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a99e91a9-b4d2-492f-b11a-1145c526e644"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f70b0c26-0ef1-4588-8079-5c16f539542c"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/782d11f5-04bb-4246-a0a0-37ab3868ef36">
    <rdfs:label>Pitavastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37d72170-3c5a-42aa-94f3-f0b510bd98bb"/>
    <dc:identifier>DB08860</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc08fa40-ce4f-45db-ac89-e1673eddde83">
    <dc:identifier>done</dc:identifier>
    <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91ecc086-af2f-4998-acf4-cc8ca6e6c9b2">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d2080819-6c24-4ee6-ad20-cfb0bc43b7d9">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7698a3c1-6fc6-4795-9148-39cd8d0dc7fd"/>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8fb41d7-7f47-4380-98be-a373b231907e"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce591d46-513d-46a1-bb6c-65d606ffcb37"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38325361-b1c1-4dac-9134-2fb4ab6cbbae"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86fd24c5-aa11-4b1e-839b-744a938aa4ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e482708-1fec-4206-8339-722e80a52fcb"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31b01c26-cd5a-4a05-bcad-18d22997d648"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7e0b4e56-1e0b-417c-b529-0dc1e81fa34d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86fd24c5-aa11-4b1e-839b-744a938aa4ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfe2b2e4-be3b-47eb-a918-561b7717ccb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1b0d93-e6a3-4409-8423-7d453cfd6ad1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB03404</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <rdfs:label>Hemin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b899ad0-9647-4822-bed0-2ce9a7e10d87">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/854a308a-a3f3-4cbf-ba36-7799e6a91fd8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75cfa682-06a5-45b4-83b7-5ddb4178c95a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25350eed-6a36-4ce1-9517-5b1ebdb89287">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f2ca08fd-41b7-4d41-be33-602fe06b6b70">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9e98f39-8898-436b-a22a-5b38a6ed6dea"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/673a64f8-6ed6-4504-bb1d-545d1c44857e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9e98f39-8898-436b-a22a-5b38a6ed6dea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB11133</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3798541e-a254-40b8-97e6-289cbdb466b9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d84691c3-1d89-4fde-95b4-c1cbeccc64ee">
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4692a16-b974-482b-9c90-2f25a80792e3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Intellectual disability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/262a35fb-ae5d-48ec-98ad-9b36736c7f68">
        <dc:identifier>HP:0002188</dc:identifier>
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ef87af-042b-4b9c-8811-74fa513b7b81"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/350accf1-9b58-484b-8e4d-5e597adea30d"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/10eec8c6-7a08-4fde-9b39-2f3d5fe3c16e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff395c6c-d6e3-4f22-9f91-e6d5d4bd6c1c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86199025-7031-41f7-b01f-13af8e9cac61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50684aa9-666b-44c7-a72b-0fb74d05a443">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c44a1a1-ff6e-46d8-88b0-641215e770b2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107</dc:identifier>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adb7d6a8-f8c3-4408-b573-589cfebddaca">
        <rdfs:label>Dyslipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/254f53a7-9b73-4c28-b33d-c1e52735feed">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e4cdbd07-a772-45dc-83ae-519b7efd5c29">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d2c0881-cfbf-4615-8f0a-400ab7487498">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/375ab6fd-a59c-4878-8922-703e364bf504"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b78044f4-811f-41d3-a33c-d04dae27e687"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88a8fb35-ec19-42d6-ace8-e295a196358a">
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/497cc17a-f0cc-4a61-a78f-218829875ef2">
    <rdfs:label>endothelial dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c785e752-500f-4e86-b8a8-6b47b47887ac">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b0d4652-3731-4acd-88b6-6d7bc8fa3fd3"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55559ce0-34f5-4855-b719-28c6cca934bf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46781e10-67ea-420a-8eb2-d52f2fd5e595">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/571c0c87-aebb-4c48-abb4-9d78e809b531"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c045aaa9-e215-47b3-8972-94047b2d17f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1119751d-aa41-42cf-9b7f-3968c46b17cf">
        <dc:identifier>HP:0001263*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7aa997d-296b-42cd-9698-3fff93a0dcde">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f09ce3d9-41a1-449e-91c7-d8e387a01b8e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010977</dc:identifier>
        <rdfs:label>defected phagocytic function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e35d2d32-672e-44b7-bb79-a0be813adc4b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1798b229-8b2b-416e-b75b-782648c990fc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72ce5192-f09f-4ec9-8835-e17180d27b5d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>recurrent infection</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51c65e1d-8ac0-45bf-a1f5-fe9238eafb6d">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/569ae0be-8eb8-4aea-8b23-738c6ad75a30">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d2473fe-fa04-4d3e-a8eb-eb5caadea127">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/402102a2-7829-4108-abe0-0d6aec0083ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb4ad9ca-e809-4ed3-9f28-ad71ead3662e">
        <rdfs:label>edematous</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad87683a-a7df-48bf-88b9-b0f900f84168"/>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d8ca0c-8174-4456-b304-c96514c46b20">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>gait abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7de3b05-e1d3-4157-a1f9-9f2fd7780a66">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:label>incoordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a8b4e9c-4077-475e-b883-8455ff0a2623">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000789</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <rdfs:label>infertility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/12710111-bc7b-4dc4-ba54-6152b3089eb9">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a49d913-b628-4648-98f7-9f984c492ccf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a81dede2-f8aa-412e-99b2-7ec0bda748f0">
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e5f3768f-3383-405b-9cca-7c25d1de3c4c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0687244e-284e-46d0-be3f-23737b2f7ef5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a9e6ec7-ea7a-45cf-985d-c87dee483ca6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/275cc2e8-8777-4488-9374-d27e83c8d25e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3544529-db77-4943-9519-f1e026ab7bd7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e8c0246-aad4-4bc6-8440-f31a0009c0af">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001653</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:label>Mitral incomptence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f3acb2dd-6b45-4ea0-90c9-885c5acd42f3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d1d155a-048a-4493-af2c-a06dffc601ac">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <dc:identifier>HP:0025460</dc:identifier>
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f10599f6-50d5-4b74-9387-731f7e31633e">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <dc:identifier>MP:0012604*</dc:identifier>
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/299b3360-7f41-4cd7-b7a3-cb996cfff957">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:label>Inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42a8f477-6de3-4f46-b087-5c31c436a132">
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011118*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b20c3828-9618-4d7a-8932-245cf86f33e6">
    <dc:identifier>HP:0001386</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
    <rdfs:label>joint swelling</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4cc0440-3472-4be8-8387-9e2762f417a1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9385d65b-7912-413b-ba2b-8da8887defc5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2193a54d-dd1d-463c-b1dc-17d025b25c48"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7756abce-1397-4357-a0d0-5913a880e3a5"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01325</dc:identifier>
    <rdfs:label>Quinethazone</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/056115b3-d7b7-4ea9-ae31-2a7a5f2ebb8b">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86ce400c-d6f3-4ce2-8df3-4ec4ae8b1c3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d33fa03-b5fc-4d77-956b-a57db099646f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f32c912-896f-4a35-9134-ed83bdb19fd8">
        <rdfs:label>abnormal muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bae799f9-ed13-447b-8375-201d0c43f0ac">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/383c92c8-2d49-48c4-b1ff-a33459c8a25d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce462349-0ea4-471a-8ccb-d3f7e4bad451">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000938</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:label>Osteopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/beabe563-a6b5-4b11-824e-a3ff8e85d4bb">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Objective response rate (ORR)</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e78e7be-7a55-49ac-875f-1f57b14a724d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581dbd2c-9f6b-4c49-a097-2c6829f37994"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cccd2a2-a8c8-42d6-8e89-f4293b4393b8">
        <dc:identifier>HP:0005340</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:label>spastic bladder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30e58355-aef7-447b-af75-c2b02a918171"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f3b73c5-a169-4f5d-9412-9de3a82098d6">
    <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <dc:identifier>HP:0001943*</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
  </owl:Class>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7bcbf82b-3787-4a89-82e3-b111d1ef7a77">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd84a1be-7f55-40ee-8105-acd4b6194ad7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a27ded7-ba3b-44ff-985d-5067506f343a">
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4fc9917-1663-4b63-86a6-4ddaebb1534e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Abnormality of muscle physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3eaf2477-7172-4c11-b41f-08210d7430a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e482708-1fec-4206-8339-722e80a52fcb">
        <dc:identifier>HP:0000822</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:label>hypertension</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b341c7ae-ddeb-48a6-bbdc-6a135349bd28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e02e6db3-c15f-437d-8827-acd4a5bac132"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee349e33-6a2c-47aa-96a0-26d675532791">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/497cc17a-f0cc-4a61-a78f-218829875ef2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cce05d72-0351-4162-8b52-a3333b99b6a8">
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3c466da-9eac-439a-9d18-5e3403e9fd44">
    <dc:identifier>DB06372</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5db1e47d-5c7a-4801-be12-95704f42f93f"/>
    <rdfs:label>Rilonacept</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0c4e8666-490d-4ecb-8116-df024c71ba9f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c8a311b-7b42-471e-894a-0c7ed234c05d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdb230bf-3c83-4da9-9ae9-4292049ad296"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc196956-e0ef-45fd-8f83-3f778100b3c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ecb5468-8dee-4924-a839-3c419881e818"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0dd243dc-e954-4e72-ad44-619b39d6578c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaeb6362-5a19-4b8f-a259-f3f2f87e0f96"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/703106c6-6ff3-479e-846d-788fb4ce8732"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71253433-3c1a-4472-a284-b4f59407bf4d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dd2c009-9dbf-4404-8bc1-851f8ada660a"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2251382d-1c02-42f5-9246-d4ed40aa4bf4">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3569c783-6742-4537-a772-8f0acc279999">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2f887dd-1648-49db-a9b5-4ad3849266df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd94b1ca-e8ec-46e3-813b-8cf36c53d5f8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f003f20-4bff-4888-8ddf-4187569520bc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9f8d052-c9cb-4bc4-ac29-13bf22d3c2fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a58b836-eca7-4667-9f57-88303e42cb6d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f68d69-400c-408d-8629-2fb52a122b5e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41518c2e-a45b-43f3-b5b9-35e9eda86e86"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Zinc</rdfs:label>
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fabe2f2-506c-4ed3-8088-7c39d25a487b"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f3dadb96-a529-4537-8511-8eed2b3faa92">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fdaba59-a475-4873-90ad-f9b04a883be3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a94db8c8-156c-42f4-a4c9-2cee01456386"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ee6f291-81e6-4b51-be4c-4e1aaaddc4af"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41518c2e-a45b-43f3-b5b9-35e9eda86e86"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6baffc6a-9558-47fc-80fc-3093ffb477ad">
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3d94dcc-b80d-4039-a34c-45b731174ab3">
        <dc:identifier>HP:0008222</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Female infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/96d6a9c3-2f88-4b61-b74f-873bd402292d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c7ce0f6-cf25-472a-b7ce-768f4a24d880"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c51b4f84-76aa-4df8-9647-92c64baaf000">
    <rdfs:label>low intracellular cysteine*</rdfs:label>
    <dc:identifier>HP:0010918</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/febb6002-af7a-4d00-9468-3dbc6274430e">
    <dc:identifier>HP:0002014</dc:identifier>
    <rdfs:label>diarrhoea</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef0b3e52-81bd-47a5-9760-cc124693361a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c711c2e4-04f4-4155-ad36-7d5a679501cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f32fef6d-6597-4796-98c8-69bf39bed216"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/425d9905-5e3f-4b71-b2fb-b038d7086d6b"/>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f672d8c-bf97-42e6-b444-139730c0697e">
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7d176a64-7b49-470f-ac72-86ab844dde00">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/770a8b8e-f30a-4d23-9ee9-4f1e96378d73">
        <rdfs:label>Misfolded AGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e79340e3-e3b0-4d88-a891-59274eb9786c"/>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3ff16b6-f7b0-45cc-bc2b-c36a88ef37ae">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3111fe4-c37e-4a6d-9627-3b9c06fbef97"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b43d04e6-94d6-49e0-8fa2-c9e6130b77d9">
        <rdfs:label>Abnormal AGA processing</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/eca5449c-7aea-4e0d-ba59-578d5e4030b1">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8f36a69-b2a0-43be-8924-7a0c1910796d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b788098-0d40-4356-b2f0-bba4a06163c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94755115-98f6-4dba-8180-6ea57caa4107"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b95c234-c7a3-4e97-906f-9d776c8792f9"/>
    <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e97b7cd-53be-47c6-b87a-51272d2a3d11">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
    <dc:identifier>HP:0000841</dc:identifier>
    <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2223d4f8-fe87-483b-bd1b-417387cbb21c">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7351ab29-46e0-4b51-b9dc-1995e33bb61d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d334efc6-8ba2-450c-a333-f44fafd7a5d7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3e6dac03-b14e-48ed-bf94-3707738865be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b19d04e9-3b03-4e3a-8a9b-14e3a2e24320"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bbfe43e-6941-40c8-8dd0-3ba4635be466"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a1d6f2b-d78a-4e24-9896-7c10f754eb01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/766b8883-452d-4088-b89e-f8980d249eca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17e869f4-636a-4d91-a248-ab2941f4661c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c33b8665-3950-4839-bac2-bdc882b83458">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4470d40c-7b14-4dfd-b54c-c585cf969e84"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97aaafa0-bfa1-40b0-b15f-3b4e19c21f9a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9d8b03c-779d-41b4-b8b7-95b274af5275">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80722cd5-68ee-4f94-b530-95bbf4239480"/>
        <obo:RO_0003304>R229W</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddab033d-d1bc-495a-a4ea-135069afa4b1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac2dc131-16ef-4730-b2aa-c7f2ebd5c9c6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f47c4938-09f0-4dc9-8142-1702f421e329"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00165</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf56ea21-852d-423c-aff8-479dd2ba73ce"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/83577f4a-eb95-4914-9eb4-76e4332b9aa3">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53993367-7094-49b5-bfee-d9749f932622"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae26eace-f7fe-4a3c-81a4-a54925c01b39"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3986ae93-48d5-4641-bd42-84336a1e4f6a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee86276a-6069-4cdb-b90f-d2d4b20e3913"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44852d88-281e-42f3-8c9b-b7163122dddc"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5e9cd746-3121-4953-b6c0-ed0405270ab9">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/caefa4fb-6b0f-4d8b-a7e3-12d246e3b5b0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/12915fb6-d264-4c8d-bd2d-7f508bf4936b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41ce5810-fd42-490b-9fcc-e9ffed8dded3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4da542a-aa42-4cf6-9b95-38292a694931"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/032eb796-3535-411e-894c-43cd8a1ff425"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b061172-cc74-4621-be94-501ce332100d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ccb39ac-2f07-4289-aa1c-8b04bf46fb1e">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae0d7a18-d8d9-4e87-9f51-cb5cc5f71eed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/40084364-c933-457b-916e-71001e5a4dc9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/331effe9-0ab8-4493-ae78-a6c3ef33d25d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00d53e78-0440-4efc-a9e3-fd5362fbe1cd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e3a43399-c48d-4eb3-a3c4-47348ab73b9c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23f2152a-ee65-485d-90e1-a0fcfce7feb9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aba5de9c-72cc-443d-9bdf-969e1f0f4106"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fadc6356-9819-437f-b121-7860a5bbe3a1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f9cfb1-6416-4ece-b3cf-7840c6750092">
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <rdfs:label>dysphagia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2047f6d-2acb-412c-b856-cbfaa1f9590d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002900</dc:identifier>
    <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
    <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/947f9074-b02f-4ee9-8406-f79435787dca"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
    <rdfs:label>GRACILE SYNDROME</rdfs:label>
    <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55cc91e6-3993-48c9-9a02-9e52f629146d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d32765ce-dd84-4816-a38f-104373a9cd0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2283094f-3a30-4077-b85d-a955880d0443"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ca7716e-f9fc-4d36-bcee-af3fe7747a9b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal walking distance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4d76579-9119-4814-ab97-5c306b7f47af">
        <dc:identifier>HP:0012514</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <rdfs:label>Lower limb pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a61f003-e750-431c-939c-1291766e90f1">
        <dc:identifier>HP:0011023</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e4297cd-ec69-422e-89f1-ea0013e042e0"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86a7a3c1-964b-4a32-8951-03a15a6c33f5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <rdfs:label>Curcumin</rdfs:label>
    <dc:identifier>DB11672</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/26562d03-e0ff-43a6-9942-8dda05d9816c">
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0b85369-b32a-4ffa-b0c0-224f3181fc8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c91936cb-6e78-426c-815c-67d8df5e0c01">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <dc:identifier>DB12783</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae2c7f38-bdf6-43c8-9e2e-d5e741ec151d">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e86d16df-a337-4d06-82f8-bf4db32a4fb8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d93f221-4f83-4c85-9649-d1780276e614"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Benserazide</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a2a28aa6-9e09-4a50-9326-f411eb323495">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/13146fd5-49b8-4a45-9db5-2521030cad3d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a33cd116-817e-4084-a433-f2d34cac6a20">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af534bf9-8cdc-42c3-9a54-9851102d8e23"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f738bfc6-5383-495a-8ad8-e1085afb95ec">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4a664ac-f36e-4e8f-a9a7-b23a0ee01372">
        <rdfs:label>abnormal liver function</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffead287-751e-4264-8c11-3af6fddc9fc1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c9069e1-ea43-41e3-a7f7-bf2df8e1d366">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a7c911e-2f4a-4a6d-9e57-b190f6b5ecff">
        <rdfs:label>Abnormal muscle physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/249f12c5-28da-4648-b961-04a676eb4826">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b061172-cc74-4621-be94-501ce332100d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>exercise intolerance</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/408ff632-6a28-45dd-ba9b-67083196df25">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <dc:identifier>DB14307</dc:identifier>
    <rdfs:label>Green tea leaf</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23c76b52-dbc2-46ee-aef8-9a2202c439d4">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb0d66f2-7bf3-4f00-a018-2bf3e1c50c77"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92fb0c06-30a6-4a67-84c2-43ac35c9c45d"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac61e80e-093e-44a5-b29d-fb5d3a0c34e6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1bb2259e-8325-4346-9604-f068d958a735"/>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82162deb-484a-40d0-a8c9-df9c095052f8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f4a82a-5e73-4372-a871-450fcdefc799"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df395c9e-cb64-4c63-a7a9-9557802efa78">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d1c6eab-c016-4dfd-bab0-05e24a4bc0e9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d75a15e-098c-402e-bdf3-661f7f643c16"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b074bde9-f1b5-4d3e-a26b-bf006bd1bf69">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c90a114d-563b-4eb7-a84b-94586fc85e72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfee01e6-b418-44fe-ba66-b4083f78e82b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/001efabc-635b-4d73-83ce-55ed5d284285">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9e5a6b6-f562-4d6d-83de-a9d8da84a740"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/478a65b5-d8c8-4f58-9293-2d3088bf3e6b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <dc:identifier>HP:0010919*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99bd1594-8c79-47cc-8d66-4ded735ef3a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a13869c-8135-4209-9b4c-333f43b70b42"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7f88cbf-a6f3-42c0-934c-e19e2235d7c6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a24f5b99-b4af-4f31-8635-82e1ba0dcc22">
    <dc:identifier>C07</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
    <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/16fb2868-679c-4e02-b674-9e2f561ff9dd">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22dbb9a5-1731-4c4b-9084-147ecd56dbfa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e2c1ddb-5922-49de-8d82-0260be2c27b0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd2b03d8-3318-49eb-bbb6-4a2fa4743a41"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b370ce2-eff9-492a-a852-8e8293e352f8"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69caa330-c2f8-40eb-9707-eff8ce2b14b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f347b94-0553-489c-b701-42574858ffd9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71da8695-8ab3-4fda-aa45-9b6ef9a9948f"/>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd229f30-b091-4057-8f25-10be7e55915d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b513d504-b2c0-4ebc-b3d7-3278298e3df5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/220b1b1f-237e-4961-842c-e0d2a05438b2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a1193a7-feca-4bef-9c95-d6056e74082b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d065d69a-7d14-41d3-868b-fec2ce518298">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001931</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:label>low hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/efc632e3-5d05-464b-9466-90ee901a2c49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c50c2511-a46e-4afb-9100-c305d208d2e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5f340be-27d8-4ca7-86c2-cf23363cd30a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04d3a528-b7ff-4330-82f2-3de3ad29b3f2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1d4cc7f-4c0d-4e64-acf9-03f8a6c0394a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1c84cef7-0421-42e6-810c-5b2b92616f13">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fbecf95-5c2a-4bd7-8da5-df9b901da7fd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <dc:identifier>DB00126</dc:identifier>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e894cae0-ac0a-4517-887f-187e8f9d383a">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0d75f78-54ad-4a3b-85bf-c66032ab914f"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b7e318a-9d2c-45a6-8ba7-f54b50239e7a">
    <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe7a48d4-5e3c-49a1-8742-6654d066d982">
    <rdfs:label>retarded growth</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66544571-842f-4b6e-a1dd-35e165d5f07c">
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>Speech problem</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a5549334-aeab-49e7-826e-2b2941a26d1b">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/39890d66-6dbf-4fa7-af24-845b9a74e4db"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4665e4eb-2a57-4a9e-a339-5701edb57ded">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80c6d16a-7489-40b1-b5ae-db19218f350a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9945337-6304-4fe1-bff5-148658c8248b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c1ca0b2-9f9f-4344-b316-f910d6e25ada"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc0e6b66-4d21-41ad-91cb-4e751edff970">
        <dc:identifier>HP:0003111</dc:identifier>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee69027e-706b-45b9-8cdf-556244b3a5ac">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/43dfd1cd-9ec1-44f9-96e8-f90bcd2452e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c5c9da-764b-45ee-aa72-d64f587010cb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60ed2da1-e4ce-4fd4-bb48-65330690807b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0699106f-27b6-46f1-b82b-e51c36aa0b88"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b02ed988-0f55-4658-82d6-ef5daf13ef7c"/>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <dc:identifier>DB00166</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5cda7427-39fd-4f18-820a-74f017979446">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f2cc4b4-3cd4-4132-bb31-7625dde371fa"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78c5c9da-764b-45ee-aa72-d64f587010cb"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc846813-6456-4628-b195-95dbaa4f9378">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/953230f3-30d6-48f6-9644-b25ef3b9e250">
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37956c99-f681-4488-8f1a-a9d2b6b71e06">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012238</dc:identifier>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26"/>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e50d076a-b8e3-4b99-8bc4-eaa2574cf091">
        <rdfs:label>Low HDL-C</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c72ba20-62f2-4787-a99e-441c1b16ca21">
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/372b491a-b469-4b58-b180-d16731971bf9"/>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41e63552-629f-48a4-b94d-f0ee178d0bbc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfa335f9-37b3-4aa0-a8a9-6bc8d2d25806">
        <dc:identifier>HP:0001013*</dc:identifier>
        <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4713e53-fe5e-4f99-9f06-c0b643e7baf4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Recurrent bacterial infection</rdfs:label>
    <dc:identifier>HP:0002718</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28ca184f-8900-4c8a-b337-f9a681553d7c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High blood ammonia level</rdfs:label>
    <dc:identifier>HP:0001987</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8371cb43-7707-49e5-b028-b7118efd1dbc">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001290</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5869566-d522-4be0-b305-1b424cf58ead"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
    <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfe2b2e4-be3b-47eb-a918-561b7717ccb1">
    <rdfs:label>Acute episodic abdominal pain</rdfs:label>
    <dc:identifier>HP:0002574</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e39e4f1-cc58-4695-939f-76ac39af4181">
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:label>Hepatic steatosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a72af486-eee4-461a-9ff2-177fb65f9867">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>decreased visual acuity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0214052-0a29-4053-8314-a2bf85d2ad1a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
    <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003200</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17072a71-844c-4ac2-bb07-c78de613a7fa">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <dc:identifier>HP:0002872*</dc:identifier>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/89e77d1e-3ccb-4fd6-bf92-7c4df83fb24a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/522f5207-6349-420a-a5ed-fa814f184a9e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcbfe271-525e-4f43-b96e-048bc617390b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0ceba95b-2e28-4b8c-8561-c4a9283a3225"/>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a3e28f0-45cc-48cc-b885-2ab19e81bab7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5efc5677-7420-4912-b92b-f70453764670">
    <dc:identifier>HP:0002902</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyponatremia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ceef75bb-24c1-4c56-8810-0adfc8cd0de9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bf88f5f-aa3a-48c6-821a-47e928d02f11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a629183-aa7e-410e-a542-52fe16603e22">
        <rdfs:label>Myopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6a523cb-bc26-4fee-9be2-b6723d9a16b3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/01084ef2-76fe-44d0-8708-98eab0e29402">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d5dc2cc-a723-4181-bae4-e808eb58700e"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Pargyline</rdfs:label>
    <dc:identifier>DB01626</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b948154e-a0bb-4641-8473-12db3301b986">
    <rdfs:label>Mortality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92e260c5-1f63-4804-81b8-0944565bb6cf">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5459f100-5b7e-48f7-b101-b3d5f6f17147">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/758b6395-dd56-458a-af37-8f5f2d841aa2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f9c110e-3d6c-4390-b612-5a36d43a6846">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <dc:identifier>HP:0031884</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e5eded7-c075-4707-be2f-5d2c59487a62">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8993605c-d43f-4fff-87d5-f86135c07b75">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <dc:identifier>HP:0007166</dc:identifier>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c22213ff-46f3-4d70-8936-48bd97c31770">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4c759a8-0ca2-4dd9-8bcf-0ed059bcf08d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b5c7c96-e999-4340-b6f0-616a81052b37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9362855b-178f-4a5a-972e-e1482eb79255"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b37733-1d18-45af-b190-5ca9c7bda55a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e56e4cc2-ef11-42fa-a448-b34e546f1a3a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a101e038-9af8-4302-9f3d-b4f5c5a0e73c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce948b2c-086d-450e-ad47-69ad9d10ebd2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a9e9e6a-3843-4119-a027-7e54720bb9d1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a9b83010-3c52-4e81-b935-21dc1ca6ff16">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4748f1a-cc09-4555-a3fa-038a7b23d142">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/558f1ccd-edd7-4a2d-bead-d6ace2668070"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e60d113-a60f-4253-9884-2aaeb033594d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87a71b6d-fc9d-4fef-a473-b7d9e7060a0d">
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de8b68ca-1848-4562-aa1a-90e821988a1b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High blood ammonia levels</rdfs:label>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fbecf95-5c2a-4bd7-8da5-df9b901da7fd">
    <dc:identifier>HP:0003688</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5b9e4bcd-b158-431b-81de-fad2ce2204bc">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/754dba62-ef21-4a7f-9fa6-c645d885c77f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/841cdad8-7892-4116-a63c-4f3c9a14fbcd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0e0a133-4ef3-4a25-84dd-b2380aade5a4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50d02435-1b9d-4473-a774-a9de9ad0e16a"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e5cebb6-f588-4920-9cd5-3ecb0730b8e6">
    <rdfs:label>limb hypertonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002509</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de443be7-9e5f-40b4-8794-2afed502ba08">
    <rdfs:label>Tiredness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/299f8e9e-10c8-423a-aad8-0c65f125c198">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/383f0b81-4e64-4e78-b70c-a62af9499a42">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>mitochondrial dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/222eb0c7-d1fe-4a0c-b346-58fafd2e6b30">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/583a1133-05a2-421f-bced-2e839d4786ea"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/117e38db-04c5-4171-9e1b-d2719341dbb7">
        <rdfs:label>Decreased life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5d597dc-c388-47ef-8d44-a30b4f345d3b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef366d95-8bdb-4743-b242-396ce288fe6d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44088910-182e-4e6b-9452-63ab438db53f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1889741-af1b-4ef6-b5a2-1dcfddcd3e3a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee861003-be2c-456e-85e7-5f497cbb5263">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
    <dc:identifier>HP:0001712*</dc:identifier>
    <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c83bf17c-447d-475f-a7e4-d15eb27a2343">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a27ded7-ba3b-44ff-985d-5067506f343a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f688a6dc-37cb-4f0e-90b9-135d3f1fae39">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92fb0c06-30a6-4a67-84c2-43ac35c9c45d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Oxidative Stress</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/07e98a9d-775e-4625-93b8-0d8767b949ec">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dc58794-8b68-4744-9e9c-987f5fdea33d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7518c543-0474-43ad-ae33-d5c4d7025401"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a687f674-5d5a-4f22-b4b5-da4062bbb760">
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eabb7b91-f8e6-43b6-b12c-5a0e774b5afd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2abb3594-d704-4c90-b26f-594c361582db">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
    <dc:identifier>HP:0002360*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acd21f9a-9ec4-4f41-98ee-0c360340b63f">
    <rdfs:label>Status epilepticus</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fc062c10-52b7-45de-a551-ca10d9a01fc8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6b5b59f-cc48-4816-b78c-ce4428e33a08">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Psychiatric disturbance</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/195291ad-13d3-446e-9fd8-1d8fd2389e02"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e355f511-9673-437c-a9c8-736c64cd13a1">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:label>Myoclonic epilepsy</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/927d3392-ca6f-428c-bcaf-680515a8fd9d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ede4c1fc-0476-4a90-b33a-4ee7ac9b757c">
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:label>Abnormal circulating renin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/910d4500-3713-45dc-b4a3-cb3d0849d002">
        <rdfs:label>Bone mass loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29b126f4-0faf-4696-be11-89add3af5973"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8b28d4b-5d81-4c12-8639-d2b2fe3b849d">
        <dc:identifier>HP:0040085</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/771af536-ef66-46d9-b424-4abc861ca82b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fab5360-d45f-40a2-ba66-853ff90fcc1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be9d55f3-7073-4648-95d6-17b3182176be">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthric speech</rdfs:label>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c621b14b-23b8-47ce-9607-194d39e637f7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c322587b-744d-4826-95ac-b3c4ac083df9"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6798a40c-154e-4aff-bae5-b4e7f5c79fb2">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5116760b-a3db-4631-843d-4a8cd3ab0f82"/>
        <dc:identifier>DB00583</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16164bd2-9eea-48bf-9a06-06b0d1753da5"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d95a9f34-2eb8-4dde-b880-49700d6f385a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/039f0dc6-227f-45b0-947b-dfdaeb74b49d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f171630-0530-4ebc-9744-87fdfd049bc8"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2946ce5c-87a7-4406-8016-9b559a66a8dd"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b79237ef-a7cd-49bc-bd71-0efa8393a61f"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c9069e1-ea43-41e3-a7f7-bf2df8e1d366"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3af1d07f-1e94-4275-a25c-939b639def3d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/299f8e9e-10c8-423a-aad8-0c65f125c198"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe0b848a-740d-4f37-b647-a88c17a6a1be"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bcbf82b-3787-4a89-82e3-b111d1ef7a77"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f6155ef-084c-48c0-ba93-7102ee3936e6"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/806cd99b-1b07-4e8f-a778-179104b338e8"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b59a49a0-b41d-4dca-9c8e-b932502da316"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/977e049b-fe90-4b1e-abcc-e8123f1935b5"/>
        <rdfs:label>Levocarnitine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9386382c-7603-4c02-8fcc-664ade7ba1c3"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eaa3cd4-aae6-4408-94af-09115109df71"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c83bf17c-447d-475f-a7e4-d15eb27a2343"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c00c6d1-aca2-46c3-9755-61508adfb1e9"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2678ee31-f6a6-42ca-8bb8-93acb11a8b1b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5687ec8-a78c-4b82-b840-c17f129e082a"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97eed27b-db2f-4d9f-875a-a96e5b29754f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cce3d023-cb0c-4801-82b4-ec5f899111c9"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/977e049b-fe90-4b1e-abcc-e8123f1935b5"/>
        <dc:identifier>DB00123</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d3cd3ec-abf8-4c84-8bea-f0ac88581a50"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
        <rdfs:label>L-Lysine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/24818836-d39a-4eea-9575-271f57ceec44">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1ca763-caf9-4502-bbbd-fcc06b16f61b"/>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67ce1746-c3b3-4cab-99ee-759b93b9064a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17cbdb77-74d1-4aa9-9fc2-2648f7bbe27a">
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photophobia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15c5a987-9615-4635-a938-651014d51108"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22b7ca5b-c181-4c92-bef3-4be4b9cf5673">
        <dc:identifier>HP:0010918*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d260d4b-8841-417f-b544-9262f9e3ef1f">
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cbe3ada-49fd-4318-a5ad-151c01811d6c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:label>corneal crystals</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02630a25-b424-4d74-be90-7be24aa84841">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
        <dc:identifier>HP:0003358</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc8b8e73-6bb9-4745-b113-50abaefa984c">
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>renal function declines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d044e39-3fee-45ac-8250-9a8349c88bda">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03c831b2-b88a-4b52-8fc7-382c1d951397">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000095*</dc:identifier>
        <rdfs:label>glomerular damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5e08c79-29a1-4ac9-9550-26e0f778feb1">
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c50af32-f5c6-483c-972b-9fc2e00920f3">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <dc:identifier>HP:0000821</dc:identifier>
        <rdfs:label>hypothyroidism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/51b92d38-ce87-4cb7-b4e1-4d693cade896">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/784a6705-a71a-428d-b18a-7ca29c2fc382">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:label>Carnitine deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9714be8f-dcd2-4a31-9c49-23d414f2e744">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2be71b58-7ba8-4361-a141-64d3dff575ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd565e6b-8f50-46f7-b252-49e2d8dc103a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000952</dc:identifier>
        <rdfs:label>Jaundice</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8b48331-855a-4004-a05b-f5c0261137a9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypersomnia</rdfs:label>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761bb147-5ece-49f3-866f-3cad5c234d96"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f">
        <rdfs:label>Hypotonia</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37a429dd-d708-4ae0-b6d6-24d50943cbdb">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>phospholylation of RET</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/67a470a4-548b-46e4-bd14-cba452a85f61">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9936b38c-f973-47bc-b3c4-ae4b6192fc78">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b92d3993-4837-4f8f-a368-28a95798ca3b">
        <rdfs:label>Ataxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/822ca513-29ba-47fa-b9d6-3ba64dbb8234">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
        <dc:identifier>HP:0100513*</dc:identifier>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7e568742-1545-45ad-8aab-dcd6eddd2c26">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52368c01-9604-4cb2-a499-593ceacea017"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11c2383b-8c1a-4a10-8e74-5dcff2c57127"/>
        <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1582977-328e-4175-b709-79dff11f02db">
        <rdfs:label>Decreased muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c85c1f9-10bd-4b8d-91c1-b466acd40789">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d0a0a8b-ce32-457e-8bbe-cafe0005bbe5">
        <dc:identifier>DB05134</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
        <rdfs:label>Tanespimycin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5109652-6535-467d-a14c-5a76eadf8935"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ca2d08f-4496-4429-8477-afd8ce39a51b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e20cfd4e-df62-49ff-8f54-c3599be999ba"/>
    <dc:identifier>DB01041</dc:identifier>
    <rdfs:label>Thalidomide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6e71a759-8131-48bb-b09e-ec0999fbe9a5">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e28456d-0885-4b45-93ee-20c709259303"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/859fac16-7c88-4bc1-928c-d95c16980c8d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/243799ea-6d4d-47e9-ba2a-5b25f48ec5f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5a2dd1d-f852-431c-b20a-ec730255cc7b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <dc:identifier>DB09393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c565c51-27e8-45d4-b6f6-06b6c4f37d1e"/>
    <rdfs:label>Amino acids</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c4f3b082-bd4a-4ef6-8437-b46e89ab8570">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b56ab228-6ebe-435c-81c3-b66fdf76b4ae">
        <rdfs:label>Complex partial seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9ad0a73-f32d-4d83-b48f-ad7f159ad83a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized convulsion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06cb552f-f016-4a2d-8fc0-532a894c5ddd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28369c96-5fd1-4397-981e-f0aeaab7a883"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2f887dd-1648-49db-a9b5-4ad3849266df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a98c2a5-22f8-400c-a8b2-2cb497c84690">
        <rdfs:label>Aggressive behavior</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <dc:identifier>HP:0000718</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a611b9a-29c1-421c-9ba8-3ea50ad8fb1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f8e4d92-d1b1-49a8-bbe8-0b0e99c1be16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9d8e5dbd-8e60-4d4f-93a4-9b29288d750f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0329b30-8aee-404f-b3f0-5aab1ba90eb1">
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f96d1c16-a353-4539-9e29-22739a53c5d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa344ca3-4c60-4efc-852f-f98c3313382a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e640a45-2522-4152-90fe-0a53e5b86129"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a5449c57-f5e6-4f13-8317-bb51e758559e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7436bef-bd44-46cf-bef4-d160720362c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef60f945-6bc8-45df-9e1a-6f3bb2dd7119">
    <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
    <dc:identifier>HP:0012321</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/34fcd9ed-2ed2-4a4d-a118-922894ffd112">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18c01682-38d5-4a42-a545-6049788ee0b3">
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fa87fdb-a1f8-468b-8d43-ac62714993ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98fbf56d-8584-450c-8a12-3d3145cdf86e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe5735fa-2731-4a1e-9f59-f005e8006425"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fc4b1132-f634-4fac-8ca3-f37ae45c3421">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9e34cd3-b1c9-4731-96bd-4b45032d97fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/504fa6b0-a5ce-4870-a1f6-1b04aec18d63"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da989717-5791-413c-aaf5-f4a7aa644b0f">
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/804d6434-0216-45e2-81d1-bae38d2b9965">
    <dc:identifier>DB01022</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae4531e7-eba4-480b-b680-9918a3ce4fbe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/977fc78d-07c0-46e6-bbce-49c02a282984"/>
    <rdfs:label>Phylloquinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92b8153a-e425-493c-8fb6-c9c76a498ce8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001138</dc:identifier>
    <rdfs:label>Optic nerve damage</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba8ae757-1868-4cd2-83b9-e64238b4a06b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <dc:identifier>HP:0003254</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/569646d4-f7bd-4ade-8072-1a1f6f70e424">
    <rdfs:label>Depression</rdfs:label>
    <dc:identifier>HP:0000716</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55907745-315e-4223-926c-06b3d34910d6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d855926-3682-42b1-9e40-4484e71014ff"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3f7a1306-64a7-4c0e-aa6a-6c021f686a23">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b948154e-a0bb-4641-8473-12db3301b986"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dc58794-8b68-4744-9e9c-987f5fdea33d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0017be7-5db3-404d-a3f0-bc4ebfc7282b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/33527f00-167e-4439-ad71-72cfe21a035a">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88bdf20c-a5b4-4c33-bfad-3409a1ec20a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ab85c22-4773-4390-9aae-94ea0503d916"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8fede44c-b2d9-4ac4-a87a-036ecd00dea9"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <dc:identifier>DB00437</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48965d2f-280c-4b0e-a040-cb9efeca30b4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <rdfs:label>Milrinone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4b7c42de-0eb9-47f1-ba0d-87ea7248d43d">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6574160a-e4cf-42d4-ac3e-f9cc60016fe7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6cb15baa-546f-4be1-bad7-1d33d50ec322"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08944f56-902a-447f-83fc-94ecfdfee159"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8050612f-4c7d-4083-9f11-76143f170882"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11de18cc-c880-4f8f-8f67-ab9248906826"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00235</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bbfcfbc-e661-441f-bbb9-3531b6a3504a">
    <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
    <rdfs:label>Neutropenia with IBD</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7041ce95-7ac2-4be1-a49e-94b8cd5250eb">
    <dc:identifier>DB00158</dc:identifier>
    <rdfs:label>Folic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41d7615b-0681-4dc1-b996-7d9f12a2f916"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d6f85f2-26d3-48f6-84ec-9717b9a9c0ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d90a58e-e91d-43b8-b2cf-c0921bf911dc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>osteopenia</rdfs:label>
        <dc:identifier>HP:0000938</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bce7ed98-4e95-4aa4-9cf6-344a8089ae54">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Vitamin D insufficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c80e84b0-6776-42db-bf25-6d419a55dadb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011021</dc:identifier>
    <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e8dd7d8-da49-46f7-9e83-76f2dd82cfba">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53dd862b-e50e-4fe8-b2f2-3ba4a845f3e8">
        <dc:identifier>HP:0011943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c759fc2-419d-483e-978c-44525d9a1f27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7084c080-0d1b-4e73-b36e-2f1be7e2f143"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1758aef6-7fc3-4756-89a7-6bfd73fa7a8b">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6eb9660-152c-47dc-b580-236f2797f92e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b217ad6-d7db-4524-9596-4c034c69f3e2"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c75b07e-411d-49d9-8cd5-9c198c9f6037">
        <dc:identifier>HP:0012030</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
        <rdfs:label>Abnormal urinary steroid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8072909-a460-4407-b847-c19b2b6479e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa1564d-a05b-4606-9fde-0fd6f0fafb77"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dc420314-dda1-4beb-a9ad-ee3a16e50290">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0e4faa3-c26f-4de8-abd1-70f81c736101">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001337</dc:identifier>
        <rdfs:label>tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50ce15c5-a632-451b-861c-b3b9c003f31b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8f0c0ae8-b066-4193-9ff0-677b40d18541">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fde0d9f-91bf-46ad-99bb-aa0b34069033">
        <dc:identifier>HP:0012477</dc:identifier>
        <rdfs:label>Voice tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71705dcb-5658-4a33-b491-16bf9ae78de0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:label>Poor fine motor skills</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/137e78d2-f1ee-4b1d-8e7f-bf714522a219">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:label>myoclonuic Jerk</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79fc2b9e-1ae2-401b-aae4-aaa5ebb74cda">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/652ca187-552c-4218-9aab-8042aea84e0c"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d6e6ad06-f751-448a-97fd-87c8a11eb662">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad259bd-062c-4d3f-be23-0da0aaf5efb5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28676986-b571-4839-a293-de153d8ff6c8">
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>W99R</obo:RO_0003304>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f1c3d56-537a-424c-8d94-9003907dacf6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:label>muscle pain</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/d857dcc5-89bc-4421-bba0-2c9f0b706b93">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c9eb055-7851-47f0-a871-7131385957e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91ec15cb-ff4f-4413-b591-4987ac4b7420"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b61e17f-406b-44eb-a79c-8100161ceb87"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3ce8216-f0d3-4415-92a6-036a0b3be34f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:label>White matter changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
  </obo:DDIEM_0000009>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7453d2da-69a8-4952-8a83-33eb0fe64193">
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c1bb465-73d9-45b4-8bce-5c70511506c9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>high liver volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85f591bf-ded7-4fd5-b60e-c19c932ee117"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/256a08d3-df8e-468d-b940-c5eaecc885d1">
        <rdfs:label>High spleen volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1001f184-8ec1-466d-be92-58e6748ca3c2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/112ec4ad-fcc1-4612-8250-3940c7d04969"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9fb18c2c-46cc-4351-9388-eae3b48587b0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/813f9d90-32d4-4222-b81b-7f22f15f5fec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/792c946e-2183-45e7-8731-e1c6cb7b8493"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/243afeca-f592-4bd7-84e5-4ffbe5ad7626">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1f1bcc-fa40-4bed-8ded-abacfcb7bb35"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/420bbd61-254f-44f9-9523-865941399b92">
    <dc:identifier>DB12449</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/56e6f11e-976f-4a51-9d27-4878a11fe660">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd7313f1-36f7-4df7-abe7-c536b3e47a6d"/>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/976dee0e-eb00-4a55-a054-49d3d5fdb9d2"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005242"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f7a4790-9398-43a7-ba48-76874d8acc4f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c4034eb-ba1f-4f59-b517-be56026683e2"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <rdfs:label>Tempol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5715b4f5-2caf-4022-836a-923236072d1a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <dc:identifier>DB01247</dc:identifier>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ec92f69e-44a5-4ec5-8ac6-d34e87e6370c">
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6c9dc39-9ac7-4104-96df-48924be6ec4b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93f36d71-77f1-417c-8031-53590ac52fe0"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d2e51e68-1271-4795-883d-c16d874442ee">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16b264b4-7050-4a7b-96d8-47476dc15982">
        <dc:identifier>HP:0000486</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
        <rdfs:label>strabismus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d499e90-28ed-4e7e-95a6-bc01b6ecf646"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85eeb3b9-695a-4e13-aac9-473195b383c3">
        <rdfs:label>esotropia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31b24219-f72f-474c-84c8-5bc27c5b8adc">
    <rdfs:label>Self-injurious behaviour</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46d3dbad-6608-4546-80a4-b66964df830a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/701ffdbb-e3d2-4ef0-9cf2-5443eeab5ffd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2297cb90-745b-4a6d-a72f-fe09801cfb79">
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a6e774c-fd34-411a-ab48-89c2767fa794">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb665413-1ecd-433d-9b50-ee4286884f09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6180a744-e189-4d4f-893a-e17621072405">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7cc6767-5d13-4907-99c3-a5570e18dd3f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/306f26e0-331d-45ae-8158-2ce689abf143">
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/14569bfd-b446-40b2-a33f-5a3b56421b16">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bf20dce-0827-43b4-acbd-8d91cd8c20e2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05482037-dfac-44a3-a678-a39ebb6cb94f"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/941c7a26-5a82-44df-b1fb-2635ed50001b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <dc:identifier>HP:0002123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e60d113-a60f-4253-9884-2aaeb033594d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c3cbbc9-c0a6-4bad-9ef4-ea47940b2403"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b236208e-0469-4392-97ca-b9aad1ccf7c4">
        <rdfs:label>astatic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56ffa74c-c5f7-416e-923f-317ea8f21528">
    <dc:identifier>DB00594</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/093512c3-9d0f-46e7-ba6c-0157f81a9294">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a13c36f-3b35-4fda-a7d2-01f18a87f446"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/948f1971-abd0-4f29-a972-1aacc5aa6c2e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e641d88e-3c80-4bf4-ac4d-f3d65dea5eaf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Amiloride</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/723addaa-d2ba-48c9-a4d2-75158a433dca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce5654e6-6b53-4d08-8219-288798764621">
        <rdfs:label>Growth impairment</rdfs:label>
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69543cd1-b00b-4734-85ed-feb75e630741">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bc59fa0-804d-413b-b8f0-0e83a5c596ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49a53f38-6d8b-41c7-9603-31e5363c9382"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c03e98fc-c63c-409b-826d-db85ca9727d6">
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3559ece8-e6fa-4a41-b8ac-9b8e2d12e882">
        <rdfs:label>Hypocitraturia</rdfs:label>
        <dc:identifier>HP:0012405</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/efd0ad9d-4a27-45b6-9d6f-832d30010d47"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef60f945-6bc8-45df-9e1a-6f3bb2dd7119"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6f9b036-eba2-4dee-bb0a-f83e7d038b13"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e9c1f655-6295-48ad-bcfd-a3fec5760e1e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3215ee73-23ea-4262-bcf1-dd389ad914ec"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ead5a49-07ba-4139-afd3-5f5df8ded6e4">
        <dc:identifier>HP:0004295</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
        <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bdb1444b-0590-4f14-b87f-247321b01280">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9fb47b8-3882-482f-a01f-8870b1c36e97">
        <dc:identifier>HP:0031034</dc:identifier>
        <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38e1ab36-dd18-4663-84d0-101e64240609"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1aae0655-746e-4cfd-a2ee-6be462884e0f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb07ab1a-59fe-4906-9b51-3d8f7cc252e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal circulating GH level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
        <dc:identifier>HP:0032367</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d30e5a48-63a7-4952-b174-e24b55bbc69b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045082</dc:identifier>
        <rdfs:label>Low lean body mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a511cb7b-c126-4d14-8e47-c4fed0a1c329">
        <rdfs:label>low insulin senstivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
        <dc:identifier>HP:0008189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be579552-3fd3-4caa-a92e-be83f684b612"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdde00ad-edc8-43e4-bdcc-bf660295f732"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ced7a660-5922-4e0e-9562-cf82563f1675">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:label>Insulin resistance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7884cbcb-2b31-439c-a544-238d83412ed0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040215</dc:identifier>
        <rdfs:label>Abnormal circulating insulin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc3cf30b-ddfd-427a-a6dc-42f7c8e5a1bf">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>Low height velocity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d6a8c873-7e20-4376-a9f3-9f6c0bb3b4e6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1a1ce6d-d2b4-425c-81bc-a1b20d180e2b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/642b84da-8792-4156-a3c5-ecd56477bd2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9c4c41-84af-4e99-858e-673ed0d5367d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab34023-e326-45d6-8b9c-c6411dcba232">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
    <dc:identifier>HP:0003473</dc:identifier>
    <rdfs:label>Low energy level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c50a0256-1ee7-481f-8661-fcd639e2802a">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/405ff2a8-0b95-42da-aabe-2939af0db7ca">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3af231e5-7d1e-4367-aa97-64eeadb423b9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5310ddd5-e1bc-4e1d-97e2-a19e09d24fd9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c13f4488-5d96-4c26-ba49-619fced36df7">
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e092e9-c7df-4399-840f-b016494ae352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abe55b60-c4c4-4b95-8734-3b72aa36fe3d"/>
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36dc8477-0ebb-44cd-8d28-de808e74d884"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67a470a4-548b-46e4-bd14-cba452a85f61"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9cc6e81b-d7d9-4ecd-b64b-52012a3547d8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8a55e09-85a6-4cda-8419-b8c769fda539"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/73a55621-245d-4919-b65f-3dace6f48b75">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1566938d-474e-4df5-8b12-b9702318486d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faea2799-c014-4aba-9f23-4c8305fc7d17"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1377c94a-24b6-4473-8316-8b49c4bde955"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9bc78e4e-7980-468b-be6e-af019f359dba">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58c248bb-d460-4d0e-8c3a-5a30985dc169"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93a88992-c3dc-4f3c-96e2-f2a373d02846"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cdf8afd-18ef-4fcf-8ec4-5168d4e7b363"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0ba9d72a-a319-401e-b3b7-9d3133e57526">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47fd1d6f-0163-44a8-9fda-8768e473e26f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0917102-91bc-456c-926a-4767e5f3e00f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba09584a-ec41-4797-9794-dafaa1ff5fb8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:label>cognitive impairment</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0cee905f-4a9d-4690-a82f-bf6cf7416801">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/698fb637-9df1-4dc5-a6fa-6114dad637ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd8c7c6b-b03d-4cc8-955c-e3849a10b627"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aecd6bf-097a-4cf9-bd3d-818b2af24907">
        <dc:identifier>HP:0000479</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:label>Retinal ganglion loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8f521dc-bfba-4be6-bb03-dc360c32f517">
        <rdfs:label>Visual loss</rdfs:label>
        <dc:identifier>HP:0000572</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33aa8f32-fa9e-4695-9e42-e797b2962589">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/606e5766-3860-4645-9cc9-bc3dcfd92f6f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <dc:identifier>HP:0003738</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbecab73-7643-4bde-a6c4-01a0bc6b003d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a36f0cc4-ca42-46e0-ac53-2f6e17631f97"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615511"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29fdd8fc-4f71-4b19-bbd1-91220b912c39">
        <dc:identifier>HP:0003394</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle cramps</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c6a45ac-2d10-4b49-87e2-714a242cf48f"/>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb18ad3e-a436-4760-a1f9-5ff8b16a85d3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/50ba7933-5cb1-4e38-ba5b-26fcf247b0de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/854a308a-a3f3-4cbf-ba36-7799e6a91fd8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/75cfa682-06a5-45b4-83b7-5ddb4178c95a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7d45cdf-a44f-4285-b9ef-c1eea6d49f5a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0374a8a-b74e-434b-81a2-863496529cd9">
        <dc:identifier>DB01124</dc:identifier>
        <rdfs:label>Tolbutamide</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2acbef60-7d8a-4af8-b081-3fd577e985d7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8460871-9187-42f6-a2f7-ae3fe9519a26">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e688d1e9-0974-466a-abba-f2bb6039d68e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f54731a-3afd-4f7e-979e-39ab272e9c79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7e68185-3123-494e-b2e8-e148213446f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/4354d518-f0de-49ac-b227-eb2d2c301325">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bde885f-13b1-463e-b6ee-bd12196253c8">
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e63b3f06-fa44-4571-b039-37ab1fbf5dee">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>High total cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6eb21c66-13cd-44c1-9b06-84c9ccc33ba7">
        <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cedf995-4c95-436f-9cc7-187c8bb1d676"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf"/>
  </obo:DDIEM_0000009>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f33e2bb9-a610-4d4f-b479-6cbf9a231a6d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
    <dc:identifier>HP:0002152</dc:identifier>
    <rdfs:label>hyperproteinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff9bce37-8e69-489b-a74e-e9173461f6c6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bb2cf74-7236-42d2-8e06-80c40a832f22"/>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53d5b066-97ac-4776-ac58-f56e2f4cdfab">
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7f009c-f0c1-41a1-b4b3-cba0c488138e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6b47265-3651-4c3b-84bb-50708623a1d7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack of eye contact</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0644234e-799a-4161-a0b6-512085426520">
        <dc:identifier>HP:0003785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a614ae07-ab68-4213-9f8b-3a0e3f75e2ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypokinesia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99687bbb-b0fa-4b50-b3d1-d6683e3e9c67">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed mental development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55fadcfa-125e-4c04-907c-bd8f95bdcac2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1baf3583-ed71-4704-a7c0-efbd52de6454">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:label>lack of gross motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50b00f9f-d8e8-4040-b428-e1fc43c56ec5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus jerk</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3f80ed0-7ad8-474d-b5f1-e9acb2e50b59">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ad892796-a78a-489d-8c54-171408ea8cce">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90486c08-3877-4eb2-8213-19a1f4c5b488"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678378d9-3876-4212-8b6e-84fb7223b45f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c51b4f84-76aa-4df8-9647-92c64baaf000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/546fa518-d051-4993-b62d-fa67f396e0c0"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/709ae2d1-1dc6-4685-96da-4f8b5d57fc30">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6abd0dc-ca39-49d9-9324-a1a7b81f15b9">
        <dc:identifier>DB13173</dc:identifier>
        <rdfs:label>Cerliponase alfa</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f248d52d-6e65-43d3-b7a3-ec604be396b7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5dc807c-b617-4191-a8da-e9d86f197c4a">
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>lack of strenght</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3979a327-2bfc-4f84-9854-0b0c82e127c4">
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e61a6039-f092-48a9-97e8-bf43c8e5b396">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e64a1922-125f-43c7-ba35-a143bfae8b8e">
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <dc:identifier>HP:0010553</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f54901c4-5914-4597-bc3c-4a0b87bb5714">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/831dcd73-eeaf-448d-8c9c-bc561eaa94e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e10ef396-6951-4266-9e18-d9c79c1866be">
        <dc:identifier>HP:0002459</dc:identifier>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec73915e-8a89-4eb7-a63d-59c4367b4da6"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/592bf0f4-793a-4f8c-bad3-dcee3cbad034">
    <rdfs:label>Increased ROS production</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/512fc02a-1536-487b-b18d-fd5be4dbd624">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e69c087-2a91-4f8a-bfea-cf8e952b0a93">
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7a5c393-860c-49d2-bbf3-696deb9db2b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adfcc505-d91f-4ca2-b9fc-1420bf4950aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/876b77ad-801c-470b-9836-b5e3a9bab82b">
        <dc:identifier>HP:0010876*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/144b6752-64b4-4e18-a63c-d54c1a5c847d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
        <dc:identifier>HP:0012133*</dc:identifier>
        <rdfs:label>Decreased red blood cell production</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc8a4181-dd33-46bf-af4e-dbfdf98b1e25">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d967869d-0712-4177-832a-28131713a19c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40690af2-8635-4faf-ba93-12754112da3f"/>
        <dc:identifier>DB14681</dc:identifier>
        <rdfs:label>Cortisone</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1d7da37f-c7c9-4d23-83ab-9c1ae19941a1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7dae6ee-444b-4f12-b7ff-0b5ce8a12e83"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/317550d3-7f07-4c3f-9cb7-bb1b72e18d49">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a6725ce-6827-4994-beff-cfe2a580ff8b"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ed038d0-5d30-4a43-ae07-1d3ea60e3991">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
    <dc:identifier>HP:0040181</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Perioral dermatitis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddcb2daf-8edf-4aa2-9b61-9a1d483b7ceb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Low IQ</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001249</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f343584b-e107-4701-b5bc-2ec0cf8a3cda">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
    <rdfs:label>subclinical hypothyroidism</rdfs:label>
    <dc:identifier>HP:0000821</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4f52dcbc-5ffd-42cd-a344-b5e552b7b23e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55a9f2c5-6c21-4438-8b24-c3437fa3127a">
        <dc:identifier>HP:0008347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fc5c415-5538-4187-b21d-857efdac439d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad645e6f-b180-4027-9145-14d18033a652">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6bc55a43-9cc7-48c9-995f-691663acaae9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/592bf0f4-793a-4f8c-bad3-dcee3cbad034"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24af2586-031a-4983-ae4b-42b19e0019b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8520dc53-2622-4668-aa11-efd04377c7c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99ad1a32-a7e4-44fd-b3b0-9474ea405aae"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08a1ffc4-5544-4360-bacd-8a331933b3c6"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01e923c1-09b0-4a3a-9f36-69f85de62221"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82b51ada-93d4-4170-b565-eed5774bcaae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/741a046f-7d7c-4adb-baac-57c7c9f4669d">
    <dc:identifier>HP:0003072</dc:identifier>
    <rdfs:label>Hypercalcemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02d4166b-871d-4c76-b930-b2a34b159ddc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0003218</dc:identifier>
    <rdfs:label>orotic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/271a15d8-70d5-45d1-882c-052e85882f11">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4b27663-3aad-4a35-9388-2b6fa6ac9c77"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140e54c3-d3dc-4042-8925-9a6b477cd5e5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2ed6c8b2-3485-47d5-8cf3-2a078707bc57">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d13ba9b8-58cd-4670-a98f-07bf3dbc8e2b">
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47879bf1-7823-448d-a608-35a1c3b185cf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23742974-3e2c-4359-91ac-c63d47ee8a84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf0f569b-5d1c-4e4e-92ee-bf6c9380a8ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc79eb48-a2cf-4761-acee-ebfc25d8cd2f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperuricemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80871588-ee7d-4b70-965e-bbce985a6e14">
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31c44466-8b81-4ffc-a3b1-abd7f27559a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <dc:identifier>HP:0000105</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/583a1133-05a2-421f-bced-2e839d4786ea"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
    <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c4e6e68-2b5f-482b-a654-4e8ec599e708"/>
    <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
    <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85f9abf8-141f-42d8-ba7d-13dc0e9c67b1"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6780daae-488c-4da7-81c7-d2162fbbc1f2">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0e39a63-2439-4e8b-ad0c-6cbe15b80fd0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Low ATP synthesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7200294f-af05-4b26-bce1-5818f4d2f08e">
        <dc:identifier>HP:0000648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Optic atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4698e9e4-3f8f-4c82-a854-77f79ea396ae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01caeaeb-d825-4ba4-b468-602a9e9960f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b424b5eb-8182-4c41-9628-72de954e0411">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
    <dc:identifier>HP:0000962</dc:identifier>
    <rdfs:label>hyperkeratosis</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/18e64755-62ec-43dc-b116-4a51a0fd9f86">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613150"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b00fd089-4c70-4bfa-aaef-46cb2b9810a4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:label>congestive cardiac failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c711c2e4-04f4-4155-ad36-7d5a679501cd"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eb5f812-2bf8-4749-a95f-d74411e5621a">
        <dc:identifier>HP:0002789</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tachypnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99299e7a-c748-4143-80b3-ed97c724f1f4">
    <rdfs:label>orthostatic hypotension</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
    <dc:identifier>HP:0001278</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/17f29bad-5d28-471f-ad17-e1742ba23ddc">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9acb0dd8-d3ec-46f3-8a84-d41e585da229">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003326</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
        <rdfs:label>Myalgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fad14cd7-acaf-4043-b104-42a35c2f535d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbd8ec16-8784-484a-929d-cafc8a57295c">
    <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/99d1b188-e220-44ba-a393-a49f2fc6ad5b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9968439a-4b05-4508-bbc2-8e4a15d7da37">
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ad7bb64-c16a-47fd-aa31-ab5b44b3c4e4"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad53a0e2-05bd-48e2-a4eb-c7e416f8d1ec">
    <dc:identifier>HP:0025142*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a9ecfb6-229f-4059-9417-d95deb19a1ef">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/07084c47-6ab1-4e9c-ab0f-b3277b31adae"/>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ad7bb64-c16a-47fd-aa31-ab5b44b3c4e4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d75a15e-098c-402e-bdf3-661f7f643c16"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da311163-3ebb-4273-93af-1bf3ea365b77"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc79155d-627a-4529-9729-4b8045a1954b">
        <dc:identifier>HP:0004348</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/f19c154f-ca80-4f4d-8138-2abce139de43">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d855f28b-9eb7-4f30-9aaf-8991fec24078">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e42044e2-52d2-4cc9-b707-b5f66d59e8ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88cd4e6e-cdc4-4ab0-9633-3bed972ced83">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Imapired muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b427f099-62ee-4861-8adc-417f2bf462ba">
    <dc:identifier>DB06775</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/96b109ec-9a2e-473f-bdcc-b2255dde97b5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82cd8abf-df3f-4b43-9943-5dae78790b37"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7dae6ee-444b-4f12-b7ff-0b5ce8a12e83"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d7da37f-c7c9-4d23-83ab-9c1ae19941a1"/>
    <rdfs:label>Carglumic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8225000a-9ec2-49e9-8b37-6836b6cd2157">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <dc:identifier>HP:0009830*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73bed9a0-9a3d-44f2-a874-5296a3903eef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/237a07d8-a573-42e5-97c7-b96f8469a4fb"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/143096f7-d433-4e0b-8ed0-f6aa6850fcc8">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68a12c9f-b97b-471d-aab9-edf6a9b3b577"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601776"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04062a2b-836e-4709-ba9d-dcb79ef26c51"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0bc415c9-6950-491b-9ad3-7b6468c06ff7">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04062a2b-836e-4709-ba9d-dcb79ef26c51"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ead9e0a0-ecf6-4fef-b69a-46ebcf86739c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14513</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f784e123-4887-4636-afce-47c22120661f">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acd21f9a-9ec4-4f41-98ee-0c360340b63f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04062a2b-836e-4709-ba9d-dcb79ef26c51"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203700"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/855944d4-7dff-4353-bc98-5bd08e3a470f">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55ea98da-e3a6-4def-8289-228a592a103a">
        <dc:identifier>HP:0011167*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/675104df-2a6c-4712-b2c0-edc933f9ef51"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6690662f-7ffb-4ec3-87f5-b9a34e4fb7a7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/584b1647-2dc5-4476-9a61-db38cec437b2">
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/652ca187-552c-4218-9aab-8042aea84e0c"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0ac2ff0-a821-4e67-9cd7-3bb322fa5913">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <dc:identifier>DB14712</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87c727bf-031b-4e14-b6ca-f7f8995bedc7"/>
    <rdfs:label>Elapegademase</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f942a6f3-a81a-4e3f-89e7-d7903d61ccd2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a527335-950b-49c6-b475-10d7346e9627">
        <dc:identifier>DB08875</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
        <rdfs:label>Cabozantinib</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8499920f-7d12-4db5-afd5-79baab768e87"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b612921-d7b7-4b02-b26d-b3e377b19584">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46edcc73-6c3e-46af-9258-0fca30d4a72c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f506d0ec-c423-4be4-9cee-68a2f0e57d2a"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
        <dc:identifier>DB00103</dc:identifier>
        <rdfs:label>Agalsidase beta</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8f13b13-32d5-4143-8881-116d2e2e46b3"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cafe6b60-58d7-4bd9-9732-9e75080a206b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5c54718-594a-47db-b338-ff129beb2700">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor eye contect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a063ebcb-785c-47f8-92c4-b4584748085a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
        <dc:identifier>HP:0012433</dc:identifier>
        <rdfs:label>abnormal interactivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bce0e1a6-b973-4b00-a302-231eb31d6cd6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/2946ce5c-87a7-4406-8016-9b559a66a8dd">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fb46ced-e5e0-4a08-a802-2458486be5ed">
        <rdfs:label>Decreased plasma carnitine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000008>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e6587a82-d6a7-4604-8d43-a577bc41bafc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60c37644-e24a-4d97-b85a-fe7efad1c939"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9fe6db6-6825-41c1-a201-77cb93661c3c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/80070695-7a2d-462b-92db-6bd1c5a061a9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/569646d4-f7bd-4ade-8072-1a1f6f70e424"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0400fa84-eaf2-4ceb-8d3e-773497a26d8d">
        <rdfs:label>Serotonin deficiency</rdfs:label>
        <dc:identifier>HP:0003117*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85f5e716-2d33-451d-936f-a599a1ff73e5"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bb2cf74-7236-42d2-8e06-80c40a832f22"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd99f9d1-9507-414c-88b6-f0719ecb69f0"/>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e02e6db3-c15f-437d-8827-acd4a5bac132">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3eaf2477-7172-4c11-b41f-08210d7430a6"/>
    <rdfs:label>Nitric Oxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <dc:identifier>DB00435</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/07b207df-109e-452f-a2f6-8601325a661e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d348d8c0-6423-43d2-b058-35c18aee16a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c86a8dee-b5e4-45b0-8634-ff9c17945333">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5109652-6535-467d-a14c-5a76eadf8935">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb2e5b74-70f5-469d-b437-fcaf6e03106b">
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff5020d4-a449-41a6-980f-0ceaa424fb30"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/865bc7a7-bffc-4918-81e5-2c25cf8bb540">
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bfa59c02-6f8c-49a6-86d4-edda9ddcd86f"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c85c1f9-10bd-4b8d-91c1-b466acd40789"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7804bee-c898-4ade-aaed-79aea86bfcb0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mislocalization of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/033656bd-5e56-4436-81bc-7697a284be53">
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95bf4ad7-6a49-4340-ab0f-44c5f94ea10d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59e832be-de8f-4760-a1a5-9a7b13053989">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42a5a35c-3acf-427c-b7a0-dce69e43437b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6cbc68d-c0dd-4526-b8b0-7b386bd8881d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cebb3e29-69b0-4870-a271-7a1ec86cb415"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/eff4ce1e-e9b0-4ee9-acc3-50ee51806d31">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efd3444c-4028-40bc-a2c8-e25a98481a67">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001980</dc:identifier>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5dfb721-f3cd-40ec-ab17-1989ac89a2d6">
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41fd78d7-bc40-41de-8c23-031146e59750">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
        <dc:identifier>HP:0025454*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca9ca021-feda-4deb-94c3-31593954f0ba"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a14d8c14-d6e8-4f96-be6d-da1566be6a3b">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/664c4b2c-6a3e-41c3-8548-3bad3541f82c">
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3da3f122-2968-4677-9a4b-05e9bd728d13">
    <dc:identifier>HP:0000964*</dc:identifier>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/bb744d37-16d6-4195-9a7a-92e6eb9525ef">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81962e55-ae79-4df5-b02d-53b56626795c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b823323-4bc6-4d82-b972-cca4133c356c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/d1fe6a6f-b15d-484e-866f-5772a304959e">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed82cc64-597b-4587-bd7e-3ce1229886b8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low muscle mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c2dfce4d-120b-4519-a7cd-5edc84735e22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8cc2ad37-a1c1-4b40-951e-61b51b81ee45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af749e94-69bb-400d-8a56-2242baf6cc96"/>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27e67ede-3bf5-439e-87b4-76f13b5cebca">
    <rdfs:label>Elevation of creatine kinase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003236</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c36a3dd-3424-45d9-98c1-665a7ca4fb0f">
    <dc:identifier>DB00091</dc:identifier>
    <rdfs:label>Ciclosporin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bae799f9-ed13-447b-8375-201d0c43f0ac"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b33b2a1e-2fc0-45eb-ac53-3d58904746df">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/383c92c8-2d49-48c4-b1ff-a33459c8a25d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/551d7141-efb8-4d8c-a82c-0314454988f1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/383c92c8-2d49-48c4-b1ff-a33459c8a25d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/985365f6-506d-4152-b24b-1d7714905e72"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4c9c9b3-0d56-41f2-adce-785ecc78e048"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a1c13d1-f320-434b-9053-cf7dc1df1821">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011013</dc:identifier>
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/536d5e79-3d71-430f-8cfa-a419435a89b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6a25c54-a137-405b-9213-042cd4f16435"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa1564d-a05b-4606-9fde-0fd6f0fafb77"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f60a0fdd-6675-43ab-8a5b-4b0e9d153d01">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/96cb8666-6018-42d5-a0d6-8b9ff5ca7dfb">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f4a5b53-9c36-4c24-9504-58ab80ab7565"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581dbd2c-9f6b-4c49-a097-2c6829f37994"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <rdfs:label>Amcinonide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e78e7be-7a55-49ac-875f-1f57b14a724d"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0e41e72-8b02-4562-a426-0f0958e8fed4">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9629b5f8-4e69-4bc7-a4c3-8156843c1c77"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2bbd5d8-bda5-4761-9439-d6ace5f99953"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/581dbd2c-9f6b-4c49-a097-2c6829f37994"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2652921-f588-4cf6-8a51-66728d37fea5"/>
    <dc:identifier>DB00288</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da07bfcb-58b3-4692-af9b-9533da3ea352">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>rickets</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5624289f-324c-4818-9d6a-6b0d91132a8d"/>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d74a7ea2-c5d0-4417-8428-54f69e77f6c0">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c227da2a-8e2a-484d-b92e-bf5cbe782b78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f83083f4-2106-4bc1-837f-32af2f0463e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2703065c-1219-41f8-a4f3-56f6510cdd9d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/832b34f6-9418-44e0-914a-ca52f596950d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6816926-4af2-4e46-af51-7a5929a10f0c">
        <rdfs:label>Pyridoxine phosphate</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3084f7cf-ca13-4dff-bdac-b64267995500"/>
        <dc:identifier>DB02209</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b52c1438-0f24-46e9-b612-88ad28cc2d6a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f095ccfb-ca40-4e84-bdab-70f9c362c323">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0e39a63-2439-4e8b-ad0c-6cbe15b80fd0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ffc71ee-7830-4d8f-bbcd-2a519dcb8c8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f49598e-7e60-401f-8ade-79b2921c92f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c24461f-bfd8-4fc9-b469-82ed78fbff59">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ae26752-cdc9-442e-90a8-aa119d710035">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e04f9401-fa98-4a75-9124-d21b7f302482"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/78876760-5730-41b3-8e85-5ad69c19942d">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235200"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3ccac08-32f9-4aa4-b27f-a9c112c20b41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4de20c0d-39e6-4b30-b25f-bbdd8a407385"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1085d95-52a3-4f37-b5fa-a85c53b39989">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/105145e6-9fef-4105-81e7-140375a5391d"/>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/c63004b9-b99e-4847-a7c2-4aa43543e860">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6da24abb-eda8-4a2b-93e5-262074dc231a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <rdfs:label>Ketosis</rdfs:label>
        <dc:identifier>HP:0001946</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeae5eec-cb69-4a50-b646-1616b33a1444">
        <dc:identifier>HP:0012051</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/486d1a9a-0c13-4a28-9edc-9ae31cb1eb1c"/>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47a2255e-04eb-40df-ab8a-eabef017c588">
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f738bfc6-5383-495a-8ad8-e1085afb95ec"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cee81d0b-0101-465b-b93d-e4bd32fcd6f5">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8a188d2-7c30-457e-8359-08175fa34ec8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ac29dd7-5e06-4764-8f7a-30f9f15eee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7e4325e-e0f6-4f0d-8640-e73deddf9adc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5783f13-6685-4de2-862c-fb37126e0797"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adb90cdf-1b42-4632-87e4-9bca0951134f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bf20dce-0827-43b4-acbd-8d91cd8c20e2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/045722df-9cb5-4dfa-bcef-6cc79b9e0134"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0023195-b2e1-4372-b5f6-bab886d68eb9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e60d113-a60f-4253-9884-2aaeb033594d"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12e8ab07-f2cd-4a91-a744-d8f7d2aaaa46"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b41aa745-b9a7-46ec-9c03-b4354431ffac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8a1a090-c686-4452-bc10-94d32d3bf46e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/17048387-cbb0-4c4e-bf54-d5ea6927fb21">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179c64fa-9584-408b-9306-640373061bbc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1758aef6-7fc3-4756-89a7-6bfd73fa7a8b"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/78f8b1fd-d541-43f8-bc37-f69ff31aab77">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbd46fd3-9166-4ed3-bffc-ad0cb0654073">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59fc7415-f0ed-4164-a38c-e4ddf9b9e9df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2e523e7-65e3-4ed5-98e0-cdf3836a83b5">
    <dc:identifier>HP:0004359*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2b17018-ddb0-4182-b0c0-6403f0c701ce">
    <rdfs:label>Phosphorus</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/98b3f403-22cb-40a5-a7a9-42ec5c8014ff">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2302519a-0fff-4be4-8f1a-5644107ca05c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08dfd182-ee02-4149-a89e-43c0a2f549bb"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB14151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0312cc8f-ce94-43ac-bf49-9c106c0dc7fb">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c000b0d-556f-4f5f-9b61-a2accb05b917">
        <dc:identifier>DB00065</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed1805c2-ba25-41b5-aca8-acabe8ae0785"/>
        <rdfs:label>Infliximab</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd8c7c6b-b03d-4cc8-955c-e3849a10b627">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <dc:identifier>DB11917</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1a649ee7-bb3d-4fb5-98b9-fdf2dc34cafe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698fb637-9df1-4dc5-a6fa-6114dad637ff"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5db0a450-2bbd-4c54-a02b-965f706e1f02">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698fb637-9df1-4dc5-a6fa-6114dad637ff"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0cee905f-4a9d-4690-a82f-bf6cf7416801"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efae52d1-2386-4ac0-b800-adb63589a113">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
    <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004364</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a905833a-4694-4bf3-89f9-15c7e93eae3b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d499e90-28ed-4e7e-95a6-bc01b6ecf646"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f881fd4-9cbe-4fce-a6a9-79a1a02bad98"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89108fb5-e90f-4c7b-8474-69fed025e5b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acidosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42db4f81-c977-4254-a4d2-129587603f21">
    <dc:identifier>DB00393</dc:identifier>
    <rdfs:label>Nimodipine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/20ad91d8-ba41-4d50-a452-af0d8100d16f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c80e84b0-6776-42db-bf25-6d419a55dadb"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/90f3ab94-8288-4514-85f0-90f8166a2709"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb466f7e-3f9b-41de-bdeb-f46df97ecf1a">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd760c1d-383b-4aac-9649-a75775e386c8"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d95a9f34-2eb8-4dde-b880-49700d6f385a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6f9b036-eba2-4dee-bb0a-f83e7d038b13"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a70be51c-5828-4252-9dcb-5b4730168738">
        <dc:identifier>HP:0002415</dc:identifier>
        <rdfs:label>Leukodystrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e46bf337-dd46-4796-8328-529581cd5598"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f07593b0-f3e0-46a7-8506-bfed1fad8320">
        <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91e6ff59-2ea3-4194-b1af-c6989f5888b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d1af543-a034-465d-b21e-c1b3bd642ecd">
    <rdfs:label>Droxidopa</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d402042-c57a-4ada-88cf-6cf314f60d23">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/89cc18ff-7637-464d-a687-1eb8c321d960"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/223360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99299e7a-c748-4143-80b3-ed97c724f1f4"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB06262</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ff227f0-6ceb-4452-83bb-832073e1ec36">
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9f8d052-c9cb-4bc4-ac29-13bf22d3c2fe">
    <dc:identifier>HP:0001596</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
    <rdfs:label>Alopecia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/654003e3-37b0-4a94-a75e-504c04132fdf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0987d636-ff1b-4049-b778-75ff0f37030d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9af44a84-3f5f-4e59-b14a-7a6d8d85b78c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d69f1956-6e6b-468e-9f38-77fec95ceb75">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adb7d6a8-f8c3-4408-b573-589cfebddaca"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88595365-4d3c-4c40-9efb-9b1c362536c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98b052b5-c4fa-46b6-94ad-71dbc0c7ada7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b34c5c4-ef2b-4891-912d-45dcc049953a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79d173e3-c5a4-470e-aaad-e99076c5d064">
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/cc50ea46-fd12-4140-ae5d-70e1461fdf79">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8aac8b86-f734-47b6-a2cc-11cfe94d3e3f">
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low IQ score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eefc135b-be55-42e7-b739-cfdd3f327012">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3cd162d-fd9c-462a-bc80-6eb3d36320b5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Low developmental score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602360"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/268ace7a-08c6-4bfc-96cc-bd1279cb5daf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f90119c5-f824-46b4-8685-dd8679c4db03"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c86c32d5-43f3-4d74-bc0a-5bff3ba809df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c572b0cc-c8ec-4be4-a013-4d3c262d95e1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
        <rdfs:label>communicative skills abnormalities</rdfs:label>
        <dc:identifier>HP:0002474*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4675cb1-40ce-4ea8-ad89-2c7193273ab9">
        <dc:identifier>HP:0012758</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurodevelopmental delay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc3ff4b1-8d16-4f88-8afe-2e9c3ca360f4">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavior al abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db684a2e-aa20-45d4-9235-280b1c2f0265">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012113*</dc:identifier>
        <rdfs:label>Low cerebral creatine content</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02ad2574-f177-409d-9c02-03de304ee84a">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21101092-8258-4b1f-a92b-6842d93e1cfd">
        <dc:identifier>HP:0002463</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>language impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14ac27a0-b16a-4de8-86dd-52dcca0c5bbe">
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>psychomotor retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e979489-9066-471f-8aa4-222bad677a9b">
        <rdfs:label>muscle weakness</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9305bea5-faf3-41a7-9d46-456eeb5c64f2">
    <rdfs:label>Decreased physical function</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/032eb796-3535-411e-894c-43cd8a1ff425">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05001839-b91a-44e7-a421-0545da65b8de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6cabb0db-56bc-4b0a-aeed-97265304f7a1"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3ea497c-467e-476e-924c-5cbb8173761f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/38480f94-a3a8-48e5-9ed7-e7504009fab8">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e2712cd-4e7a-40a3-95b7-45e14227604b"/>
        <rdfs:label>Serine</rdfs:label>
        <dc:identifier>DB00133</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39aef831-4cf9-4e3a-b373-b4ebf4e0415b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d1a745b-2b1f-4701-9e8b-7a3f92488b23">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5991bdf0-9288-4319-9e6f-d45f5869824e"/>
        <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e04b098-5d8e-41ba-8d28-a33d1a13ff89">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/842dc54a-98a8-4381-b7e3-9432af194360">
        <dc:identifier>MP:00011911</dc:identifier>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b28b63ca-a0aa-4b21-9db8-2088f66a5043"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d459df12-c49e-4490-bfed-cc3d38a96b9e"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad598ee0-ebb4-4aa9-b350-247cab76d23a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:label>Brain pathology</rdfs:label>
    <dc:identifier>HP:0001298</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc0cb6ce-d531-4110-9120-74c34abfc5a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac363c73-a220-4e74-8d28-a7712f64552b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a57c338-f382-4623-a63b-281d763836eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0870e9a6-3fee-472e-9ed4-38f4cdd896a5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3a562f1-b7b8-4051-b70f-f6947e1ce0e7"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/508b4f5f-b99c-4780-8049-9c4ac5be928f">
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:label>Defect of bone mineralisation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be0e7fcd-2266-4ed4-b228-4b220f8f2630">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/54fa7013-283c-4f05-90dc-f483db688d7e">
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46568c79-8e01-4386-a61e-8df334015b5a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e651931-0a41-440b-8d2c-3cce17d2d499"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3215ee73-23ea-4262-bcf1-dd389ad914ec"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82e138c9-9e4f-4dc8-bcb2-1c5160cf267c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Azathioprine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76163d50-2f4b-4384-a9bb-7243ab2772a5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <dc:identifier>DB00993</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e28e2d26-ec9f-4ffa-b3ca-8bf9956e3af6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86088bba-3f68-4029-b9b9-a8d5b4dba0a5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/679b0f75-563e-4b59-8a01-d5818425dc69">
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28ca184f-8900-4c8a-b337-f9a681553d7c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a42b6f8-6f5d-4c93-baf5-0b91401f9cf1">
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c176c81-1299-4c26-887e-d4f3f4831b37">
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0337cce-5de5-4ab1-9d56-821d99f6bd13">
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9fee30f-54c5-4fac-aa6a-b9742c29fbda">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL-C  level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b0e7c7e-8533-4848-9bf9-43cafd5a4a0d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/706b91d0-78ca-4359-936b-2d7b40cc341b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67b78a0d-7cd8-4403-aedf-c29c71b845e8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7b7eceb-2451-4324-b3f4-3e58a6e24f7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003648</dc:identifier>
        <rdfs:label>high Lactic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/371f8923-4951-4e80-92e8-b20adbe8243f">
    <rdfs:label>rh-HMBS</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6a9c126d-f967-4e47-87d5-a8bb8e1a1abe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd928818-3359-47c8-95b3-de02e12debfb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a587bdc6-8a2b-4440-9e01-c5f3cdb7c63f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4c54780-24d9-48ea-b8c5-928328452e0f"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fbd2f09-a8b6-42eb-92df-2e0804449689">
    <rdfs:label>poor skeletal mineralization</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <dc:identifier>HP:0006462</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b718f72e-c349-4e2e-b4f5-f8966c16c07b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/800ad657-c0ee-4619-9515-aa6821a0e75a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc79eb48-a2cf-4761-acee-ebfc25d8cd2f"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15ad15bc-0311-41b6-b619-f21a0d38572e">
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec6ed6d0-c876-4b71-9db8-17e256b3f216"/>
    <dc:identifier>DB00114</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac61e80e-093e-44a5-b29d-fb5d3a0c34e6"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/314dd92c-cb44-4a9e-8dff-01850ee3a9e9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82162deb-484a-40d0-a8c9-df9c095052f8"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41ce891a-cd28-40ce-8e26-32383514fc02"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d584f5b7-4a99-4f7c-9c86-35ab7aa1344c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b5cb7af-ede4-4971-87ed-b53cf0e5e3ae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10a8796b-950a-409d-982c-41c9ad266b74"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dc341b1-35cf-41b5-8812-8daff5d0ae42">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>High serum iron</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00c94a5e-ea80-4759-81e9-a1a78da8977c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:label>failure-to-thrive</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/09d17419-367e-4116-aaf8-3ef664a896ac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/465415c8-257d-4202-aac4-f538c25f7673"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adb7d6a8-f8c3-4408-b573-589cfebddaca"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a28fb71a-ef68-4987-bb8c-bffcd6e4f82f">
    <rdfs:label>pseudoexon activation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1dfd1447-ff9e-4bd0-8199-6428835a8ebc">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e092e9-c7df-4399-840f-b016494ae352">
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>steatohepatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6a25c54-a137-405b-9213-042cd4f16435"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f12ff25-2fbb-4d16-bada-f60906e58149">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/413308fd-e296-4469-8e52-3c03e8256255"/>
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b44925b4-3171-4340-b8cd-5c03de26f4e7"/>
    <dc:identifier>DB00121</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/759dab83-5d0c-4c32-b192-c68eb370b194">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33280c6d-2d38-4ce6-aafe-e16ef1045e90"/>
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c2dfd68-fc35-4cea-b89b-d3c08d7dad61">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7c3d595-9e69-4297-8ac4-143e5c6c4355"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43cd70f-30be-4156-99e0-acf336e22b15">
        <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
        <dc:identifier>HP:0009124*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f9a92d2-9edc-4e34-86b3-2d3a73477fda">
        <dc:identifier>HP:0008993</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
        <rdfs:label>Increased intraabdominal fat</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f297202d-0ec5-44f1-aa46-74ddbe99a123">
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f41aff2f-01aa-4458-8392-3bee70d5fee2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b28b63ca-a0aa-4b21-9db8-2088f66a5043"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a5173edb-da14-4165-a166-c1b1761f24af">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b26f6e6a-34ea-4680-a5a7-a42775cdc081">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e7721f1-207c-4613-aa3d-9f4190b8fe33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1141efd7-2950-43cb-8aea-cc60031379af"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b59a49a0-b41d-4dca-9c8e-b932502da316">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad09ec08-61be-4a94-995f-fc1f709dc241">
        <rdfs:label>High urinary malonic acid</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/150a5eda-6160-436e-a20c-e5e1d4a2b3b0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f010f97-56e0-498b-8807-4cd2f36e321b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54d00604-c14d-4325-8c53-fd9336a02312"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d55e1b08-78d9-47ea-aea1-1325688dfd12">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b822f59f-4862-47e8-9ae7-1ad46c9df129"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9dc735d9-7572-4a4e-bdb0-f855cda0867e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7db9aa17-a8e5-4c32-82c1-85a734ddccf1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9712171-61f6-41ef-8f7f-8656e88b375b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3c125cdb-26f3-4a79-841c-082ba67e4010">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f010f97-56e0-498b-8807-4cd2f36e321b"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7829c5dc-169a-452b-80f5-4d26f8667b64">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/badd9626-39c1-4540-97e5-02a1a28d244a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64748aad-8069-457b-8aaa-9ea0661fa8af">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0200ee3e-551d-480c-ab0c-389eb840bb9b"/>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/861407f3-8bf0-410d-b3d9-cc9b0a320561">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/388f3993-6050-4d7f-a4d7-529073c2a37c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
        <dc:identifier>DB03904</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1a216a2-3a97-4fa1-b0ef-e21557cf3ad5"/>
        <rdfs:label>Urea</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a971e804-5c62-41b1-9aee-e09d0feb2b05"/>
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f48e04c2-c2c2-4c18-9b69-70bc748d1ddc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e640a45-2522-4152-90fe-0a53e5b86129"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e860abc4-3533-4591-8257-46ce4a7281bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7077f70e-023d-4f3b-a8a5-d2c633961cb3">
    <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <dc:identifier>HP:0001336*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/7a20d75c-f7ba-4e58-b6ee-0f3be8397a32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfd0d3da-5ce1-4aad-bd1b-a65ab4f63ec6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3313236d-a50c-45df-8c36-b041b07c6514"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ec3e570-501b-4a0f-afe8-47a0e365073e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/27657052-15f6-4e79-a3f0-0fd2485a5b23">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf219fa0-59ee-42f4-8911-302901e870c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1eb121ff-bc8f-4cdb-aa46-73da25e4b31b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2b4f5d3-24f7-4b95-9515-4b4d81bbc6ad"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e715b3b-9a47-4b2e-9ad0-e6d272db44ed">
    <rdfs:label>Low cell autofluorescence</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/112ec4ad-fcc1-4612-8250-3940c7d04969">
    <dc:identifier>DB06720</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7453d2da-69a8-4952-8a83-33eb0fe64193"/>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8b39e52e-3ca0-439c-93ae-6068df9522c8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f797b47-dbde-4309-a77b-7ba381df75f5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ee34cc9-5602-46f9-867b-6a4465207765"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6af6dccb-b963-4004-9f95-acc6229aff35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1001f184-8ec1-466d-be92-58e6748ca3c2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6fbdedc-18d3-484a-9bd7-e21d1d9f436c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22242320-f357-4a99-9c39-4b78bbfa8c4c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/956d1abd-a17f-4608-8cdd-39c00bba2e88"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36989d68-7cfb-41fb-8418-13e1fe01db47"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11dc018f-0fc0-4b0e-ae79-f406c3ffe26a">
    <dc:identifier>DB03793</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c6d063b-eec8-4241-881c-998b7e96c3dd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70547826-21f2-40f6-8f22-c6a27b20a62c"/>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cb91f48-6422-40aa-a95c-7a752f2f8226"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a518c4d-0bd3-4ca8-ae62-94c902e72a4e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
    <rdfs:label>Oligodendrocyte loss</rdfs:label>
    <dc:identifier>HP:0100709</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46be1146-d12f-44e5-89dc-6054308edb95">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b9163fd-c4bb-4d9c-8b61-f403fdabac37">
        <dc:identifier>DB01606</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ad195b0-e66f-44a3-b2f6-17deef775df1"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
        <rdfs:label>Tazobactam</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0720afbe-8474-403c-b981-8cb64d70fed4">
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <dc:identifier>HP:0010472</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b88a941d-5e82-40b8-9545-1dc8283b8038">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72db09cd-6793-4500-b59b-81d604dab0a9">
        <dc:identifier>DB06168</dc:identifier>
        <rdfs:label>Canakinumab</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ced34975-7664-481a-b94d-ac67366b853c"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/727e4d1d-b04a-4c5b-9280-4178285caefd"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fed437d-ca2a-40ab-a83f-2e4ed0a75950">
        <dc:identifier>DB00026</dc:identifier>
        <rdfs:label>Anakinra</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/727e4d1d-b04a-4c5b-9280-4178285caefd"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01bb30b9-74fa-4ee5-9aa2-7a791f104ffb"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c9c7c12-a890-4dcf-8f11-1d9d71acac33"/>
    <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b24ff687-6a76-45f8-acd3-81db02a92cea">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140e54c3-d3dc-4042-8925-9a6b477cd5e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0725baf-78ba-4f87-8989-ea0dd155db7b">
        <dc:identifier>HP:0040306</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
        <rdfs:label>decreased male libido</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4b790bb-e018-468e-86de-1bb798382be8">
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low physical activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f8250e9-b9d8-47c9-9941-4ef8083b2726">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>decrease muscle strenght</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a5ea1aee-69dd-4188-9434-5c0d50d6a97a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1889741-af1b-4ef6-b5a2-1dcfddcd3e3a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ff227f0-6ceb-4452-83bb-832073e1ec36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5d597dc-c388-47ef-8d44-a30b4f345d3b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b35933d-a4ab-462b-8dae-38d493f6446c"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/028b7a9a-a907-45cc-8dd4-670ab6fcbce3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff4fcca9-362f-4a9c-a208-81837708930d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fac5859-06d9-4ffa-88b2-47ed385abdb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/931629af-ce09-49c9-8f83-bb51b6a559af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ad90013-2cbd-44d5-b0f4-d05a35436ed5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1e2a6f1-4cf4-433b-9354-a78e6b0dcde2">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7753a4f7-5909-407a-9ea4-d76e931d0b69"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ff3fbcc-e9c2-42e3-b396-3db03a594c6d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e120986-44d6-4487-9429-d412016015a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/821de18b-acd8-4ca3-995e-5d67fc0af5eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/256fe564-44b4-4f94-9307-274b5e933c1e">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad53a0e2-05bd-48e2-a4eb-c7e416f8d1ec"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/830686d9-3496-40ec-a854-49c04dc168ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a01f589-1893-4c52-9b64-d3cb1b7f12af"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f83093f-69a8-44c6-9e64-6277ed0e646c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <dc:identifier>DB04931</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d1819716-a67a-4c8a-a1ed-5ffcef89e533">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eae0fb8b-32d7-4605-b56c-e4828e6503e6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbb81349-0657-4eca-8654-9d0a69af483f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/069fd4e7-cff1-4b20-a0ee-8175ac4b7b52"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Afamelanotide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/50a632e7-f564-4faf-8997-ce08d7065ed6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6ee4370-522a-4448-85c7-8aa883f81961"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f248d52d-6e65-43d3-b7a3-ec604be396b7">
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/036af187-a84f-4636-9714-a75122af29ed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurologic deficits</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/709ae2d1-1dc6-4685-96da-4f8b5d57fc30"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe84a2e0-4c1c-4c8f-9658-dd2eebfb970f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological disease</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50852027-a562-4b34-a769-b1e4c4e1d67e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcfee2ca-926a-400a-ac29-ef9d52b2106c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:label>loss of ambulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02ad2574-f177-409d-9c02-03de304ee84a"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0d15e78-14b4-42cc-869a-4d07883c1b35">
    <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/558e3976-d0cd-4483-9d10-c049e4c2ff3c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42352a54-801b-4e86-b214-96250c08c07a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c131b6a1-d930-439b-b24e-b63d0c214159"/>
        <dc:identifier>DB06667</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e12c6e81-2af0-4f92-bc24-fcfee8d707e3"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/311e8cc8-bb7a-47be-ae89-be7b1178c6dd">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b34a942-57d5-44b3-ad07-cde2cbf60dbc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e94eec25-8f06-4d1b-8cbe-cea2a7818148"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/087a2e39-a174-4823-afa4-472db5c8d59d">
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e3d9cb5-2695-4f11-b7f3-a11e82ab5c54"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
        <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea97423a-9b42-4417-b542-2b7688f7dad9"/>
        <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/522961ce-8c33-405a-89d5-f5ad9c0af8ce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/327f6724-ea94-4aa3-809c-ce6142de1d29">
        <rdfs:label>sensitivity to sunlight</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b73ff3f5-e45d-44d9-b5da-9f6bfe4247e9"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4154e542-87a1-47de-bf70-917094b8a1e6"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/febb6002-af7a-4d00-9468-3dbc6274430e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ce63fed-451c-443e-b38b-4b1878d981ce">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dementia</rdfs:label>
        <dc:identifier>HP:0000726</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cfd8fe0-935b-4ec7-91b5-02052acef502"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fb5bc71-32e8-4063-970f-316d9706a377">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/77774bea-2abc-4999-91db-2aa1f723cf72">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bafc20a9-9c5c-4b6a-9418-7f08a09ad41f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b061172-cc74-4621-be94-501ce332100d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Fructose</rdfs:label>
    <dc:identifier>DB04173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d34200c7-a964-4197-9af6-54148d6caa20">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d75a15e-098c-402e-bdf3-661f7f643c16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8d31ebb-6148-40ea-8238-b195c1a48933">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c39f5613-0eff-484a-9d1b-cf8c16771a26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b55dfedb-05ff-4a06-9e7b-d0b34d0de720">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74eefe72-6a94-433b-b126-b0ee77d8ef5e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac205c69-251e-4c13-9f99-40ef4a78e5cb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012594</dc:identifier>
        <rdfs:label>Microalbuminura</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0e69cfe-286e-4259-84f9-fd99d0f515fd">
        <dc:identifier>HP:0002907</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
        <rdfs:label>Microhematuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84235ce3-7c70-4797-b1a9-6ab1a141c873">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010836</dc:identifier>
    <rdfs:label>hypocupraemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/876aa880-f04c-4586-ad07-78a6b3b5bdb4">
    <rdfs:label>Increased inflammatory response</rdfs:label>
    <dc:identifier>HP:0012649</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02e39f11-46db-4d08-bdb0-e31af1b9058a">
    <rdfs:label>Methotrexate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f29dd0b8-4a8f-40ef-82b9-62745526c91a">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f0552a0-ebc8-436a-b662-3db3d4aadfb1"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54ef6c74-b260-4640-8a62-0ba0196ba883"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b37733-1d18-45af-b190-5ca9c7bda55a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <dc:identifier>DB00563</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/de2a9132-059b-44f3-b6b3-33abe9ef6d0b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efae52d1-2386-4ac0-b800-adb63589a113"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f54731a-3afd-4f7e-979e-39ab272e9c79"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/6dd3a728-33f8-4a8d-8510-31b44d0ac31d">
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2b5296d-88eb-48ee-8da9-3b94ef253c18">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:label>obesity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc7cec43-1a08-44e7-ab35-97e70d9cca27"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44d85a72-b4cd-41b7-bc16-7980fa33738b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e2fdc78-e0f9-4f03-b020-c697c9f7d9c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60ed2da1-e4ce-4fd4-bb48-65330690807b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84f1b835-536b-48cf-998a-39c137f5f84c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperlipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a414235b-c735-4892-82ae-acfafd7da33a">
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000855*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ff663a5-e3da-4b8f-8630-d586932476da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/680d93ef-a5a6-422c-8262-fd490d9eb452">
        <rdfs:label>proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000093</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ded3207-173c-4fbb-81ae-77e13144d574">
        <dc:identifier>HP:0000083</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kidney failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91141707-edc2-4a72-9f7a-3861225215fd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e26ef69f-fee7-4cf9-9678-820bf6f5575e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e482708-1fec-4206-8339-722e80a52fcb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16d496f4-8d87-45bc-a435-adcd38432b3b">
    <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
    <dc:identifier>HP:0004345</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2736c52-1ee6-498c-9dcb-ae90c5dd0290">
    <dc:identifier>DB01132</dc:identifier>
    <rdfs:label>Pioglitazone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8c2e5648-b058-450f-84ac-3e8e45cf21e0">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01bcfe7f-0d83-47c8-9c56-f5392f5d4999"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ced7a660-5922-4e0e-9562-cf82563f1675"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29b126f4-0faf-4696-be11-89add3af5973"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c180299b-f1b4-46ad-8d8f-1e06eca89388">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69853395-b75c-4590-9d2e-34b38fc4ff3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9093a735-24cd-4143-b05f-c9bb9ae57fb8">
        <rdfs:label>defected excertion of 3- MCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77ee0e92-a910-434c-918f-c07afca5e32f"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7756abce-1397-4357-a0d0-5913a880e3a5">
    <dc:identifier>HP:0002150</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:label>High calcium excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5b9e90e-d5b7-4c86-acfc-686cee566bdb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0b435d9-9441-4c58-875e-7f282f6fc2f0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <rdfs:label>Regramostim</rdfs:label>
    <dc:identifier>DB05386</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4947beb-2136-4e56-86b9-204e1ffa9d05">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <dc:identifier>A11EA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f79523f-5ce9-46e6-8ec0-d283cd295199"/>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/6e042d79-4948-4bd6-b6ee-42c45bc5104c">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40983207-6e21-4b0e-a47d-1b3f297ebc78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5bde9b93-5154-486e-b477-5e5c2e809996"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab1b217b-d3a7-443f-9b08-b9da51632ac4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f3c0ebf-d15d-4758-9b73-14a4118c2f4a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c5ee24e5-bd98-47e7-b312-4135aafb9299">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84f68d69-400c-408d-8629-2fb52a122b5e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>diarrhea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c21478ba-082d-4092-9511-d0fc2a9f3d93">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high EMA levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
        <dc:identifier>HP:0003219</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/00d14dfd-2bea-424b-b9be-abd46359d5ce"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/19d0d303-4031-4956-be2f-be3982f3880d">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e1195ad-68de-4e9d-93aa-ecd5a0e1565e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92b8153a-e425-493c-8fb6-c9c76a498ce8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea2fe4b5-6d46-4521-ac4f-c87cbd423578">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc86b4be-03f3-4ff9-b1f8-d3ab59a70c65"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/06b8b84b-d34e-4a16-84af-c09137e7ed02">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41518c2e-a45b-43f3-b5b9-35e9eda86e86"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/240cd13a-4537-4d1f-9245-deff57b54fc3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9be100e8-0a82-4ca3-8731-d15cb506da1f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8d07656-108c-40c3-976b-c1ad30faac8d">
    <rdfs:label>Activated charcoal</rdfs:label>
    <dc:identifier>DB09278</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fbb4e84-c137-4fd7-a070-898dd1ddc7ee"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/217521a2-f9ba-4be0-b1af-6c6de4323349">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ef1295d-e519-46ab-8dcc-6bc176d3f93e"/>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7490dda9-87cb-4bb9-95fd-61ae7ac5e821">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b35933d-a4ab-462b-8dae-38d493f6446c"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5ea1aee-69dd-4188-9434-5c0d50d6a97a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50448211-bed2-43fa-808b-b56d6b78b049"/>
    <dc:identifier>DB00328</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab608e83-b9ce-4dc2-b3bb-52d3067e2479">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <dc:identifier>HP:0012217</dc:identifier>
    <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4d600d4-7867-4714-900b-95abb2777b37">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c25f012f-8eda-4c19-954f-72e3e9e308ec">
        <rdfs:label>Haloperidol</rdfs:label>
        <dc:identifier>DB00502</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6477e0d-c4ab-4ad6-95db-d53b7befd73a"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fe74586e-a6c0-417e-9fac-24a6d85e642c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f97ccf4c-15d9-468d-88a2-c6b48704febe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93bff3f1-6dc7-4520-8915-4819700ae9e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/551ac471-bcdc-42f6-a423-7968d4b78554"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82b8deef-cc50-4aea-b282-13990d2666c6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7a851e76-3771-497c-a78f-b20fa9b0e717"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a91dcbd8-ab21-4bf4-ba18-c154f88b6235">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/379fe8c0-881f-49ec-8697-44395827e63d">
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/803f73b6-73ab-4e4a-b4de-6b4972361154"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d55ff7a0-ad8a-45e0-b8c9-e4bf4fbe9896">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28a213d5-2880-4504-8ae9-02af529cfa5e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d6bc8b5-406d-4467-b5f1-3015d6ed30e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/467b2a75-0bcc-44b7-b7f7-6b0ef527c2b9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
    <dc:identifier>HP:0001609</dc:identifier>
    <rdfs:label>Hoarseness</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5a85b3a-a0d0-45c2-96e8-508569479f56">
    <dc:identifier>DB09539</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d4820b0-a444-4433-9b35-aab3d15c2c26">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfc21e3c-5c38-42f2-9f5c-3dcd2a658693"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eed61eb0-6e99-421f-a0a7-033fd7b6db03">
    <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62cefd31-2040-4f0d-847a-56f1e545f786">
    <rdfs:label>Lucerastat</rdfs:label>
    <dc:identifier>DB14872</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c3e69dc-3c31-41e9-be54-d7c021dad2e2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e702772d-9f1a-467a-a6ee-402e77c822c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b061172-cc74-4621-be94-501ce332100d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d002d5b-a8f9-4756-a13d-45eb1774222d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4d9809f-e9a9-4004-ae2f-4f8b5601f42d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/74faf64d-4fb2-4038-aead-84feeba31745">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da311163-3ebb-4273-93af-1bf3ea365b77"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d02c09c5-494b-468b-93b8-a236544e2d6b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49188e85-c4c1-4d59-bca4-c4bb1d4af2d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6fbdedc-18d3-484a-9bd7-e21d1d9f436c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/444d2abc-4d7e-4f93-afc4-1a992eff4691">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0cd8df3-c21f-4bb9-96f1-08827df89001"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/806cd99b-1b07-4e8f-a778-179104b338e8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12470572-1b3c-4f67-a1d3-700c334f4f87">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Metabolic Decompensation</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb711064-3d0c-4917-8c8d-5a25794847a3">
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of movement</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a51670ee-f252-4a32-85ae-126b1b7eef6f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
        <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3fdff1c6-bc90-4f91-bfc9-d489b451e8ed"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/48f122ab-c626-442b-a05d-241f81acf885">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adcc782f-84af-492e-b408-6280a0a66241">
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f8c6cc3-7ab0-4717-9bd2-64eb2ebbeb7f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ae9718-b3bf-4449-80a2-6d6c1d3ac3e9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddf25211-9747-415d-a69a-ebdd66b649d3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
        <rdfs:label>Oral ulceration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32ff7984-888a-4ef2-ac45-f63c6135086f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5932fb55-c9d4-4169-8759-adb8d00129a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e86d16df-a337-4d06-82f8-bf4db32a4fb8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
    <rdfs:label>oromandibular dystonia</rdfs:label>
    <dc:identifier>HP:0012048</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/05a84d16-934c-4287-bccc-8a774a314fe9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cbe3ada-49fd-4318-a5ad-151c01811d6c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1ca763-caf9-4502-bbbd-fcc06b16f61b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/87f994f5-d9ab-48e0-a3b4-d78c33761645"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98fcc16f-0aa5-40cf-8f26-40c4fe4acb08">
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/22c1e094-bd86-480e-87de-89d779648606">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4c75885-94d3-47c5-b8cd-dbfa078c025a"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee546695-d047-4353-b78e-34ebe83ac83a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>growth delay</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3979a327-2bfc-4f84-9854-0b0c82e127c4"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5853c844-62e9-4192-947e-17050a6bc825">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>hemolytic anemia</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/2d3cd3ec-abf8-4c84-8bea-f0ac88581a50">
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8d16ddc-809f-4964-b849-422a77362ea8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97eed27b-db2f-4d9f-875a-a96e5b29754f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9af71b72-a2ee-4238-bb6d-ea1819150335"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/498826f7-5e18-4b16-8e03-029633d456b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be9d55f3-7073-4648-95d6-17b3182176be"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc62b5d4-9118-480a-9696-9e01a12a88e4">
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Gait abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f8c6c76-aa1e-404d-a340-e87b6af28b91">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001251*</dc:identifier>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd4b26e8-bc77-4a56-9ab0-92a0d3c07b1b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b061172-cc74-4621-be94-501ce332100d"/>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e9b7cf7-f93a-42bb-95eb-39a677d53868">
        <rdfs:label>ataxic gait</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <dc:identifier>HP:0002066</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06015a70-7b59-4aba-bf29-733e86e64c3a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/220e7c48-4d6d-4667-9fe9-f9e66506323f">
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>hyperlactatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7077f70e-023d-4f3b-a8a5-d2c633961cb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0e4faa3-c26f-4de8-abd1-70f81c736101"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66544571-842f-4b6e-a1dd-35e165d5f07c"/>
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c6aec8e-bc56-4d97-80a2-f383c4dfe170"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26edb501-50db-4aa4-abc2-11378f779ee3"/>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3a05a300-fc63-49f0-ad92-d45dffdfac5a">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d066a36-71bd-41c9-9428-457d5c640fdf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b0a13a3-84c5-4dc5-a069-b5a13efa3e49"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e19aebbf-1afb-45e4-8187-fc64c7e99a36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2504e381-87cb-41dc-ae72-0ae1c9fb4633">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002453*</dc:identifier>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4ad195b0-e66f-44a3-b2f6-17deef775df1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46be1146-d12f-44e5-89dc-6054308edb95"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adcc782f-84af-492e-b408-6280a0a66241"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/65a495d9-650d-481d-9aba-d0b95a3b3420">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a13c36f-3b35-4fda-a7d2-01f18a87f446">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ec0f163-f3a6-4381-85ea-b040d3c9b43d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bea8a02a-a01d-48b1-94e1-756f273d180a">
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d8361ca-c833-4a9a-98f4-2d958a99f07a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77ee0e92-a910-434c-918f-c07afca5e32f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3111fe4-c37e-4a6d-9627-3b9c06fbef97"/>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/334ce453-9b5d-4f5d-b49f-f9bb2fec9db6">
    <dc:identifier>DB00472</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/83f0d92e-8f72-4026-ac3f-56fa900637a6">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3ab6c5b-8ca8-45a9-9c89-12130b74cd3e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/874b32e1-1cba-4560-b2a9-3293d1eda701"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4954b28c-2c86-4fb1-865b-108abaadc92f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Fluoxetine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26588078-c20a-4c15-90d7-9cbd1ef59746">
    <rdfs:label>No Studies were done on this drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bce0a15b-9a5d-4fa2-8d10-fc06e796e7b6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5ac122f7-0752-4866-8cfd-9b716c9c0e05"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
    <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81d79ae2-7b76-4407-a4e5-bcf6b64dc8e6"/>
    <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1482cdc-2e6c-446c-8990-0c7548636013">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d77c6eb-8f7b-4ca2-af2a-fc91db8b8d63">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4b3b308-d709-4d78-bf9e-6dbf602a911f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0de53106-c585-48a5-b86b-fdf63a5e2a1b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24c44753-6be5-4296-8444-fc25c24b3e8d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43dd340a-6b5d-45ca-87e7-f6be97cfaed3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42706a0a-e8d2-4229-b662-a9bbddb40b6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7137f847-2faf-4691-82d4-782818b09f92">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98969b66-8edb-4659-a927-ed38fc1b890b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f97ccf4c-15d9-468d-88a2-c6b48704febe"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85fdeb75-c230-4bc5-a21d-81a12163c617"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a13869c-8135-4209-9b4c-333f43b70b42">
    <dc:identifier>DB11991</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/001efabc-635b-4d73-83ce-55ed5d284285"/>
    <rdfs:label>Oprozomib</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/34252e65-3943-42f5-9dcb-3ff545064562">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67f1b609-85dd-46f4-a7ec-89631fbf6c37">
        <rdfs:label>Joint disesae</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
        <dc:identifier>HP:0001367</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/718e786a-934e-4a75-8650-51dedef3d3ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ochronosis</rdfs:label>
        <dc:identifier>HP:0030764</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af8e9d9a-b138-42ad-899f-3bc7e8e2a2c4">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e30f0a2-6ecd-465a-b2ba-8843591f25f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78ccf14f-cfd8-4e13-985d-abd9b8d672c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/91d70a3d-756c-495d-9086-6f92aafdba55">
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52e00e0e-85db-4c93-87a2-5d24862faca0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60985286-f430-47c0-a6bc-409945e7b4d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/517a5bd8-e504-4962-9eed-da0393f97967">
        <rdfs:label>anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f81fd0f-0d9f-4f4d-b301-8d5ee4e37215">
        <dc:identifier>MP:0003949</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <rdfs:label>dyslipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ce454d9-63d4-4c4f-b34f-967987809292">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <dc:identifier>MP:0003193</dc:identifier>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b3bef62-2ba1-4ad3-b897-b08a2cc6515e">
        <dc:identifier>MP:0011598</dc:identifier>
        <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97db9f59-1497-4331-b62d-b0604183ac5a">
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/254f53a7-9b73-4c28-b33d-c1e52735feed"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1aff03-aee9-4111-8cfc-1e38cc1dc91f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>low HDL-C level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/680d93ef-a5a6-422c-8262-fd490d9eb452"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e187dd45-349c-48b0-9915-0939b6255433">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>low HDL level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39b62d48-023c-4d92-8b53-d450217480f9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:label>low APO A level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3437c9ed-14fe-4aaa-893a-4016f351f91c">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b879183b-04fd-45ab-83fc-18d35282d766">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef92dcae-d5b4-4a9e-ba75-2623730349a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f1c3d56-537a-424c-8d94-9003907dacf6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b7e318a-9d2c-45a6-8ba7-f54b50239e7a"/>
        <dc:provenance>PMC2676979</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17f29bad-5d28-471f-ad17-e1742ba23ddc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5af5b64a-e820-4c58-b41b-57ca85cbcbca"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2315f212-4378-4106-96e0-2e3ad9d9095c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64ce6daf-076e-4eb3-b9c0-6e92c1e2437c"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c381a9d2-bb36-453d-b171-c5b37a4ce847"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f1c3d56-537a-424c-8d94-9003907dacf6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263570"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f57ab270-2576-4c30-b294-429158c3ed2d"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e218d8e-e4d8-496d-b312-9720ecb51894">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f464433-8507-4b07-9d35-8314333af7d2"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a1c13d1-f320-434b-9053-cf7dc1df1821"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc29954b-e555-4075-b2ea-74bd9edea5f1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Triheptanoin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/382b7801-833d-4a77-9a54-7312be0f67c5"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/727e4d1d-b04a-4c5b-9280-4178285caefd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8defca1-97b3-40f6-91b6-30334ad0fc2b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14a3beab-76b9-4d9b-b69b-7445295ac229">
        <rdfs:label>Synovitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100769</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/230fd407-8c9b-4432-be31-f55aded5aaf1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
        <dc:identifier>HP:0031375</dc:identifier>
        <rdfs:label>Refractory Arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b88a941d-5e82-40b8-9545-1dc8283b8038"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9362855b-178f-4a5a-972e-e1482eb79255"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3a3e3a8e-f6a3-4e2b-867a-3da91728751a">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c1ca0b2-9f9f-4344-b316-f910d6e25ada"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe0e1ca1-7308-42e7-89d8-40ba7496c9b3">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002354</dc:identifier>
    <rdfs:label>working spatial memory impairment*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d0df9414-2317-4f74-aaab-3b0ffcae07fc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5efc5677-7420-4912-b92b-f70453764670"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd0c248f-dc0a-4971-a889-4faf4b2be47a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6390ead-1c9f-4c08-8dad-229ec3c7f32a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b6f6893-396a-4df4-8e8f-0ab4107bb07a">
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d7382b6-f3cb-482a-a746-4e898c1a145c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73e50404-5384-4747-b406-92e4205fee4d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab45aa14-ac03-471a-94db-fee5b0e7680c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0e34bd9-4770-4c53-a6d4-2f45c1202537">
    <dc:identifier>HP:0007015</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
    <rdfs:label>gross motor dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48d2e2f9-5153-44c9-b4fb-23980119fdf6">
    <dc:identifier>DB00005</dc:identifier>
    <rdfs:label>Etanercept</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b7cf2f07-a794-4ba5-ad8e-7272934a8297">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/018e063e-df1c-48fa-bd5a-97bef3f78c4d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a19d22ec-18b9-44e0-96c6-4457737994c3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46568c79-8e01-4386-a61e-8df334015b5a"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79529d03-614a-4e0b-9577-b52fbbb6d743"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43595f25-4b54-43a1-8f00-ee59ae8a2ea9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae745b09-3508-4293-8547-97c8dfa5d143"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ac55b2d-0ae9-4990-93bb-7d358e3a9296">
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004910*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51b6ee5f-e818-4e66-aac4-b313ffcc4fa2">
    <rdfs:label>Cardiomegaly</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
    <dc:identifier>HP:0001640</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8f13b13-32d5-4143-8881-116d2e2e46b3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aca18ad9-85ce-46b8-b7e4-c225af694a94"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b612921-d7b7-4b02-b26d-b3e377b19584"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3be32f59-010c-4e46-90ed-2ccc64890b13"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/52e67272-f19a-4b02-9b32-fd805d706a36">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d254e147-86ef-4d40-a9c8-0de06a4547a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
        <dc:identifier>HP:0012040</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Corneal Oedema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fd8b28b-f329-4f8c-93e4-6e0bc4df334c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <dc:identifier>HP:0003362</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ebdf8fe5-183a-4ae2-8b46-9b4edc45c6e9">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26fca3ea-5670-4a32-bc00-163c3603d522">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d5f06a3-e6e0-44a6-be6a-308decef8677"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/569646d4-f7bd-4ade-8072-1a1f6f70e424"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e2fdc78-e0f9-4f03-b020-c697c9f7d9c5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6dd3a728-33f8-4a8d-8510-31b44d0ac31d"/>
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b794f25f-4d09-4ec9-8823-d07e067ac0be">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614462"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c367f84f-406f-41c7-a1bd-ab794b5e782c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6ee72c0-a67f-4d3e-b7ec-1a241f579e2a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72ae1b9-a10d-444d-9ea7-b3c8ce2a2bc2"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aec3e346-8545-4ecb-86e2-8233a2d7e929">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
    <dc:identifier>HP:0001958</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dbdae46-237f-4caf-b231-fc72e1addeca">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011018</dc:identifier>
    <rdfs:label>extended G1 interval</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a0c9dcf-6bb7-4d4f-a357-4d49f5ed5e51">
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003800</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71e2f2bf-01e5-4c05-9f4e-7e3fa73aa4d4">
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/52f52c6d-d22c-4d36-a3bb-1b4ec7734069">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
        <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b72ae1b9-a10d-444d-9ea7-b3c8ce2a2bc2"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Topiramate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdad02e3-1614-4311-9260-26f11ae7f684"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7880850-8769-4a26-86d2-0fbfe33c593e"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/40690af2-8635-4faf-ba93-12754112da3f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cc8a4181-dd33-46bf-af4e-dbfdf98b1e25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e54dd8cb-381c-4ede-969c-8998237f7e7b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
        <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5dd5adaa-9085-42ef-8571-c1effbb35ee7"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f464433-8507-4b07-9d35-8314333af7d2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:label>abnormal fat metabolism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9cb2c7a6-af8f-4f51-bb74-4de84fcb6147">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd40fdb4-f6e4-4fab-bed2-4f237b9118f1"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/350accf1-9b58-484b-8e4d-5e597adea30d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9558fae-e2e2-4abe-9c93-a7f5eb18e24f">
        <dc:identifier>HP:0003117</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aba779cb-dc26-4753-a207-8b34504ed1fe">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <rdfs:label>Diazoxide</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7eec5cef-bf6f-4bac-a36c-662d6a2679f4">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad259bd-062c-4d3f-be23-0da0aaf5efb5"/>
        <obo:RO_0003304>R1353H</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0003304>E1506K</obo:RO_0003304>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0003304>delSer1387</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8e0dc87-268f-46e3-a6fc-195bb3df9113"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6e6ad06-f751-448a-97fd-87c8a11eb662"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76a6e7e1-cf2e-4827-9810-a8419155918a">
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ed038d0-5d30-4a43-ae07-1d3ea60e3991"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65096bd2-324a-45fe-b618-1eff7fe8214e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea74d3c3-a72c-4e50-8ad3-13c553c1b565"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/190dc10c-3f32-4861-b227-7e98fd7c49ac">
        <rdfs:label>Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f637994c-b9c5-4104-b8bd-3c409de6c1c6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9f8d052-c9cb-4bc4-ac29-13bf22d3c2fe"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ca81f80-aa87-4c7d-adf8-093b26ae63f8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total plasma cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/646ccbb2-3c31-40b9-80b3-020942a07146">
    <rdfs:label>Axial dystonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002530</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6693fe50-3be7-4609-83c9-4f604e6427dc"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/988bacd3-74b5-4999-9d5d-897b81b5197e">
    <rdfs:label>Dental Defects</rdfs:label>
    <dc:identifier>HP:0000164</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ade5ef1-f816-463e-9fe7-917ac4e47301">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/800ad657-c0ee-4619-9515-aa6821a0e75a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dc58794-8b68-4744-9e9c-987f5fdea33d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86199025-7031-41f7-b01f-13af8e9cac61">
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10eec8c6-7a08-4fde-9b39-2f3d5fe3c16e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <dc:identifier>DB11563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b67e191-354e-463b-a912-55f15b41dbfb">
    <dc:identifier>DB03227</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0ac07760-b101-4453-8d0a-3972e8a12722">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80c0f465-5194-48ed-8de1-0e74c1039467"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a0c9dcf-6bb7-4d4f-a357-4d49f5ed5e51"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/375ab6fd-a59c-4878-8922-703e364bf504">
    <dc:identifier>CHEBI_26537</dc:identifier>
    <rdfs:label>retinoid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4cdbd07-a772-45dc-83ae-519b7efd5c29"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66624795-6494-4fb9-9632-a7d2082e4d1a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abormal liver size</rdfs:label>
    <dc:identifier>HP:0002240</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8aac2fc8-5098-4420-9867-ce30324c4d68">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c01590e5-a1a6-4756-b71d-9402fd2af2d2"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be976290-903c-42cb-881b-cdf274981ba2">
    <dc:identifier>HP:0000508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
    <rdfs:label>Ptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73f1607a-3f76-4728-895e-37f592dc2c9a">
    <rdfs:label>waxy scaling plaques</rdfs:label>
    <dc:identifier>HP:0040189*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc59f94b-a0f6-4cd2-9a30-50f1a02f27f1">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ae88a32d-96ee-4f43-96d7-185a3d763c1f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf08837e-e32e-4225-a6a4-179d7f1c0a7e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77f124a2-5900-45c0-b911-3eab59610366"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/948f1971-abd0-4f29-a972-1aacc5aa6c2e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/999cf704-5622-4610-a2b2-3a544f4eeb08">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/093512c3-9d0f-46e7-ba6c-0157f81a9294"/>
        <dc:identifier>DB00700)</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6f2897c-c996-47c1-b657-a2000426631b">
        <dc:identifier>(DB00328</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/093512c3-9d0f-46e7-ba6c-0157f81a9294"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56ffa74c-c5f7-416e-923f-317ea8f21528"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34e0a3e6-3403-455d-935e-b60342e9b51e">
    <rdfs:label>impairment of reference</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6552b1df-619b-4c12-bd1a-7b162bb2d80e">
    <rdfs:label>Pantothenic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7abcdc8-0822-476c-90ee-fef57f3dacee"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <dc:identifier>DB01783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53993367-7094-49b5-bfee-d9749f932622">
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0f227b3f-a0c6-4e8d-a255-f0cb9a76588d">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87d1c5af-35a5-40d6-b992-f3c0ec1adad6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9434661e-e6cf-4f3d-9b7b-5ff40fb8425d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6b70ba8-462c-4f92-8d34-85911c0b7f62"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26b5f7cc-7f06-44cb-86e1-d5834f986b02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28509e24-6af4-4008-a983-6ee40cfec27b">
    <rdfs:label>Reduced ejection fraction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012664</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e891127d-7ec5-47fb-bd02-cfdd14671dd4">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/75350d90-df95-41d9-8c3f-910b2bb6fe79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f007b35-e519-483f-891d-98d92d1a0d07"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5668dbf9-9021-4685-81b6-88588056545e">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
        <dc:identifier>HP:0011990</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9003c4db-96c6-457f-aafc-e10ab7c33d90">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d89a8ca7-49a0-4a3b-8406-ba12f2cd0185"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01caeaeb-d825-4ba4-b468-602a9e9960f8">
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6780daae-488c-4da7-81c7-d2162fbbc1f2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be0e6e08-fb00-498a-8a88-d0c2dfae783b">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/360967dc-15c7-472c-8c43-c2c5a2baebef">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55ea98da-e3a6-4def-8289-228a592a103a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b5e6dd4-d463-432c-ac33-c35e9fa8abb6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
    <dc:identifier>CHEBI_32030</dc:identifier>
    <rdfs:label>Kaliumbromid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78fd34be-11a0-4f90-8c50-7acebbb409bd">
    <rdfs:label>Nystagmus</rdfs:label>
    <dc:identifier>HP:0000639</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3449e558-8d1d-4142-9e9a-c598f56fc2ff">
    <dc:identifier>HP:0100543</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal mental status</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae87a860-000c-465f-ae37-687ca815ad17">
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b7c42de-0eb9-47f1-ba0d-87ea7248d43d"/>
    <dc:identifier>DB0084</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4116581c-4b12-4fed-b04d-2a66143b65ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc964cc3-2ee6-4e40-be4a-a0ad5a3980e0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1eb121ff-bc8f-4cdb-aa46-73da25e4b31b">
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27657052-15f6-4e79-a3f0-0fd2485a5b23"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/86906bbc-e276-4176-aebc-669ac105ca73">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c9416619-273c-474e-8eb0-824d7abf52c8">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e979489-9066-471f-8aa4-222bad677a9b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/556546c3-f56c-44a2-a3ab-343628e9da4c">
    <dc:identifier>HP:0012592</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
    <rdfs:label>Albuminuria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1744b140-c3ab-4510-981e-b13350efccc2">
    <dc:identifier>HP:0031798</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
    <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/6eaa3cd4-aae6-4408-94af-09115109df71">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfee01e6-b418-44fe-ba66-b4083f78e82b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d044e39-3fee-45ac-8250-9a8349c88bda"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba09584a-ec41-4797-9794-dafaa1ff5fb8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5494e8a3-bbe6-4b4d-9185-0920213c5f3a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
        <rdfs:label>fasting ketogenesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8bc0a279-7c8d-4e50-8af5-6a2617982696">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e82b4be-2a18-4d9e-be79-4dbfc3503226"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98e43462-8803-46a7-a881-463048171eee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5d08e72-e6b5-499d-b7cd-bbec628a81e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9e9fb10-a003-4f6c-b429-ccd7e43acc10"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c77c7902-a10b-4e5c-8048-889c41975b16">
    <dc:identifier>HP:0001369</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acute arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f1e3367-9794-4baf-b35b-a2c0c9f6443f">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/445dc7db-e73b-4c19-805a-d11e6bd13d57">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/803ef6a9-0c9e-4d72-87ac-765d9ed9c54f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0655ba29-a6c3-4fe8-8de3-68971789a1c0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/15dfcf3f-4043-46e5-bb10-8588925e6437"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5932fb55-c9d4-4169-8759-adb8d00129a3">
    <rdfs:label>Tocilizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a7e85dd0-5ac9-4a02-963a-0bd54de8e97c">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32ff7984-888a-4ef2-ac45-f63c6135086f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9362855b-178f-4a5a-972e-e1482eb79255"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48f122ab-c626-442b-a05d-241f81acf885"/>
    <dc:identifier>DB06273</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/74f24af3-ec3b-499e-8ecf-1378c1683247">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666c60ac-3634-4f61-80d1-d6680233774e">
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65a6ce53-8b21-4564-b60a-a7930141c6f6">
        <rdfs:label>delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71101da0-6826-44bc-b283-8833b308f849"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56890202-5764-4643-9df2-88d660a181bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7b48543-7dbd-405d-918e-7fde9971c7d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
  </obo:DDIEM_0000008>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/78157023-02e2-426d-a376-a5214a5dbc38">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/849ac3c3-c924-45d9-9c3e-3e4546a3fcb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef5b7af6-dbb6-48d9-b447-28c11db9e59d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0e4faa3-c26f-4de8-abd1-70f81c736101"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9f23edc-336b-489b-bb7d-2c5f001859c6">
    <dc:identifier>DB01015)</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/357c0c20-31ac-4ee4-a08a-b6d68072a5d9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba8534e1-0450-4038-92f2-6b154fbcdaaf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6658b030-9f6d-443f-ba41-4b48291231a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/df271d5c-5c38-4c25-b5b4-8f2024d98b51"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c33e536c-2f82-4a9f-8356-f20e48531446"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5058ece2-a7df-48e4-99af-8a4fc311ccfe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01353b1f-f103-45e5-b99e-f59b54f04137">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003737</dc:identifier>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bcaec611-a42e-4377-a930-268b4966a2d6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27e67ede-3bf5-439e-87b4-76f13b5cebca"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a98fb933-a250-480f-aa72-1754ab5dd902">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17aad222-22b1-48f7-b4da-b53e58fe12b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d51740a-28a2-4995-ae90-f9dbc6e50bfd">
        <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003710</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/0bb6041d-90bb-4b30-9858-176c65699430">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad598ee0-ebb4-4aa9-b350-247cab76d23a"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbdd84b4-735d-43ca-a951-0ff0f91f91d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f92a493a-eb06-493d-8a28-f49439f1f3ca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50d02435-1b9d-4473-a774-a9de9ad0e16a"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcca9e97-c774-4189-ae45-c18cac755aeb">
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a81dede2-f8aa-412e-99b2-7ec0bda748f0"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/969cef88-0553-4824-a7fa-a78dd636648d">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dab34023-e326-45d6-8b9c-c6411dcba232"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01353b1f-f103-45e5-b99e-f59b54f04137"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52e67272-f19a-4b02-9b32-fd805d706a36"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19a7db8f-3108-4051-9d5f-66377be0a822"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f90573ce-2dec-4b2a-9f5e-92761b7f31d1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5dc807c-b617-4191-a8da-e9d86f197c4a"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/498826f7-5e18-4b16-8e03-029633d456b9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ceef75bb-24c1-4c56-8810-0adfc8cd0de9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9416619-273c-474e-8eb0-824d7abf52c8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cafe6b60-58d7-4bd9-9732-9e75080a206b"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/89f96ed8-b356-4b34-b733-873be536bce9">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38910cb6-0509-43b5-98c6-22f9cc1ce6a1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB09270</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c693e312-4f0e-4416-ad65-e9211283f838">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebf80f3c-d300-440c-ac81-79d789ba4d2c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eaf2e96-953b-4263-a2c7-8d86ed8404e5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e64a1922-125f-43c7-ba35-a143bfae8b8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e10ef396-6951-4266-9e18-d9c79c1866be"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e76f2e6-b073-4485-9522-9291af19ab40">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <dc:identifier>HP:0000002*</dc:identifier>
    <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edee6e6a-9794-4df7-b5d6-bc82d594499c">
    <dc:identifier>DB00060</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e71a759-8131-48bb-b09e-ec0999fbe9a5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <rdfs:label>Interferon beta-1a</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b495154d-bfa3-4eea-8479-5bd2479b0c6d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67224238-d48a-4f72-a86e-80cef4fe67d0">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65f63fc0-7731-41b7-a6b6-4f76f0b31816"/>
        <rdfs:label>Triamcinolone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
        <dc:identifier>DB00620</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c26c0140-1383-4cd3-84e0-3b9e7e165577">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/632460e9-dd0f-468d-8aa1-d0062f2626a6">
        <dc:identifier>HP:0000739</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
        <rdfs:label>anxiety</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b37c338-5ea3-4117-99b7-38f7d0319ee4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ad4a2fa-e0cd-485a-bc01-46385da89fa4"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6bb79930-1c07-4383-bf3c-18842926ade9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1500a1d9-13bf-4117-be28-93475917c493"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c81859a-2b1c-421e-8f7c-7f5ed9de647c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <dc:identifier>HP:0002148</dc:identifier>
    <rdfs:label>Hypophosphatasia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32884435-06b2-4e14-ba97-296078bd0a54">
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
    <dc:identifier>HP:0008344</dc:identifier>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/df8453d7-eee9-4028-9822-db0f3b981206">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e64a1922-125f-43c7-ba35-a143bfae8b8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e10ef396-6951-4266-9e18-d9c79c1866be"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b201b19e-47be-4bcd-97fa-9c77e0f5295f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34d92945-a530-4930-98b2-0cceabd34e69"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eaf2e96-953b-4263-a2c7-8d86ed8404e5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ccfdc7a9-2b4b-4072-9904-c77a15dbe273">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603358"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7903e8ce-f60c-4412-b109-7821dbc20fd8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lactic acidosis</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee86276a-6069-4cdb-b90f-d2d4b20e3913">
    <dc:identifier>HP:0001337</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
    <rdfs:label>Tremor</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f13e7e1-3e94-4474-92a2-3ffaa68a359e">
    <dc:identifier>HP:0003287*</dc:identifier>
    <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3b7e96f-4e83-4272-96c5-7c00b0577dbb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4a2ad10-5194-47f2-ae8e-debadb150d12">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f382619-fc7c-4e3f-b93a-ab386578a798">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e6e2245-94ce-4ec8-ab04-ad2688bdfc14">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cdcc191-a855-4ca8-91c1-16337c5f119a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ff3fbcc-e9c2-42e3-b396-3db03a594c6d"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/260be4a7-1d79-42ab-8497-673df1e17faf">
    <rdfs:label>Fish oil</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5628cf99-153f-406e-bf98-ddd6221bbd2e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/577006ac-06cf-4d90-b235-b2a572c053cb"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <dc:identifier>DB13961</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5abf853-297d-4a61-94fc-d31b65d37161">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <dc:identifier>HP:0008282</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79529d03-614a-4e0b-9577-b52fbbb6d743">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48d2e2f9-5153-44c9-b4fb-23980119fdf6"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71aad6b2-4e4f-4e05-946e-01d6a7b9da68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
    <rdfs:label>Inflammatory myopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0009071</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/abca3fb1-76ba-4c69-8ab1-80c7fadb334c">
    <dc:identifier>DB01306</dc:identifier>
    <rdfs:label>Insulin Aspart</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50a632e7-f564-4faf-8997-ce08d7065ed6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e472f70-33a4-4d41-987d-05e5255f8ce5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80c6d16a-7489-40b1-b5ae-db19218f350a">
        <dc:identifier>C09A</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5549334-aeab-49e7-826e-2b2941a26d1b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b370ce2-eff9-492a-a852-8e8293e352f8"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338"/>
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a24f5b99-b4af-4f31-8635-82e1ba0dcc22"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9dcd1b3-084f-45c9-82d3-2651caae882a"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f32fef6d-6597-4796-98c8-69bf39bed216">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef0b3e52-81bd-47a5-9760-cc124693361a"/>
        <rdfs:label>DIURETICS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b370ce2-eff9-492a-a852-8e8293e352f8"/>
        <dc:identifier>C03</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18e64755-62ec-43dc-b116-4a51a0fd9f86"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88487ef9-4cbd-42a0-87eb-4c1aff453894">
    <rdfs:label>Cysteamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24818836-d39a-4eea-9575-271f57ceec44"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d7887244-a5a5-42b6-a7bf-95ef7d57749b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baccc242-f593-4940-91c2-068d8f129c35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd1ca763-caf9-4502-bbbd-fcc06b16f61b"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/103fabb5-791c-407e-99af-b39cfcfb4f0a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05a84d16-934c-4287-bccc-8a774a314fe9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <dc:identifier>DB00847</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21b9f3de-a1fb-4b9e-a644-9f24ab32ad07">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6502d2f0-05c1-4e17-b916-32b986b16132">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001072</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
    <rdfs:label>Elbow skin thickening</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a8a099e-a045-4a86-b122-d231e7487c5a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67b78a0d-7cd8-4403-aedf-c29c71b845e8"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/950b3533-020d-4506-bc26-234818227911">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7e50fb1-321c-444e-8df6-991503aae494"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/10cbe8fd-dccc-4dc9-929f-e17a7f269982">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e72e1aaa-d04b-4b87-802e-893a18d25d46"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1f1bcc-fa40-4bed-8ded-abacfcb7bb35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2499ae24-adbe-4efa-a69f-c047fbe59491"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/521a5aac-b270-478b-82af-fd45c7f029f0"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3acb2dd-6b45-4ea0-90c9-885c5acd42f3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/011e3acd-45da-41a4-86a7-a206a85c8873">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bab6def-a4ff-46a1-9aa7-66a88dca3128"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/744ee568-0446-403e-9d3f-2e9e14c7cb20"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d044e39-3fee-45ac-8250-9a8349c88bda"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45a30ad2-b45a-4f26-9a6b-e7182c2fa21e"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Acetylcysteine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/64f40162-6cff-472f-81b6-4eac30154cd6">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f010f97-56e0-498b-8807-4cd2f36e321b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/062e0c5b-9296-4b4d-b7b2-1192a07b0bf0"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edb5d374-b510-47dc-ac8b-3d08585f846e">
    <dc:identifier>DB00230</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/410b42f1-7e87-4621-a74a-9648e58bf8c8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8986b4f4-ee88-4bb3-a5d2-394b4a6cc6fc"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca9d4ffb-7050-48ea-9ae3-2ca4079944f1"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pregabalin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e3cc7c9-ccfd-4677-8598-d41631ec23cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c180299b-f1b4-46ad-8d8f-1e06eca89388"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d8361ca-c833-4a9a-98f4-2d958a99f07a"/>
    <dc:identifier>DB00145</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <rdfs:label>Glycine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6371d8c2-8525-459c-8be0-7cda65eeb7cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66423125-0784-40ff-93c1-22c5e9c02c89">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>short stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d923e19-99e0-47f8-855e-03935926719b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fce9bbfd-ec30-47a9-b242-f650c4747a4a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f302911-c676-4af4-8938-71a760fe3155">
    <rdfs:label>Copper Histidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac2f51b0-5791-4d90-9561-18b02c973de5"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/393ee0f8-2ff5-4433-bf6c-01ebaee78c84">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/adf0850e-be51-41f5-a1ed-21d63aee936f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b5bbd86-0ec1-478e-8b57-ba274767e685">
        <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab54e3f9-5e93-4b24-8743-f30ed7b8ff7a"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7df02af3-c5c3-4c09-bea3-4fe5d585a50a">
    <rdfs:label>increased fecal fat excretion</rdfs:label>
    <dc:identifier>HP:0002570</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17aad222-22b1-48f7-b4da-b53e58fe12b6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcaec611-a42e-4377-a930-268b4966a2d6"/>
    <dc:identifier>CHEBI_32362</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
    <rdfs:label>enanthate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0d5c359f-02d4-4319-a685-2957a44692e5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53c16214-9b22-474e-8f9e-7a1a628b57a8">
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
        <dc:identifier>HP:0001945*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16fbf8cb-0dc2-4681-859a-22e4b355523a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65e62b23-08cb-47ee-a1e2-a8763e4d84b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5e6b8de-c82f-4502-979a-85f0032e2393">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a9e9e6a-3843-4119-a027-7e54720bb9d1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fb833470-f507-4f8f-a51f-c613f7e81081">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c863fd3-3610-47fd-a8b3-be776f22baa3">
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
        <dc:identifier>HP:0010909*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efa9d31-e112-4758-87ac-7485c6e1f214"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8711a95-4d1b-4310-9278-cc015adb2729">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b072f8fe-a2cf-46f0-a6b4-9880780a9955">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d52cb213-136b-4282-98f2-3c557680b13a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d800dcd6-471e-4024-b05f-038a74531efc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/caa451c6-1ef9-4eb5-9ffe-8067d38b491f">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42f6c75e-e89a-4c29-823f-bc983c329b54">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>high serum phenylalanine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9ccdacd9-0cf0-4b5c-9f26-71cc68861669">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50852027-a562-4b34-a769-b1e4c4e1d67e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f559847-6d10-4ed3-b770-e5ff6804c8db"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1905a824-3c40-4d05-9941-00f0c20d7a14">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df604baf-3377-4348-9659-6af8bb3d9f27">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b84a409-ecc5-442f-a38a-3e958aef2218"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bd7f949-f738-4430-b36f-7f71543b522e"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_2786</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/51c6069b-e368-4937-9392-eda606063d3c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a40fbbf-8301-42b6-bb74-e3104289ed32">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f3834ce-e9dd-4e6a-86d7-3b2b97404bbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bc59fa0-804d-413b-b8f0-0e83a5c596ac"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f54731a-3afd-4f7e-979e-39ab272e9c79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f2cc4b4-3cd4-4132-bb31-7625dde371fa">
    <dc:identifier>HP:0002529</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
    <rdfs:label>Neuronal death</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36baaadd-7ba8-492b-a4d8-43cbe0f366b1">
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6edf2d6-74d0-41bf-a1f2-425001803b36">
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <dc:identifier>HP:0012202</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36345d2f-adb0-4939-9c1b-6a31f361e46f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed0e832e-b6f6-4386-8012-f1706b74b0a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d509689-c202-4f35-8fa8-8f6322b5339a">
        <rdfs:label>pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eed61eb0-6e99-421f-a0a7-033fd7b6db03"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e38a4aa7-fd13-4134-aaf7-2e0cece3b6aa">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c34eea08-c8fd-40a1-a3bf-a810500c7ea7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003155</dc:identifier>
        <rdfs:label>high serum alkaline phosphatase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b6a25c54-a137-405b-9213-042cd4f16435"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/76841825-4ebd-4e53-9dd1-c4f156809a4f"/>
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1ef3f2b-6076-4180-903a-ac53c8c94904">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6176e8bd-13a1-4a07-a02f-861a9219a9d5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2151a70a-b56a-4a1a-b5b2-f023fc4d9e34"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03366bec-be0a-4609-98a1-1638b6b2cfd5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Warfarin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <dc:identifier>DB00682</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6daf453f-d22b-4c78-8bbe-f2cbce38a584">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6c8f5c02-eda3-43ed-ae02-ee2003b342a4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f13e7e1-3e94-4474-92a2-3ffaa68a359e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdd9fd00-16cc-47f8-bbd7-1bb20b1064fa">
    <dc:identifier>DB13257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9ed7db8-93d6-4545-8b4a-3de25d4a68e4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f007b35-e519-483f-891d-98d92d1a0d07">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e891127d-7ec5-47fb-bd02-cfdd14671dd4"/>
    <rdfs:label>Uridine</rdfs:label>
    <dc:identifier>DB02745</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f4aae54-6169-4817-8675-55710bdaa7e1">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09c4d20f-9c3c-4a74-bcda-841fed5235da"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2af6372b-e9a1-48c1-a775-83bfb6f2ed57">
    <dc:identifier>HP:0001954</dc:identifier>
    <rdfs:label>Periodic fever</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/039f0dc6-227f-45b0-947b-dfdaeb74b49d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a629183-aa7e-410e-a542-52fe16603e22"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d381bd98-396b-4c01-839f-b915e34089cb"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5ba69abd-9bb3-4261-9a22-0521229178ea">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5e2bf9d-a90d-4318-8c42-4fac6b0b44d3">
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30802d1d-5ed5-42de-94bb-b69c66c0e34c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03d78dff-bb81-4856-958d-c26a659b032d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d54f49d-ffa3-4148-b8d8-8aafa691f64a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/883904ce-5658-40e7-8fd8-dc7e1fecb68d">
        <rdfs:label>Rituximab</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
        <dc:identifier>DB00073</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ac09569-99a1-4742-b2fb-4744a7d5d446"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0412d721-f32f-41ff-811c-8013924d72fb">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6911de14-9f8a-44de-90d0-ec37d2747f79">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
        <rdfs:label>Chloral hydrate</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bdf7b7c-4cd8-42bd-8c9a-90915c1d7b4f"/>
        <dc:identifier>DB01563</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78427c76-3780-43cb-bef8-bbe208f47e18">
    <rdfs:label>pathogenic exon trapping</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/23a18d9d-7c2d-4d04-b7c2-027523defd94">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8cee700-93b6-4264-af69-afd6455efda8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c399c819-6727-4f71-b338-44f5e9739694">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd668030-b753-4b97-ba6c-d28b4d2bce73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/38222a05-7b0a-464f-9a7e-e3a2f856a643">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14a5db13-c287-460c-941d-5d4b92d6243f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f932a6d2-8a1c-432c-8495-c8969ac771b4">
        <dc:identifier>HP:0040134</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
        <rdfs:label>elevated liver iron concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e99c2a85-5e76-4732-99af-f65f60165167">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5f8cd474-0248-4b78-8408-3a456fb3d700">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4a3a9cc-5449-46ce-b960-91fa8c1ad812"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ff3fbcc-e9c2-42e3-b396-3db03a594c6d"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a32ccd7b-3f03-417a-8409-80d9b903ce7c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <dc:identifier>DB00783</dc:identifier>
    <rdfs:label>Estradiol</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/98c72aa5-03ba-48dd-82d6-4b2a2a58b658">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd982d6-99a8-472a-97bb-cc08550c238c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e42044e2-52d2-4cc9-b707-b5f66d59e8ed">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f19c154f-ca80-4f4d-8138-2abce139de43"/>
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6af6dccb-b963-4004-9f95-acc6229aff35">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>avascular osteonecrosis</rdfs:label>
    <dc:identifier>HP:0010885</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3bc579a-8bee-4f59-a491-24eb8a0493d7">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b4dd528e-07d9-4652-9cda-bec4d98a76ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d175981-8021-4fe9-98a5-36fd92a0921a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613027"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/240a76da-8077-4094-9e7f-e3dce829f765">
    <dc:identifier>HP:0003713</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:label>fiber necrosis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e2c1ddb-5922-49de-8d82-0260be2c27b0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a24f5b99-b4af-4f31-8635-82e1ba0dcc22"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1188fa2-3598-4e5f-8395-98595993e1d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73ac724e-194a-42b6-90a6-9ece92629d26"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c46855a8-2a23-4d1a-96ef-62a5b267ced3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a79e3c4e-625a-4e32-bbda-ae10fd25264f"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
    <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/da321f11-f29e-439b-9e0c-0a294b480ea0"/>
    <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
    <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/05a7a429-f647-434c-aa4f-6f377acd4429">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5e2f645-0e83-4234-94d1-bf324b2ea36a">
        <dc:identifier>HP:0001903*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b0744fc-fa0a-469d-b8e0-30ee939dbd6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e406359f-d6d7-4584-823d-6a48ac6b87c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7a1238f-17c4-4382-a60b-ded99d379da9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e97b7cd-53be-47c6-b87a-51272d2a3d11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bb2f363-83f3-456a-a482-25f9c9c6dec6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>splenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f0a5d8a-1eed-4955-8d2a-03f4c3f010d5">
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1a30586-f0d9-4bdc-acfd-6ffc41577874">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ed1805c2-ba25-41b5-aca8-acabe8ae0785">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7471db99-96d1-49ea-870f-b4bd027bd43b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000491</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81f41b13-74ee-46f3-996b-beb87c91d330">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e8447df-efe4-46a6-8cac-f5e0e555b26a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
        <rdfs:label>Corneal scar</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000559</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0312cc8f-ce94-43ac-bf49-9c106c0dc7fb"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/653aaa9e-306e-4343-99a6-77f0b6d7e4d0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/912dbbb7-f395-4aa1-9c74-19231bd172a9">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d33b9a49-d68a-45e0-958d-4a84e213678d"/>
        <rdfs:label>Tocopherol</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
        <dc:identifier>DB11251</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43843d11-19d0-44e4-a032-e9513452aca2"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f0c17b4-9c08-48d2-84bf-d9c0fed4cefc"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/fe0b848a-740d-4f37-b647-a88c17a6a1be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ce0ecb6-ccba-43c0-a9e8-d85c7ec01fce">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4fc9917-1663-4b63-86a6-4ddaebb1534e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0487e46e-832a-4030-97ac-abcd7ba83dc9"/>
        <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000009>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3084f7cf-ca13-4dff-bdac-b64267995500">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12f5ccc4-60c2-416c-8e52-81b9d35e5187"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/832b34f6-9418-44e0-914a-ca52f596950d"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b56582bb-01e3-4b1a-a00e-b9a8546c87ff">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2c51710-3835-4684-93b6-d1839eff5ef2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/868e3b7b-0d91-4d9b-89fd-d7985d1666f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e272847-d80a-459c-8111-d13fcf01cd42">
        <rdfs:label>neurotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8a55e09-85a6-4cda-8419-b8c769fda539">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02ad2574-f177-409d-9c02-03de304ee84a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d33b9a49-d68a-45e0-958d-4a84e213678d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e885f383-eb2b-43d4-80fa-de15b2934e80">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/653aaa9e-306e-4343-99a6-77f0b6d7e4d0"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8a55e09-85a6-4cda-8419-b8c769fda539"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6b70ba8-462c-4f92-8d34-85911c0b7f62">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f227b3f-a0c6-4e8d-a255-f0cb9a76588d"/>
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd000b2b-ea4c-4609-86af-445963eedd4b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d50f193-16f4-4a9a-9b5b-b1b93b0a6663">
        <dc:identifier>DB03756</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02ff769d-faf6-4a71-b8ce-54813f887901"/>
        <rdfs:label>Doconexent</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26f63f72-d27a-46be-be23-6fd8b70e0f2d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
    <dc:identifier>MP:0001845</dc:identifier>
    <rdfs:label>inflammation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5357028-a45a-47da-b335-0af99729326c">
    <dc:identifier>HP:0012100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d9f98088-10fb-431d-a1e2-01f6d83c2ebf">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <dc:identifier>EC0:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a4fe646-9fdd-4271-bb05-54b62044231e">
        <rdfs:label>Delayed Develoment</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28385e76-429c-4a1a-b1e1-7ebce9b55a6c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79fd8170-9f32-42f5-b321-52cd8aaba7ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2833bcfc-e935-461b-bbfd-dddfb5a43d43">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/baa53c16-5187-4413-8de4-2990d833d5e4"/>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30b8ba9a-ba69-4ef3-8fb7-d607fbdd0ab1">
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29b6cc8b-d439-4f81-b3e9-64c3d8fa7cea"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96787b22-8959-4623-9e00-f8effe0a57ba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB03256</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66a0f59e-2b9b-4e73-81ab-c2b31afcbc7c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <dc:identifier>DB02959</dc:identifier>
    <rdfs:label>Oxitriptan</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3798541e-a254-40b8-97e6-289cbdb466b9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cb2c7a6-af8f-4f51-bb74-4de84fcb6147"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80070695-7a2d-462b-92db-6bd1c5a061a9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f8e4d92-d1b1-49a8-bbe8-0b0e99c1be16">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <dc:identifier>N05A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4f3b082-bd4a-4ef6-8437-b46e89ab8570"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f752b72-f6ff-4338-bc49-b65be7b3d37e">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e59a8e88-dc53-4f97-8ad5-d52a63b8c388">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85433033-1c70-4387-8e56-16cf2fad23b3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3435bcac-2d2a-42f7-9b29-7472afad901c"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b0d7e419-579b-4a8b-a497-405920e5af76">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a98c2a5-22f8-400c-a8b2-2cb497c84690"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3435bcac-2d2a-42f7-9b29-7472afad901c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31b24219-f72f-474c-84c8-5bc27c5b8adc"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ebaf1378-752f-46da-bcd6-aa13e7f862bd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d84691c3-1d89-4fde-95b4-c1cbeccc64ee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/162d6001-5d3c-47be-a99a-60f223c867f7"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d74b079f-002c-4635-bfa0-d44a85dd897c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3435bcac-2d2a-42f7-9b29-7472afad901c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41be1a69-980e-42ba-9cef-009708e1ef4b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0dff735c-51d0-48a0-afc9-2caeb241c7bc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/191e0599-dd83-4211-a003-38631985e1a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29e555f7-f9bd-4d95-977f-2cdfdfe87a64"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfd2c748-b53d-45c3-a7ed-4547fa4389eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d2e89b4-ff4e-4b17-bc6a-17830ef93e55"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82b09e4e-8de6-40a0-8559-81d8daa97727"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5645180f-653d-400d-af92-85c18e7d844f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c3e9ce9-f917-45f3-91f8-534bbd8869ad"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd86b784-c463-49ba-a2c8-caef90434dc8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1dc0a487-772e-4efc-ae3f-92053359a990"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b7bd32-f19a-4657-bba7-5ddeb6dbb61f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8371cb43-7707-49e5-b028-b7118efd1dbc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddcb2daf-8edf-4aa2-9b61-9a1d483b7ceb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac92f566-ff77-42ef-a659-207ec0eba1b4"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f837664e-e95f-4058-9284-3876efe29b43">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ec843c6-5418-48aa-92de-e070f877b656"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88a8fb35-ec19-42d6-ace8-e295a196358a"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f"/>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5711155b-34c1-4065-a9e3-fff4412882b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301835"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af4b39ea-573c-4da5-b272-0ab481f5b7b5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf9d9475-7ec3-4690-b500-3401dcac8772"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3435bcac-2d2a-42f7-9b29-7472afad901c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fca2c415-f94e-4497-a2b7-43e777b5cc4e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Ademetionine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a326148-10e5-4d8f-b1f4-429a28fbc3a0">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3aaaeef3-259f-4b88-bc75-e378c7608fff"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9629b5f8-4e69-4bc7-a4c3-8156843c1c77">
    <rdfs:label>Muscle necrosis</rdfs:label>
    <dc:identifier>HP:0003713</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8f0c17b4-9c08-48d2-84bf-d9c0fed4cefc">
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b64f5619-da8d-42e7-934e-9629123a33ac"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6952fec2-0608-497d-8716-5d455eff83e9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/653aaa9e-306e-4343-99a6-77f0b6d7e4d0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69a4740b-0e43-4c30-a239-ece783bd2e16"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42bb02f1-8ea1-4030-947f-194e881e12ad">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/818cae68-31f8-4ba1-be0a-2f2003ee102f">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b138b255-69df-47e4-90e3-f5ca785fe4cf"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6faf3e6-e956-4c45-9105-48ec35554609"/>
    <dc:identifier>DB01098</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1be79bc-4ff8-40db-9e01-90708e730f38"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c234eea0-def0-4f12-a8fd-4d4b339ce3fe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37d72170-3c5a-42aa-94f3-f0b510bd98bb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4354d518-f0de-49ac-b227-eb2d2c301325"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b85fe616-2ea4-4730-8b71-3aff168f5261">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3c2024c-2963-42f6-ab67-0b8bd8029138">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b00cdcb-a67d-4088-97a8-62a2789c27ad"/>
        <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
        <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
        <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
        <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
        <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb237fd4-9aff-45f2-be82-7ff9356b7a06"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2e523e7-65e3-4ed5-98e0-cdf3836a83b5"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a3b2670-8741-4113-8bc7-1abe76396553"/>
    <rdfs:label>Bezafibrate</rdfs:label>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/83ae49a2-dad6-41c2-ae7f-e0b7e0d8459d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e979489-9066-471f-8aa4-222bad677a9b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b00cdcb-a67d-4088-97a8-62a2789c27ad"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a629183-aa7e-410e-a542-52fe16603e22"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e682c929-3892-48c1-9dd6-b7c68e6af965"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76034d3a-a394-48d4-8a00-566822ccaf45"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/240a76da-8077-4094-9e7f-e3dce829f765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d326afe-d1af-474c-a2e7-75f13689023f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da3b06b-6776-4902-9ad8-f920e17b40cb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>Increased liver enzyme activities</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9be9f20d-87a5-491a-9916-0477bb05e7d5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b31299b5-d049-4ac5-8fe3-4967e7949e60"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0009cc4a-57f1-4851-bc79-c8583e859461">
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>involuntary movements</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b92d3993-4837-4f8f-a368-28a95798ca3b"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1f52345-e8ed-4317-b23b-87065efe5b92">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6839ece-13a2-4ece-9551-6744e518b8c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/458f4f34-dcdd-4dc4-8dbc-82ad6e4f9b77">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <dc:identifier>HP:0010472*</dc:identifier>
    <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4491ff9-2861-433a-9ad8-f13b0f3cca40">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a9ecfb6-229f-4059-9417-d95deb19a1ef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99d1b188-e220-44ba-a393-a49f2fc6ad5b"/>
    <rdfs:label>Eliglustat</rdfs:label>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/918edba5-66fa-4a39-8eeb-8510ddd27454"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5e82eb9-41c7-49ec-a360-0ae5afb71e4e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da358fe9-d5c8-4d57-aa76-7a7edae74f3c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Proximal tubular dysfunction</rdfs:label>
        <dc:identifier>HP:0000114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d967642-5a40-4682-b268-77edeebc162b">
    <rdfs:label>hypokinesia</rdfs:label>
    <dc:identifier>HP:0002375</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
    <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb5e5a6a-808f-404a-b442-021ae939330d"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/87dcae04-003e-4013-b9e2-9bcfddfa07c1">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68726af4-e092-4ec6-8d22-d6246150b0c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a96dc102-8050-4dc0-8d03-ca9794368c97"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c2d92ff-0a5f-4391-a365-81f454389a7b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e641d88e-3c80-4bf4-ac4d-f3d65dea5eaf">
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fb37f56-4206-47f0-b172-f55fca23c364"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/625be5d6-9ebc-4ae7-a322-4b348a71c737">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <dc:identifier>HP:0011042</dc:identifier>
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e682c929-3892-48c1-9dd6-b7c68e6af965">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012240</dc:identifier>
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3931ef5c-2f50-4bef-a134-1ad0fcd7297a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5becbcb3-7e24-4709-bec2-f80d0e700575">
        <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
        <dc:identifier>HP:0030098</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4b0d7ac-e7e3-4a39-a1fa-7b843064241d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a85c35e6-4d53-4733-9801-48706be2b2fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78427c76-3780-43cb-bef8-bbe208f47e18"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97fdcab7-65bb-41a4-907d-d75695c1e2dc">
    <rdfs:label>Adalimumab</rdfs:label>
    <dc:identifier>DB00051</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/492cc352-49fb-475a-9b4b-ec526b99d5f6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1117aaef-4a71-4955-b9f7-da265aad64c6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe81ab06-3e25-46b0-b367-65d76ac35d80">
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <dc:identifier>HP:0002071</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0252907-f412-4425-bbd7-4b961fe99088">
    <rdfs:label>Setrusumab</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f07c580b-e504-4114-92b1-78a0895b75d2">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ff5d26e-5823-4560-9913-db0a3068ae3d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20390f72-9a9f-4b35-a438-101eaedb621a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0b7e5cd-d0c3-4791-971b-c6d67843141a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b15fd880-b367-4bf7-a1ee-3e948dae0abe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af8539c6-13c3-420e-869a-056cda0377c7"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <dc:identifier>DB14778</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a4066c28-6b28-46aa-9164-523c3b35ea51">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e428e9a-99fc-4cc4-99ca-231629d36523">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c41f5269-4589-4f6a-90f0-59c657a1a541"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec110bfc-818a-40b7-8198-92c3e5e82804">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3305cb6-1b33-48a7-a112-335ea7864593">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c41f5269-4589-4f6a-90f0-59c657a1a541">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4066c28-6b28-46aa-9164-523c3b35ea51"/>
    <rdfs:label>Methylene blue</rdfs:label>
    <dc:identifier>DB09241</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d72feead-8424-4108-b67f-15575ceec12b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36914b43-feba-4428-9395-bf736801a613">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a14187d4-15e9-40ba-8013-92700c8569cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/112932c1-407e-4139-8a27-280c3e247dde"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a828d67e-2009-4099-8bd1-0472e5115ae4">
    <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <dc:identifier>HP:0100529</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/102d16d9-b03b-43d3-8a3b-ce225fdf976d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b424b5eb-8182-4c41-9628-72de954e0411"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/df271d5c-5c38-4c25-b5b4-8f2024d98b51"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/035c7cfa-c220-49ee-827a-2d326ce02e3c"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4b81e00-9336-4816-824f-07a196fc11de">
        <dc:identifier>HP:0012500</dc:identifier>
        <rdfs:label>verrucous lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50590fa9-7a6e-4352-99d4-51378e8f7b88">
        <rdfs:label>Skin lesion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011122</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35afaa0a-eec5-48f0-af80-884571510a48">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mucosal lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/467b2a75-0bcc-44b7-b7f7-6b0ef527c2b9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10b36bd7-230b-4ce0-a8c0-d96cae58b7b9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
        <rdfs:label>Skin papules</rdfs:label>
        <dc:identifier>HP:0200034</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6502d2f0-05c1-4e17-b916-32b986b16132"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86dfc98a-5267-4682-9838-1128bc82b68d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c81859a-2b1c-421e-8f7c-7f5ed9de647c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d9574a-f00c-4f21-9c46-7b7cef3e8ab8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/603e7486-7d37-4afb-86bb-32adce46755f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9a0bded-f529-4aa1-b1cd-260f84175d3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d175981-8021-4fe9-98a5-36fd92a0921a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3bc579a-8bee-4f59-a491-24eb8a0493d7"/>
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21db5658-30e9-4d1c-b502-2a96094db68d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f71779a-1f86-45ab-ae88-89f061ddb96a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/934c04f9-cbb1-4d9d-bf6a-a2db753348a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fcd63b7-0f7b-4cc7-81e3-5fa19aa223ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00175</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95a13eb5-f6b7-4314-b28e-d9f1578679d9"/>
    <rdfs:label>Pravastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a56d4252-2dd9-458b-866c-f2a9d970c48f">
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0003304>R219K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/317550d3-7f07-4c3f-9cb7-bb1b72e18d49"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e4eaa7-624e-4a43-8deb-526cd6dded62"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5b9e591-b9cc-4bc3-8823-976637b98848"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/934c04f9-cbb1-4d9d-bf6a-a2db753348a5"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb7d04ff-e3a7-4a55-b549-b72f1a9f58b4">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ef2c2856-2405-4f32-96db-614ab99a7e1c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
        <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b457ecc9-3efa-47c3-bae3-82cf6790cfb7"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33ab5b92-8f84-42db-b476-9f4d85668466"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ff463dbb-990b-47c8-b1d2-bcb324a6774f">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0987d636-ff1b-4049-b778-75ff0f37030d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e5c6bdd-e70a-4466-bb1f-154707628115"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3af1d07f-1e94-4275-a25c-939b639def3d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/67145f69-b7e5-471a-aa54-3e80bafb070e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d62e7d35-de27-437b-9b3f-be4bd958153b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/694a9e82-234c-4e3f-9f67-06b473b7dcba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d15310f-ddbb-4e88-b324-f5c72ccb0a9f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <dc:identifier>DB08834</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9ab5411-9cba-4421-b36a-cee2e5657b55"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a1c7109-3ee5-4abf-b544-ade68c7197ed">
    <dc:identifier>HP:0031377</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8e9f76b-4227-42d5-a64e-dd2c19d358f1">
    <dc:identifier>HP:0002633</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vasculitis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c131b6a1-d930-439b-b24e-b63d0c214159">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/558e3976-d0cd-4483-9d10-c049e4c2ff3c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/736d7668-2f0a-4d2b-8cd7-3fd3ef5f1591">
        <rdfs:label>No result is  added</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/501c8883-0b74-423a-a352-5b361b561d4b">
    <rdfs:label>Levothyroxine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ffdb2f26-fa6b-49c9-85ee-fe7eca1d60cc">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0b5dc7d-a5d8-406d-b9f6-0eef8d7d6818"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c50af32-f5c6-483c-972b-9fc2e00920f3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2c848e8c-eabe-4fe8-8ed7-69826241305c">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0b5dc7d-a5d8-406d-b9f6-0eef8d7d6818"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f343584b-e107-4701-b5bc-2ec0cf8a3cda"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00451</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/196bc0c9-5ba4-4163-bff0-44018b141ba3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55a97889-0993-4b18-827c-d0287653d0bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28893bf5-4447-48c4-9585-6de90aa97768"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bbfcfbc-e661-441f-bbb9-3531b6a3504a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72aba17f-1d4e-4fc0-af4c-21a4b9635f1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3946bdbe-53ef-4a0b-a00e-9ac2ec80b42f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9c6b698-5f49-4990-b439-f6551f3259fe">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3626044-e627-46dd-af4b-f2267db2ba0f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>Renal salt wasting</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b97b0ea2-5d04-49a5-b136-6a23789ee699">
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5f959ee-c5f3-466f-969d-26a7a4fc9429">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed98b88f-69ac-4f31-9686-33bee5ac0da8">
        <rdfs:label>Speech and languague delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87ab5568-a609-47cc-9ae6-68fa312a110e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3df6e389-4e39-4491-a58b-7e794a296865">
        <rdfs:label>Developmental impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82cd8abf-df3f-4b43-9943-5dae78790b37">
    <dc:identifier>HP:0008281</dc:identifier>
    <rdfs:label>acute hyperammonemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/02ff769d-faf6-4a71-b8ce-54813f887901">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb1c2f31-1417-4f9c-b4ed-cb924202e0c9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf72a545-950d-4b11-99d0-73e9ffcfd2ae"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd000b2b-ea4c-4609-86af-445963eedd4b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72abcf22-9a35-4d11-9daa-279a6d810415">
        <rdfs:label>Reduced visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fb656061-be18-4242-b900-2f9a610e7323">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9c6b698-5f49-4990-b439-f6551f3259fe"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66f7361e-41a6-4567-b7e8-a70024631b95"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e2ee268-ce71-4f80-9770-fc1e74aa8997">
        <rdfs:label>speech impairment</rdfs:label>
        <dc:identifier>HP:0002167</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f3c0ebf-d15d-4758-9b73-14a4118c2f4a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3b0744fc-fa0a-469d-b8e0-30ee939dbd6a"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36989d68-7cfb-41fb-8418-13e1fe01db47">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormality in bone mineral density</rdfs:label>
    <dc:identifier>HP:0004348</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/eb2b1342-8383-4df0-ab2f-e25ed93f819b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0023195-b2e1-4372-b5f6-bab886d68eb9"/>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6f9b036-eba2-4dee-bb0a-f83e7d038b13"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb6653f6-3d97-4518-98fb-c171a2f2d57c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1968fa8-a2dd-4e00-a5ed-f5b0994c82c5">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8eaeb8fc-5c97-4b1c-9343-a957105d3c5c">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85fc3fef-fada-4210-b684-be4d92801b2d"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa423a86-db02-422d-9045-dc7a3cfcc6d7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5018ccfa-7a3a-426a-aa3a-2a53060814c4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <dc:identifier>DB04844</dc:identifier>
    <rdfs:label>Tetrabenazine</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/99b4cd12-b983-4e5e-9078-8052d3c4c18b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8293f86-5031-4ef2-8f57-4fb4539f4526">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b0ddff6-7e84-41ba-98d8-5f35bf397e44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53760ab8-df40-4377-86c9-c91cf0d3a46a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001877</dc:identifier>
        <rdfs:label>low RBC count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/43700b5e-d2f7-4cad-ac6e-6dd0ff76bb47">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05726185-3a4f-4e1f-8870-07e27b958236"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79d173e3-c5a4-470e-aaad-e99076c5d064"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba3566e3-f210-48e1-ba46-4a812a976365">
    <dc:identifier>HP:0012213</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
    <rdfs:label>low renal glomerular filtration rate</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9be100e8-0a82-4ca3-8731-d15cb506da1f">
    <rdfs:label>Linoleic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06b8b84b-d34e-4a16-84af-c09137e7ed02"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b36ea9a-8557-46f7-a5ba-db763cac70f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17810f92-e463-4cf8-8087-38f00e0db66e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b52c1438-0f24-46e9-b612-88ad28cc2d6a"/>
    <dc:identifier>DB11981</dc:identifier>
    <rdfs:label>Elamipretide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0322cf68-9e07-4b23-9bf9-5b1f4cbda0c7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f014341a-77cc-411f-8538-3372cfe69923"/>
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/158e0c4c-ef81-4e82-bffe-d5b3372479ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/600bf51b-1c0f-4e28-a5f4-2c9b0f1ab0d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45c380e9-7666-4222-9411-ea1579e79948"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842dc54a-98a8-4381-b7e3-9432af194360"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4a205694-37fc-4979-84f6-0ed299838fc9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/678c569c-0ff1-43d0-bd09-b073451e4b0f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/70155c21-367f-4d12-9fb7-d2abfeb1a0a3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d0ea735-0a3a-465b-83a1-93e7708e5775">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum bilirubin level</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e52fce3d-9cba-40ef-986f-0ddc2bf6c30f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/708f5fe7-a7c6-491e-bfca-18d17a88707c"/>
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <dc:identifier>DB06285</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c365cd11-13fd-40be-8961-9dcea9988c61">
    <dc:identifier>HP:0002500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
    <rdfs:label>White matter alteration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0465afad-16a4-4070-b36e-4d714dd69822">
    <rdfs:label>Heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83d06fd9-71ea-4ff3-9bf9-7f3eae3bb9d2">
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ccfdc7a9-2b4b-4072-9904-c77a15dbe273"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e038171-594c-4f19-b805-24abebea4df1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5e82eb9-41c7-49ec-a360-0ae5afb71e4e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef2c2856-2405-4f32-96db-614ab99a7e1c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fadc6356-9819-437f-b121-7860a5bbe3a1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/243afeca-f592-4bd7-84e5-4ffbe5ad7626"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be15b678-14c7-4c1e-8bba-e266e697b88b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1d90252-0917-4ca0-8253-100c48d08437">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c18fc7f-e502-476c-b947-9bea3b91056b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb8f20f3-f1a8-4227-ab62-6f6ad33d75c2">
        <dc:identifier>HP:0001735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d60830ad-967e-43c6-9128-1f589db8cfbe">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edba40df-b5c2-4d7f-bc05-b76d411e6ab7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a1995ed-35dc-4217-9e01-0f192f2deb7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e01dd8ff-6edb-4fc3-9898-cf24ae445c5f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3af231e5-7d1e-4367-aa97-64eeadb423b9">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63e6a39f-9d8d-45cd-be6b-9c5d4c54b42c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5aae91f7-3d10-4e1c-ba7c-c09b2f43fd8e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010975</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
        <rdfs:label>Abnormal number of b cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a2aacec3-eba6-4c42-a336-2be27c4f4d7f">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7518c543-0474-43ad-ae33-d5c4d7025401"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a828d67e-2009-4099-8bd1-0472e5115ae4"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef5b7af6-dbb6-48d9-b447-28c11db9e59d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
    <dc:identifier>DB00376</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c0cbaf3b-0c2c-424b-8e59-cbb3abc0a819">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c477e51d-bc95-4943-a574-95daa65349f3"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72dd0d26-69eb-4103-9a72-97f466b8dbb9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78157023-02e2-426d-a376-a5214a5dbc38"/>
    <rdfs:label>Trihexyphenidyl</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0fee95b6-2401-4010-99a9-f72805c050d7">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601987"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01d4a2c7-a5e1-4c02-bece-2f38e5e399d2"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7990fe93-c0cb-4ad9-bc4e-f27c6ad20bc4"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/70469f3f-88ed-4b85-95ee-975a001d97f2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cf76b18-ab7c-40a3-8366-f44079da93a1">
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
        <rdfs:label>psychotic  disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d56de33-4eb8-429a-af4d-a4ce3291c629">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/700f288f-4aa2-4df4-8cad-513bac711d7f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/312119eb-0e6f-47af-a290-bdc63556f853">
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <dc:identifier>HP:0012647*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/635186f3-90a9-4000-9645-760c6609fd5a">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3bd521c-6a11-4e8c-9a5c-8e84f1272606">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0acb08e-0952-4162-a89f-5cfa12a85f73"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0845c6a-14fd-46ae-bd21-a4b3f275c96e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00055442"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed7a0dcb-09df-4b82-9f8a-c1043a794194"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
        <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e945566-c984-450d-b444-a33192433eb1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8e9f76b-4227-42d5-a64e-dd2c19d358f1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15622a52-5d64-434f-8bd7-1e7258b0562a">
    <dc:identifier>HP:0011999*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/521a5aac-b270-478b-82af-fd45c7f029f0">
    <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bff1f57c-351e-49ba-984f-971aa31722d1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7436bef-bd44-46cf-bef4-d160720362c3"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88dfccc6-5d14-4681-9bc3-0757bee83be0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42bb02f1-8ea1-4030-947f-194e881e12ad"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c568bc44-4fd8-4f0a-b9ba-ed941781d0e6"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/782d11f5-04bb-4246-a0a0-37ab3868ef36"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/76ac221e-868f-4b4a-a05c-d368823f9090">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1df1921f-d74f-46bd-8f92-b92dc03e57a1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e8b80d4-d31f-4500-8245-6940237c5a22"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74eefe72-6a94-433b-b126-b0ee77d8ef5e"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6da9f49-24a2-4e24-a643-943c9d6b7e48">
    <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82b51ada-93d4-4170-b565-eed5774bcaae">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2a28aa6-9e09-4a50-9326-f411eb323495"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6e076f84-a783-4d6c-a9a7-fbd0b92b3cde">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e355f511-9673-437c-a9c8-736c64cd13a1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Valproic Acid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cf7f472b-2d35-4c9d-a9d6-ef110b1b2aff">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b97b0ea2-5d04-49a5-b136-6a23789ee699"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8aac2fc8-5098-4420-9867-ce30324c4d68"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7893740a-5de0-4c0e-a067-b547848ed36f">
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24af2586-031a-4983-ae4b-42b19e0019b2"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/899c7fba-76d4-4f7b-98da-b0d9d265fce6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87354b28-b128-43dc-ba36-bbe5406d5294"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00313</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5140a666-6bfc-4968-a450-957ae3cee99a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55305ab7-5d4c-49be-b935-fefd2c045213"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fee95b6-2401-4010-99a9-f72805c050d7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98c72aa5-03ba-48dd-82d6-4b2a2a58b658"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22c1e094-bd86-480e-87de-89d779648606"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b718f72e-c349-4e2e-b4f5-f8966c16c07b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ade5ef1-f816-463e-9fe7-917ac4e47301"/>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/723addaa-d2ba-48c9-a4d2-75158a433dca"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e28e2d26-ec9f-4ffa-b3ca-8bf9956e3af6"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/decdb4d4-48e3-4ed1-a7a8-09be1ed33dce">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c46a1b0-3c26-421f-b07a-4814b196b3f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/190dc10c-3f32-4861-b227-7e98fd7c49ac"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11278a42-67b6-4800-b2fd-7013f03fe4e6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8cee700-93b6-4264-af69-afd6455efda8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ea61f6d-7ec5-4338-a0ae-6465e8946076"/>
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca9d4ffb-7050-48ea-9ae3-2ca4079944f1">
    <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
    <dc:identifier>HP:0010832*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fe61f5c-e7a0-4bbc-a496-817e2f7a7c07">
    <dc:identifier>B01A</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00479d9d-8217-43a4-a6aa-c2263014b341">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea74d3c3-a72c-4e50-8ad3-13c553c1b565">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76a6e7e1-cf2e-4827-9810-a8419155918a"/>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
    <dc:identifier>DB09115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baccc242-f593-4940-91c2-068d8f129c35">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dc88142-eb94-4d80-863e-baefb557b840">
    <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
    <dc:identifier>HP:0010535*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c33e536c-2f82-4a9f-8356-f20e48531446">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
    <rdfs:label>Periodontitis</rdfs:label>
    <dc:identifier>HP:0000704</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0699106f-27b6-46f1-b82b-e51c36aa0b88">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:label>pyruvic acidemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/688d8cc7-e522-4360-af19-464453a39bba">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0322cf68-9e07-4b23-9bf9-5b1f4cbda0c7"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19e4372e-aac6-4560-b8a6-6abaf0bc5ab5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/963a5564-769e-4846-9a92-19d6e0d08f54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e651931-0a41-440b-8d2c-3cce17d2d499">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e90b86f-b5cf-4d3c-bf7e-89bc1ae584f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5058ece2-a7df-48e4-99af-8a4fc311ccfe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <dc:identifier>HP:0000982</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9e04d21-40d2-4ed1-9918-f51640410924">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <dc:identifier>A06AA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/adf41a86-b87a-4bc7-8ef5-af4ef6f4634a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb513799-44a1-434a-9b9e-aa90fec7e33a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c64d1835-849f-42c7-86c1-c53323f54942">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f92ba3ab-8950-400e-87fe-7fd0b6c37b25">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/475ae2d1-b763-4900-9537-460216badcf6"/>
        <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0aae31e1-6055-43e9-a6b2-95746a1c2c89">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/475ae2d1-b763-4900-9537-460216badcf6"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00252</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0845c6a-14fd-46ae-bd21-a4b3f275c96e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002621</dc:identifier>
    <rdfs:label>Arterial pluque</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0ddb8700-34da-4c9b-af46-f50a1b9b011c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87397094-de71-4794-be2d-59c21496a7fe"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/172df0ba-bb6b-49ee-add4-635a7b1c9aec">
    <dc:identifier>CHEBI_84293</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22715c38-26a2-41a4-80f8-b674db7dd60c"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d51f3a90-e41f-4ed3-a21e-ab1c1945f5cc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/06cb552f-f016-4a2d-8fc0-532a894c5ddd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/569646d4-f7bd-4ade-8072-1a1f6f70e424"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16ad073e-2fda-4c94-b471-4e55c6962796">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000722</dc:identifier>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87475880-5599-4592-a0b2-8fcd73bc0e30">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
    <dc:identifier>HP:0000467</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neck muscle weakness</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fafe5faf-aadc-478e-acac-3693a1ada930">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bea8a02a-a01d-48b1-94e1-756f273d180a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a13c36f-3b35-4fda-a7d2-01f18a87f446"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31c08c9c-95ec-4666-bbb8-a85e581fba0a">
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e72e1aaa-d04b-4b87-802e-893a18d25d46">
    <dc:identifier>HP:0004396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>decreased appetite</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5687ec8-a78c-4b82-b840-c17f129e082a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5357028-a45a-47da-b335-0af99729326c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a4c0ddb-dd48-4a4b-b95f-edca24d41a79">
    <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29e555f7-f9bd-4d95-977f-2cdfdfe87a64">
    <dc:identifier>HP:0001347</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyperreflexia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00d155f4-539e-4c58-80aa-dc464d1bae71">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
    <dc:identifier>HP:0005978*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2ef61993-e02f-4653-9f78-54cb7b000550">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee19cbea-843b-4ddc-bff4-d7245cd5c4a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee59b8df-533c-4c8a-adb2-292d91e9fb75"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89616262-d6c0-429b-9c28-8b2ab0f54ab5"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c77c7902-a10b-4e5c-8048-889c41975b16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3544529-db77-4943-9519-f1e026ab7bd7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5f3768f-3383-405b-9cca-7c25d1de3c4c"/>
    <dc:identifier>DB00390</dc:identifier>
    <rdfs:label>Digoxin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e39d78e-1e1d-4de0-8ced-eb222e25d15e">
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
    <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
    <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
    <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43ff2654-6269-4249-b177-ccf2e43c6b99"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/918bc093-96e0-4947-bb45-43d5a2c00ccb">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8d7368a-1db9-4f96-bd56-465c252cc94f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d9106f0-24aa-4b04-a9af-f7c0e7b11633">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30045e72-bc1d-45ec-9fae-eb9d98b373a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5fbe756-9ce3-4d6b-9aca-7969db676053">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee19cbea-843b-4ddc-bff4-d7245cd5c4a3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8defca1-97b3-40f6-91b6-30334ad0fc2b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b37733-1d18-45af-b190-5ca9c7bda55a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12e8ab07-f2cd-4a91-a744-d8f7d2aaaa46">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:label>EEG abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b00d2b02-460c-4c8f-966a-6a6cb95fab35">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bce0a15b-9a5d-4fa2-8d10-fc06e796e7b6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9f3d239-c4fd-4782-9fa5-55602f4df866">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85033449-f91b-4e8e-a0e3-f075c87e0dc5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5624289f-324c-4818-9d6a-6b0d91132a8d"/>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77f124a2-5900-45c0-b911-3eab59610366">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <dc:identifier>HP:0012379</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8d4221a-e075-4199-a327-c704edac6377">
    <rdfs:label>Furosemide</rdfs:label>
    <dc:identifier>DB00695</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb018ced-49c8-4d1f-b61b-dad1cff0588d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b5885dd0-ffce-4474-b82a-09a48795b38d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51b6ee5f-e818-4e66-aac4-b313ffcc4fa2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28509e24-6af4-4008-a983-6ee40cfec27b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/275cc2e8-8777-4488-9374-d27e83c8d25e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66624795-6494-4fb9-9632-a7d2082e4d1a"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/384101a0-cef5-45fa-9be8-6f51a68338f6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6be20e83-b5c5-4695-bd37-09bd6b6f014a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1566938d-474e-4df5-8b12-b9702318486d">
    <rdfs:label>Retinopathy</rdfs:label>
    <dc:identifier>HP:0000488</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/19f66f39-da5a-446a-8968-0add0cceeb31">
    <rdfs:label>Adrabetadex</rdfs:label>
    <dc:identifier>DB15146</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99d7c691-ec13-404f-a39f-d152e63de824"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/311e8cc8-bb7a-47be-ae89-be7b1178c6dd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5220cd6b-ea97-43a8-96c1-f7024853fbea">
    <dc:identifier>HP:0000488</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/821de18b-acd8-4ca3-995e-5d67fc0af5eb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1e2a6f1-4cf4-433b-9354-a78e6b0dcde2"/>
    <rdfs:label>mitochonic acid 5</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0de53106-c585-48a5-b86b-fdf63a5e2a1b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1482cdc-2e6c-446c-8990-0c7548636013"/>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <dc:identifier>CHEBI_15724</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd73c015-71df-4da1-b273-7adaff48231f">
    <dc:identifier>HP:0001266</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
    <rdfs:label>choreoathetosis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a51bfcbd-5f61-42d8-96c4-c8ff74e1ac4d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7600263-f16b-4a1d-a7ca-9a93e10f909c">
        <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d5e034b-b142-46f6-9221-6b4c2adcf1c9"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0010bbf0-3d72-47c1-918a-ae56ccdc75ed">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
    <rdfs:label>Oculogyric crises</rdfs:label>
    <dc:identifier>HP:0010553</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c627c01e-5432-428e-954b-368fad47caf1">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/371eec5f-f954-46a1-8980-e588cbcc537f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59e832be-de8f-4760-a1a5-9a7b13053989"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d582162-9aa6-4369-a68c-7171e0a8f4ee">
    <dc:identifier>DB04540</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <rdfs:label>Cholesterol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e04b098-5d8e-41ba-8d28-a33d1a13ff89"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f297202d-0ec5-44f1-aa46-74ddbe99a123"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9009fb1-b7ce-42fe-9e7a-b327a1e1bebd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/c9ec74a4-2714-450d-a080-4ff321ad881e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/193b3838-ad97-4744-94c1-d4b4dd5bb1f7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7027b79-d5c2-4c90-b09e-fae1b74a5a1b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de443be7-9e5f-40b4-8794-2afed502ba08"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba8ae757-1868-4cd2-83b9-e64238b4a06b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae6c098d-b8df-4ef8-b4a0-118eff2b6793"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/583b20ee-280f-42d3-9bc6-ad1d1923271a"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91e6ff59-2ea3-4194-b1af-c6989f5888b6"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
      </obo:DDIEM_0000006>
    </obo:RO_0000056>
    <dc:identifier>DB00016</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41d7615b-0681-4dc1-b996-7d9f12a2f916"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/601ea546-63e7-4104-baf3-3cb2c2be36b4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7f1bd6e-ee10-4bb5-afc3-174e6f49a4ef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d6f85f2-26d3-48f6-84ec-9717b9a9c0ff"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a686c3eb-8b12-4acb-8dbd-47d528c57f10">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a8abb2e-d68c-4af0-ad21-c1c381483c98"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6ea43567-d53f-4898-ae16-dd1454ef0323">
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c765c0ba-fe2b-46f8-96b4-531b5a3f6557"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/33d81955-3ee4-4a38-8a6b-fe3b733e376d">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5ae76b0-172f-4913-8542-72c176e7c375"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4dd52231-3d44-48d1-96ea-a8cdc47f5d8b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86906bbc-e276-4176-aebc-669ac105ca73"/>
    <rdfs:label>Vitamin D</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/700f288f-4aa2-4df4-8cad-513bac711d7f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70469f3f-88ed-4b85-95ee-975a001d97f2"/>
    <rdfs:label>Lithium citrate</rdfs:label>
    <dc:identifier>DB14507</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8ecf17b-2c2c-4df6-8044-19bdb28c0a37"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6bc55a43-9cc7-48c9-995f-691663acaae9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f52dcbc-5ffd-42cd-a344-b5e552b7b23e"/>
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ad4a2fa-e0cd-485a-bc01-46385da89fa4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c26c0140-1383-4cd3-84e0-3b9e7e165577"/>
    <dc:identifier>DB00404</dc:identifier>
    <rdfs:label>Alprazolam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a58b836-eca7-4667-9f57-88303e42cb6d">
    <dc:identifier>HP:0011123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:label>skin inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a66d31f-8aab-48d3-beb4-70f09e8c6390">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Short Progression-free survival</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f7a4790-9398-43a7-ba48-76874d8acc4f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012211</dc:identifier>
    <rdfs:label>Abnormal renal function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a69da9e-15fd-4095-ab14-042b6b14a311">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>myoclonic seizures</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf0f569b-5d1c-4e4e-92ee-bf6c9380a8ce">
    <rdfs:label>Ad-mG6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47879bf1-7823-448d-a608-35a1c3b185cf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025a56ec-c339-435f-b23d-7f26373e50be">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
    <dc:identifier>HP:0100708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Microgliosis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c79f6e22-1d9b-4f35-b3bf-1c73b0b48fc9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d18c66ce-d6f0-4945-9076-2f540d9dc2e1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ec9fc6c-3319-4997-9f04-cd9f38b25711">
    <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/857e9942-3fc2-4150-bb69-a1cc126c37e3">
    <dc:identifier>DB00151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b0bc5397-9f77-4e98-9be4-b73d009012c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <rdfs:label>L-Cysteine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c39f5613-0eff-484a-9d1b-cf8c16771a26">
    <rdfs:label>Eculizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <dc:identifier>DB01257</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04c52a88-98b4-4375-bc70-8522034e4763">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8d31ebb-6148-40ea-8238-b195c1a48933"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fb0f903-4e22-4ad1-8765-165013ef290c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d34200c7-a964-4197-9af6-54148d6caa20"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01e48f58-d755-4c33-939c-5cec3ef47dc8">
    <dc:identifier>MP:0009587</dc:identifier>
    <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1bdb5f14-c4ce-489a-b65d-c1c787f1a7ec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5b9e591-b9cc-4bc3-8823-976637b98848">
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4154e542-87a1-47de-bf70-917094b8a1e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e4eaa7-624e-4a43-8deb-526cd6dded62"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e70f905-eeca-4795-b4e2-662d770cfc5b">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/242e6f32-769f-4972-ade2-4495a9b63e3e">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bd885f6-d656-48e0-99f7-59725afc3f03"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/246084d4-a2b9-46da-ae64-456f3aaf277c"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4b27663-3aad-4a35-9388-2b6fa6ac9c77"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <dc:identifier>DB00603</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c747c24c-f737-410e-b80d-0aaecfb1b873">
    <rdfs:label>Cerebellar dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60aa5ba1-7a24-414b-b0e7-61c9eb2787e3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a49d913-b628-4648-98f7-9f984c492ccf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fd8b28b-f329-4f8c-93e4-6e0bc4df334c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e609e54-b192-42d2-9d26-5f32f8be2717">
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bde885f-13b1-463e-b6ee-bd12196253c8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63b3f06-fa44-4571-b039-37ab1fbf5dee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b15fd880-b367-4bf7-a1ee-3e948dae0abe">
    <dc:identifier>HP:0002757</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>bone fructure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
    <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4d3de198-7b8a-426b-8948-adeec4e7d4c6"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cda2a1f-1048-42b8-b0d9-72153b612627">
    <dc:identifier>HP:0012379</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/018e063e-df1c-48fa-bd5a-97bef3f78c4d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010978</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:label>Abnormality of immune system physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed0e832e-b6f6-4386-8012-f1706b74b0a0">
    <dc:identifier>DB01045</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <rdfs:label>Rifampicin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36baaadd-7ba8-492b-a4d8-43cbe0f366b1"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e652d9b4-9382-44d0-b9f1-f2915b291470">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd70c903-4ef9-454e-8f80-599e75430610">
        <rdfs:label>Carbenoxolone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19383c2e-e3f4-4a40-887e-4926ead836d2"/>
        <dc:identifier>DB02329</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/384101a0-cef5-45fa-9be8-6f51a68338f6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8d4221a-e075-4199-a327-c704edac6377"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcee1473-a2d5-4905-9631-3dd4ac66251a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioural disturbance</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4653b645-27ac-4bea-ae9e-f690da826a7e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46502557-6191-4110-bac9-1257e6cd477f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum GDF15 level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63d68f5a-3ef7-4a79-a159-030b7bd1fba7">
        <rdfs:label>Elevated serum lactate level</rdfs:label>
        <dc:identifier>HP:0002151</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d66451e-b7ce-47b8-944b-d87246376f9d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b05e926-cc4f-4fd3-b9f3-5f83bd418924">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ceed1675-0bc7-42b5-b40f-0c8c60fd684b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
        <dc:identifier>HP:0200125</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c710008-53cf-426f-9aac-09175ad965f3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e5ab73e-7c5b-4347-86b9-27ca418dce27">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8301e174-ddbc-453e-bcd6-53ca88ef9b00"/>
    <dc:identifier>DB00162</dc:identifier>
    <rdfs:label>Vitamin A</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/97479f69-863b-40a0-9cdc-f49a3cca9d41">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28127ec4-9cf9-4e9a-8625-e665c2e2fc60"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5243f798-c832-4cfe-b16a-21fc3d7095dc"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9141574e-eb27-4876-b3df-dd76997f40c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5220cd6b-ea97-43a8-96c1-f7024853fbea"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50034b94-8e83-4239-bbbf-61a0d75d3c29">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c6cd97d4-b965-456e-abfb-0db2c5433a91">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fbd9e39-6811-4e7a-8a06-9ad7598aed7f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0958ad39-7632-4358-8c1f-1afff336e788"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04d6391e-2a2f-46cb-b2ec-b5ecd527874d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a69da9e-15fd-4095-ab14-042b6b14a311"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <rdfs:label>Perampanel</rdfs:label>
    <dc:identifier>DB08883</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef92dcae-d5b4-4a9e-ba75-2623730349a9">
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <rdfs:label>rhabdomyolysis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/218dce71-277a-49a7-9d2b-893bafdb19a0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76f85a00-9cb1-4310-b29e-79e168c45f0c"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cfeacf4b-8480-4fe9-819f-9430e84fe00a">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50d02435-1b9d-4473-a774-a9de9ad0e16a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cda17d63-dbf7-417e-aef9-e534bdc5220f">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1caf140f-d89e-46b5-a44b-ed22442667f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0aec22b2-c361-40f5-b0a4-d9454a4a65d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8d29b0c-867b-4937-8c0c-aa6907a1af1b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3696676c-7a72-4ba9-9a43-2cb1a6186ee8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <dc:identifier>HP:0004918</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bc59fa0-804d-413b-b8f0-0e83a5c596ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/027b8fd2-beb8-4b01-8c81-b1858b8a8164">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fcd5f76-012a-4036-9676-3dd1026639b4">
        <dc:identifier>HP:0002111</dc:identifier>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b13917a-95cd-4e3d-a06d-a0f45ceae42e">
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e710bbb0-214a-4706-9a4c-2c64e844169a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Six Minute Walk Test</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8dc88142-eb94-4d80-863e-baefb557b840"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75b6e1f0-713d-4fea-a4dc-e9a5b55ca70c">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34ca1d12-904f-49ad-a6df-b14090a36a40"/>
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e822c069-ff10-4744-bba2-644a0ff59359"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736a8ee9-7e37-47c1-8ab2-36f0c2031cc4"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/859fac16-7c88-4bc1-928c-d95c16980c8d">
    <rdfs:label>NO revealed clinical benefit</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/49dae47f-20ce-4b4e-8bdf-4b94940dfff1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c3717bb-fcd7-429c-9ec5-5466af9242d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89562c63-fb78-4ab5-86d8-16abddde86f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab45aa14-ac03-471a-94db-fee5b0e7680c">
        <rdfs:label>Ployuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e52c29f-192c-4bd2-8306-576805350301"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c22a53a1-3b97-471f-8c58-e675c82ff1dc">
        <rdfs:label>High serum osmolality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/45ecd7cf-50bb-4600-a1d0-a0865863e285">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98fbf56d-8584-450c-8a12-3d3145cdf86e"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64d0ebf7-1eae-41c9-9224-ca52ad96896a"/>
        <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
        <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
        <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c16351e2-0cab-4999-96d7-08374f9be09e">
    <dc:identifier>DB00334</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/74c13c99-6890-4166-912b-3602ab811904">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f1d1d3c-b385-467b-90b9-e9405b6ee743"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15622a52-5d64-434f-8bd7-1e7258b0562a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce157b1a-b305-4ee3-8adb-7ebce1da17fd"/>
        <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f764f350-e9ef-48ac-993b-b056fd0b43c9"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Olanzapine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1319629-6263-4e1d-a18c-2a98a4d300c4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcee1473-a2d5-4905-9631-3dd4ac66251a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce157b1a-b305-4ee3-8adb-7ebce1da17fd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28369c96-5fd1-4397-981e-f0aeaab7a883">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d51f3a90-e41f-4ed3-a21e-ab1c1945f5cc"/>
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81bc34db-dacf-4553-a21d-ab23570d80a9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <dc:identifier>DB02701</dc:identifier>
    <rdfs:label>Nicotinamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9275e36-8047-49d5-ac25-996df37d2ddb"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b103210d-d68a-422d-a89f-b5c1116777b5">
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d348d8c0-6423-43d2-b058-35c18aee16a3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ffed74d-1ce2-4563-8260-38e181c65d95"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07b207df-109e-452f-a2f6-8601325a661e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bda5c5d0-da10-4e87-b9b7-c1bb4d71ffb4">
    <rdfs:label>Probucol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <dc:identifier>DB01599</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9ea5c8c5-7759-48b0-a22d-36073dff2b56">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16e53bcd-ea31-4377-b274-0257766a5d44"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04164702-8c2d-4337-9cd4-d234f7789f28"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d48af569-2edb-4fca-8480-376509d52142">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8a7748e-8121-4c46-92a3-ab6e59ff20be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/674b7f95-99af-428b-90e0-3e5df2d01f2e">
        <rdfs:label>Decreased serum IGF‐1</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
        <dc:identifier>HP:0030353</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
    <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
    <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/22d8068a-e6c3-4243-8c75-86d3ef5e8d0c"/>
    <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
    <rdfs:label>CYSTATHIONINURIA</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2bbf733b-055a-4ec2-8509-93bff0c07d7c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d8ee2d5-67a5-42a8-b716-9cfb98b6ac8b">
        <rdfs:label>Personality disorder</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
        <dc:identifier>HP:0012075</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86ef87af-042b-4b9c-8811-74fa513b7b81"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faf83ed2-84a4-4195-8359-b41e772fe9c2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f764f350-e9ef-48ac-993b-b056fd0b43c9">
    <rdfs:label>Psychosis</rdfs:label>
    <dc:identifier>HP:0000709</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2283094f-3a30-4077-b85d-a955880d0443">
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
    <dc:identifier>S01BC</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55cc91e6-3993-48c9-9a02-9e52f629146d"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e97a1548-8d6f-410b-b746-304e1979f7cb">
    <dc:identifier>HP:0000093</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
    <rdfs:label>Proteinuria</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6390ead-1c9f-4c08-8dad-229ec3c7f32a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <rdfs:label>Sodium acetate</rdfs:label>
    <dc:identifier>DB09395</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0df9414-2317-4f74-aaab-3b0ffcae07fc"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e12c6e81-2af0-4f92-bc24-fcfee8d707e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/974442f0-ed7c-4856-9427-bbc20b35da31">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Trial is no longer available</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/558e3976-d0cd-4483-9d10-c049e4c2ff3c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8bd5da9-1d51-4a64-be6a-256fe43da655">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ff17079-185b-409c-9d48-d501ccfaaf53"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d97b0f6-1ae2-4dfc-9331-7d93f4f2c076"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3786c5ef-92ca-4618-b52d-acffa5052552">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff5020d4-a449-41a6-980f-0ceaa424fb30"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2047f6d-2acb-412c-b856-cbfaa1f9590d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
        <dc:identifier>EC:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f97ccf4c-15d9-468d-88a2-c6b48704febe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a52d269d-d909-4b6a-a643-b53dfccde477">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84235ce3-7c70-4797-b1a9-6ab1a141c873"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
        <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdffb6b1-f2f1-4c4b-90f4-a2991044d2bb"/>
        <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/243e811e-b84f-4f6b-958d-4c1fa1868418"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20390f72-9a9f-4b35-a438-101eaedb621a">
    <rdfs:label>low bone mineral density</rdfs:label>
    <dc:identifier>HP:0004349</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59fc7415-f0ed-4164-a38c-e4ddf9b9e9df">
    <rdfs:label>HDAd-G6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78f8b1fd-d541-43f8-bc37-f69ff31aab77"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b206c6c-758c-4348-b0c5-4fbbdab44846">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma MCP-1</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/744ee568-0446-403e-9d3f-2e9e14c7cb20">
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cataract</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67127965-ff97-4ea7-88fa-40e0c5a80de3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal exercise physiology</rdfs:label>
    <dc:identifier>HP:0009020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c65cca97-7314-4f97-abab-bf313bf4c0d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253601"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16c28e8d-2221-4d9a-957a-928cb1953164">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b4d5f9b-e8bf-47fe-8708-56df8407c466"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34802085-d5ba-404c-9565-abbc42601092"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a606cdab-9dcf-400e-88dd-9bd439af56fe">
    <dc:identifier>DB00111</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/81c5c4a4-b9d8-4bb1-b992-7ba582f6bf5c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe07897f-c8b3-4b0e-8fc8-698ed6920894"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53760ab8-df40-4377-86c9-c91cf0d3a46a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1629d304-1b56-45b5-be15-4cc824510a55"/>
    <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10a8796b-950a-409d-982c-41c9ad266b74">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d584f5b7-4a99-4f7c-9c86-35ab7aa1344c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c381a9d2-bb36-453d-b171-c5b37a4ce847">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:label>Lack of energy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90785db8-f6b2-4614-9890-61ffbeb5b5d4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98923d44-c770-404e-b3be-8da2e6d4bcce"/>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0655ba29-a6c3-4fe8-8de3-68971789a1c0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>abnormal muscle strenght</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aba5de9c-72cc-443d-9bdf-969e1f0f4106">
    <dc:identifier>DB04729</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00d53e78-0440-4efc-a9e3-fd5362fbe1cd"/>
    <rdfs:label>Gentamicin C1a</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d5f06a3-e6e0-44a6-be6a-308decef8677">
    <rdfs:label>Duloxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <dc:identifier>DB00476</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebdf8fe5-183a-4ae2-8b46-9b4edc45c6e9"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f9e16cf-d321-44a2-9568-4a7e03f5cf80">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dbe7008-9e87-4d47-8c10-d2dc31d49fa1">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39041eff-4b9c-4a22-9c91-7723e66447d5"/>
        <rdfs:label>GNeo-IDUA</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/39041eff-4b9c-4a22-9c91-7723e66447d5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7074945b-e346-45bd-ab21-779e4ea290f8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <dc:identifier>HP:0004371</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f9e16cf-d321-44a2-9568-4a7e03f5cf80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0d1ef6f-d86d-4a5d-a0b9-f2dbbcb03100">
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9388934-80ad-4fd4-8987-ff8614b65c06">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1faf861c-668d-4fc1-a4ba-2712e2e80139">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb2b1342-8383-4df0-ab2f-e25ed93f819b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7829c5dc-169a-452b-80f5-4d26f8667b64"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c1b8cbf0-f95b-42a2-a240-63dc969ba7d8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e5c6bdd-e70a-4466-bb1f-154707628115"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa047d84-db64-4130-ae59-889231f1e8f8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0214052-0a29-4053-8314-a2bf85d2ad1a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2041231-e33a-4c84-8a6e-a6b625f87719"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dab8b437-5ba6-4dbd-84c3-c508d8ba1c83"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a629183-aa7e-410e-a542-52fe16603e22"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6daf453f-d22b-4c78-8bbe-f2cbce38a584"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aff149d3-95eb-4229-b94b-6b22208c2bc8">
    <rdfs:label>Baclofen</rdfs:label>
    <dc:identifier>DB00181</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50ba7933-5cb1-4e38-ba5b-26fcf247b0de"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b899ad0-9647-4822-bed0-2ce9a7e10d87"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75bce3df-0795-4f9f-8cf0-43f0b9a90efd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d967642-5a40-4682-b268-77edeebc162b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8745e25-c80c-4781-8c02-7e36b3392e07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a54a6e9e-da81-4aa8-a38c-39688f63eb91"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5cebb6-f588-4920-9cd5-3ecb0730b8e6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0010bbf0-3d72-47c1-918a-ae56ccdc75ed"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd73c015-71df-4da1-b273-7adaff48231f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/804c40fe-04b2-4daa-ab65-20f70f6720f0">
        <rdfs:label>axial hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c738790-0c65-463e-b79e-909389f3a7f5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c37e24a-bce8-4bf6-b46e-c4f77a5ef938"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e10ef396-6951-4266-9e18-d9c79c1866be"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/843def3a-4e5c-446f-8dc0-de8b86493aaf">
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bd7f949-f738-4430-b36f-7f71543b522e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1905a824-3c40-4d05-9941-00f0c20d7a14"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caefa4fb-6b0f-4d8b-a7e3-12d246e3b5b0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:label>somnolence</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9a0bded-f529-4aa1-b1cd-260f84175d3d">
    <rdfs:label>Pamidronic acid</rdfs:label>
    <dc:identifier>DB00282</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86dfc98a-5267-4682-9838-1128bc82b68d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d95df9b-1c7f-41c0-bfa5-4554926ae944">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100660*</dc:identifier>
    <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8b2608b-e3a9-44e5-ad6e-46ad24788c9d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43595f25-4b54-43a1-8f00-ee59ae8a2ea9"/>
    <rdfs:label>Polythiazide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1016df30-95a6-40b7-b452-eaa42d740622"/>
    <dc:identifier>DB01324</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bae2e13b-d0bb-4fc2-bebd-cabe44306418">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76ac221e-868f-4b4a-a05c-d368823f9090"/>
    <rdfs:label>Iron</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <dc:identifier>DB01592</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9549949f-5336-4b26-9b4f-d28b26c536ac"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f37691f6-e403-4ba0-8927-c78aa23ab6db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34e0a3e6-3403-455d-935e-b60342e9b51e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e699c50d-f96d-4d03-8307-6b7e4dafdfc0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad800484-5bb5-4d84-a65f-281ac02d2b21">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4660682c-b70d-419e-bbcb-3097981c24f2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/232d697b-83c3-4a20-878f-9f9c1b111aa2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2347f544-18b2-4e50-b8e0-d6b4f8516c0e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe0e1ca1-7308-42e7-89d8-40ba7496c9b3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9da866e-adcd-4164-8d0e-a8d509a00ce7">
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbb1cfb4-db89-4e2d-b7d2-1a7c3f936ce0">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100725</dc:identifier>
    <rdfs:label>skin thickening</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f506d0ec-c423-4be4-9cee-68a2f0e57d2a">
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b4c5a25-ab8d-46da-bd4a-442f5e867a1c">
        <rdfs:label>cardiomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b612921-d7b7-4b02-b26d-b3e377b19584"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38325361-b1c1-4dac-9134-2fb4ab6cbbae">
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba3566e3-f210-48e1-ba46-4a812a976365"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64f4f5dc-8357-4eda-a185-60bf00adea89">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/150a5eda-6160-436e-a20c-e5e1d4a2b3b0"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe5735fa-2731-4a1e-9f59-f005e8006425">
    <dc:identifier>DB01151</dc:identifier>
    <rdfs:label>Desipramine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34fcd9ed-2ed2-4a4d-a118-922894ffd112"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45ecd7cf-50bb-4600-a1d0-a0865863e285"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57d42981-1750-42f4-9eb4-730dd6845ebe">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/551d7141-efb8-4d8c-a82c-0314454988f1"/>
    <dc:identifier>DB00098</dc:identifier>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38f708bc-b753-4b72-bc82-28a4ae3eaf47">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <dc:identifier>HP:0008282*</dc:identifier>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5cdbcad1-c48d-4a2b-923d-1f23a0b7a3ef">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/498b4777-84f3-401d-9e5c-05fdbeeeff8f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84f9f52c-94c8-4b84-b5d7-a9a8d99973be"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Levetiracetam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ed6c8b2-3485-47d5-8cf3-2a078707bc57"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4af927fd-5787-4792-8228-485b8541a049">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/700e9194-d5ad-4bd5-a2f5-206e783f3097"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98fcc16f-0aa5-40cf-8f26-40c4fe4acb08"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35a5329f-cf2f-4cdd-9916-027fcaac23c2"/>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ad4dad42-d27c-4702-9ce5-b0771502ac5c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f377ef-c9bd-432c-b321-c2943da95a96"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b00facf8-3a7e-42ca-9267-a79efcde8335"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3fc14c7-7bdf-4832-82d1-b07469250722">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed30845b-4c2f-4c66-a4c7-8173616ae0e8">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54eb5eb8-940a-46fd-828e-72dc18b2eb8b"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
    <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
    <rdfs:label>KANZAKI DISEASE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e356bb6d-7dce-411f-b3ff-2abb42f891c9"/>
    <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28df7831-08d7-4a46-aa43-92afa7c854be">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0769c0aa-ae26-4fd5-a8a5-08bb2147c3d9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2448de5-07ce-4518-9a80-99d83bd63693">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum bilirubin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef90c2ee-1fd7-4bcf-b2ef-a931e55c2e1f">
    <rdfs:label>overall survival( premature death)</rdfs:label>
    <dc:identifier>MP:    ....</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
    <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e503e930-21cd-4d71-89be-bb55194d5966">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6dc6b0e-c76e-43ca-b5bc-4aa9bb87eb6d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/522961ce-8c33-405a-89d5-f5ad9c0af8ce"/>
    <rdfs:label>Niacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb29a242-25de-4da4-a603-799e65c27669"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2986d0c1-7158-4cd0-ba58-382288cb357e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41e63552-629f-48a4-b94d-f0ee178d0bbc"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ca81f80-aa87-4c7d-adf8-093b26ae63f8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e50d076a-b8e3-4b99-8bc4-eaa2574cf091"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c72ba20-62f2-4787-a99e-441c1b16ca21"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4154e542-87a1-47de-bf70-917094b8a1e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bde885f-13b1-463e-b6ee-bd12196253c8"/>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bdb5f14-c4ce-489a-b65d-c1c787f1a7ec"/>
    <dc:identifier>DB00627</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df4e4e8a-0f70-4658-a026-74bf6175c5e4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2d898b2-510e-4759-95ef-190c964779d1">
        <dc:identifier>HP:0002155*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>high fasting triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48d2c302-9130-4737-b776-05da02fd3533">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f909cdec-1271-4eaf-b8cb-62836c11f98d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2e8fd848-fb26-4160-871c-e1bde6dc7be6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05759883-3817-4cec-ad45-935ea5a99bcc"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0dddb17-3214-4a73-b7bc-10f3d47d6746">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c33e454a-5b19-4db3-a054-77dce1b33e2c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e39e4f1-cc58-4695-939f-76ac39af4181"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/342f4f63-16a8-40f1-93ca-fdb9714f44ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/655d5dcc-3418-4a25-b29a-d023d4888c61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85033449-f91b-4e8e-a0e3-f075c87e0dc5">
    <dc:identifier>DB12839</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <rdfs:label>Pegvaliase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b00d2b02-460c-4c8f-966a-6a6cb95fab35"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/96a6c741-c30a-44a2-ba37-4560bd8a45b6">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/403e576e-85f3-4f41-b80a-6e67ca226fdc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/602799a5-d854-413a-95e5-4ff59b5eb7be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3449e558-8d1d-4142-9e9a-c598f56fc2ff"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/840f35ae-4fa8-4ebf-823b-e8ccef8df66c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c616c53-e75a-4081-b77b-c608863dcbe6">
        <rdfs:label>Ramipril</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50baf010-4fd6-4e5a-9a51-834c78165ca7"/>
        <dc:identifier>DB00178</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74768b4f-86c5-4c51-b5c6-1b7adbd1fe4f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57a9ae98-3f11-4efb-a36c-151e84abb66a">
    <rdfs:label>Low level of serum B12</rdfs:label>
    <dc:identifier>HP:0040126</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c682d367-b5fb-467c-971c-3717ee13aed9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c33e536c-2f82-4a9f-8356-f20e48531446"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/df271d5c-5c38-4c25-b5b4-8f2024d98b51"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f659889a-e1ef-4477-977f-02c787a8da38">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
    <dc:identifier>HP:0000504</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal central vision</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f3834ce-e9dd-4e6a-86d7-3b2b97404bbc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <dc:identifier>DB04272</dc:identifier>
    <rdfs:label>Citric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51c6069b-e368-4937-9392-eda606063d3c"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dba6a1d7-d826-4ae8-a6eb-00175a7e3ce6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9c4c41-84af-4e99-858e-673ed0d5367d"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3c27a28-a985-4705-ba92-746bf4b1ba41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1226fd9-ed1e-4453-8d68-e9b2d05c3247"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d78e242-014a-428d-8733-2592bded9c3d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45d57aa4-3449-4f87-91b0-84d4c10dea23"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c3e9ce9-f917-45f3-91f8-534bbd8869ad">
    <dc:identifier>HP:0000737</dc:identifier>
    <rdfs:label>Irritability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
    <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2e9d2356-0227-4546-aad5-2a69591fc59e"/>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e22d8a3f-6098-4371-b83d-0edb8ff018db">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/393ee0f8-2ff5-4433-bf6c-01ebaee78c84"/>
    <dc:identifier>DB00688</dc:identifier>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2678ee31-f6a6-42ca-8bb8-93acb11a8b1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/784a6705-a71a-428d-b18a-7ca29c2fc382"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7e68185-3123-494e-b2e8-e148213446f8">
    <rdfs:label>Sodium citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8460871-9187-42f6-a2f7-ae3fe9519a26"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de2a9132-059b-44f3-b6b3-33abe9ef6d0b"/>
    <dc:identifier>DB09154</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ab26e8d-9550-4b0f-b88c-f28a4c1585a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a629150b-e932-4a91-856c-8b68ca9c626e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d66451e-b7ce-47b8-944b-d87246376f9d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5243f798-c832-4cfe-b16a-21fc3d7095dc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b95b9cc-a8c0-4ca8-9ba6-236fa5f8d33e">
    <dc:identifier>DB13245</dc:identifier>
    <rdfs:label>Thiram</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22715c38-26a2-41a4-80f8-b674db7dd60c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67e4beb6-650b-4a20-8897-1d58b0901d98">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbf3224c-7482-4838-9c33-27701afaaa97"/>
    <rdfs:label>Somatotropin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4746e71d-00a1-4c2e-9d08-0fabff487304">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe7a48d4-5e3c-49a1-8742-6654d066d982"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fc08574-28b2-4f88-b7bd-13050d0fcdf9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6f4fb312-b8a5-4857-b68c-77d59e414f41">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3cc7e8db-211b-4f20-977b-09129199eb06"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f3403f4-a8b3-4b24-88c3-ff4057e836c3"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8da3c6f3-7238-4191-8ab6-19c9231f716b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d48af569-2edb-4fca-8480-376509d52142"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/592cc64f-e9fd-47bf-affb-120fabb4916a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c689117-9e7b-4369-b9b4-10518fbd5bef">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased serum iron</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21857920-b930-4125-bbda-fb43918b9295">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd8f004f-e34f-48cc-ba32-2af341f4d898"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/458f4f34-dcdd-4dc4-8dbc-82ad6e4f9b77"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/853619f7-e739-41c5-b944-9293130db26a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
        <dc:identifier>HP:0012463</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7be09c8-419a-410a-b24e-10ed93bd117b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68576a69-b17d-4eaa-bb5d-c237d7f444ca">
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0627fab-8270-4a7f-8fd7-b3afbfeb9018">
        <rdfs:label>Increased liver iron level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <dc:identifier>HP:0012465</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d93f221-4f83-4c85-9649-d1780276e614">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c91936cb-6e78-426c-815c-67d8df5e0c01"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2be71b58-7ba8-4361-a141-64d3dff575ef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51b92d38-ce87-4cb7-b4e1-4d693cade896"/>
    <rdfs:label>Cobalamin</rdfs:label>
    <dc:identifier>DB14098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b89a2a2-2c61-43dd-b7e2-e2683284ba77">
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/862a50c4-1f8c-48be-94bc-4eb3b4a9dd80">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2448de5-07ce-4518-9a80-99d83bd63693"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe083267-dc56-4b24-9438-4622e6bc35b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f4cf13c-5bc8-4ebd-8d58-89a0002be95e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fb0f903-4e22-4ad1-8765-165013ef290c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004818</dc:identifier>
    <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93bff3f1-6dc7-4520-8915-4819700ae9e1">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/08f56f7e-97a4-4fe8-a36a-2f7e49a66154">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c748b55a-b576-4b8b-816e-d4d7d326ed9f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f97ccf4c-15d9-468d-88a2-c6b48704febe"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7737c8d4-951e-45e9-b775-235d2ce2f6ff">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17072a71-844c-4ac2-bb07-c78de613a7fa"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f97ccf4c-15d9-468d-88a2-c6b48704febe"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7137f847-2faf-4691-82d4-782818b09f92"/>
    <rdfs:label>Acetazolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3786c5ef-92ca-4618-b52d-acffa5052552"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/211ef46b-a11f-41fa-9e27-c107b740a65e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f81d4e1-c8b7-443a-8f83-42b76b2fb97d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>Increased total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11e3aa45-adea-4a62-886e-fd0726195684">
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased LDL cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02bd939f-23ca-4390-a4a4-90def6108eb9">
        <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2292700-d462-46b5-b4b0-3f0a34a15bd8"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8fb41d7-7f47-4380-98be-a373b231907e">
    <rdfs:label>Acute attack</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
    <dc:identifier>HP:0011009</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64ce6daf-076e-4eb3-b9c0-6e92c1e2437c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>defective heart function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/a4ae54e4-97f2-41a7-a101-d14063b21415">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80dd499e-cce1-4088-936f-8e2e290376fd"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3289ab5-2322-4eb3-9935-b859f96a9918"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3f2e98a9-4115-4da5-845c-ab1f46794ddf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4adecc8e-47ba-466c-b506-cfc21d6ab2be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34cb0658-7842-46d6-904c-a049d60b1aef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e5bfa41-db8c-4d46-a193-04401c63abdc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0958ad39-7632-4358-8c1f-1afff336e788">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:label>Diminished intellectual abilities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6b3b8b9f-0565-4494-9c0f-c84fcda93f41">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a8442aa-996d-4a52-a121-2143743ecfc9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b979e1d5-d7e5-4809-8a5d-6e5fd4177901"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/df628e91-499b-42c9-a887-50ffb742b4f0">
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e7275fd-f5e4-4753-85bb-27ebd2de887b">
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001976</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d77b144-3188-4e66-9fe2-824a79c51c1e">
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>Abnormal aPTT level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86a96844-0398-47da-8f0f-3af5f41b8841">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ea591d4-308a-4639-9c59-ce4cd8a6f06f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aa80b3f-420a-4d4c-9f11-a608676a24dc">
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56b95bec-8748-474f-a096-f18516e6d61c">
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003645</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64069ebc-2dfc-4d8f-88d4-69b571a3b160">
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ec9fc6c-3319-4997-9f04-cd9f38b25711"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0d15e78-14b4-42cc-869a-4d07883c1b35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9003c4db-96c6-457f-aafc-e10ab7c33d90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/988a38b8-0894-4ce5-9d22-2b15126f1f49">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12696d71-aaf6-4db5-a6bd-f713c1c6ae61"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44e51447-c581-4d65-a77c-693906396d30">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2223d4f8-fe87-483b-bd1b-417387cbb21c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/914c6dae-1109-487a-a089-b35007640bc0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9fe6db6-6825-41c1-a201-77cb93661c3c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9fa84aa8-753d-4cd9-956d-555c4ca486b9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Lovastatin</rdfs:label>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/211ef46b-a11f-41fa-9e27-c107b740a65e"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ee9680b8-6a95-4607-91f3-fa7d2e10c42c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9003c4db-96c6-457f-aafc-e10ab7c33d90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6574160a-e4cf-42d4-ac3e-f9cc60016fe7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a5ec850-f1ea-450f-a78d-15de4d569c3d">
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f79317d0-f627-495c-b85b-7bb632c8120c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16fb2868-679c-4e02-b674-9e2f561ff9dd"/>
    <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
    <dc:identifier>C09</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67aac8d2-0ec2-4384-87f6-88d4c1f19446">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b61bcbd7-edc0-428a-980e-b941d12374be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf3998bd-d6d8-421e-b760-5bb0807a8e2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e14f7bb2-00b0-414f-a399-b6a9f5f2088f">
    <rdfs:label>rhPBGD</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/638cc0f5-8240-4aca-9ce6-69bc683df3ed">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab608e83-b9ce-4dc2-b3bb-52d3067e2479"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74ffba14-fced-4927-b712-3f73b4938d9a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/064322ac-3bde-4daa-92ec-3c6da399989b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0aec22b2-c361-40f5-b0a4-d9454a4a65d8">
    <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfeacf4b-8480-4fe9-819f-9430e84fe00a"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/163b2bb0-4cf0-43b0-8f41-11c77b623fe2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/064322ac-3bde-4daa-92ec-3c6da399989b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2f06577-dbb9-40d9-a7f2-bd0a14e99e89">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f90119c5-f824-46b4-8685-dd8679c4db03"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f85228b-698a-4109-8737-b8ca96a2b2bc">
    <dc:identifier>DB06742</dc:identifier>
    <rdfs:label>Ambroxol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a2d63ed-571c-4a5c-954b-02f899471e90"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0d663fd-7964-44e7-ba5c-d3efe3cb8452">
    <dc:identifier>HP:0040006</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:label>mortality</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/81f2bbf4-de01-4e37-bfaa-7b4f37d60711">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25778f7f-a18c-4d6d-a893-23590161e323">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
        <dc:identifier>HP:0001977</dc:identifier>
        <rdfs:label>Thrombosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfb2ecd1-6739-4489-934b-3e345fe3d5cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5d7a6786-5b2e-42a2-b295-003973b680ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c46a1b0-3c26-421f-b07a-4814b196b3f2">
    <rdfs:label>Low weight,growth</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <dc:identifier>HP:0004325</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf7cc404-6b04-4d1c-87c4-c8f6c001e57f">
    <dc:identifier>DB06756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97aaafa0-bfa1-40b0-b15f-3b4e19c21f9a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d176a64-7b49-470f-ac72-86ab844dde00"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <rdfs:label>Glycine betaine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a44bbd38-7618-4b45-8451-972e3fa4ebe0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05759883-3817-4cec-ad45-935ea5a99bcc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c477e51d-bc95-4943-a574-95daa65349f3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32252bf9-2b14-4894-9e0b-e8a89dbcf5cd">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
        <dc:identifier>DB01219</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0cbaf3b-0c2c-424b-8e59-cbb3abc0a819"/>
        <rdfs:label>Dantrolene</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2c9e676-448f-4769-acaf-a1c52fe76c96">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
        <rdfs:label>Tizanidine</rdfs:label>
        <dc:identifier>DB00697</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0cbaf3b-0c2c-424b-8e59-cbb3abc0a819"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8764044-628c-4f85-b25e-a0da059b6891">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0cbaf3b-0c2c-424b-8e59-cbb3abc0a819"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
        <rdfs:label>Benzodiazepine</rdfs:label>
        <dc:identifier>DB12537</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef5b7af6-dbb6-48d9-b447-28c11db9e59d"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47562037-5abc-4c1d-86f3-0cf051134137">
        <rdfs:label>Amphetamine</rdfs:label>
        <dc:identifier>DB00182</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0cbaf3b-0c2c-424b-8e59-cbb3abc0a819"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4c54780-24d9-48ea-b8c5-928328452e0f">
    <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012217</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5991bdf0-9288-4319-9e6f-d45f5869824e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/312119eb-0e6f-47af-a290-bdc63556f853"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b206c6c-758c-4348-b0c5-4fbbdab44846"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9bcca5c-a893-4aa0-94ec-4c8b6b8d7831"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d044e39-3fee-45ac-8250-9a8349c88bda"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01e48f58-d755-4c33-939c-5cec3ef47dc8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39aef831-4cf9-4e3a-b373-b4ebf4e0415b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd111af2-507c-41cb-9978-29bdf1abba01">
        <rdfs:label>Joint inflammation</rdfs:label>
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4824afd6-fb1b-44a4-a428-16a6a0cfc386">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0152f1f9-45e9-4e5d-9087-2539d757f9a7">
        <dc:identifier>MP:0020582</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:label>High cermaide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6cf968b-cbd5-425e-ad0a-e2b93cf0c8d0">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <dc:identifier>MP:0020582*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/511ce23b-c99d-47a0-91f0-2bf3a07f6792">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9af44a84-3f5f-4e59-b14a-7a6d8d85b78c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e2712cd-4e7a-40a3-95b7-45e14227604b">
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3ea497c-467e-476e-924c-5cbb8173761f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c0308ab-1d15-4b5f-8f2e-153ed40dad72">
    <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
    <dc:identifier>HP:0012378*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/228169f8-901a-4b93-8511-23ee6ac84ba5">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc964cc3-2ee6-4e40-be4a-a0ad5a3980e0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9e98f39-8898-436b-a22a-5b38a6ed6dea"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd000b2b-ea4c-4609-86af-445963eedd4b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82c97047-c36a-4851-a8ae-1b5bfe52a662">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05a9dc92-ff47-4030-9e92-7bf4a7c2975a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34cb0658-7842-46d6-904c-a049d60b1aef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f2e98a9-4115-4da5-845c-ab1f46794ddf"/>
    <dc:identifier>DB11098</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/869f43d4-c6ac-445d-b3d7-95693053e738">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d95df9b-1c7f-41c0-bfa5-4554926ae944"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1f52345-e8ed-4317-b23b-87065efe5b92"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b79237ef-a7cd-49bc-bd71-0efa8393a61f">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f13e7e1-3e94-4474-92a2-3ffaa68a359e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
    <dc:identifier>ECO:00055442</dc:identifier>
  </ddiem:Evidence>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5da8ede-79fe-47ec-822e-f8974e5ac131">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <rdfs:label>Calcitriol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc1fa6a5-b2c0-4305-bcd7-00e167f039cf"/>
    <dc:identifier>DB00136</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee59b8df-533c-4c8a-adb2-292d91e9fb75">
    <rdfs:label>Naproxen</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c757fd22-3b58-4a34-b778-be359bd74f1c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee19cbea-843b-4ddc-bff4-d7245cd5c4a3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bea8a02a-a01d-48b1-94e1-756f273d180a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00788</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5fbe756-9ce3-4d6b-9aca-7969db676053"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ef61993-e02f-4653-9f78-54cb7b000550"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9faf39b-9efe-493b-845a-239a4d200d5a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
    <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
    <dc:identifier>HP:0003495</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dbd2acad-1eca-4bf6-b73e-caf1608c628a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff4fcca9-362f-4a9c-a208-81837708930d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f8675cb-addb-4ff3-8ff9-d2ac1b215e85">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>affected functional activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931629af-ce09-49c9-8f83-bb51b6a559af"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2338fe73-7800-4811-a75a-3add185a5257">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f693f0de-3b54-4b36-8bac-d688326f8860">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc7ef9f1-8a16-406c-b256-be3e7cccd8ff"/>
        <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
        <dc:identifier>D07A</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d74b079f-002c-4635-bfa0-d44a85dd897c">
    <rdfs:label>Brain demylination</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
    <dc:identifier>HP:0007266</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b893c863-26c0-4a40-987a-be38284827d3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd4c3b99-389c-4158-9230-75d8157d9bdd"/>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bc7ef9f1-8a16-406c-b256-be3e7cccd8ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3da3f122-2968-4677-9a4b-05e9bd728d13"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2338fe73-7800-4811-a75a-3add185a5257"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5645180f-653d-400d-af92-85c18e7d844f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Delayed development</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001263</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8499920f-7d12-4db5-afd5-79baab768e87">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37a429dd-d708-4ae0-b6d6-24d50943cbdb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f942a6f3-a81a-4e3f-89e7-d7903d61ccd2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a66d31f-8aab-48d3-beb4-70f09e8c6390"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3865a867-12d8-4254-b46a-880035b7f518">
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
        <rdfs:label>Low tumor response rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef90c2ee-1fd7-4bcf-b2ef-a931e55c2e1f"/>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99641708-f8ad-4ff5-ac2f-8382299c8cb7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d95bf5e0-a5c8-4106-8ddc-0bdd79946ba2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <dc:identifier>DB11859</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4deab3a0-f341-4c5b-86c9-30da074395cb">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9faf39b-9efe-493b-845a-239a4d200d5a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b948154e-a0bb-4641-8473-12db3301b986"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3119e9e8-bf4a-43ed-ad33-36ba31734664"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16d496f4-8d87-45bc-a435-adcd38432b3b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/750f1bee-ced8-4a05-b6b0-2f24d8fa6feb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Brexanolone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b269948f-3a90-443e-9681-10495fd6a44b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/239dd8e7-6b22-425d-a2aa-787357fb7505"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/750f1bee-ced8-4a05-b6b0-2f24d8fa6feb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
        <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66f7361e-41a6-4567-b7e8-a70024631b95"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ac09569-99a1-4742-b2fb-4744a7d5d446">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d54f49d-ffa3-4148-b8d8-8aafa691f64a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53760ab8-df40-4377-86c9-c91cf0d3a46a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7a851e76-3771-497c-a78f-b20fa9b0e717">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe74586e-a6c0-417e-9fac-24a6d85e642c"/>
    <dc:identifier>DB00869</dc:identifier>
    <rdfs:label>Dorzolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/599cb057-4848-4372-b554-5c4d0513a1c5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/652ca187-552c-4218-9aab-8042aea84e0c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55ea98da-e3a6-4def-8289-228a592a103a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3d2871c3-8895-4f07-9402-d51fb3f5e35f"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
    <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c29c9433-6e99-4e48-8be5-a1e561d4b05e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5e6b8de-c82f-4502-979a-85f0032e2393"/>
    <rdfs:label>Vigabatrin</rdfs:label>
    <dc:identifier>DB01080</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e56e4cc2-ef11-42fa-a448-b34e546f1a3a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a72a8b47-b132-4477-b974-03b048f452f4">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a4c0ddb-dd48-4a4b-b95f-edca24d41a79"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a9e9e6a-3843-4119-a027-7e54720bb9d1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44852d88-281e-42f3-8c9b-b7163122dddc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07ac1a85-980a-4874-b757-be58a4417ca3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/296a4752-9160-4ecb-bd01-a601941bab40"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e05ad91d-c002-447f-b687-75e1b83f8d48">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91159b3b-9a95-46b9-a540-c3daa09bd5d9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a9e9e6a-3843-4119-a027-7e54720bb9d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c450a7ff-5a58-4ba2-a015-c343267071a3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54fa7013-283c-4f05-90dc-f483db688d7e"/>
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4365f6c2-3666-4ecd-a3e8-1c50ec8999e7"/>
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9c1f655-6295-48ad-bcfd-a3fec5760e1e"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cce3d023-cb0c-4801-82b4-ec5f899111c9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8d16ddc-809f-4964-b849-422a77362ea8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbd8ec16-8784-484a-929d-cafc8a57295c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/726aaccd-5a57-4f57-a9af-a410de20a3f0">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <dc:identifier>L04</dc:identifier>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/105cef1a-daa6-4acc-ae13-c1e3f682d35f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ec843c6-5418-48aa-92de-e070f877b656">
    <dc:identifier>HP:0002719</dc:identifier>
    <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adfcc505-d91f-4ca2-b9fc-1420bf4950aa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <rdfs:label>L-Leucine</rdfs:label>
    <dc:identifier>DB00149</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/512fc02a-1536-487b-b18d-fd5be4dbd624"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05a9dc92-ff47-4030-9e92-7bf4a7c2975a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/228169f8-901a-4b93-8511-23ee6ac84ba5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
    <rdfs:label>Icosapent</rdfs:label>
    <dc:identifier>DB00159</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e69c273-3962-4153-b049-31e00fbfe5ab">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002093</dc:identifier>
    <rdfs:label>respiratory insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9ce227d-2106-4058-9b3b-4b10f5a5f92e">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f8029c04-9bca-462f-9110-bb89a9f8eeb9">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52e0bbb7-b3a1-48d7-b070-5341a77c1670"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6b54b11-03b2-4a8c-a33d-7450df0fcd38"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/43843d11-19d0-44e4-a032-e9513452aca2">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b64f5619-da8d-42e7-934e-9629123a33ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/653aaa9e-306e-4343-99a6-77f0b6d7e4d0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22242320-f357-4a99-9c39-4b78bbfa8c4c">
    <rdfs:label>growth faliure</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8050612f-4c7d-4083-9f11-76143f170882">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1e7e60a-b547-4c05-b03e-cbac0969e04c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b7c42de-0eb9-47f1-ba0d-87ea7248d43d"/>
        <dc:identifier>DB00232</dc:identifier>
        <rdfs:label>Methyclothiazide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac2dde9d-1706-4ce0-838c-b13dfcdb9f81">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
    <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0017be7-5db3-404d-a3f0-bc4ebfc7282b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52f6dc7c-2f84-4f6f-b20d-1e5db3338c81">
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <dc:identifier>M01AX</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d801b913-700a-4b9e-b8c1-37f5ca3b1d6a"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b02eda78-9955-4feb-9fab-847ae4f4903e">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e37c8e3-69cc-4254-8f65-193628a5df11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f74510b-5407-4ac4-882a-ac0968af7135"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e52f62e-d044-4a9d-93ec-3f8ec177ab29">
        <dc:identifier>HP:0040217</dc:identifier>
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/865377dd-58f9-4e85-9f2d-55871ae78016">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <dc:identifier>MP:0013277</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/310b10c3-6d3f-4e05-a565-4a9c17aa7a63">
    <rdfs:label>Torcetrapib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <dc:identifier>DB06281</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49db992b-77ea-48e1-af1b-c8ba8da83eaa"/>
  </ddiem:Drug>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/1fa8bd65-fbcd-4565-a9f9-dda014a46001">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0987d636-ff1b-4049-b778-75ff0f37030d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aec3e346-8545-4ecb-86e2-8233a2d7e929"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e1fb8a9-1311-4b8c-8e89-6fdf5edceb47"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ddc0d62-215b-447e-8ee7-193c158657e6">
    <dc:identifier>HP:0040300</dc:identifier>
    <rdfs:label>abnormal free fatty acid levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe227ee2-8a9c-41cb-b58f-7043820bc71e">
    <dc:identifier>C04</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460b12eb-0422-4f1e-bae6-1bbce7047338"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b5c7c96-e999-4340-b6f0-616a81052b37">
    <dc:identifier>DB01394</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <rdfs:label>Colchicine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c22213ff-46f3-4d70-8936-48bd97c31770"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3e5e864-fbfb-4b1e-aa0a-d495a2e2dc36">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34f6468e-b429-4355-bb1d-8f8d77d444d2">
        <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46502557-6191-4110-bac9-1257e6cd477f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0d66451e-b7ce-47b8-944b-d87246376f9d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63d68f5a-3ef7-4a79-a159-030b7bd1fba7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b05e926-cc4f-4fd3-b9f3-5f83bd418924"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af534bf9-8cdc-42c3-9a54-9851102d8e23">
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13146fd5-49b8-4a45-9db5-2521030cad3d"/>
    <dc:identifier>DB09269</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f522e3f-b378-4de3-b14e-6aad20933e1b"/>
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/95daa43d-cb5f-492f-a311-e08bbfc597b6">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e76f2e6-b073-4485-9522-9291af19ab40"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14cc0f9b-9125-492f-8ffb-a8d44cb262f9"/>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c0336e9-4d73-4c6a-8fa8-11a6e8bd49e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d5dc2cc-a723-4181-bae4-e808eb58700e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6a523cb-bc26-4fee-9be2-b6723d9a16b3"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/01bb30b9-74fa-4ee5-9aa2-7a791f104ffb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53b37733-1d18-45af-b190-5ca9c7bda55a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b20c3828-9618-4d7a-8932-245cf86f33e6"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7194e340-e711-4999-9bf2-93e05e7f2003">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fed437d-ca2a-40ab-a83f-2e4ed0a75950"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b788098-0d40-4356-b2f0-bba4a06163c4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eca5449c-7aea-4e0d-ba59-578d5e4030b1"/>
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/239dd8e7-6b22-425d-a2aa-787357fb7505">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f90119c5-f824-46b4-8685-dd8679c4db03">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/163b2bb0-4cf0-43b0-8f41-11c77b623fe2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc50ea46-fd12-4140-ae5d-70e1461fdf79"/>
    <rdfs:label>Phosphocreatine</rdfs:label>
    <dc:identifier>DB13191</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed7a0dcb-09df-4b82-9f8a-c1043a794194">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/635186f3-90a9-4000-9645-760c6609fd5a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fd68f6c-7a97-42c5-a318-60f79699bd42">
    <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <dc:identifier>HP:0012187</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da5468af-0ccf-4f46-9543-2267fdb42599">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8fe9bf08-b8aa-4f30-8b1b-a55ea0f02cbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e09c9ca-c242-4e67-bec9-d086b655b088"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6bb44d0-a206-4c1b-adea-f322e6528a87">
        <rdfs:label>No result was accessible</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0daca590-cdbb-4285-8037-1cd31a361688"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fef3c28d-9a87-4658-892e-2c333a8db2d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89108fb5-e90f-4c7b-8474-69fed025e5b4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f893612e-7259-48ae-816f-325d5d914bdb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b57dc1aa-7202-4bb3-a1c2-6edc89f27fd6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8317ba5b-0873-4fdb-9afd-cd7f5771ead2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c5faff7-416c-4949-acd4-7b0134c2c660">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <dc:identifier>DB08809</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/378e0bfa-ed1f-4a65-a037-66ae1e71a073"/>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
    <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
    <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
    <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45befccd-4adc-426e-9a1e-3d3af41c2030"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be264992-32a0-4067-b1e6-2a10bb3e4c68">
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fcd63b7-0f7b-4cc7-81e3-5fa19aa223ac">
    <dc:identifier>MP:0002647</dc:identifier>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/191e0599-dd83-4211-a003-38631985e1a9">
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36f736fc-9ac9-4944-9fc1-b34f4880bbc2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d800dcd6-471e-4024-b05f-038a74531efc"/>
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81a1a65b-b1de-402a-a59e-0bcc7c7fcdec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23f304ea-57d5-4edb-b2bc-8b655723e4a1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a205694-37fc-4979-84f6-0ed299838fc9"/>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90486c08-3877-4eb2-8213-19a1f4c5b488">
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>behavioral abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/279c101a-62b4-4575-b53b-721c558c4cc6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1472de05-8315-4b09-a491-971475dbc377">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/556546c3-f56c-44a2-a3ab-343628e9da4c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e237d30b-0f36-43ca-adf2-e89a765fc2cf"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7dec3bf7-b24a-416b-a2e6-f08f1f02f5ae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Spirapril</rdfs:label>
    <dc:identifier>DB01348</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0b5dc7d-a5d8-406d-b9f6-0eef8d7d6818">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/501c8883-0b74-423a-a352-5b361b561d4b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79fd8170-9f32-42f5-b321-52cd8aaba7ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9f98088-10fb-431d-a1e2-01f6d83c2ebf"/>
    <dc:identifier>DB12351</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
    <rdfs:label>Siagoside</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/640222d3-e661-45ee-b6cc-95742b4cd17f">
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2e51e68-1271-4795-883d-c16d874442ee"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a905833a-4694-4bf3-89f9-15c7e93eae3b"/>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6855ec1-31c6-446c-b3a2-0c1ee5480df0"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8c39420-b4f4-4007-9ec3-0ca1bc214d02">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec204835-e285-4446-9040-fb11f4c74b99"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d808b420-3c76-4e46-908a-9893beff5f89">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b99b20f6-ea8e-45a3-8e17-7cad05218b5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ff3fbcc-e9c2-42e3-b396-3db03a594c6d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56e457c1-34f0-48cf-ba4a-64d2d61662ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4f8e737-dd0a-4060-8bda-f42b48d2ad29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94db4179-fa44-4350-98d4-b94c0bb9e847">
    <rdfs:label>NA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3449ca3e-778e-4700-93b9-77ad033d3eb6"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
    <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5624289f-324c-4818-9d6a-6b0d91132a8d"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
    <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ba1fbbf-6b7d-44a5-bb34-5bccf9518cee">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3add7d71-3bb3-4847-ad3f-3e456c798e13">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/681bf210-7b57-4e34-bdb7-806867c4c908"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45ca4080-3bf0-4530-935f-7ba92e549d7c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/50baf010-4fd6-4e5a-9a51-834c78165ca7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/840f35ae-4fa8-4ebf-823b-e8ccef8df66c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67127965-ff97-4ea7-88fa-40e0c5a80de3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2f1a1e0-1b9d-4552-b77c-ad257c70c975">
        <dc:identifier>HP:0004302*</dc:identifier>
        <rdfs:label>disability(Functional motor problems)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d303668-dc69-4913-811c-965ec8b1ed6f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e30f0a2-6ecd-465a-b2ba-8843591f25f6"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c0308ab-1d15-4b5f-8f2e-153ed40dad72"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2f171630-0530-4ebc-9744-87fdfd049bc8">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffba7519-cfcc-4bc1-9a54-88783e19a9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21b9f3de-a1fb-4b9e-a644-9f24ab32ad07"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5953d9bd-9fdc-4b72-8b87-083145d3920a">
    <rdfs:label>choroidal neovascularization</rdfs:label>
    <dc:identifier>HP:0011506</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/053ebb4f-cdb6-47ac-8b23-4f8e2fb923a6">
    <rdfs:label>Methotrimeprazine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d6477e0d-c4ab-4ad6-95db-d53b7befd73a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4d600d4-7867-4714-900b-95abb2777b37"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6aa9ab00-df16-4600-8402-f2774701405c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f764f350-e9ef-48ac-993b-b056fd0b43c9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <dc:identifier>DB01403</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4d9809f-e9a9-4004-ae2f-4f8b5601f42d">
    <rdfs:label>Sucrose</rdfs:label>
    <dc:identifier>DB02772</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e702772d-9f1a-467a-a6ee-402e77c822c8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c765c0ba-fe2b-46f8-96b4-531b5a3f6557">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab2ec0a3-36d8-42f1-bd25-f303b732f1ec">
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <dc:identifier>HP:0040087</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce59c889-ca3a-4b2f-8618-64eca684a1ec">
    <rdfs:label>Glycolic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/217be06e-68c0-4838-a051-bcfdd0b7762f"/>
    <dc:identifier>DB03085</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/558f1ccd-edd7-4a2d-bead-d6ace2668070">
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9b83010-3c52-4e81-b935-21dc1ca6ff16"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/de4ccd54-4239-4df7-96f5-108f0bd89a1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08a4ad63-0a1d-417e-aef7-efefd6be7a50">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66e41ae0-7fe6-4be4-a059-bdcc37953122"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc86b4be-03f3-4ff9-b1f8-d3ab59a70c65">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19d0d303-4031-4956-be2f-be3982f3880d"/>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81d00e50-3f05-4496-9854-996049c4ba31">
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f0b97ce-2698-4161-b690-d6b23eea8339">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ec49bc1-c733-46b6-867c-3c207bf181aa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a28fb71a-ef68-4987-bb8c-bffcd6e4f82f"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6be20e83-b5c5-4695-bd37-09bd6b6f014a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Developmetal delay</rdfs:label>
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99ad1a32-a7e4-44fd-b3b0-9474ea405aae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/855944d4-7dff-4353-bc98-5bd08e3a470f"/>
    <rdfs:label>Phenobarbital</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d1c76c4-89d5-4415-8591-0dd3b1b393bb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24af2586-031a-4983-ae4b-42b19e0019b2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb7d04ff-e3a7-4a55-b549-b72f1a9f58b4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00479d9d-8217-43a4-a6aa-c2263014b341"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70155c21-367f-4d12-9fb7-d2abfeb1a0a3"/>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cc407562-4d56-4195-bb20-eba4d5160acc">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ae3a39e-047a-4bc1-837a-f513d15dec15"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9975313e-7a8c-438d-8fca-081eff5851b8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fecd4d0-367e-46bf-a122-220e5170b4b0">
    <dc:identifier>DB09130</dc:identifier>
    <rdfs:label>Copper</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a52d269d-d909-4b6a-a643-b53dfccde477"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af4b39ea-573c-4da5-b272-0ab481f5b7b5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb642674-ddb2-4d76-9983-f7f061002cdf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/adf41a86-b87a-4bc7-8ef5-af4ef6f4634a"/>
    <rdfs:label>Acitretin</rdfs:label>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c682d367-b5fb-467c-971c-3717ee13aed9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/102d16d9-b03b-43d3-8a3b-ce225fdf976d"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/93c5072b-a4cb-4094-a205-5c0b02ef4529">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/025a56ec-c339-435f-b23d-7f26373e50be"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a518c4d-0bd3-4ca8-ae62-94c902e72a4e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b580779e-32f3-4bab-846f-fe92a4ab84e9">
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6b587e3-1990-480e-af2c-63fd8c3992f7"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f9cd806-87ee-4016-b0f3-e5d9af2231c8">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
        <rdfs:label>Astrocytosis</rdfs:label>
        <dc:identifier>MP:0003354</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27f75796-e139-4357-88d5-d08dd81d5485">
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcca9878-068f-40da-ac5c-00bfb79e06c0">
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5e044c4-deb5-4630-a33c-7d84aa5cc235">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0000880</dc:identifier>
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1be6a867-4d94-4a8b-b96e-360e7abe0d28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4663549-f52f-46c6-a759-abb5e91c9c85"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88b0c023-5f0f-4394-adc8-51a04fd2b0bd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
        <dc:identifier>HP:0002062*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62524506-ed7f-4dc2-ae2d-715c6f4dbd0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
        <dc:identifier>HP:0002446</dc:identifier>
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74768b4f-86c5-4c51-b5c6-1b7adbd1fe4f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b789d9f-a32a-4760-9464-d477acc86f2d">
        <dc:identifier>MP:0013438</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypomyelination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22cc5767-39a5-42ca-968c-ba1cb804a8a7">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c18fc7f-e502-476c-b947-9bea3b91056b">
    <rdfs:label>Heparin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
    <dc:identifier>DB01109</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be15b678-14c7-4c1e-8bba-e266e697b88b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf7af3b5-5fda-46d8-957a-a0511c870656">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc062c10-52b7-45de-a551-ca10d9a01fc8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7edc730-e126-49a8-a6f6-1fd577916ea3"/>
    <rdfs:label>Risperidone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7f6ee6a-0378-44e9-9347-1e481e94b8a4">
    <dc:identifier>DB12374</dc:identifier>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75193a2e-0d51-4fae-96e3-2b009db28227"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/2d0d169e-86b4-40c5-a65c-ed1cfff932c3">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f96d1c16-a353-4539-9e29-22739a53c5d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b04dc21-57dc-418e-a06e-48bac7775ab1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>liver fibrosis progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <dc:identifier>HP:0001395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a6b2710-d7d8-44de-b497-0e818ef536e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f1733a5b-0a66-435a-8a1b-24ce00ce8159">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d9574a-f00c-4f21-9c46-7b7cef3e8ab8"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3fc0de01-92f7-4d94-98c1-3702a0a7e7f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c5fd105-3b90-4c8f-b6eb-722130df4b86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/62c49c82-25b1-4ac3-a642-0599be86aba9"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a8abb2e-d68c-4af0-ad21-c1c381483c98">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:label>concommitant low vit D level</rdfs:label>
    <dc:identifier>HP:0100512*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9e7906ac-fc49-4f62-8121-b0fb8b80ca20">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6da9f49-24a2-4e24-a643-943c9d6b7e48"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/762b4a3d-6c39-42ba-8c6e-1e4b70354ce1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b29e75cd-25f0-480e-9474-552d0fcaa4ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f1800b0-f415-4e16-886a-1ea2f52ad24d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66423125-0784-40ff-93c1-22c5e9c02c89"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a139d1e6-5ac6-4e27-9cbf-0428ced73490">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa344ca3-4c60-4efc-852f-f98c3313382a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <dc:identifier>DB00877</dc:identifier>
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d8e5dbd-8e60-4d4f-93a4-9b29288d750f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d0d169e-86b4-40c5-a65c-ed1cfff932c3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f04a79bf-89e6-4662-be95-f3bd941cbb29">
    <dc:identifier>DB00586</dc:identifier>
    <rdfs:label>Diclofenac</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/036fa013-9ce6-4ce5-87b9-5f071e5762db"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a5ea39d-3d95-4fa0-a7b7-5b16b0cbae77">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f17b072f-5405-444b-a980-69412f5a5ff2"/>
    <rdfs:label>Cholic Acid</rdfs:label>
    <dc:identifier>DB02659</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8237787b-6bdf-4a1b-9f10-617a8c1a5cd2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8cc2ad37-a1c1-4b40-951e-61b51b81ee45">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d1fe6a6f-b15d-484e-866f-5772a304959e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffd3b8ae-b8f7-4d4f-899c-55335670b01a">
    <dc:identifier>HP:0040063</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
    <rdfs:label>Decreased adipose tissue</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/de14d532-9082-4541-8bc9-653cfb5918f0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41acc4aa-392c-4a5f-96e3-1a16966f89bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f3b73c5-a169-4f5d-9412-9de3a82098d6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2abb3594-d704-4c90-b26f-594c361582db"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:DDIEM_0000010>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af8539c6-13c3-420e-869a-056cda0377c7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low bone formation biomarkers</rdfs:label>
    <dc:identifier>HP:0031429</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b99b20f6-ea8e-45a3-8e17-7cad05218b5a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8c39420-b4f4-4007-9ec3-0ca1bc214d02"/>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <dc:identifier>A11EB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d89eb76-34cb-4a0c-b0d4-99ab2d35ef4e">
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3c65c756-4577-4c13-b7e6-c640d58ace13">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/243e811e-b84f-4f6b-958d-4c1fa1868418"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52f6123f-876a-4bdf-8cb3-123b44bf9eb1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15d5d97e-b3bf-4cbd-ac1f-8ed10d14d703"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b89a2a2-2c61-43dd-b7e2-e2683284ba77"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f5d4291-82ed-483b-9a97-ce2bd78660b3">
    <dc:identifier>HP:0001913</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
    <rdfs:label>Granulocytopenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e26ef69f-fee7-4cf9-9678-820bf6f5575e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ff663a5-e3da-4b8f-8630-d586932476da"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <rdfs:label>Benazepril</rdfs:label>
    <dc:identifier>DB00542</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ee6f291-81e6-4b51-be4c-4e1aaaddc4af">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001410</dc:identifier>
    <rdfs:label>Liver dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e05c0326-080a-438c-a89d-6eea326b54e8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3aff46e2-f2db-4d20-a3b4-9a149b003af5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac864456-7e1c-4e52-8253-37701deb2cdd">
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8f13b13-32d5-4143-8881-116d2e2e46b3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161ed7f1-083a-4069-bee0-e9aa8c458d2c"/>
    <dc:identifier>DB14992</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46182742-80c9-4f75-b571-caccf666f965">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74436fe5-9175-4462-8d27-18be399b56f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0237ce7-c8cd-4754-915c-bc2b7253a853"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18098143-fd56-4ca9-93ac-08ebd5ff2150"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ec0f163-f3a6-4381-85ea-b040d3c9b43d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fafe5faf-aadc-478e-acac-3693a1ada930"/>
    <rdfs:label>Potassium chloride</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <dc:identifier>DB00761</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65a495d9-650d-481d-9aba-d0b95a3b3420"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fbd9e39-6811-4e7a-8a06-9ad7598aed7f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50034b94-8e83-4239-bbbf-61a0d75d3c29"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/868e3b7b-0d91-4d9b-89fd-d7985d1666f3">
    <rdfs:label>AAV-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b56582bb-01e3-4b1a-a00e-b9a8546c87ff"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc08574-28b2-4f88-b7bd-13050d0fcdf9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
    <dc:identifier>HP:0000117</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7084c080-0d1b-4e73-b36e-2f1be7e2f143">
    <rdfs:label>Neomycin</rdfs:label>
    <dc:identifier>DB00994</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e8dd7d8-da49-46f7-9e83-76f2dd82cfba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29385abd-a782-4813-b45e-6b66ad637645">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e860fa8-02bd-4c64-980a-0e4a4e2b22b4"/>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2302519a-0fff-4be4-8f1a-5644107ca05c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002748</dc:identifier>
    <rdfs:label>Rickets</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f4a5b53-9c36-4c24-9504-58ab80ab7565">
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4a545c4-f324-4e20-b16b-253b719b9bb9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db8b223c-3e5d-4b55-8b27-457598bdcf35"/>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ba2b5fd1-8bf2-4b41-a514-35ab6ae3757e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f3a9d75-5cdc-45f2-9305-520c215653ec">
        <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce82e4f2-d9eb-43f6-882a-7695a0fec8ff"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba0ebfa6-bc71-4e5f-bf7e-616ba342124b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/036fa013-9ce6-4ce5-87b9-5f071e5762db"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <dc:identifier>DB00311</dc:identifier>
    <rdfs:label>Ethoxzolamide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/396b6c46-16ba-4fc0-9421-ee64d37be653">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ca8346d-7945-470a-ad3c-e48bbe74d110">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased lung function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89cd1ea0-c2cf-479e-8e23-b73eda847795">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dfafd716-ab83-49bb-939e-48714b764588"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd5a7324-6a0e-4706-b5ff-f42a7657d64f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81e820fd-a71c-47fb-9548-e4d8a7cdf4d3">
        <rdfs:label>Progressive emphysema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002097</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30045e72-bc1d-45ec-9fae-eb9d98b373a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/918bc093-96e0-4947-bb45-43d5a2c00ccb"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <rdfs:label>Mannitol</rdfs:label>
    <dc:identifier>DB00742</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3de240ca-6588-4088-8bfe-0576458d71ce">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de14d532-9082-4541-8bc9-653cfb5918f0"/>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5d24a076-fc94-4b92-979d-66a4d7e697c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eac2546d-c2bd-4271-b4e0-48b68a8476a2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d242b910-32aa-40eb-8238-46abb2687160">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4226e3e-ee51-4c7a-9bfa-28d54e70fb51"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7b244c0d-3dbf-4a3c-a455-d780079bc1bf">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4068b189-e4f3-426c-a96d-5083bbecc4a5">
        <rdfs:label>Hyposthenuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003158</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab45aa14-ac03-471a-94db-fee5b0e7680c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3facf70-04f5-4ffc-8df1-f5beffd179f6">
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>deambulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a059549c-d1a3-496a-b2b7-1437276dc5b0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4ae54e4-97f2-41a7-a101-d14063b21415"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95daa43d-cb5f-492f-a311-e08bbfc597b6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e7906ac-fc49-4f62-8121-b0fb8b80ca20"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36838b75-0843-4f08-9553-9b8c30fdc7cc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c63004b9-b99e-4847-a7c2-4aa43543e860"/>
    <dc:identifier>DB11599</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/09124551-c688-4e2c-8da5-7412edee33d6">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd70b43d-947a-48c3-84ad-6fb2b36b6620">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c3d081c-4b7a-429b-8191-55cdb1d569b0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57f4e9c3-c60b-4faf-8329-691f17ea45c8">
        <rdfs:label>Sulfide toxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46b10ad3-ac0f-4958-ada5-38d27179351f">
    <rdfs:label>Arginine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebbf60f1-ce99-47e7-8e69-cad415f5181c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04d6391e-2a2f-46cb-b2ec-b5ecd527874d">
    <rdfs:label>inability to walk</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002540</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/634c748b-c7f1-44f8-a5e0-cdc0de7b1433">
    <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fb3199e-8163-4c03-8de7-352fce5967ce">
    <rdfs:label>L-Citrulline</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ddb8700-34da-4c9b-af46-f50a1b9b011c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <dc:identifier>DB00155</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d501342b-0d23-4e68-a4d4-32b295881839">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/999041aa-3977-4b25-99d2-380b14362fc6"/>
    <rdfs:label>Testosterone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b24ff687-6a76-45f8-acd3-81db02a92cea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/271a15d8-70d5-45d1-882c-052e85882f11"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c424884b-0ba5-4d9f-8651-cce8335175e1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e9b7cf7-f93a-42bb-95eb-39a677d53868"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66f7361e-41a6-4567-b7e8-a70024631b95"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/322cea71-1aea-4715-9075-9f7211b6b58a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7b48543-7dbd-405d-918e-7fde9971c7d1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74f24af3-ec3b-499e-8ecf-1378c1683247"/>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/622eb153-9b63-44f3-a847-49100a687aa1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69a33d72-4c0d-461a-8f5b-30dcdb4d0d73"/>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/caa451c6-1ef9-4eb5-9ffe-8067d38b491f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43700b5e-d2f7-4cad-ac6e-6dd0ff76bb47"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/511ce23b-c99d-47a0-91f0-2bf3a07f6792"/>
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bbf733b-055a-4ec2-8509-93bff0c07d7c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93d7453b-03f9-4210-b403-51532a4818f7"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b36090c3-2dbf-4c56-870b-0a760c1d8ef6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d44cee04-92a1-4b39-9bf2-a0a990aa0303">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f31e4be-cdf1-4de2-98fa-f45e57f09f87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea4629c7-e693-443c-bfb0-ca7fd4999364"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/642b84da-8792-4156-a3c5-ecd56477bd2b">
    <rdfs:label>flavanols</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d6a8c873-7e20-4376-a9f3-9f6c0bb3b4e6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf240715-62ae-40c3-99e3-e314abb6943b">
    <rdfs:label>Gene therapy *</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/f0fcbf15-fd74-4070-8973-ac0536b91862">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cda2a1f-1048-42b8-b0d9-72153b612627"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/551c52ec-f896-4050-87d3-e13d27c31461"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd86b784-c463-49ba-a2c8-caef90434dc8">
    <dc:identifier>HP:0012449</dc:identifier>
    <rdfs:label>Delayed mylination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce591d46-513d-46a1-bb6c-65d606ffcb37">
    <rdfs:label>abnormal mental status</rdfs:label>
    <dc:identifier>HP:0100543</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b09694dc-d8e8-4d0a-a18f-aa884d437815">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/536d5e79-3d71-430f-8cfa-a419435a89b3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dfd1447-ff9e-4bd0-8199-6428835a8ebc"/>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <dc:identifier>DB01586</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2acbef60-7d8a-4af8-b081-3fd577e985d7">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00d155f4-539e-4c58-80aa-dc464d1bae71"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7d45cdf-a44f-4285-b9ef-c1eea6d49f5a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbff36b6-c38c-495a-a17c-a9a879e97ab2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/104892d4-c057-4256-b4df-df54d8c75e59"/>
    <rdfs:label>Propanoic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <dc:identifier>DB03766</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c5fd105-3b90-4c8f-b6eb-722130df4b86">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1733a5b-0a66-435a-8a1b-24ce00ce8159"/>
    <rdfs:label>Cholecalciferol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fce9bbfd-ec30-47a9-b242-f650c4747a4a">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6371d8c2-8525-459c-8be0-7cda65eeb7cf"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67b5c1b7-6666-4093-b60c-a2d2a114336c">
    <dc:identifier>DB05271</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c693e312-4f0e-4416-ad65-e9211283f838"/>
    <rdfs:label>Rotigotine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41ce891a-cd28-40ce-8e26-32383514fc02">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:label>Low enzyme activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012379</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/2405d468-0a28-491f-a7ee-29025996c55a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24486da5-dfed-46fe-bd8d-e8406ec4ca8e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cf90126-ff67-4b4f-9dbf-41ad03c23f03"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/112932c1-407e-4139-8a27-280c3e247dde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae6c098d-b8df-4ef8-b4a0-118eff2b6793">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Frataxin expression level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72268952-7838-44e7-9188-18096dbab6b2">
    <dc:identifier>DB14933</dc:identifier>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/486306e7-ae7d-4515-bc33-e3f4c98f0aef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e35af37e-fa1b-499d-ab4c-79357ab84cf7">
    <dc:identifier>DB04789</dc:identifier>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d84f2a91-33b6-4c56-aa1c-a40eab618c3d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6298fd6-853f-47ee-a9df-c64a4dff5dc0">
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:label>High serum total cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebc22e96-a328-489e-8f59-a06374de24e9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd733857-45a3-4261-8763-b20b952441f7">
        <rdfs:label>Metreleptin</rdfs:label>
        <dc:identifier>DB09046</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06377bc0-1581-42e4-b4b4-b605dd2adab4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a06db302-bcd4-412a-a68b-2cd78947ce42">
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <dc:identifier>DB14002</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a9b8ae4-c302-42df-9e8f-c17de2760c2b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5e65a18-f51e-4f93-9663-b00fc22f26aa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:label>Increased muscle fatiguability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f566e6b-969c-455a-b727-e57c00ddb601">
    <dc:identifier>DB04075</dc:identifier>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd269e6d-5e4a-4adf-aba2-86ac36d0a558"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/843c41c5-fad0-4afc-9578-476bab34ed06">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>skin photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faea2799-c014-4aba-9f23-4c8305fc7d17">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurologic dysfunction</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d2e89b4-ff4e-4b17-bc6a-17830ef93e55">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor traction response</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d52cb213-136b-4282-98f2-3c557680b13a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb833470-f507-4f8f-a51f-c613f7e81081"/>
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40023f35-84f6-431a-a1df-f29a9c2bb87d">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/54ab0aaa-0689-4e9f-8b7c-448440d5daea">
        <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c921f953-54f5-4b8b-a455-b8eab8e1c633"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05759883-3817-4cec-ad45-935ea5a99bcc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a44bbd38-7618-4b45-8451-972e3fa4ebe0"/>
    <dc:identifier>DB00776</dc:identifier>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e8fd848-fb26-4160-871c-e1bde6dc7be6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd7beeab-f95a-453d-a33d-ea2db3250414">
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebb5358d-d733-434c-8a06-d449ebc6860d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4116581c-4b12-4fed-b04d-2a66143b65ef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14a07da8-e409-47fe-bd3b-3c207a725abd"/>
    <rdfs:label>Fenofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a344a1f-d9db-468d-a558-1beb677655a6">
    <rdfs:label>Deferiprone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/910591da-57c3-4ae5-b007-ea3fff61c3a2"/>
    <dc:identifier>DB08826</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38222a05-7b0a-464f-9a7e-e3a2f856a643"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22cf5f1d-f0f0-4484-8ae1-6a27710a004d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/642f7f69-4eac-4cc2-8c10-cc537adde5cb"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a94fecb-7933-42d6-b9fe-43f4094f9e04">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc420314-dda1-4beb-a9ad-ee3a16e50290"/>
        <rdfs:label>Carbidopa</rdfs:label>
        <dc:identifier>DB00190</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/002ab948-5ba4-474a-b5e9-aaf0d83b493d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf611714-48f8-44b7-9a10-fafcc51cbb5a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75f0c261-739d-4962-953a-d6dde2f2fa0e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cebe9d0-473b-46bc-8e56-d51bb93b6ef3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4383ee28-bb7b-45df-9b6e-78a13767e6ab">
        <rdfs:label>Norleucine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4478f38-7ec9-44f7-99fb-0246dec1cdee"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65e62b23-08cb-47ee-a1e2-a8763e4d84b6">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <dc:identifier>DB00477</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d5c359f-02d4-4319-a685-2957a44692e5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd668030-b753-4b97-ba6c-d28b4d2bce73">
    <rdfs:label>VITAMINS</rdfs:label>
    <dc:identifier>A11</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23a18d9d-7c2d-4d04-b7c2-027523defd94"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4de20c0d-39e6-4b30-b25f-bbdd8a407385">
    <rdfs:label>Pantoprazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78876760-5730-41b3-8e85-5ad69c19942d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <dc:identifier>DB00213</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3313236d-a50c-45df-8c36-b041b07c6514">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a20d75c-f7ba-4e58-b6ee-0f3be8397a32"/>
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f284280-126d-40dc-bc92-4ea3408352ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ab26e8d-9550-4b0f-b88c-f28a4c1585a5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4653b645-27ac-4bea-ae9e-f690da826a7e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3e5e864-fbfb-4b1e-aa0a-d495a2e2dc36"/>
    <dc:identifier>DB00119</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <rdfs:label>Pyruvic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4470d40c-7b14-4dfd-b54c-c585cf969e84">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:label>high ornithine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f1d1d3c-b385-467b-90b9-e9405b6ee743">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
    <dc:identifier>HP:0008765</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Auditory hallucinations</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fca2c415-f94e-4497-a2b7-43e777b5cc4e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
    <dc:identifier>HP:0004369</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low levels of purines</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e28456d-0885-4b45-93ee-20c709259303">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edee6e6a-9794-4df7-b5d6-bc82d594499c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae0d7a18-d8d9-4e87-9f51-cb5cc5f71eed">
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dfafd716-ab83-49bb-939e-48714b764588">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/396b6c46-16ba-4fc0-9421-ee64d37be653"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <dc:identifier>DB05481</dc:identifier>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c26293a7-46ba-47ac-b329-3ca0370e34b8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41dfdbc2-39e0-4d3e-9b61-02020a3c34a0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <dc:identifier>DB04159</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bac894e3-e86f-48c0-a29c-3b657833b5e3">
    <dc:identifier>HP:0003199</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low skeletal muscle mass</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/65f63fc0-7731-41b7-a6b6-4f76f0b31816">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/470392f8-e525-45da-b329-0a5cf52fd87d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b495154d-bfa3-4eea-8479-5bd2479b0c6d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27953ee5-3fc0-403e-8c86-ad19330aaaa2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/538c4105-3ffe-4605-bec0-d9bca04c49c7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c12e044-a2ea-45bd-8a11-14ae7432ea64">
    <dc:identifier>HP:0012825</dc:identifier>
    <rdfs:label>Mild attack</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c6b7447-927e-477a-b4d7-bc390983c2fb">
    <dc:identifier>HP:0002572</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Recurrent vomiting</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7bfe255b-9b12-4d19-aef1-21c244e7c3a6">
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5549334-aeab-49e7-826e-2b2941a26d1b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7882a5a-7689-428b-931b-ef427bb33b8f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
    <rdfs:label>Normocytic anemia</rdfs:label>
    <dc:identifier>HP:0001897</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d5e034b-b142-46f6-9221-6b4c2adcf1c9">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a51bfcbd-5f61-42d8-96c4-c8ff74e1ac4d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16e53bcd-ea31-4377-b274-0257766a5d44">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81e06143-35a2-4842-90ac-5ccf85cd3373">
    <dc:identifier>DB02952</dc:identifier>
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/37763a29-757c-402a-834d-52ebdddba1ae">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c58a0d1d-d466-4851-aa7e-7e7fb2d53cb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2595768-24fb-4b66-bbea-aa51bf2ec6db"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4663549-f52f-46c6-a759-abb5e91c9c85">
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93c5072b-a4cb-4094-a205-5c0b02ef4529"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b69d1170-d24b-4dae-9323-fd2f8ac75e34">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa623e52-2977-4c5b-aba4-4a96f9299562"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47c70c13-8064-475d-a61d-a92a8eb5e5d4">
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00243f40-69be-4a46-8b72-3d63e080ba75"/>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fd59463-de14-4906-8573-89a09c19f134">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eff4ce1e-e9b0-4ee9-acc3-50ee51806d31"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6350f68-ae44-499d-867b-a7ec2e9f8df9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14569bfd-b446-40b2-a33f-5a3b56421b16"/>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/73ed8068-09e3-410e-af50-e132739df3e3">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c365cd11-13fd-40be-8961-9dcea9988c61"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0ec47fa-ef75-4516-8934-ecedbf9f747c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3facf70-04f5-4ffc-8df1-f5beffd179f6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a993212-2625-4a76-b717-2cfd521f118a"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5f918b0-26ef-4b97-8a20-6360a83a5ff5"/>
    <dc:identifier>DB00650</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e1618cd-a3fc-41fc-aad9-abb82a07118e">
    <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/62d18710-5b08-4ea9-b693-3ceb97e6bf66">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e39e4f1-cc58-4695-939f-76ac39af4181"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eeed10b3-74a1-4438-94a9-61012b17f3fc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72114344-b4b9-4e16-86b8-a13735499124">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b3b7b34-6bfd-471a-a4f7-718067efc042"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f70a0d96-7d9f-4e0e-bf28-7c43e028bbd8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <rdfs:label>Selenium</rdfs:label>
    <dc:identifier>DB11135</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f48e04c2-c2c2-4c18-9b69-70bc748d1ddc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/758f9e95-676a-4d21-aaf5-5c08761b6f1c">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <dc:identifier>A11E</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/becc3a59-a7fc-4a91-985d-cb20245fde7b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e7721f1-207c-4613-aa3d-9f4190b8fe33">
    <dc:identifier>DB07425</dc:identifier>
    <rdfs:label>Sobetirome</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5173edb-da14-4165-a166-c1b1761f24af"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01bcfe7f-0d83-47c8-9c56-f5392f5d4999">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2736c52-1ee6-498c-9dcb-ae90c5dd0290"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fab5360-d45f-40a2-ba66-853ff90fcc1e">
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ca6ec302-fa55-4909-a35a-710b4c9ca7c2">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a1c7109-3ee5-4abf-b544-ade68c7197ed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/771af536-ef66-46d9-b424-4abc861ca82b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <rdfs:label>Dexamethasone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/927d3392-ca6f-428c-bcaf-680515a8fd9d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ab47009-1bb7-4277-92db-2c7bae0d9cd3">
    <dc:identifier>HP:0100716</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:label>Self-injurious Behavior</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/193b3838-ad97-4744-94c1-d4b4dd5bb1f7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f28a4bb-f387-48df-8f55-63b6285f62d8">
    <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/766b8883-452d-4088-b89e-f8980d249eca">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <rdfs:label>Beta carotene</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e6dac03-b14e-48ed-bf94-3707738865be"/>
    <dc:identifier>DB06755</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49a53f38-6d8b-41c7-9603-31e5363c9382">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8d29b0c-867b-4937-8c0c-aa6907a1af1b"/>
    <rdfs:label>Potassium Citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <dc:identifier>DB09125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69543cd1-b00b-4734-85ed-feb75e630741"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/551c52ec-f896-4050-87d3-e13d27c31461">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf240715-62ae-40c3-99e3-e314abb6943b"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c4478f38-7ec9-44f7-99fb-0246dec1cdee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3641236c-17a8-4cdf-90ef-fec3a0485cd9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1230fb8-9eb9-4adc-bb40-43237476272d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High α-ketoisocaproate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32884435-06b2-4e14-ba97-296078bd0a54"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cebe9d0-473b-46bc-8e56-d51bb93b6ef3"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd655256-8824-4be8-a1fe-1193c9fe2974">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
    <dc:identifier>HP:0001112</dc:identifier>
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ec49bc1-c733-46b6-867c-3c207bf181aa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81d00e50-3f05-4496-9854-996049c4ba31"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79542252-67e2-45fc-b309-3f68ad8eee97">
    <dc:identifier>HP:0001959</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/54f8ffe0-ca8c-4733-9b5a-e75c9cb10ae1">
    <rdfs:label>Complex Carbohydrates</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/940e0cc7-efa9-4a6b-85ee-55f9e8ec58a5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c52d81c4-79df-4479-8bc0-a1cda7ab2e23">
    <rdfs:label>vitamine K</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8bd5da9-1d51-4a64-be6a-256fe43da655"/>
    <dc:identifier>CHEBI_28384</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cb15baa-546f-4be1-bad7-1d33d50ec322">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48965d2f-280c-4b0e-a040-cb9efeca30b4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d91970a-176a-4ab4-a7f6-c5cc506a8658">
    <rdfs:label>Amitriptyline</rdfs:label>
    <dc:identifier>DB00321</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e816d93f-1673-42aa-bd7f-6e8bd22bc91a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/831dcd73-eeaf-448d-8c9c-bc561eaa94e4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <rdfs:label>Dihydrexidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e61a6039-f092-48a9-97e8-bf43c8e5b396"/>
    <dc:identifier>DB12890</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a744236-cac1-48bf-a210-1d4166d48438">
    <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
    <dc:identifier>HP:0000972</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e392336-7f53-4dbd-973f-b297fd293d6f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1fa8bd65-fbcd-4565-a9f9-dda014a46001"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff463dbb-990b-47c8-b1d2-bcb324a6774f"/>
    <dc:identifier>DB01914</dc:identifier>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/009b2035-37d4-4cf6-93ef-e12a84a8e824"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/654003e3-37b0-4a94-a75e-504c04132fdf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5ae76b0-172f-4913-8542-72c176e7c375">
    <dc:identifier>HP:0100753</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
    <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
    <rdfs:label>schizophrenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/655d5dcc-3418-4a25-b29a-d023d4888c61">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0dddb17-3214-4a73-b7bc-10f3d47d6746"/>
    <dc:identifier>DB05990</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd928818-3359-47c8-95b3-de02e12debfb">
    <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c6ea638-1eff-47bc-9b5e-d14137c3eaf4">
    <rdfs:label>Benzbromarone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba370630-42e7-472e-baeb-69c920565b9f"/>
    <dc:identifier>DB12319</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/06377bc0-1581-42e4-b4b4-b605dd2adab4">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/865377dd-58f9-4e85-9f2d-55871ae78016"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e52f62e-d044-4a9d-93ec-3f8ec177ab29"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebc22e96-a328-489e-8f59-a06374de24e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/258f1ab4-215b-4897-b9f7-adc31fdc1d3a">
        <dc:identifier>HP:0000287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ddc0d62-215b-447e-8ee7-193c158657e6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f909cdec-1271-4eaf-b8cb-62836c11f98d">
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df4e4e8a-0f70-4658-a026-74bf6175c5e4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e952b9c-4a94-41a1-bb5b-821fc837a3c7">
    <dc:identifier>HP:0005961</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49800004-5112-4637-b4b4-962bcddd096c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3848d87e-240b-40ce-85df-2e6534dd47ea"/>
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82bb6101-f1cf-45af-80b6-741359c77b5b"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f83083f4-2106-4bc1-837f-32af2f0463e1">
    <dc:identifier>DB02691</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d74a7ea2-c5d0-4417-8428-54f69e77f6c0"/>
    <rdfs:label>Glycocholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7cba3624-a5b4-4cf2-b794-2f53ff619fd6">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/105cef1a-daa6-4acc-ae13-c1e3f682d35f"/>
    <dc:identifier>S01EC</dc:identifier>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08a1ffc4-5544-4360-bacd-8a331933b3c6">
    <dc:identifier>DB01068</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4af927fd-5787-4792-8228-485b8541a049"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88624e7a-3655-49f3-bb5e-3fc537705ca0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24af2586-031a-4983-ae4b-42b19e0019b2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/599cb057-4848-4372-b554-5c4d0513a1c5"/>
    <rdfs:label>Clonazepam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6690662f-7ffb-4ec3-87f5-b9a34e4fb7a7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f0c0ae8-b066-4193-9ff0-677b40d18541"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e406359f-d6d7-4584-823d-6a48ac6b87c4">
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05a7a429-f647-434c-aa4f-6f377acd4429"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dcfce55-1979-4389-894e-9fa699597a6a">
    <dc:identifier>DB01277</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdb1444b-0590-4f14-b87f-247321b01280"/>
    <rdfs:label>Mecasermin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a234b73a-30b8-4bc1-bcff-9c5b75aa9078">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5711155b-34c1-4065-a9e3-fff4412882b8">
    <rdfs:label>frequent hospital admission</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f633c381-660e-4a29-a855-28bbb03ea047">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a05a300-fc63-49f0-ad92-d45dffdfac5a"/>
    <rdfs:label>Ornithine</rdfs:label>
    <dc:identifier>DB00129</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ba290e9-3ffb-40e9-a1ca-d2a4cf9fe24d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Limb dystonia</rdfs:label>
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebf62dd6-233d-4cae-be30-ca154170abc7">
    <rdfs:label>Metronidazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5ee24e5-bd98-47e7-b312-4135aafb9299"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <dc:identifier>DB00916</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ae2a504-e448-42e7-bd5f-c363c5e2b793">
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d95a9f34-2eb8-4dde-b880-49700d6f385a"/>
    <dc:identifier>DB03147</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eae0fb8b-32d7-4605-b56c-e4828e6503e6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f83093f-69a8-44c6-9e64-6277ed0e646c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58d679c3-7a44-4ded-b7b2-10f138c20711">
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f58b4748-0a21-4b19-a2e3-f6ccda8f4b1b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af9b1ef9-5ded-4f83-9acc-f53b3699938c">
    <dc:identifier>DB01205</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55fe6dcb-c15b-4317-b249-1a5b00bd6a4d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <rdfs:label>Flumazenil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2bb68ca-0239-418c-a288-d70de0af85e3">
    <rdfs:label>Abnormal facial expression</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <dc:identifier>HP:0005346</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/19383c2e-e3f4-4a40-887e-4926ead836d2">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e652d9b4-9382-44d0-b9f1-f2915b291470"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9dbdae46-237f-4caf-b231-fc72e1addeca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e715b3b-9a47-4b2e-9ad0-e6d272db44ed"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e1618cd-a3fc-41fc-aad9-abb82a07118e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebe53c3d-2e8f-4d98-b4a8-6b7e6380e975">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60f7ec0a-5506-422f-bb41-c074334ba029">
    <rdfs:label>Glutathione</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c7aa0c2-2913-444b-8986-52298b9630ba"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <dc:identifier>DB00143</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a6d9abf-a625-4c11-9dd0-3d6d06add5c0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/923a8d29-271f-413f-9c21-ec49505f8b0a"/>
    <rdfs:label>Prokinetic agents</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f31e4be-cdf1-4de2-98fa-f45e57f09f87">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b36090c3-2dbf-4c56-870b-0a760c1d8ef6"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae26eace-f7fe-4a3c-81a4-a54925c01b39">
    <rdfs:label>High total homocysteine level</rdfs:label>
    <dc:identifier>HP:0010919</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58087c53-b643-4846-b063-28f0f0db0de9">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a15b9ad-a33b-4c73-80d3-58f43b855af7"/>
    <dc:identifier>M02AA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f92a493a-eb06-493d-8a28-f49439f1f3ca">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bb6041d-90bb-4b30-9858-176c65699430"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88bdf20c-a5b4-4c33-bfad-3409a1ec20a9">
    <rdfs:label>High plasma uric acid levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c226ce17-b71c-4bca-81c7-4bc4a344aec3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <dc:identifier>HP:0004732</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45c380e9-7666-4222-9411-ea1579e79948">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <rdfs:label>Ketoconazole</rdfs:label>
    <dc:identifier>DB01026</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/158e0c4c-ef81-4e82-bffe-d5b3372479ff"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f74510b-5407-4ac4-882a-ac0968af7135">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <rdfs:label>Albiglutide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b02eda78-9955-4feb-9fab-847ae4f4903e"/>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbfbf2d0-ec23-46aa-9360-8103cac9e06a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78c7b2ac-3360-4f3d-b84f-ca8a6fbbb697"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <dc:identifier>DB13178</dc:identifier>
    <rdfs:label>Inositol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/697ea308-2fd9-4c12-97e4-aa098cee0156">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2f5341a-31ad-4f29-857c-248b3336ea57"/>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <dc:identifier>DB01611</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9cccb17-7431-428c-833f-e9405e4426a9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5549334-aeab-49e7-826e-2b2941a26d1b"/>
    <rdfs:label>Potassium</rdfs:label>
    <dc:identifier>DB14500</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a3e3a8e-f6a3-4e2b-867a-3da91728751a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33965aae-aaf6-45eb-9e63-54aee58aec53"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c50c2511-a46e-4afb-9100-c305d208d2e2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/220b1b1f-237e-4961-842c-e0d2a05438b2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <dc:identifier>DB00034</dc:identifier>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d434524c-7395-489c-92db-29ea48e81f24">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88595365-4d3c-4c40-9efb-9b1c362536c7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/280d953e-b8aa-4d4e-866b-63f8698db1c3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41be1a69-980e-42ba-9cef-009708e1ef4b">
    <rdfs:label>Behavioural abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2bbd5d8-bda5-4761-9439-d6ace5f99953">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100614</dc:identifier>
    <rdfs:label>Muscle inflammation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cc1697c-7ba1-42cb-937c-729ef06d8a0a">
    <rdfs:label>Megalobalstic anaemia</rdfs:label>
    <dc:identifier>HP:0001889</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0dbf796c-06f2-4b4a-8ffc-916693f6d9f4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b7c42de-0eb9-47f1-ba0d-87ea7248d43d"/>
    <rdfs:label>Dopamine</rdfs:label>
    <dc:identifier>DB00988</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04164702-8c2d-4337-9cd4-d234f7789f28">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bda5c5d0-da10-4e87-b9b7-c1bb4d71ffb4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/242b0a0a-71e5-49d3-8d6b-9f2f5d95aeb1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff73725-54de-4ee1-92e2-5d1fe6dd8d19"/>
    <rdfs:label>Zonisamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb466f7e-3f9b-41de-bdeb-f46df97ecf1a"/>
    <dc:identifier>DB00909</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4af927fd-5787-4792-8228-485b8541a049"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd74485e-2f62-45fd-914f-fb0870cbe285">
    <dc:identifier>DB12536</dc:identifier>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1698c7c8-430b-45b8-9f0e-6b387c8f3580"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37d99a31-0c68-4e7d-840e-f821589cdcce">
    <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
    <dc:identifier>HP:0000570</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68a12c9f-b97b-471d-aab9-edf6a9b3b577">
    <dc:identifier>HP:0002019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
    <rdfs:label>constipation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6ee72c0-a67f-4d3e-b7ec-1a241f579e2a">
    <dc:identifier>DB00555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b794f25f-4d09-4ec9-8823-d07e067ac0be"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <rdfs:label>Lamotrigine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66e41ae0-7fe6-4be4-a059-bdcc37953122">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de4ccd54-4239-4df7-96f5-108f0bd89a1b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f3507a1-3c81-4321-a7ea-efd3e0ff5951">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc846813-6456-4628-b195-95dbaa4f9378"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1315bd09-7451-4793-ad7b-7f1b4899b1e8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6587a82-d6a7-4604-8d43-a577bc41bafc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1188fa2-3598-4e5f-8395-98595993e1d2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/acaa7b2f-50c6-44f3-a080-c50fe9e8cffd">
    <rdfs:label>L-Glutamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c2ed7c6-91ff-4dc0-a36b-69386122ca38"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c565c51-27e8-45d4-b6f6-06b6c4f37d1e"/>
    <dc:identifier>DB00130</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ead9e0a0-ecf6-4fef-b69a-46ebcf86739c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <dc:identifier>HP:0002917</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b07b2f97-55af-42da-91e4-01e64e3de0d6">
    <dc:identifier>HP:0000819</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Diabetes</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f8211aa-c390-4843-a406-41679e83cb17">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c78f586a-e34e-4c7d-8e7e-3e52b63b613b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a47cc31-dc30-439b-b02c-4a1b82c37b69">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/310b10c3-6d3f-4e05-a565-4a9c17aa7a63"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ecb5468-8dee-4924-a839-3c419881e818">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c4e8666-490d-4ecb-8116-df024c71ba9f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <dc:identifier>DB04854</dc:identifier>
    <rdfs:label>Febuxostat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42706a0a-e8d2-4229-b662-a9bbddb40b6b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24c44753-6be5-4296-8444-fc25c24b3e8d"/>
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4226e3e-ee51-4c7a-9bfa-28d54e70fb51">
    <dc:identifier>DB04552</dc:identifier>
    <rdfs:label>Niflumic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d24a076-fc94-4b92-979d-66a4d7e697c4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
    <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/110969e9-a150-4dcf-b2cf-60d671ed3085"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49188e85-c4c1-4d59-bca4-c4bb1d4af2d8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74faf64d-4fb2-4038-aead-84feeba31745"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <dc:identifier>DB08876</dc:identifier>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e852b1b8-e728-4954-9e3d-94e5309093b9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7241ece-d476-4814-aedd-841b3de5d2e9"/>
    <rdfs:label>Propranolol</rdfs:label>
    <dc:identifier>DB00571</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08dfd182-ee02-4149-a89e-43c0a2f549bb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2b17018-ddb0-4182-b0c0-6403f0c701ce"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22c46b47-09fa-4dc4-9853-7f317f487094">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a46cf0b2-1e68-4201-aaa9-172d71f30ed7"/>
    <rdfs:label>Laronidase</rdfs:label>
    <dc:identifier>DB00090</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/027b8fd2-beb8-4b01-8c81-b1858b8a8164"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/84bede05-2189-485b-bf73-0441204e7652"/>
    <rdfs:label>GLUTATHIONURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb237fd4-9aff-45f2-be82-7ff9356b7a06">
    <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff48149f-6c6b-4473-af68-daf813d3313f">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30142f63-f142-42d3-b7f4-b66002d848b6"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82b09e4e-8de6-40a0-8559-81d8daa97727">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
    <rdfs:label>Foot clouns</rdfs:label>
    <dc:identifier>HP:0011448</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c6b295f-22d6-4018-99ad-f3b157b59628">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <rdfs:label>Calcium</rdfs:label>
    <dc:identifier>DB01373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb4b5e9c-f173-4723-be17-6e71d2fbe141"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60985286-f430-47c0-a6bc-409945e7b4d8">
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91d70a3d-756c-495d-9086-6f92aafdba55"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52e0bbb7-b3a1-48d7-b070-5341a77c1670">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9ce227d-2106-4058-9b3b-4b10f5a5f92e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/963a5564-769e-4846-9a92-19d6e0d08f54">
    <dc:identifier>DB14644</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/688d8cc7-e522-4360-af19-464453a39bba"/>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/758b6395-dd56-458a-af37-8f5f2d841aa2">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92e260c5-1f63-4804-81b8-0944565bb6cf"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3946bdbe-53ef-4a0b-a00e-9ac2ec80b42f">
    <rdfs:label>Mesalazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/196bc0c9-5ba4-4163-bff0-44018b141ba3"/>
    <dc:identifier>DB00244</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f883700-8c3f-4dfa-bb17-7cbd73a89fbc">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025034*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
    <rdfs:label>erythroid progenitor depletion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42a5a35c-3acf-427c-b7a0-dce69e43437b">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <rdfs:label>NeuAc</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c627c01e-5432-428e-954b-368fad47caf1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95bf4ad7-6a49-4340-ab0f-44c5f94ea10d"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5cf90126-ff67-4b4f-9dbf-41ad03c23f03">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2405d468-0a28-491f-a7ee-29025996c55a"/>
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c10b310-2e55-49a8-9c58-07ab6f9106da">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012130*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
    <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3435bcac-2d2a-42f7-9b29-7472afad901c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f752b72-f6ff-4338-bc49-b65be7b3d37e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e237d30b-0f36-43ca-adf2-e89a765fc2cf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
    <rdfs:label>glomerular proteinuria</rdfs:label>
    <dc:identifier>HP:0000100</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66c016b3-c624-4c63-ae1e-42c5ba69aa52">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Abnormality of metabolism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fac3629e-6b95-4cb2-a07c-a04c0266d231">
    <rdfs:label>Increased plasma CEA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031029</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96daf737-2b00-4ddf-8472-77f0b2ecb8bf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c424884b-0ba5-4d9f-8651-cce8335175e1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb656061-be18-4242-b900-2f9a610e7323"/>
    <dc:identifier>DB00419</dc:identifier>
    <rdfs:label>Miglustat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44088910-182e-4e6b-9452-63ab438db53f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/222eb0c7-d1fe-4a0c-b346-58fafd2e6b30"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <dc:identifier>C03D</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38910cb6-0509-43b5-98c6-22f9cc1ce6a1">
    <rdfs:label>high-anion gap acidosis</rdfs:label>
    <dc:identifier>HP:0001941*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/706b91d0-78ca-4359-936b-2d7b40cc341b">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c176c81-1299-4c26-887e-d4f3f4831b37"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0b85369-b32a-4ffa-b0c0-224f3181fc8d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86a7a3c1-964b-4a32-8951-03a15a6c33f5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8bdaf66-0c67-4eb4-850a-45f4e626f324">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60aa5ba1-7a24-414b-b0e7-61c9eb2787e3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12710111-bc7b-4dc4-ba54-6152b3089eb9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <rdfs:label>Fenofibric acid</rdfs:label>
    <dc:identifier>DB13873</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b41aa745-b9a7-46ec-9c03-b4354431ffac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>neurological dysfunctions</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cdf8afd-18ef-4fcf-8ec4-5168d4e7b363">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>Neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bd885f6-d656-48e0-99f7-59725afc3f03">
    <rdfs:label>Amenorrhea</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bab6def-a4ff-46a1-9aa7-66a88dca3128">
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
    <dc:identifier>HP:0000144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1226fd9-ed1e-4453-8d68-e9b2d05c3247">
    <rdfs:label>Nifedipine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dba6a1d7-d826-4ae8-a6eb-00175a7e3ce6"/>
    <dc:identifier>DB01115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/291db2ae-89b1-4606-b9a7-abb208896f2c">
    <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8a188d2-7c30-457e-8359-08175fa34ec8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
    <dc:identifier>HP:0040129</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f00d9c19-334e-432f-985a-005ca2911f86">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low hb level</rdfs:label>
    <dc:identifier>HP:0001903</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a36f0cc4-ca42-46e0-ac53-2f6e17631f97">
    <dc:identifier>DB02053</dc:identifier>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33aa8f32-fa9e-4695-9e42-e797b2962589"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15fe08c5-87af-40f8-9138-f810ff24b081">
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4ae7269-a70b-4cfa-bc13-eb0d94d5dbd2">
    <rdfs:label>Functional loss of vision</rdfs:label>
    <dc:identifier>HP:0000572</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a54a6e9e-da81-4aa8-a38c-39688f63eb91">
    <dc:identifier>DB01200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75bce3df-0795-4f9f-8cf0-43f0b9a90efd"/>
    <rdfs:label>Bromocriptine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/296a4752-9160-4ecb-bd01-a601941bab40">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd8f004f-e34f-48cc-ba32-2af341f4d898">
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/592cc64f-e9fd-47bf-affb-120fabb4916a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <rdfs:label>Chloroquine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7c3d595-9e69-4297-8ac4-143e5c6c4355">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/759dab83-5d0c-4c32-b192-c68eb370b194"/>
    <dc:identifier>DB01001</dc:identifier>
    <rdfs:label>Salbutamol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/694a9e82-234c-4e3f-9f67-06b473b7dcba">
    <dc:identifier>DB00331</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <rdfs:label>Metformin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67145f69-b7e5-471a-aa54-3e80bafb070e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a96dc102-8050-4dc0-8d03-ca9794368c97">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87dcae04-003e-4013-b9e2-9bcfddfa07c1"/>
    <dc:identifier>DB00533</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <rdfs:label>Rofecoxib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/207d5e2c-827b-409f-bce6-7f5f8e55d294">
    <dc:identifier>DB12528</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d2354db-ce54-4198-a7f9-4e3c5c7dccd1"/>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99db20f3-f5bb-4e40-9f3f-6ca5a0cfe8b1">
    <rdfs:label>Gliosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
    <dc:identifier>HP:0002171</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/026c8ec5-211e-43ff-8dd2-7bbc62220c8e"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15d5d97e-b3bf-4cbd-ac1f-8ed10d14d703">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c65c756-4577-4c13-b7e6-c640d58ace13"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <dc:identifier>CHEBI_25548</dc:identifier>
    <rdfs:label>nitrilotriacetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/681bf210-7b57-4e34-bdb7-806867c4c908">
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ba1fbbf-6b7d-44a5-bb34-5bccf9518cee"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/187a3a1a-dac9-464a-ae40-44d42ed0e87a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rigidity</rdfs:label>
    <dc:identifier>HP:0002063</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ce9a21-9ba4-4e8c-abfd-200a8f3fe2b3">
    <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22dbb9a5-1731-4c4b-9084-147ecd56dbfa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f79317d0-f627-495c-b85b-7bb632c8120c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fdaba59-a475-4873-90ad-f9b04a883be3">
    <rdfs:label>tissue damage</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2041231-e33a-4c84-8a6e-a6b625f87719">
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>Fatiguability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9579314d-5c80-434c-9dbe-29c31a171bb8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <dc:identifier>DB01233</dc:identifier>
    <rdfs:label>Metoclopramide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8e09587-2462-4129-ad1a-3db601656201"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e1d1aaf-729e-4faa-8ba1-fd3e6fb19e9e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ec35733-0e50-410f-bd3e-a38fb1b5d77c"/>
    <rdfs:label>Pergolide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <dc:identifier>DB01186</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df8453d7-eee9-4028-9822-db0f3b981206"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a587bdc6-8a2b-4440-9e01-c5f3cdb7c63f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/371f8923-4951-4e80-92e8-b20adbe8243f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a1995ed-35dc-4217-9e01-0f192f2deb7d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d60830ad-967e-43c6-9128-1f589db8cfbe"/>
    <dc:identifier>DB00061</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4033c14d-6985-477a-a0ef-370c8753cf97">
    <rdfs:label>Growth Failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6b54b11-03b2-4a8c-a33d-7450df0fcd38">
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040006*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01e923c1-09b0-4a3a-9f36-69f85de62221">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
    <rdfs:label>Midazolam</rdfs:label>
    <dc:identifier>DB00683</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24af2586-031a-4983-ae4b-42b19e0019b2"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e656016f-e3b2-4ab9-8f05-9fbee6a5d2ad">
    <dc:identifier>HP:0011925</dc:identifier>
    <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0b7e5cd-d0c3-4791-971b-c6d67843141a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0252907-f412-4425-bbd7-4b961fe99088"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a55326aa-f7df-4017-b431-641638fd0fed">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5d52d7e4-e004-4822-988b-46ec659896c8"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5310ddd5-e1bc-4e1d-97e2-a19e09d24fd9">
    <rdfs:label>neutropenia</rdfs:label>
    <dc:identifier>HP:0001875</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4954b28c-2c86-4fb1-865b-108abaadc92f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/334ce453-9b5d-4f5d-b49f-f9bb2fec9db6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e09c9ca-c242-4e67-bec9-d086b655b088">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da5468af-0ccf-4f46-9543-2267fdb42599"/>
    <dc:identifier>DB04076</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <rdfs:label>Hypoxanthine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9e9fb10-a003-4f6c-b429-ccd7e43acc10">
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <dc:identifier>DB6756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8bc0a279-7c8d-4e50-8af5-6a2617982696"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80c0f465-5194-48ed-8de1-0e74c1039467">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b67e191-354e-463b-a912-55f15b41dbfb"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/700e9194-d5ad-4bd5-a2f5-206e783f3097">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cdbcad1-c48d-4a2b-923d-1f23a0b7a3ef"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08a1ffc4-5544-4360-bacd-8a331933b3c6"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/242b0a0a-71e5-49d3-8d6b-9f2f5d95aeb1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24dfb7b7-915a-432a-8915-616a7ad133ad">
    <dc:identifier>DB01037</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff9bce37-8e69-489b-a74e-e9173461f6c6"/>
    <rdfs:label>Selegiline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6bb79930-1c07-4383-bf3c-18842926ade9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c26c0140-1383-4cd3-84e0-3b9e7e165577"/>
    <dc:identifier>DB00829</dc:identifier>
    <rdfs:label>Diazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65962b9f-c70c-4b0d-9fa8-d7c9cea6853a"/>
    <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/039ebbd4-12de-46df-83b5-64ef874057b4">
    <rdfs:label>Stroke-like episodes</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
    <dc:identifier>HP:0002401</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57110376-8214-436d-aab9-1b3f320cdea7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6914ebe5-e979-4daf-a5b9-ee19d5150103"/>
    <dc:identifier>DB01609</dc:identifier>
    <rdfs:label>Deferasirox</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/bbfd77c6-7db4-4e1a-9571-d59c8806065a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9fe6db6-6825-41c1-a201-77cb93661c3c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb358c6-9dd9-4aa6-8e2c-9f50fbaa8f13"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7e50fb1-321c-444e-8df6-991503aae494">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
    <dc:identifier>ECO:0005242</dc:identifier>
  </ddiem:Evidence>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91ec15cb-ff4f-4413-b591-4987ac4b7420">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d857dcc5-89bc-4421-bba0-2c9f0b706b93"/>
    <rdfs:label>leucine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7f5816f-8762-47c6-a4d7-8edc5a612d3f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>fine motor dysfunction</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/792c946e-2183-45e7-8731-e1c6cb7b8493">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fb18c2c-46cc-4351-9388-eae3b48587b0"/>
    <dc:identifier>DB00996</dc:identifier>
    <rdfs:label>Gabapentin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2347f544-18b2-4e50-b8e0-d6b4f8516c0e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f37691f6-e403-4ba0-8927-c78aa23ab6db"/>
    <dc:identifier>DB14476</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d33fa03-b5fc-4d77-956b-a57db099646f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/056115b3-d7b7-4ea9-ae31-2a7a5f2ebb8b"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fad9618a-b813-40e3-add6-0bfacfe34bd8"/>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/402102a2-7829-4108-abe0-0d6aec0083ec">
    <rdfs:label>rAAV-PPCR</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/569ae0be-8eb8-4aea-8b23-738c6ad75a30"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfd2c748-b53d-45c3-a7ed-4547fa4389eb">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Awake EEG</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <dc:identifier>HP:0002353</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd94b1ca-e8ec-46e3-813b-8cf36c53d5f8">
    <dc:identifier>HP:0000712</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
    <rdfs:label>emotional disturbances</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/053086d0-6677-4f83-9250-bec02771af20">
    <dc:identifier>DB01956</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31246c32-9d42-437a-8062-f22311fd579c"/>
    <rdfs:label>Taurine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/429fe02b-52ef-4af6-ab2b-36327577d209"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a380bf19-3828-4400-aa9f-834ee2262c74">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
    <rdfs:label>Weight loss</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001824</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f0ae8fd-155f-4605-8f5c-20a19d042fa4">
    <rdfs:label>low quality of ife</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddab033d-d1bc-495a-a4ea-135069afa4b1">
    <rdfs:label>Clonic contractions</rdfs:label>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec94bc57-8e62-402e-9b43-a0fdf580bf67">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/024612c3-5ce4-4701-8565-5f494f0c82cc"/>
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2da5a653-455c-47ed-970c-8829858ebed3">
    <dc:identifier>(DB00440</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/357c0c20-31ac-4ee4-a08a-b6d68072a5d9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98b052b5-c4fa-46b6-94ad-71dbc0c7ada7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d69f1956-6e6b-468e-9f38-77fec95ceb75"/>
    <rdfs:label>Cholestyramine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <dc:identifier>DB01432</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d434524c-7395-489c-92db-29ea48e81f24"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1377c94a-24b6-4473-8316-8b49c4bde955">
    <rdfs:label>nervous system abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
    <dc:identifier>HP:0002011</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78ccf14f-cfd8-4e13-985d-abd9b8d672c5">
    <rdfs:label>Nitisinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d303668-dc69-4913-811c-965ec8b1ed6f"/>
    <dc:identifier>DB00348</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34252e65-3943-42f5-9dcb-3ff545064562"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10c50e20-09bc-4aca-979d-a8c585fd9134">
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e568742-1545-45ad-8aab-dcd6eddd2c26"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ad90013-2cbd-44d5-b0f4-d05a35436ed5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/028b7a9a-a907-45cc-8dd4-670ab6fcbce3"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dbd2acad-1eca-4bf6-b73e-caf1608c628a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c748b55a-b576-4b8b-816e-d4d7d326ed9f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
    <dc:identifier>HP:0002066*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b4d5f9b-e8bf-47fe-8708-56df8407c466">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c65cca97-7314-4f97-abab-bf313bf4c0d6"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf3998bd-d6d8-421e-b760-5bb0807a8e2c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67aac8d2-0ec2-4384-87f6-88d4c1f19446"/>
    <rdfs:label>Ethosuximide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58c248bb-d460-4d0e-8c3a-5a30985dc169">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
    <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
    <dc:identifier>HP:0045010</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0603950a-fcfe-41d3-974f-7ec14aae9ebc">
    <rdfs:label>Tretinoin</rdfs:label>
    <dc:identifier>DB00755</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad33cee8-53cd-4f2d-a0c8-ddcf0d88eac9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7e4325e-e0f6-4f0d-8640-e73deddf9adc">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
    <rdfs:label>Incoordination</rdfs:label>
    <dc:identifier>HP:0002311</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71a38ffc-d954-4ef7-8b0e-21d3d4c4739a">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
    <dc:identifier>HP:0008064</dc:identifier>
    <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01a0e726-e70a-4dd7-b986-07de6d229d3f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4f0f6f9-29af-48cc-81b9-2eb684baa5fd"/>
    <dc:identifier>DB00067</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <rdfs:label>Vasopressin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/239c7bae-ad4a-442f-aecd-25fc765d0404">
    <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ee47ed7-23ee-4439-b286-315bb4f31730">
    <rdfs:label>Diabetes mellitus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <dc:identifier>HP:0000819</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac92f566-ff77-42ef-a659-207ec0eba1b4">
    <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d7a6786-5b2e-42a2-b295-003973b680ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81f2bbf4-de01-4e37-bfaa-7b4f37d60711"/>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <dc:identifier>B01</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6839ece-13a2-4ece-9551-6744e518b8c1">
    <dc:identifier>DB00915</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/869f43d4-c6ac-445d-b3d7-95693053e738"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9be9f20d-87a5-491a-9916-0477bb05e7d5"/>
    <rdfs:label>Amantadine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/753156bb-0b5b-44d8-b707-648f4ba2deb1">
    <rdfs:label>Diabetic polyneuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001271</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c3d081c-4b7a-429b-8191-55cdb1d569b0">
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <dc:identifier>DB08830</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09124551-c688-4e2c-8da5-7412edee33d6"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f797b47-dbde-4309-a77b-7ba381df75f5">
    <dc:identifier>HP:0002653</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Bone pain</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3ab6c5b-8ca8-45a9-9c89-12130b74cd3e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <dc:identifier>HP:0000817</dc:identifier>
    <rdfs:label>Poor eye contact</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0237ce7-c8cd-4754-915c-bc2b7253a853">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46182742-80c9-4f75-b571-caccf666f965"/>
    <rdfs:label>CoCarbs + HPro</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5bde9b93-5154-486e-b477-5e5c2e809996">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e042d79-4948-4bd6-b6ee-42c45bc5104c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <dc:identifier>DB15066</dc:identifier>
    <rdfs:label>Givosiran</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab92b0d-58f2-42b9-bdc0-d47a8d1abf41">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:label>delayed growth(stature)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000002</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a98f0e9d-edae-4aac-a6d5-c915e24a68b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <dc:identifier>HP:0006279</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf9d9475-7ec3-4690-b500-3401dcac8772">
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002098</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c90a114d-563b-4eb7-a84b-94586fc85e72">
    <rdfs:label>Eltrombopag</rdfs:label>
    <dc:identifier>DB06210</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df395c9e-cb64-4c63-a7a9-9557802efa78"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07ac1a85-980a-4874-b757-be58a4417ca3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8317ba5b-0873-4fdb-9afd-cd7f5771ead2">
    <rdfs:label>Potassium cation</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <dc:identifier>DB01345</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fef3c28d-9a87-4658-892e-2c333a8db2d4"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9e932f3-ab2e-42e3-8f42-de4f22cc1787">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b85fe616-2ea4-4730-8b71-3aff168f5261"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c568bc44-4fd8-4f0a-b9ba-ed941781d0e6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c86c32d5-43f3-4d74-bc0a-5bff3ba809df">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba2b5fd1-8bf2-4b41-a514-35ab6ae3757e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/249f12c5-28da-4648-b961-04a676eb4826"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc50ea46-fd12-4140-ae5d-70e1461fdf79"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1117aaef-4a71-4955-b9f7-da265aad64c6"/>
    <rdfs:label>Creatine</rdfs:label>
    <dc:identifier>DB00148</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d89a8ca7-49a0-4a3b-8406-ba12f2cd0185">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df628e91-499b-42c9-a887-50ffb742b4f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee9680b8-6a95-4607-91f3-fa7d2e10c42c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <rdfs:label>Galactose</rdfs:label>
    <dc:identifier>DB11735</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb665413-1ecd-433d-9b50-ee4286884f09">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/701ffdbb-e3d2-4ef0-9cf2-5443eeab5ffd"/>
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74ffba14-fced-4927-b712-3f73b4938d9a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e14f7bb2-00b0-414f-a399-b6a9f5f2088f"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf08837e-e32e-4225-a6a4-179d7f1c0a7e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc59f94b-a0f6-4cd2-9a30-50f1a02f27f1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89d57a52-a507-45f5-960b-51340b878bae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7b244c0d-3dbf-4a3c-a455-d780079bc1bf"/>
    <rdfs:label>Clofibrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c125cdb-26f3-4a79-841c-082ba67e4010"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bbfd77c6-7db4-4e1a-9571-d59c8806065a"/>
    <dc:identifier>DB00636</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b3b7b34-6bfd-471a-a4f7-718067efc042">
    <rdfs:label>Gemcabene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/62d18710-5b08-4ea9-b693-3ceb97e6bf66"/>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5783f13-6685-4de2-862c-fb37126e0797">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
    <rdfs:label>cataracts</rdfs:label>
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62bc0fe3-d088-43c1-8e90-2b5f71f73da0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64f40162-6cff-472f-81b6-4eac30154cd6"/>
    <rdfs:label>GNT0003</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f4cf13c-5bc8-4ebd-8d58-89a0002be95e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/862a50c4-1f8c-48be-94bc-4eb3b4a9dd80"/>
    <dc:identifier>DB02285</dc:identifier>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/546fa518-d051-4993-b62d-fa67f396e0c0">
    <rdfs:label>GSH deficiency</rdfs:label>
    <dc:identifier>HP:0003343</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba0c2670-2a1d-4378-9c3a-e46ac18abc35">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50aa7186-d10f-4e7a-86a6-033bbd133d74"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4f8e737-dd0a-4060-8bda-f42b48d2ad29">
    <dc:identifier>B02BA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8c39420-b4f4-4007-9ec3-0ca1bc214d02"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <rdfs:label>Vitamin K</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eb05e3eb-e84d-48e6-8f14-ce2b336c6b24"/>
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/956d1abd-a17f-4608-8cdd-39c00bba2e88">
    <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100712</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a394a3e5-51f5-46c1-8f15-2b72b5600dcf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07e98a9d-775e-4625-93b8-0d8767b949ec"/>
    <dc:identifier>DB01032</dc:identifier>
    <rdfs:label>Probenecid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2aacec3-eba6-4c42-a336-2be27c4f4d7f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/571c0c87-aebb-4c48-abb4-9d78e809b531">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c785e752-500f-4e86-b8a8-6b47b47887ac"/>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <dc:identifier>DB03485</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89562c63-fb78-4ab5-86d8-16abddde86f5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49dae47f-20ce-4b4e-8bdf-4b94940dfff1"/>
    <dc:identifier>DB00808</dc:identifier>
    <rdfs:label>Indapamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcbfe271-525e-4f43-b96e-048bc617390b">
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89e77d1e-3ccb-4fd6-bf92-7c4df83fb24a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63173562-25ef-4de4-9ed8-4a7170c79ed3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/715fefe6-7c43-4d22-b6c8-3b7866af3f4e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b5690691-3b20-45d6-8a10-079b50f2bd95">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f00d25c-c194-48a6-b268-a366eb5960ff"/>
    <dc:identifier>DB00115</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76ac221e-868f-4b4a-a05c-d368823f9090"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce157b1a-b305-4ee3-8adb-7ebce1da17fd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c16351e2-0cab-4999-96d7-08374f9be09e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa9b8dac-4c83-43bb-9a03-d92bb08c2dfb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
    <dc:identifier>HP:0010473</dc:identifier>
    <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ff5d26e-5823-4560-9913-db0a3068ae3d">
    <dc:identifier>HP:0002749</dc:identifier>
    <rdfs:label>bone weakness</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e72e22fa-1a83-43a5-9529-110ee88288c1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c912b98-9610-4f9d-a4d9-ade710154f5a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7dec3bf7-b24a-416b-a2e6-f08f1f02f5ae">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/279c101a-62b4-4575-b53b-721c558c4cc6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a64d9970-6975-4e28-b2f1-4f75216d0e47">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8cb3931-b36e-4397-88ad-a96948dd03de"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/307264cb-41b6-4a70-a4ef-ee98e9e85fdc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
    <dc:identifier>HP:0008166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/602799a5-d854-413a-95e5-4ff59b5eb7be">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96a6c741-c30a-44a2-ba37-4560bd8a45b6"/>
    <dc:identifier>DB00186</dc:identifier>
    <rdfs:label>Lorazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26b5f7cc-7f06-44cb-86e1-d5834f986b02">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f227b3f-a0c6-4e8d-a255-f0cb9a76588d"/>
    <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
    <dc:identifier>DB14502</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8986b4f4-ee88-4bb3-a5d2-394b4a6cc6fc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edb5d374-b510-47dc-ac8b-3d08585f846e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0917102-91bc-456c-926a-4767e5f3e00f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ba9d72a-a319-401e-b3b7-9d3133e57526"/>
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adb90cdf-1b42-4632-87e4-9bca0951134f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <rdfs:label>abnormal gait</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001288</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b95b9535-97b8-473e-8b5b-ba8b9f859454">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c69f025-7896-47be-8860-10452ceebc1b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7db9aa17-a8e5-4c32-82c1-85a734ddccf1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <dc:identifier>DB14555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d55e1b08-78d9-47ea-aea1-1325688dfd12"/>
    <rdfs:label>Ursadiol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/803ef6a9-0c9e-4d72-87ac-765d9ed9c54f">
    <dc:identifier>HP:0003797</dc:identifier>
    <rdfs:label>Muscle atrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbf48d89-1e0b-4162-b938-69483669f040">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52c537a9-1f3e-4641-bff8-3f9ba71b9943"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0ec47fa-ef75-4516-8934-ecedbf9f747c">
    <rdfs:label>Low 5‐MTHF level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96787b22-8959-4623-9e00-f8effe0a57ba">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum folate</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <dc:identifier>HP:0040087</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c5c2557-c878-4175-bbbf-7bdd4a5ff458">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9be668a1-a526-461e-97d2-6fae0fd7fbbe"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3fb65b7b-12e7-4bcb-a041-bd29bc062394">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dc:identifier>DB00564</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bff1f57c-351e-49ba-984f-971aa31722d1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5449c57-f5e6-4f13-8317-bb51e758559e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c7ce0f6-cf25-472a-b7ce-768f4a24d880">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6baffc6a-9558-47fc-80fc-3093ffb477ad"/>
    <dc:identifier>DB00396</dc:identifier>
    <rdfs:label>Progesterone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2151a70a-b56a-4a1a-b5b2-f023fc4d9e34">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f1ef3f2b-6076-4180-903a-ac53c8c94904"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e945566-c984-450d-b444-a33192433eb1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
    <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
    <dc:identifier>HP:0031799</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a88e009-517e-4b0a-b385-c7973a722461">
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <dc:identifier>DB01323</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01c8d7fc-2b4e-4079-95f3-18a922e5b1ca"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4de899b3-a519-41f4-9e5e-5712320a0ad1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ccdacd9-0cf0-4b5c-9f26-71cc68861669"/>
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85ea3d9f-7dd5-470a-9859-25eb12b5d371">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4d0de93-b60e-4d09-9b77-3021f6520cfb"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2193a54d-dd1d-463c-b1dc-17d025b25c48">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4cc0440-3472-4be8-8387-9e2762f417a1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cdcc191-a855-4ca8-91c1-16337c5f119a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3b7e96f-4e83-4272-96c5-7c00b0577dbb"/>
    <rdfs:label>AAV9-TAZ</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b5e6dd4-d463-432c-ac33-c35e9fa8abb6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be0e6e08-fb00-498a-8a88-d0c2dfae783b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e04f9401-fa98-4a75-9124-d21b7f302482">
    <dc:identifier>DB04263</dc:identifier>
    <rdfs:label>Geneticin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f49598e-7e60-401f-8ade-79b2921c92f0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46568c79-8e01-4386-a61e-8df334015b5a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001954</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <rdfs:label>periodic fever</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/004dbdfd-54af-41cf-8242-b6f0539e12c3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f0552a0-ebc8-436a-b662-3db3d4aadfb1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02e39f11-46db-4d08-bdb0-e31af1b9058a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85433033-1c70-4387-8e56-16cf2fad23b3">
    <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c403e10-83e9-412c-8c12-bb08823020db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e35af37e-fa1b-499d-ab4c-79357ab84cf7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d720cccb-6245-4d18-9257-1bc9b670dd55">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb744d37-16d6-4195-9a7a-92e6eb9525ef"/>
    <rdfs:label>hepcidin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d7fcbe9-74e4-42a4-9436-7be860d978fb">
    <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6149371-46eb-41be-94da-bb49ecbebff9">
    <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef32a5f0-4489-44a8-b984-5ee4025569f0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6f93c49-9649-43d1-bfdc-c733588b0b9b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a57c338-f382-4623-a63b-281d763836eb">
    <rdfs:label>Entacapone</rdfs:label>
    <dc:identifier>DB00494</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc0cb6ce-d531-4110-9120-74c34abfc5a5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0acb08e-0952-4162-a89f-5cfa12a85f73">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/90f3ab94-8288-4514-85f0-90f8166a2709">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42db4f81-c977-4254-a4d2-129587603f21"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b0ddff6-7e84-41ba-98d8-5f35bf397e44">
    <rdfs:label>Lenalidomide</rdfs:label>
    <dc:identifier>DB00480</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99b4cd12-b983-4e5e-9078-8052d3c4c18b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b513d504-b2c0-4ebc-b3d7-3278298e3df5">
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69caa330-c2f8-40eb-9707-eff8ce2b14b6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <dc:identifier>DB04815</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a14187d4-15e9-40ba-8013-92700c8569cb">
    <rdfs:label>Ad-hBUGT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d72feead-8424-4108-b67f-15575ceec12b"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09b90bb8-6188-42c8-95ab-de5c0ebcdc02">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1f2cb63-b447-4e6e-9cb6-f0417fcba51c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fabd464d-8c5c-4349-b2d9-3b2f37358e67">
    <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6658b030-9f6d-443f-ba41-4b48291231a3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9f23edc-336b-489b-bb7d-2c5f001859c6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a01f589-1893-4c52-9b64-d3cb1b7f12af">
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <dc:identifier>DB08909</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/256fe564-44b4-4f94-9307-274b5e933c1e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b72e30cb-c6e2-4a98-a220-dc8c10a877e8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <dc:identifier>DB09422</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5302907-4f78-4cae-870b-301c54d986c1"/>
    <rdfs:label>Soybean oil</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2595768-24fb-4b66-bbea-aa51bf2ec6db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81e06143-35a2-4842-90ac-5ccf85cd3373"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb0d66f2-7bf3-4f00-a018-2bf3e1c50c77">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/408ff632-6a28-45dd-ba9b-67083196df25"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/696b9cee-3a7e-4060-9a44-dca48856ed49">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89c8c6d0-4e3a-4ca4-966c-a1b45f595d9c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9141574e-eb27-4876-b3df-dd76997f40c6">
    <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <dc:identifier>HP:0002630</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c921f953-54f5-4b8b-a455-b8eab8e1c633">
    <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
    <dc:identifier>HP:0031951</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f48203fd-1984-4a6d-b5ec-50879a91b333">
    <dc:identifier>DB00413</dc:identifier>
    <rdfs:label>Pramipexole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6a6dc40-3462-4b8a-bf66-47a34d24226c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bed1300-e534-4556-9435-72e861082a36"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11de18cc-c880-4f8f-8f67-ab9248906826">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0dbf796c-06f2-4b4a-8ffc-916693f6d9f4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91473db4-b36b-45eb-b622-547e25e4dd09">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc06348e-1378-4136-b731-d98810fb7040"/>
    <dc:identifier>H02</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba8534e1-0450-4038-92f2-6b154fbcdaaf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2da5a653-455c-47ed-970c-8829858ebed3"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe07897f-c8b3-4b0e-8fc8-698ed6920894">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a606cdab-9dcf-400e-88dd-9bd439af56fe"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6c9dc39-9ac7-4104-96df-48924be6ec4b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5715b4f5-2caf-4022-836a-923236072d1a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dc0a487-772e-4efc-ae3f-92053359a990">
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/577006ac-06cf-4d90-b235-b2a572c053cb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/260be4a7-1d79-42ab-8497-673df1e17faf"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26d20f15-e68b-480f-ab9c-76942762ea6f">
    <rdfs:label>Pathological apoptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6aa9ab00-df16-4600-8402-f2774701405c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/053ebb4f-cdb6-47ac-8b23-4f8e2fb923a6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa3ed17d-8f7f-4fe2-9d5f-7ae2bd8e948d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ece07602-78ef-403b-b959-0a8d0732657e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a85c35e6-4d53-4733-9801-48706be2b2fe">
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3931ef5c-2f50-4bef-a134-1ad0fcd7297a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08944f56-902a-447f-83fc-94ecfdfee159">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae87a860-000c-465f-ae37-687ca815ad17"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfc21e3c-5c38-42f2-9f5c-3dcd2a658693">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5a85b3a-a0d0-45c2-96e8-508569479f56"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6df09c2-c881-4ae9-8d3b-0c0bc22db771">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a86344fb-552d-4d0c-960d-c67c335cc453"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15dfcf3f-4043-46e5-bb10-8588925e6437">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f1e3367-9794-4baf-b35b-a2c0c9f6443f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4da542a-aa42-4cf6-9b95-38292a694931">
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b979e1d5-d7e5-4809-8a5d-6e5fd4177901">
    <rdfs:label>ARC-AAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b3b8b9f-0565-4494-9c0f-c84fcda93f41"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3973188-ab6d-4b26-b790-3f21ae14739a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Parkinsonism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/841cdad8-7892-4116-a63c-4f3c9a14fbcd">
    <rdfs:label>AAV-treated βgal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b9e4bcd-b158-431b-81de-fad2ce2204bc"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4c9c9b3-0d56-41f2-adce-785ecc78e048">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57d42981-1750-42f4-9eb4-730dd6845ebe"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0d75f78-54ad-4a3b-85bf-c66032ab914f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73e50404-5384-4747-b406-92e4205fee4d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b6f6893-396a-4df4-8e8f-0ab4107bb07a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03d78dff-bb81-4856-958d-c26a659b032d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ba69abd-9bb3-4261-9a22-0521229178ea"/>
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89cc18ff-7637-464d-a687-1eb8c321d960">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d1af543-a034-465d-b21e-c1b3bd642ecd"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5018ccfa-7a3a-426a-aa3a-2a53060814c4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1968fa8-a2dd-4e00-a5ed-f5b0994c82c5"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/678378d9-3876-4212-8b6e-84fb7223b45f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3f80ed0-7ad8-474d-b5f1-e9acb2e50b59"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d1b0d93-e6a3-4409-8423-7d453cfd6ad1">
    <rdfs:label>Low pancreatic zymogens</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/504fa6b0-a5ce-4870-a1f6-1b04aec18d63">
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc4b1132-f634-4fac-8ca3-f37ae45c3421"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/246084d4-a2b9-46da-ae64-456f3aaf277c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e70f905-eeca-4795-b4e2-662d770cfc5b"/>
  </rdf:Alt>
</rdf:RDF>
